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Introduction: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a se-
vere autoimmune disease causing organ damage and long-term morbidity.
Impaired clearance of nuclear debris from cells and upregulated circulating
damage-associated molecular patterns (DAMPs) and cytokines are thought
to trigger cell death and thus, further increase release of pro-inflammatory
molecules following the cytosolic assembly of inflammasomes.
Objectives: To investigate the role of pyroptotic cell death in JSLE,
which occurs following the assembly and activation of the NLRP3
inflammasome, which may be a promising target in the treatment of
JSLE and other inflammatory diseases.
Methods: THP-1 cell line-derived macrophages (Mφs) were primed
using lipopolysaccharide (LPS; 10 ng/ml) and interferon (IFN) γ
(20 ng/ml) in complete media at 37 °C for 24 hours, and subse-
quently treated with 10 mM Adenosine triphosphate (ATP) for
30 min. Primed Mφs not treated with ATP were used as a negative
control. Some Mφs were incubated with 10% JSLE patient sera or
NETosis-derived material (10 ng/ml) from PMA-treated neutrophils.
Primed Mφs were tested for cell surface markers, HLA-DR, CD282
(TLR2), and CD68 using flow cytometry. ATP-treated Mφs were col-
lected and either assayed for pyroptosis marker, lactate dehydrogen-
ase (LDH) activity, cleaved caspase-1 with immunofluorescence (IF),
or lysed for cleaved caspase-1 using western blotting.
Results: Primed Mφs showed an M1 phenotype with geometric
means ± SEM of HLA-DR, TLR2 and CD68 expression respectively of:
1177 ± 1.15, 613 ± 0.9, and 1549 ± 0.9 gMFI, respectively compared with
un-primed Mφs of 597 ± 1.0, 122 ± 0.88, and 1225 ± 0.9 gMFI, respect-
ively (n = 3; p < 0.05). ATP-treated Mφs showed increased LDH activity
compared to controls (3.4x10-3 ± 0.12x10-3) compared to 0.00 milliunits/
mL, respectively; n = 3; p < 0.05). Furthermore, a greater increase in LDH
activity was observed in Mφs that were incubated with JSLE serum and
NET material (3.7x10-3 ± 0.5x10-3 and 7.6x10-3 ± 0.5x10-3, respectively,
compared to 0.00 milliunits/mL; n = 3-6; p < 0.05). IF was positive for
cleaved caspase-1 in ATP treated Mφs; and this was confirmed in lysed
cells, using western blotting.© The Author(s). 2017 Open Access This artic
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(http://creativecommons.org/publicdomain/zeConclusion: Overall, the results indicate that Mφs undergo pyroptosis
via the NLRP3 inflammasome when challenged with a two-signal
approach of priming and ATP, and that cytokines, nuclear debris and
DAMPs may not only trigger, but amplify the inflammatory response
of this pathway. The NLRP3 inflammasome is thought to be an im-
portant mediator in the pathogenesis of certain inflammatory dis-
eases, and flare episodes associated with JSLE. Further work is
planned to investigate the role of the inflammasome in JSLE, using
pharmacological interventions with specific known and novel inhibi-
tors of the NLRP3 inflammasome. This work could prove the NLRP3
inflammasome to be a promising target for future therapy for JSLE.
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Introduction: Clinical management of polyarticular JIA with anti-TNF-
alpha biologics has been met with significant success, with up to
80% of patients demonstrating clinically meaningful efficacy. Con-
cerns about medium/long term drug toxicities and costs have driven
the clinical need to find predictors for successful drug discontinu-
ation. Emerging evidence from previous published data indicate that
T cells play a crucial role in the disease progression. Defining the
pathogenic subsets and mechanisms within the T cell immunome
will likely help stratify patients in terms of therapeutic outcomes.
Objectives: We seek to distill this pathogenic signal hidden within
the T cell compartment through the utilisation of a high dimensional
platform, CyToF, that is capable of phenotyping up to 41 markers at
a single cell resolution. JIA patients treated with anti-TNF-alphale is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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segregated into flare, active and inactive arms after drug discontinu-
ation. The central aim of this project is to identify pathogenic im-
mune mechanisms of clinical relapse and signatures capable of
distinguishing clinical fates.
Methods: Patients treated with anti-TNF-alpha biologics were re-
cruited into the study (Improved Understanding of the Biology and
Use of TNF inhibition in Children with JIA Trial) with clinically inactive
disease on treatment (Wallace criteria) and initiated with therapy dis-
continuation. The patients were followed and evaluated as flare, in-
active and active based on 6 JIA core set parameters; number of
joints with active arthritis and/or loss of motion, MD global assess-
ment of current disease activity, patient/parent global assessment of
overall disease severity in prior week, a validated measure of physical
function and ESR. Healthy paediatric controls without any inflamma-
tory diseases were recruited from the day surgery during intravenous
plug setting pre-operatively after informed consent.
Results: PBMCs from n = 47 JIA patients (Flare n = 18, Active = 11, In-
active n = 18) and n = 10 healthy controls were stained with 37
markers/4 barcodes T cell CyToF Panel after 6 hours stimulation with
PMA/Ionmycin. Dimensional reduction cluster analysis was performed
with Marvis and unique nodes representing immune subsets
enriched in flare or active disease was statistically filtered (Mann
Whitney Test, p < 0.05) and manually verified through conventional
bivariate gating (FlowJo). In patients destined to flare (vs inactive/
healthy) prior to therapy withdrawal, the CD4 memory compartment
was strongly dysregulated (p < 0.05), enriched particularly in (a) CD4
CD45RA- TNF-alpha+, (b) CD4 CD45RA- CXCR5+ (TfH), and were
skewed towards (c) CD152-/PD1-.When contrasting against only
healthy non-disease controls, patients destined to flare additionally
were up-regulated for CD4 CD45RA- TNF-alpha+ IL-6+, possibly repre-
senting as a sub-clinical disease subset. Intriguingly we noted a
migratory subset, that was not evident in earlier flare cohort compar-
isons, CD4 CD45RA- CXCR3+ CCR6+ that was present in patients des-
tined to develop active disease (vs inactive/healthy). Upon flaring,
the sub-clinical subset CD4 CD45RA- TNF-alpha+ IL-6+ surfaces and
CD4 memory subsets are now upregulating expression of CD152/
PD1 (vs inactive) in response to ongoing inflammation, but when
compared to healthy controls are still inadequate.
Conclusion: There exists a group of patients (flare) for which biologic
therapy with anti-TNF-alpha is merely controlling the disease activity
but not curative. The persistence of CD4 memory cells are likely to
play a pivotal role in disease relapse, that may be partially explained
by a weaker control through immune checkpoints (CD152/PD1) or
interaction with B cells. These results suggest that clinical fate is im-
munologically predetermined and patients who will develop different
clinical fates can be identified from prior biologic sampling.
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Introduction: Systemic Lupus Erythematosus (SLE) is a multi-factorial
autoimmune disease and the conventional oligo-dimensional investi-
gative approach involving one or a few cell types or analyses at a
time is inadequate for its study. We hypothesize that abnormalities
within multiple components of the immune system contribute tolupus pathogenesis and hence, there is a need for a comprehensive
interrogative analysis.
Objectives: We aim to employ a multi-dimensional holistic approach
using mass cytometry to study the immunome of childhood onset
SLE (cSLE) patients and unravel the immune derangements involved
in its pathogenesis. This will address the critical unmet need for a
simultaneous and holistic interrogation of the different immune cell
subsets in cSLE.
Methods: Peripheral blood mononuclear cells (PBMC) from 14 cSLE
patients and 14 healthy paediatric controls, were stained for 37 im-
mune phenotypic markers after 72 hours of culturing with and with-
out Class B CpG oligodeoxynucleotide stimulation followed by
interrogation with mass cytometry. Blood from healthy paediatric
subjects without any inflammatory diseases were obtained prior to
their elective day surgical procedures during intravenous plug setting
after informed consent. Subsequent analysis of the data was done
using a machine learning approach with dimensional reductions
followed by automated cell classification, clustering and visualization.
Unique nodes representing immune subsets enriched in cSLE pa-
tients were statistically evaluated with reference to the healthy co-
hort and its clinical and mechanistic significance inferred from their
phenotypes (Wilcoxon rank-sum test, p < 0.05).
Results: A statistically significant enrichment of a class-switched
memory B cell subset (CD19+CD27+IgG+) with CD11c+CD25+HLA-DR
+CD40hiCD86hi was found in the SLE cohort, suggesting its patho-
logic mechanistic role in lupus. Intriguingly, CD25 (IL-2α chain) ex-
pression was found in this population, indicative of its potential
responsiveness to IL-2 secreted T cells. This observation was coupled
with a reciprocal increase in the transitional/naive B cell population
that was negative for CD11c, CD25, CD40 and CD86 in the healthy
cohort. Next, a significant enrichment of the memory regulatory T
cell population (CD4+CD45RO+CD25+Foxp3+) was present in the dis-
eased cohort with a small population of these cells expressing
CXCR5. CXCR5 is a homing chemokine receptor to the lymph node
germinal centre, an important lupus related microenvironment, and
its presence may signify a potential regulatory role of these cells. In
the healthy cohort, a reciprocal enrichment in the naive regulatory T
cell population was found instead. Lastly, the B regulatory compart-
ment of the PBMC was interrogated after CpG stimulation demon-
strating an enrichment of IL10 secreting B regulatory cells with the
naive and transitional B cell phenotypes (IgM+IgD+/-CD27-) in the
cSLE patients. These populations of T and B regulatory cells may be
involved in the amelioration of the lupus disease activity during dif-
ferent phases of the illness.
Conclusion: A holistic multi-dimensional approach was able to distill
multiple derangements in the cSLE immunome with clinical and
mechanistic significance. The identification of a B cell subset with
phenotypic markers indicative of its ability for antigen presentation
(HLA-DR, CD86) and T-B cell interaction (CD25, CD40) in the cSLE co-
hort highlights that the immunopathogenic role of B cell in SLE goes
beyond antibodies production and immune regulation. Additionally,
the concurrent demonstration of an increase in memory CD4 regula-
tory cells and B regulatory cells in the diseased cohort is consistent
with our hypothesis that multiple immune abnormalities are involved
in SLE pathogenesis. These findings have the translational potential
to unravel the pathogenesis of lupus and identify the cellular subsets
for further in-depth mechanistic and functional studies for the even-
tual goal of developing novel therapeutics.
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ening diseases. The different clinical manifestations and classification
framework is partly determined by the size (small, medium, large) of
the predominantly inflamed blood vessels. Among small vessel vas-
culitis (SVV) the Anti-Neutrophil Cytoplasmic Antibody (ANCA) -asso-
ciated vasculitis (AAV) subtype includes, Microscopic Polyangiitis
(MPA) and Granulomatosis with Polyangiitis (GPA) that are difficult
for physicians to differentiate because of their many overlapping clin-
ical features1. In the absence of biomarkers, classification algorithms
(European League Against Rheumatism (EULAR2) and European Med-
icines Agency (EMA3) algorithms) exist to distinguish these diseases
in adults and have been adapted for use in children. Although rare
in childhood, the study of AAV in pediatric patients provides oppor-
tunity for biomarker discovery in individuals with a relatively naïve
immune system and limited comorbidities.
Objectives: Our group has collected blood for RNA-Seq analysis from
children diagnosed with AAV from centres around the world. Tran-
scriptome analyses were conducted in an attempt to detect bio-
markers for MPA and GPA that will help determine disease etiology
and assist physicians in patient classification.
Methods: Briefly, blood was collected in Tempus tubes, RNA was ex-
tracted, enriched for mRNA and RNA-Seq libraries were prepared
using standard methods. Sequencing was performed on an Illumina
HiSeq 2500. fastq reads were mapped to the human genome using
STAR4. DESeq25 was used for differential expression analysis while
pathway overrepresentation analysis was conducted via innateDB6
using the Reactome7 pathway annotation system. Samples from 32
patients at the point of diagnosis or flare-up at blood draw were in-
cluded in the analysis. All 32 patients were classified using the EMA
algorithm, although the EMA classification was not used in the
analysis.
Results: Hierarchical clustering based on Euclidean distances be-
tween samples placed samples into three clusters. Cluster one is
composed of only three samples, while clusters two and three are
composed of 14 and 15 samples, respectively. Cluster two contains
primarily samples from individuals who were classified (via the EMA
algorithm) as having MPA or unclassifiable SVV (10/14 samples),
while cluster three contains primarily samples from individuals who
were classified as having GPA or unclassifiable SVV (14/15 samples).
DE analysis between clusters two and three showed 3,198 differen-
tially expressed genes. The MPA cluster is enriched for pathways in-
cluding interferon signaling, the ISG15 antiviral mechanism, TCR
signaling and adaptive immunity. Conversely, the GPA cluster is
enriched for pathways including interleukin signaling, TLR4 signaling,
and phagosomal maturation. These enriched pathways suggest a
viral and adaptive immunity signature for MPA and a bacterial and
innate immunity signature for GPA.
Conclusion: The identification of preliminary etiologies for GPA and
MPA is the first step toward assisting clinicians in developing im-
proved molecular diagnostics for disease classification, and suggest
an opportunity for seeking different treatment paradigms for the
management of these two diseases.
Disclosure of Interest: None Declared.
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Introduction: Childhood onset SLE is a lifelong heterogeneous auto-
immune disease that follows a more severe clinical course than
adult-onset SLE. Previous studies have shown that HRQoL is impaired
in cSLE, little is known which factors influence HRQoL. Fatigue, de-
pressive symptoms and skin/mucosal symptoms (leading to changed
physical appearance and potential lower self-esteem) may play an
important role for a patient’s HRQoL.
Objectives: To determine the prevalence of fatigue, depressive symp-
toms and skin/mucosal symptoms in adults with cSLE and examine
the relation with HRQoL
Methods: 106 adults with cSLE were included in the CHILL-NL
(CHILdhood Lupus-NetherLands) study including a single study visit for
structured history, physical examination and SLEDAI-2 k. HRQoL was
assessed with SF-36. Fatigue was assessed with Fatigue Severity Scale
(FSS) with scores range from 1 to 7. FSS score ≥4 defines abnormal fa-
tigue. Beck Depression Inventory (BDI) was used for depressive symp-
toms. BDI score ≥14 is indicative for major depressive symptoms.
Results: 92% of cSLE patients were female and white (73%). The me-
dian age at study visit was 33 yrs, median disease duration was 20 years,
61% had developed damage (SDI ≥1). HRQoL of cSLE patients was im-
paired (7/8 domains SF36), remarkably mental health was similar be-
tween patients and Dutch norm data. Patients with damage (SDI ≥1)
scored remarkably similar on all HRQoL domains, except for the domain
‘physical functioning’. 68% of cSLE patients were abnormal fatigued
(FSS score ≥4). 15% were depressive (BDI-score ≥ 14). HRQoL (6/8 do-
mains SF36) was lower in all patients with fatigue but also in those with
major depressive symptoms. The median SLEDAI-2 k score was 4, 31%
of cSLE patients had ≥ 1 skin/alopecia/mucosal ulcers and its presence
was associated with lower HRQoL.
BDI: Exel E, Lupus 2013;22(14):1462-FSS::ad hoc committee on SLE re-
sponse criteria, ArthrRheum2007;57(8):1348
Conclusion: HRQoL in this large cohort of adults with cSLE was not
associated with disease damage, but self-reported fatigue- and major
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 4 of 191depressive symptoms were. Additionally physical appearance (skin/
alopecia) and mucosal symptoms had a clear impact on HRQoL.
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Introduction: A proportion of patients with Juvenile-onset Systemic
Lupus Erythematosus (JSLE) will have lupus nephritis (LN) as part of
their initial presentation, but others will go on to develop this mani-
festation later [1, 2]. Early recognition and appropriate management
of LN is important as early response to treatment is known to be as-
sociated with better renal outcomes [3]. Identifying those with or at
risk of developing LN is important, so that clinicians can be extra
vigilant in monitoring for LN development.
Objectives: (1) To characterise patients with LN at baseline, and how
they differ from patients without LN in terms of clinical and demo-
graphic factors. (2) For those without LN at baseline, who develop it
at a later stage, to determine (a) when they develop LN and (b)
whether there are clinical and demographic predictors at baseline
which can predict subsequent development of LN.
Methods: Participants of the UK JSLE Cohort Study, between 2006-
2016, were included if they had active LN at the time of their initial
presentation to paediatric rheumatology care (referred to as ‘base-
line’ throughout), or subsequently developed LN. Univariate logistic
regression modelling compared clinical/demographic factors of pa-
tients with/without active LN at baseline. Those without LN at base-
line were followed longitudinally, monitoring for LN development.
The association between outcome (time from baseline visit to the de-
velopment of LN) and clinical/demographic variables at baseline was
tested univariately using Cox Proportional hazard modelling. Covari-
ates with a p < 0.2 on univariate analysis were included in a multiple
regression model and backward stepwise model selection applied.
HRs, 95% CIs and p-values were summarised for covariates present in
the final model and the results were displayed graphically with
Kaplan-Meier curves and risk tables.
Results: 331 JSLE patients were included in the study. A total of 121/
331 (37%) of UK JSLE Cohort Study patients were found to have ac-
tive LN at baseline. Of the 210/331 patients without LN at baseline,
13 only had a single study visit and were therefore excluded from
further analyses. A further 34/197 (17%) patients were found to de-
velop LN after a median of 2.04 years [IQR 0.8-3.7]. Six clinical/demo-
graphic factors were found to differ significantly between those
with/without LN at baseline. These included the patient’s first ACR
score (p = 3.6 x10-6), presence of severe hypertension (p = 0.0006),
level of proteinuria (p = 5.7x10-12), serum creatinine (p = 0.00024),
ESR (p = 0.00075) and C3 (p = 1.3x10-7). Within the multiple regres-
sion model, both ACR score (p = 0.014) and C3 levels (p = 0.0082) at
baseline were also significant predictors for subsequent LN develop-
ment. Patients with a higher ACR score and a lower C3 value at base-
line were at greater risk of developing LN at any point in time (ACR
score: HR 1.45, 95% CI 1.08-1.95 and C3: HR 0.27, 95% CI 0.10-0.68).
Conclusion: Using clinical data from the UK JSLE Cohort Study, this
study has explored the ability of basic clinical and demographic fac-
tors at baseline for stratifying JSLE patients as ‘high or low risk’ for
LN development at baseline or during their subsequent diseasecourse. Consideration of such factors may help the clinician when
considering the individual patients LN risk.
Disclosure of Interest: None Declared.
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Introduction: Reactive oxygen species (ROS) were primarily consid-
ered as harmful mediators of inflammation due to their ability to
damage proteins, lipids, nucleic acids and matrix components. How-
ever, accumulating evidence point towards an immune-regulatory
role of ROS with inflammation-limiting effects and the ability to pre-
vent autoimmune diseases. Thus, a deeper analysis of ROS induced
pathways in different immune cells is crucial to understand the am-
bivalent role of ROS molecules.
Objectives: The aim of our study was to analyse the effects of ROS
and oxidative stress on the immune response by deciphering the
role of Nrf2 – the key transcription factor of the oxidative stress re-
sponse – in immune cells.
Methods: We generated mice with a constitutive activation of Nrf2 in
immune cells. Emerging CD11b+Gr-1+ cells were analysed by flow cy-
tometry, whole transcriptome analysis and metabolic assays and
compared to wildtype and LPS induced MDSCs. Finally functionality
of CD11b+Gr-1+ cells was tested in vivo by means of a transfer colitis
model and in an acute lung injury model.
Results: Activation of Nrf2 in immune cells induced a massive expan-
sion of splenic CD11b+Gr-1+ cells, which exhibited characteristics of
myeloid derived suppressor cells (MDSCs) such as suppression of T
cell proliferation in vitro and amelioration of T-cell mediated colitis
in vivo. Whole transcriptome analysis revealed Nrf2 dependent activa-
tion of cell cycle and pentose phosphate pathway, which closely re-
sembled pathways in MDSCs induced by the TLR4 ligand LPS
resulting in higher metabolic turnover and cell proliferation. In
addition constitutive activation of Nrf2 was protective in LPS induced
acute lung injury.
Conclusion: Thus Nrf2 is a critical transcriptional regulator for a mye-
loid cell population that plays a major regulatory role in inflamma-
tion and infections. Modulation of MDSCs via targeting of Nrf2-
dependent metabolism provides ample opportunities for therapeutic
manipulation of MDSCs depending on clinical necessities.
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heterogeneous autoimmune disease. Clinical markers are im-
perfect to correlate with disease activity. Broad proteomic ana-
lysis with high sensitivity and reproducibility may be used
biomarker discovery. Novel biomarkers from peripheral blood
may help characterize pathogenesis and improve disease moni-
toring and treatment.
Objectives: To define protein biomarkers dysregulated in JDM and
better understand JDM pathogenesis using novel aptamer-based
proteomic technology proteome in a well-characterized JDM
cohort.
Methods: Unbiased internal discovery and validation analysis was
done using broad proteomic analysis of 1306 protein targets using
SOMAscan assay of slow off-rate modified aptamers (SomaLogic, CO)
which generates simultaneous quantitative results with high sensitiv-
ity and reproducibility. In a discovery cohort, 27 JDM patient sera
(prevalent cases on variable treatment, average physician global ac-
tivity or PGA mean 3.9/10 visual analog scale, with 14 anti-p155/140
or TIF1, 6 NXP2, and 7MDA5 myositis specific autoantibodies or
MSAs) was compared versus 19 age and gender-matched healthy
controls or HC sera using Mann Whitney U FDR <0.10 cutoff. Result-
ing protein targets were subsequently analyzed in validation cohort
sera (14 prevalent JDM cases with similar characteristics including
MSA distribution vs 9 HC) using the same cutoff. Resulting proteins
with expression ratio of >1.3 were analyzed using Ingeunity Analysis
or IPA (Qiagen, CA). The top 10 pathways were then manually
clustered to minimize protein overlap with at least 1 unique protein
per pathway cluster. Exploratory analysis of the same set of signifi-
cant upregulated proteins in JDM were analyzed for correlation with
PGA by Spearman rank test.
Results: 311 protein targets met above criteria from the discovery co-
hort; 166 unique proteins met criteria after analysis in the validation
cohort. 80 of these proteins were upregulated in JDM versus HC and
59 had expression ratio of >1.3. From IPA analysis, 28 proteins fit into
6 pathway clusters: type I IFN notably including IFN beta, granulo-
cyte/agranulocyte adhesion and diapedesis, remodeling/damage,
acute phase response, Th1 pathway, and adipokines. There were be-
tween 1-7 unique proteins per pathway cluster but many proteins fit
into more than 1 pathway cluster. Among the 10 most highly
expressed proteins, the most common associated pathway cluster is
type I IFN with granulocyte/agranulocyte adhesion as the second
most common. 13 proteins had significant moderate correlation with
PGA in JDM from varied pathway clusters with Spearman r values of
0.32-0.41. Further analysis by MSA group is ongoing.
Conclusion: Broad quantitative proteomic analysis in a well-
characterized JDM cohort identifies key differentiating pathway clus-
ters as above in JDM versus HC including many novel proteins, 13 of
which have moderate correlation with PGA. Top upregulated proteins
are most commonly associated with type I IFN pathway cluster, with
granulocyte-agranulocyte adhesion and diapedesis as the second
most common pathway cluster. Further analysis by MSA group is on-
going. While in need of confirmation in other cohorts, these proteins
identified through a high-throughput screen bring to light new path-
ways that may be important in JDM.
This research was supported by the Cure JM Foundation and the
Intramural Research Program of the NIH, NIAMS, NIEHS, NHLBI, NIAID,
and the CC.
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Introduction: Because of the large number of common variants
or polymorphisms in genes related to hereditary periodic fevers
(HPF), genetic results often require an high clinical dis-
crimination. The Infevers database is a large international regis-
try of the different variants described for genes associated to
autoinflammatory diseases. Due to the nature of this registry no
genotype-phenotype correlation are provided, except for the
clinical phenotype of the first patient(s) described for each
mutation.
Objectives: Aim of this study was to elaborate a registry of
genotype-phenotype correlations derived from the patients with HPF
enrolled and validated in the Eurofever registry.
Methods: We created a table for each HPF describing the
genotype-phenotype correlations observed in all the patients en-
rolled in the Eurofever registry. For autosomal dominant diseases
(CAPS, TRAPS), all mutations were analyzed individually. For auto-
somal recessive diseases (FMF, MKD), homozygous and all combi-
nations of compound heterozygous are described. For each
mutation or combination, the following items are shown: number
of patients, mean age of onset, disease course (recurrent or
chronic), mean duration of fever episodes, clinical manifestations
associated with fever episodes, atypical manifestations, complica-
tions and response to treatment.
Results: We analyzed the genotype-phenotype correlations of 718
patients (313 FMF, 133 CAPS, 114 MKD, 158 TRAPS) already reported
in specific papers and validated by at least two experts for each dis-
ease. A total of 152 variants were described: 48 variants of TNFRSF1A,
30 NLRP3, 57 different combinations of MVK and 42 MEFV for com-
pound heterozygous are available. For each HPF, a table with all the
variables described has been established.
Conclusion: We provide a useful tool for all the physicians, creating a
registry of genotype-phenotype correlation of HPF based on the pa-
tients enrolled in the Eurofever registry. This tool is complementary
to the Infevers database and will be available at the Eurofever and
Infevers websites.
Disclosure of Interest: None Declared.
T1
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 6 of 191Genetic aspects of pediatric rheumatic
diseases
O10
IKZF1 mutation underlines the B cell landscape heterogeneity in
mendelian lupus
Cécile Frachette1, Sulliman O. Omarjee1, Anne Laure Mathieu1,
Thibault Andrieu2, Paul Mondier3, Gillian Rice4, Heloïse Reumaux5,
David Launay6, Marc Lambert7, Guillaume Lefevre8, Nicole Fabien9,
Christophe Malcus10, Isabelle Rouvet11, Emilie Chopin11, Anne-Sophie
Michallet3, Thierry Defrance3, Thierry Walzer1, Yanick Crow12, Alexandre Belot1
1Inserm U1111, Centre International de Recherche en Infectiologie-
International Center for Infectiology Research, LYON, France; 2Inserm SFR
Biosciences Gerland, LYON, France; 3Centre International de Recherche
en Infectiologie- International Center for Infectiology Research, LYON,
France; 4Division of Evolution and Genomic Sciences, Faculty of Biology,
Medicine and Health, University of Manchester, Manchester, United
Kingdom; 5Rhumatologie médecine interne pédiatrique, Urgences,
Pédiatrie générale et maladies infectieuses Hôpital Salengro, Lille, France;
6Department of Internal medicine and Clinical Immunology, UMR 995
Inserm, University of Lille, Lille, France; 7Service de médecine interne,
Hôpital Huriez, Lille, France; 8Lille Inflammation Research International
center, Lille, France; 9Service d'immunologie, CHU de Lyon HCL-
Groupement Hospitalier Sud, Lyon, France; 10Laboratoire d'immunologie
cellulaire, Groupement hospitalier Edouard herriot, Lyon, France;
11Biotechnology Department, Hospices civils de Lyon, Lyon, France;
12Inserm UMR 1163, Laboratory of Neurogenetics and
Neuroinflammation, Paris, France
Correspondence: Cécile Frachette
Pediatric Rheumatology 2017, 15(Suppl 2):O10
Introduction: Next generation sequencing (NGS) represents a revolu-
tion in the field of molecular medicine, and offers a new approach to
deciphering the pathogenesis of complex diseases. Paediatric-onset
SLE (pSLE) is a very rare and more severe phenotype than its adult-
onset counterpart, and is possibly associated with a greater contribu-
tion of genetic aetiological factors. We have in the past described a B
cell-related Mendelian form of lupus due to a deficiency of PKCδ.
Here, we identified and characterized a new B cell-related Mendelian
lupus secondary to IKZF1 mutation and compared this novel mono-
genic disease with PKCδ deficiency.
Objectives: The aims of the study were to characterize the molecular
impact of a new B cell related variant in IKZF1 encoding the protein
IKAROS, and to study the B cell landscape of two distinct monogenic
forms of SLE using mass cytometry (Cytof®).
Methods: We designed an NGS panel comprising 200 genes includ-
ing proven disease-associated as well as prospective candidate
genes, and analysed 132 patients. We identified a family with three
affected individuals carrying a previously unreported mutation in
IKZF1. We set up functional assays including oligonucleotide pull-
down, B cell phosphorylation and deep B cell immunophenotyping
by mass cytometry.
Results: We identified a heterozygous missense mutation in IKZF1
c.359A > T (p. D120V) in three affected patients in a single family.
IKZF1 encodes IKAROS, a key transcriptional factor in B cell develop-
ment. Functional assays showed that protein stability was not im-
paired, but DNA-binding was partially impacted. We performed mass
cytometry comparing SLE patients carrying a homozygous loss-of-
function mutation in PRKCD and our newly identified IKZF1 mutation.
We identified B cell clusters, and unsupervised analysis underlined
the wide differences between two monogenic diseases leading
to SLE.
Conclusion: Ikaros and PKCδ dysfunction demonstrate that mono-
genic lupus can occur as a consequence of distinct anomalies of B
cell development underlining the fact that SLE should be considered
as a syndrome rather than a single homogenous disease.
Disclosure of Interest: None Declared.Remission in chronic arthritis
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Introduction: The measurement of the level of disease activity plays
a pivotal role in the care of patients with ju-venile idiopathic arthritis
(JIA). To serve this purpose, the Juvenile Arthritis Disease Activity
Score (JADAS) was developed in 2009. More recently, a version ex-
cluding the acute phase reactant was tested (cJADAS). Cutoff values
for the state of remission, low disease activity (LDA), moderate
disease activity (MDA) and high disease activity (HDA) were recently
developed for the original JADAS score and for the clinical version.
These cutoff values are ideally suited for pursuing tight disease
control in a treat-to-target strategy, with treatment escalation if the
desired JADAS score is not reached. However, although cut-offs were
validated in a large and multinational cohort of patients, they were
developed in a dataset of patients from a single pediatric rheumatol-
ogy center an partly before the advent of the so-called biologic era.
Objectives: To develop the JADAS and cJADAS cut-off values of re-
mission, LDA, MDA, and HDA for oligoarthritis and RF-negative poly-
arthritis in a large multinational cohort of JIA patients.
Methods: The EPidemiology, treatment and Outcome of Childhood
Arthritis (EPOCA) study is aimed to obtain information on the frequency
of JIA subtypes in different geographic areas, the therapeutic ap-
proaches adopted by pediatric rheumatologists practicing in diverse
countries or continents, and the disease and health status of children
with JIA currently followed worldwide. More than 9.000 patients with
JIA from 118 pediatric rheumatology centres in 49 countries were col-
lected so far. For the development of cut-offs, patients with oligoarthri-
tis and polyarthritis followed in the 20 Centres with the highest
frequency of these 2 subtypes were retained. In each centre, the 75th
centile of JADAS and cJADAS distribution in patients who were subject-
ively rated by the attending physician as being in remission and LDA,
and the 25th centile of JADAS and cJADAS in patients rated as in HDA,
were calculated. The obtained values at each centre were then aver-
aged to obtain the prelimary cut-offs for each disease activity state.
Results: The cut-offs validation cohorts were made of 930 patients
with oligoarthritis from 20 pediatric rheumatology Centres and 1.004
patients with RF-neg polyarthritis from 20 pediatric rheumatology
Centres. Preliminary cut offs values for each versions of JADAS and
cJADAS are presented in Table 1.
Conclusion: New JADAS and cJADAS temptative cut-offs for remis-
sion, LDA, and HDA were calculated. Obtained values will be tested
in the validation analysis. The preliminary values are higher than cur-
rently available cut-offs.
Disclosure of Interest: None Declared.
Table 1 (Abstract O11). See text for description
JADAS10 JADAS27 JADAS71 cJADAS10 cJADAS27 cJADAS71
Oligoarthritis
Remission 1.5 1.5 1.5 1.2 1.2 1.2
LDA 3.9 3.7 3.9 3.4 3.3 3.4
HDA 16.4 16.2 16.4 14.3 14.1 14.3
Polyarthritis
Remission 2.6 2.6 2.6 2.4 2.3 2.4
LDA 5.1 4.9 5.1 5.1 4.9 5.1
HDA 18.9 18.9 22.7 19.0 20.0 25.3
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Introduction: Pediatric systemic lupus erythematosus (pSLE) is a rare
autoimmune disorder with onset before 18 years of age and charac-
terized by heterogeneous clinical manifestations, unpredictable
courses and a substantial risk of morbidity. There is no targeted treat-
ment available for pSLE. In the last decade, several gene expression
profiling and protein studies showed an up-regulation of genes typi-
callyinduced by type I interferons (IFNα/β) in the peripheral blood
and tissue samples of pSLE patients. Although blood expression
levels of IFNα/β-related genes were also correlated with disease ac-
tivity of pSLE patients, the mechanism by which type I IFN contribute
to pathogenesis has not yet been elucidated.
Objectives: In this study, we aim to investigate the role of type II IFN,
IFNγ, in the pathogenesis of pSLE evaluating: 1) the expression levels
of IFNγ-related genes in the peripheral blood of pSLE patients; 2) the
relationship between type II and type I IFNs; 3) the correlations be-
tween the expression levels of IFNγ-related genes in peripheral blood
and the clinical features of pSLE patients.
Methods: We analysed the expression levels of IFNα/β induced genes
(IFI27, IFI44L, IFIT1, RSAD2, ISG15, SIGLEC1) and IFNγ induced genes
(CXCL9, CXCL10, IDO1) in the peripheral blood of pSLE patients (n = 19)
by real time PCR. For each patient, SLEDAI score was calculated. Human
peripheral blood mononuclear cells (PBMCs) obtained by healthy do-
nors (HD) (n = 3) were stimulated in vitro with recombinant human IFNγ
and IFNα2b, expression levels of IFN-regulated genes were evaluated
by real time PCR. We used non-parametric Mann-Whitney U test and
Spearman r for statistical analysis.
Results: Expression levels of both IFNα/β-induced genes and IFNγ-
induced genes were increased in the peripheral blood of pSLE pa-
tients with active disease (n = 9) compared to HD (n = 10) and pSLE
patients with inactive disease (n = 10). We developed a type II IFN
score similarly to the type I IFN score described by Crow et al. We
calculated the type I IFN score and the type II IFN score for each pSLE
patient. As previously reported, the type I IFN score was significantly
correlated with the SLEDAI of pSLE patients (r = 0.67, p < 0.01). We
found that the type II score was also significantly correlated with the
SLEDAI score of pSLE patients (r = 0.64, p < 0.01).As it is known that some IFN-induced genes can be upregulated by
both types of interferons, we asked if IFNγ was able to affect, in hu-
man PBMCs, the expression of IFNα/β induced genes (IFI27, IFI44L,
IFIT1, RSAD2, ISG15, SIGLEC1) assessed to calculate the type I score:
we found that IFNγ treatment induced the expression of type I IFN-
related genes in human PBMCs in dose-dependent manner. Interest-
ingly, human PBMC stimulated with recombinant IFNα2b strongly
up-regulated the expression of IFNγ.
Conclusion: Taken together, these data indicate a possible role of
IFNγ in the pathogenesis of pSLE. Both types of IFNs potentiate each
other effect on tissues by affecting their reciprocal biological activity.
IFNγ correlates with disease activity in pSLE, IFNγ-induced gene ex-
pression may represents a promising biomarker in this autoimmune
disease. The potential pathogenic role of IFNγ in SLE remains to be
elucidated.
Disclosure of Interest: None Declared.
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Introduction: One of the open issues for Juvenile Localized Sclero-
derma (JLS) is the assessment and monitoring over time of the ex-
tent of inflammation and tissue damage. The lack of reliable and
standardized outcome measures has represented, over the years, a
significant limitation for both clinical monitoring of the disease and
development of therapeutic trials.
Objectives: We assessed the reliability of Localized Scleroderma Cu-
taneous Assessment Tool (LoSCAT) clinical score in comparison with
contemporary thermographic analysis. Secondary aim was to evalu-
ate and compare the sensitivity to change of LoSCAT and thermog-
raphy over time.
Methods: A longitudinal observational analysis of patients with JLS,
consecutively evaluated at our Paediatric Rheumatology Unit, has
been performed by using the LoSCAT clinical score and infrared
thermography.
LoSCAT score is composed of two indexes: the modified Localized
Scleroderma Skin Severity Index (mLoSSI) which measures disease ac-
tivity considering any new/enlarged lesion, erythema and thickening,
and the Localized Scleroderma Skin Damage Index (LoSDI) which
measures tissue damage as dermal atrophy, subcutaneous atrophy
and depigmentation.
Infrared thermography is a non-invasive imaging technique detecting
the thermal energy emitted from the skin providing a graphical rep-
resentation of its distribution on the body surface.
Three examiners with different experience in Paediatric Rheumatol-
ogy blindly evaluated all patients twice, at baseline and at least three
months later. At each visit, thermographic analysis and LoSCAT score
were performed by each examiner. The inter-rater reliability was
assessed by the Intraclass Correlation Coefficient (ICC) and inter-
preted as follows: ICC values range 0.75-1 excellent reliability, 0.4-
0.74 good reliability, <0.4 poor reliability. All statistical analyses, in-
cluding the analysis of variance (ANOVA), were performed by using
IBM SPSS (Vers. 18.0).
Results: Forty-seven patients (129 lesions) entered the study, and 26
(79 lesions) were reassessed by same examiners with the same mo-
dality after 4.5 (+1.5) months. As for LoSCAT, mLoSSI showed excel-
lent inter-rater reliability expressed by ICC 0.895 (95% CI 0.846-0.931);
the analysis of variance (ANOVA) confirmed that values indicated by
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 8 of 191the 3 examiners, were not different from each other (test F = 1.275 and
p = 0.283). The inter-rater reliability for LoSDI was excellent too with
ICC = 0.880 (95% CI 0.825-0.921), ANOVA test F = 3.030 (p = 0.052).
In the group of 79 lesions examined twice an improvement for all
anatomic sites for both evaluations of the three examiners and
thermographic detection was observed. Moreover, thermographic
analysis showed statistically significant correlation in different ana-
tomic sites with domains of erythema, dermal atrophy and subcuta-
neous atrophy of LoSCAT.
Conclusion: LoSCAT appears as a promising outcome measure in JLS,
distinguishing the different aspects of activity and damage. LoSCAT
is not influenced by the experience of the examiner. Infrared therm-
ography confirms to be a very helpful tool for detecting disease ac-
tivity and reliable in monitoring lesions over time.
Disclosure of Interest: None Declared.
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Introduction: Juvenile localised scleroderma (jlSc) is an orphan dis-
ease. Most patient respond to treatment ot methotrexate or myco-
phenolate. In case of nonresponse or partial response, based on the
promising tocilizumab (TOC) data of adult systemic sclerosis studies,
TOC seems to be a promising option. There is no publication regard-
ing the effectiveness of tocilizumab in jLS.
Objectives: To assess the effectivity of TOC in jlSC patients, who had
nonresponse or partial response on conventional therapy.
Methods: Participants of the pediatric rheumatology email board
were asked, if they follow patients with jlSc, who are treated with
TOC. Clinical characteristics and the response to TOC was assessed.
Results: Six centers responded to the survey from the email board,
with around 800 participants, and reported 11 patients. The mean
age of the patients at disease onset was 5.5 years. Disease duration
at time of the initiation of TOC was 53.5. months (range 9 to 109). 5
patients had linear subtype, 3 of them with facial involvement, 2 of
them Parry Romberg and one of them coup de sabre. Three had
generalized subtype, 2 mixed subtype and 1 limited subtype/mor-
phea. Before starting TOC patients received 10/11 Methotrexate, 7/11
Mycophenolate, 1 abatacept and 1 anti-TNF therapy. Reason to start
TOC was in 9 patients increase in Localised Scleroderma Activity
Index[1] (mLoSSI). In two patients increased extracutaneous activity
was the indication, in one increased activity of arthritis and in the
other increased activity of the central nervous system involvement.
The mean duration of tocilizumab therapy was 14.75 months. 2 patients
received s.c. according the poly JIA dosing and all other i.v.. There were
different i.v doses applied, 5 of them 8 mg/kg every 4 weeks, one of
them 8 mg/kg every three weeks, 1 every two weeks and 1 patients re-
ceived 10 mg/kg every 3 weeks. 3/11 received TOC as monotherapy. 8/
11 as combination therapy, 6 of them with Methotrexate and one of
each with Mycophenolate or Tacrolimus. Therapy success was reflected
by a decreased mLoSSI in 8/11 patients and in 6 patients by a decrease
in the Localosed Scleroderma Skin Damage Index[1] (LoSDI). No new le-
sion occurred during the treatment and in the patients with Parry
Romerg subtype(n = 2) no increase in the facial atrophy occurred. In 8/8
patients physician global (VAS 0-100) decreased and in 8/8 the patients
global disease activity (VAS 0-100) decreased. In 3/3 patients, were it
was applicable, the number of active joints decreased, in one patientsthe limb discrepancy decreased. The mean modified Rodnan skin score
assessed in 8 patients decreased from the mean value of 9.6 to 5.5.
Conclusion: Conclusion:
In this small cohort of patients TOC seems to be a promising rescue
medication in methotrexate/mycophenolate nonresponsive patients.
A prospective controlled study would be important to prove the seen
effect in a controlled way.
1. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA, Jr.: Development
and initial validation of the localized scleroderma skin damage index
and physician global assessment of disease damage: a proof-of-
concept study. Rheumatology (Oxford) 2010, 49(2):373-381.
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Introduction: We have recently demonstrated that synovial fluids of
JIA patients contain elevated levels of proNGF, the immature form of
the Nerve Growth Factor (NGF), and not mature NGF as believed in
the past. Moreover, mononuclear cells of JIA patients show a reduced
expression of TrkA, the specific receptor of mature NGF, and an en-
hanced expression of p75NTR, the specific receptor for proNGF. This
results in an inverted ratio of TrkA and p75NTR in JIA patients com-
pared to healthy donors. How this altered proNGF/p75NTR axis can
influence the inflammatory response is at present unknown.
Objectives: In this study, we focused on the involvement of p75NTR
and its ligand proNGF in regulating inflammatory responses in the in-
flamed synovia and in synoviocytes of arthritis patients.
Methods: Fibroblast-like synoviocytes (FLS) were obtained by syn-
ovial tissue of rheumatoid arthritis patients (RA FLS) after enzymatic
digestion. Osteoarthritis fibroblasts (OF) and skin fibroblasts (SF) were
used as control. Using Realtime-PCR and western blot, we evaluated
TrkA, p75NTR, sortilin, NGF mRNA expression and protein levels.
Realtime-PCR and ELISA were used to evaluate cytokine production.
Results: Our preliminary data show that, similarly to JIA SFMC, p75NTR
is significantly upregulated in FLS of RA patients, while TrkA is much
less expressed than p75NTR. Instead, OF and SF showed a higher ex-
pression of TrkA than p75NTR. Moreover, FLS express NGF mRNA and
release high amounts of proNGF, but not of mature NGF, in the condi-
tioned media. Inflammatory stimuli, such as IL-1b, further upregulate
p75NTR expression in FLS and induce the expression of p75NTR in con-
trol fibroblasts. In vitro, the addition of proNGF to FLS induces the ex-
pression of pro-inflammatory cytokines. This effect is abolished when
p75NTR activity was inhibited using LM11A-31, a non-peptide ligand
that blocks the binding site of p75NTR for proNGF.
Conclusion: These preliminary data suggest that the proNGF found
in synovial fluids of chronic arthritis patients is produced and re-
leased principally by FLS. The accumulated proNGF binds to its
T2
Table 2 (abstract O16). See text for description
Arm 1 n
= 31
Arm 2
n = 32
Arm 3 n
= 29
3 vs 1 p
OR (CI)
2 vs 1 p
OR (CI)
3 vs 2 p
OR (CI)
ACRPEdi30(%)(CI) 92.2
(82,1-
102.4)
84.4
(71.2-
97.5)
96.6
(89.8-
103.3)
0.1 1.7
(0.8-3.4)
0.8
0.9(0.5-
1.7)
0.1 0.9-
3.7
ACRPedi50
(%)(CI)
85.5
(72.4-
98.6)
83.8
(70.1-
97.4)
93.1
(83.7-
102.4)
0.3
1.4(0.7-
2.8)
0.9
1.1(0.6-
2.0)
0.4
1.3(0.7-
2.7)
ACRPedi70
(%)(CI)
69.0
(52.1-
85.9)
68.8
(51.6-
85.9)
82.8
(68.8-
96.8)
0.07
1.8(1.0-
3.3)
0.7
0.9(0.4-
1.7)
0.03
2.1(1.1-
4.0)
Inactive disease
(%)
61.0
(39.7-
82.3)
63.1
(43.6-
82.7)
61.0
(40.9-
81.2)
0.9
1.0(0.7-
1.7)
0.1
0.7(0.4-
1.1)
0.09
1.5(0.9-
2.5)
JADAS-10 (CI) 2.6(1.4-
3.8)
4.0(2.2-
5.8)
3.0(1.6-
4.4)
0.6
0.6(0.1-
3.5)
0.2
3.1(0.5-
20.3)
0.09
0.2(0.03-
1.3)
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 9 of 191specific receptor p75NTR, which is highly expressed by both FLS and
SFMC, inducing pro-inflammatory cytokine expression. Inflammatory
stimuli further enhances the expression of p75NTR in FLS, creating a
vicious circle that amplify the inflammatory response. The use of
p75NTR inhibitors might represent a new therapeutic approach for
the treatment of JIA and RA.
Disclosure of Interest: None Declared.
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Introduction
The BeSt treatment strategy for children with juvenile idiopathic arth-
ritis (JIA) has not been determined as of today.
Objectives
The aim of the BeSt for Kids study was to investigate, which of three
treatment strategies is most effective and safe, by comparing them
directly. The therapeutic target in all arms was inactive disease by
rapid reduction of disease activity and repeated monitoring and revi-
sion of therapy in case of insufficient response. We hypothesized that
early treatment with etanercept and methotrexate (arm 3), compared
to initial monotherapy (arm 1) or initial combination therapy with
methotrexate and prednisone (arm 2), would lead to significantly
earlier clinical inactive disease.
Methods
We conducted a randomized, single blinded, multicenter, treatment
strategy study with 24 months of follow up. Disease modifying anti
rheumatic drug (DMARD)-naive JIA patients were randomized to 1.
sequential DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate
(MTX), 2. combination therapy: MTX and prednisolone-bridging, 3.
Combination-therapy MTX with etanercept. For all arms, the treat-
ment protocol described a number of subsequent treatment steps in
case medication failed. After reaching remission for 3 (oligoarticular)
or 6 months (polyarticular) medication was tapered and stopped as
dictated per protocol and flare frequency was observed. Missing data
were imputed. Primary outcome was time to inactive disease and
time to flare after tapering and stopping DMARD therapy, both calcu-
lated using Kaplan Meier method with log rank test. Secondary out-
comes are adjusted ACRPedi 30/50/70 scores, toxicity, functional
ability and quality of life. Generalised Estimating Equations were used
for longitudinal data analyses. In this abstract we share the first
24 months results.
Results: Ninety-four patients were randomised, 32 in arm 1, 32 in
arm 2 and 30 in arm 3. Two patients received a different diagnosis
during follow-up and were left out of all analysis. Two patient were
lost to follow up but were analysed due to intention to treat
principle. Overall baseline median (InterQuartileRange IQR) age was
9.1 (4.6-12.9) years. 37% were ANA positive, 11 patients had oligo-
articular disease, 66 patients polyarticular JIA and 15 patients juvenilepsoriatic (polyarticular) arthritis. Baseline median (IQR) ACRpedi-
scores: VAS physician 50 (39-58) mm, VAS patient 54 (37-70) mm,
ESR 6(2-14) mm/hr, active joint count 8 (5-12), limited joint count 2.5
(1-5), CHAQ score 0.9 (0.6-1.5). Inactive disease occurred overall after
mean 9.8 months (8.5-11.1). Time to inactive disease was not signifi-
cantly different in all three arms (log rank test p = 0.23). Outcome
measures after 24 months of therapy are summarised in the Table 2.
Conclusion: Although our study did not meet its primary end point,
treat-to-target treatment in this cohort of children with recent-onset
JIA resulted in high frequencies of clinical inactive disease and
adjusted ACRpedi30/50/70 scores in all three arms. In clinical trials
inactive disease seems a feasible goal in juvenile idiopathic arth-
ritis patients.
Trial registration identifying number: NTR1574
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Introduction: MRI studies on RA patients showed that subclinical
synovitis is often present in patients in clinical remission and is re-
sponsible for progression of joint damage. A high frequency of MRI-
detected inflammation in JIA patients with clinically inactive disease
was also reported. Due to the lack of longitudinal studies in JIA, it is
unclear whether this phenomenon entails a risk of progression of
joint damage and whether it should affect the therapeutic decisions.
Objectives: To assess the prevalence of subclinical synovitis as de-
tected by MRI in a cohort of JIA patients in clinical remission and to
evaluate its association with disease flare and structural damage
progression.
Methods: All JIA patients who met the Wallace criteria for clinical
remission and underwent contrast-enhanced MRI at the Study Unit
between 2007 and 2015 were included. MRIs were scored by two
independent readers according to the Outcome Measure in Arthritis
Clinical Trials (OMERACT) Rheumatoid Arthritis Scoring System (RAM-
RIS). Joint damage progression was assessed by conventional radiog-
raphy (CR) according to the adapted versions of the Sharp/van der
Heijde score and to the Childhood Arthritis Radiographic Score of
T3
Table 3 (abstract O18). Baseline characteristics analysed as predictors
of disability eight years after disease onset
Clinical Characteristics N CHAQ/HAQ
=0
CHAQ/HAQ
>0
OR
(95%CI)
p
Cumulative active joint
count
352 3 (1-6) 5 (2-9) 1.1 (1.0-
1.1)
0.001
Physician GA, VAS 210 1.0 (0.3-2.0) 2.0 (0.7-4.3) 2.5 (1.5-
4.0)
<
0.001
Symmetric wrist arthritis, n
(%)
351 28 (50.0) 28 (50.0) 2.5 (1.4-
4.5)
0.002
Symmetric finger arthritis,
n (%)*
351 20 (39.2) 31 (60.8) 4.2 (2.3-
7.8)
<
0.001
Symmetric ankle arthritis, n
(%)
351 50 (57.5) 37 (42.5) 1.9 (1.1-
3.1)
0.02
CHAQ- score at baseline 239 0.1 (0.0-0.9) 0.6 (0.0-1.4) 2.0 (1.4-
3.0)
0.001
Patient/parent GA, VAS 234 0.7 (0.0-2.3) 2.0 (1.0-4.0) 2.3 (1.5-
3.6)
<
0.001
Pain VAS 231 0.7 (0.0-2.3) 2.7 (1.0-5.0) 3.2 (2.0-
5.0)
<
0.001
Morning stiffness > 15 min,
n (%)
276 41 (41.4) 58 (58.6) 5.2 (3.0-
8.9)
<0.001
Values are the median (IQR) unless otherwise indicated; OR, odds ratio; CI,
confidence interval. * Symmetric finger arthritis: bilateral arthritis in 1 or more
of the 14 finger joints; GA, global assessment; VAS, visual analogue scale
range 0-10
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kappa statistics. Categorical data were analyzed using chi-squared
test and Fisher’s exact test. Comparison of quantitative variables was
performed by the non-parametric Mann–Whitney U-test. A logistic re-
gression model was applied to perform multivariate analysis of the
radiographic damage risk factors.
Results: A total of 90 patients (15 M, 75 F; mean age 13.8 years;
mean disease duration 8.5 years; mean follow-up duration 2.9 years)
were included. Fourteen out of 90 patients (15.6%) were in remission
off medication, while 76/90 patients (84.4%) were in remission on
medication. Forty-five patients were assessed by MRI in the wrist, 30
in the hips, 13 in the ankle and 2 in the knee. Fifty-seven patients
(63.3%) had evidence of subclinical synovitis on MRI. The inter-
observer agreement for presence/absence of synovitis was good (k =
0.74; 95% CI: 0.5-0.9). Forty-three out of 57 patients (75,4%) with sub-
clinical synovitis experienced a disease flare versus 11 out of 33 pa-
tients (33.3%) who hadn't any synovial inflammation (P < 0.0001).
Radiographic damage progression was assessed in 54/90 patients for
whom follow-up CRs were available and was detected in 19/54 pa-
tients (35.2%). A significant association between systemic JIA subtype
and deterioration of joint damage was found (P = 0.027, Fisher’s exact
test). MRI-detected bone marrow oedema (BMO) score and the base-
line radiographic damage score were also significantly related to
structural progression (P = 0.002, Mann–Whitney U-test). The multi-
variable logistic regression analysis showed that only baseline BMO
score ≥3 independently contributed to explain radiographic damage
progression (OR 4.82; 95% CI: 1.0-23.2; P = 0.035).
Conclusion: A sizeable proportion of patients in clinical remission
had MRI evidence of persistent joint inflammation. Subclinical syno-
vitis was significantly associated with disease flare, while BMO
showed remarkable promise in predicting joint destruction. These
findings support the utility of MRI for the assessment of JIA patients
in clinical remission and may have important clinical implications for
their management.
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Introduction: Baseline clinical predictors on long-term outcome, not
only regarding remission but also on functional ability, may enable
assessment of prognosis and guide early treatment decisions in ju-
venile idiopathic arthritis (JIA).
Objectives: To evaluate potential baseline clinical predictors of func-
tional ability assessed by the Childhood Health Assessment Question-
naire (CHAQ) eight years after disease onset.
Methods: Consecutive cases with newly diagnosed JIA from defined
geographical areas in Denmark, Finland, Sweden and Norway were
included and followed over eight years. Logistic regression was per-
formed to assess potential baseline predictors of disability in terms
of CHAQ (or HAQ for participants ≥18 years of age) score >0 at the
final study visit.Results: At follow-up 98 months (median, IQR 95-102) after disease
onset, CHAQ/HAQ was available in 352 (80%) of the total 440 partici-
pants. A CHAQ/HAQ score of 0 was found in 239 (68%) of these. The
following characteristics at the first study visit 7 months (median, IQR
6-8) predicted CHAQ/HAQ> 0 eight years after disease onset: higher
cumulative joint count, symmetric arthritis in wrists, fingers, or ankles,
higher score on physician and patient/parent global assessment of
disease activity, pain, CHAQ and morning stiffness (Table 3).
Conclusion: A higher cumulative joint count, and specifically sym-
metric arthritis in finger joints, morning stiffness and higher pain
score, higher patient/parent and physician global VAS score at base-
line, predicts functional disability eight years after disease onset in a
population-based Nordic JIA cohort.
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Introduction: Juvenile Idiopathic Arthritis (JIA) is a chronic inflamma-
tory disease that affects children and adolescents and shows many
differences in clinical manifestations, assessment and management
compared to adult-onset arthritis. The transition from the child-
centered to the adult-oriented care is a challenging multidimensional
process that emphasizes a lot of aspects that need to be addressed.
Objectives: To describe the long-term outcome of JIA.
Methods: Four-hundred and fifteen patients affected by JIA and re-
ferred to a transition care rheumatology tertiary centre were considered
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 11 of 191between 1999 and 2016. The outcome assessment included disease ac-
tivity, mean disease duration, medications, number of prosthesis im-
plantation, pregnancies, mortality, social integration (mobility,
employment status and educational level).
Results: A hundred and twenty (28.9%) males and 294 (71%) females
were included; 58 (14%) patients were lost to follow up. The median
age of the patients was 25 (18-57) years, the median age at onset
was 9 years and the average disease duration was 17 years. Subtypes
of JIA at disease onset included oligoarthritis 212 (51.2%), polyarthri-
tis 98 (23.6%), systemic arthritis 51 (12.3%), psoriatic arthritis 11
(2.7%), enthesitis related arthritis 41 (9.9%) and undifferentiated
arthritis 1 (0.2%). Seventy-one (17.1%) patients had persistent
uveitis. Eighty-five implant prosthesis and 15 arthrodesis were re-
corded. Sixty-eight patients (16.4%) were also referred to the
ultrasonography-guided infiltration clinic, to receive either intrarticular
steroids or hyaluronic acid. At follow up 180 (43.5%) had low active dis-
ease activity, 84 (20.3%) had moderate disease activity, 14 (3.4%) had a
high disease activity, 72 (17.4%) were on remission on medication and
64 (15.5%) off medication. Among the 350 patients still on medication,
75 (21.4%) were under treatment with oral steroids, 200 (57.1%) with
sDMARDs and 225 (64.3%) with bDMARDs. Five deaths (1.2%) occurred
in this cohort. A hundred and eighty-one (43.7%) subjects had a higher
educational level (university), 294 (71%) had an employment, 243
(58.7%) obtained a driving license. Twenty-one (5.1%) pregnancies were
registered. The transition age was considered after the age of sixteen
years old. Particular attention was brought to the multidisciplinary ap-
proach towards each patient, that was realized with the collaboration
of other specialists (ophthalmologist, orthopedic, dermatologist, gastro-
enterologist, obstetric and psychologist).
Conclusion: In the era of biologic therapy the long-term outcome of
JIA underwent an outstanding improvement regarding a lot of vari-
ables. Two hundred and twenty-five (54.3%) patients were still on
tight control, not only because of the continuation of the biological
therapy, but also owing to the multidisciplinary care carried out even
during remission. JIA often persists over the adulthood, therefore the
long term follow-up and care of these patients needs to be con-
ducted by a rheumatologist expertized in JIA in collaboration with
other specialists.
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Introduction: Currently all children with oligo and polyarticular JIA
have to be screened by ophthalmologists for years in order to ensure
that this completely asymptomatic disease is not missed. If missed or
inadequately treated, some 50% of these children can go functionally
blind. The only useful biological marker currently available is ANA
status. However this is neither sensitive nor specific enough to sig-
nificantly alter regular clinical screening. It does however suggest
that autoantibodies, as yet undiscovered, may be important in the
pathophysiology of this disease.
We undertook this proof of concept study to see whether a novel
technique capable of producing multiple proteins could be used to
screen for autoantibodies that are associated with uveitis develop-
ment in JIA patients. This could enable us to identify children, at the
time of diagnosis of arthritis, who are highly likely to develop uveitis.
Objectives: To Identify novel antibodies that predict the develop-
ment of uveitis in children with JIA.Methods: Nucleic Acid Programmable Protein Arrays (NAPPA) enable
the in situ production of multiple proteins from DNA templates which
are immobilised on a solid phase. Methodology is described in detail
elsewhere [1]. NAPPA slides with 2200 genes were produced.
Pubmed search identified ~60 genes associated with uveitis path-
ology and ~30 genes associated with arthritis development. The
remaining ~2100 genes were randomly identified from a ~12000 hu-
man gene collection (http://dnasu.asu.edu). The arrays were then
probed using plasma from JIA patients with (n = 20) and without
uveitis (n = 20) and from healthy age and sex matched controls (n =
20). Proteins with higher levels of antibody detected were confirmed
by ELISA.
Results: NAPPA image analysis revealed distinct signals from plasma
antibodies of JIA patients with Uveitis which had reacted with spe-
cific array proteins. Hierarchical clustering heat maps were used to
visualize clusters of proteins with higher array reactivity for JIA or
Uveitis samples, realtive to controls. ELISA's were developed for nine
highly reactive proteins including BATF, FO5, PROSAPIP1, CCND1,
NOUFV3 and SSB. Antibodies specific for single-stranded DNA-
binding proteins (SSB) were confirmed to be at significantly higher
concentrations in the plasma of JIA patients with uveitis, relative to
JIA patients without eye disease.
Conclusion: These results indicate that the NAPPA technique is a
sensitive tool for screening antigens including specific nuclear anti-
gens which distinguish JIA patients with uveitis. We plan on develop-
ing a nuclear antigen array with over 2000 features to determine
further uveitis patient reactivity. Prospective studies are also required
to establish if these immunoglubulins are present at detectable levels
in JIA patients prior to development of uveitis and to assess their
predictive utility.
Reference
[1]: Bian, X., Wiktor, P., Kahn, P., Brunner, A., Khela, A., Karthikeyan, K., Barker,
K., Yu, X., Magee, M., Wasserfall, C. H., Gibson, D., Rooney, M. E., Qiu, J.,
and LaBaer, J. (2015) Antiviral antibody profiling by high-density protein
arrays. Proteomics 15, 2136–2145
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Introduction: Biological agents (BA), especially TNF inhibitors, are
high efficacy options for current therapy for patients (pts) with juven-
ile idiopathic arthritis (JIA). They are successfully used not only for
the arthritis but also for JIA-associated uveitis, however, development
of uveitis de novo in pts treated with BA is a well-established para-
doxical adverse event.
Objectives: to evaluate the frequency of new onset (no-) uveitis, oc-
curring under BA therapy in JIA pts, to establish clinical features,
which may be associated with development of such phenomenone.
Methods: retrospective cohort study involved all JIA pts (760) who
were treated with BA in our clinic from 2004 to 2017. All cases of no-
uveitis were collected for the describing of their clinical features in
disease onset and course, activity level, JIA category, exposure to
Methotrexate (MTX) and BA, presence of ANA, HLA B27.
Results: among of 760 pts treated with different BA we identified 22
(2.9%) pts (12 female/10 male) with no-uveitis under BA, mostly dur-
ing etanercept (ETA) therapy (22 cases from 302 ETA courses, 6.6%),
1/120 - in abatacept (ABA) and 1/249 - in adalimumab (ADA). There
are no cases of no-uveitis under other BA Frequency of no-uveitis is
much higher in ETA group (2.46 events per 100 patient-year (PY) vs
T4
Table 4 (Abstract O22). Microparticles (MPs) levels in AAV patients with
active or inactive disease and healthy controls
Active AAV Inactive AAV Healthy
controls
p-value
(respectively)
median IQR median IQR median IQR
Tissue factor 265 247 174 107 105 84,5 p < 0.01* p <
0.001**
NETs 112 24 103 18 44 35 p < 0.05* p <
0.0001** p <
0.001***
Pentraxin3 1332 1810 347 294,5 184 146,5 p < 0.01* p <
0.0001** ns***
HMGB1 684 452,5 380 258 77 61,5 p < 0.01* p <
0.001** p <
0.001***
TWEAK 131 83 141 102,5 67 53 ns* p < 0.0001**
p < 0.05***
Plasminogen 86 23 89 23 44 33,5 ns* p < 0.001** p
< 0.01***
C3a 201 91 147 87 89 72 ns* p < 0.001** p
< 0.05***
C5a 131 86,5 111 65 51 30 ns* p < 0.001** p
< 0.01***
*between active and inactive, ** between active and controls, ***between
inactive and controls
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(mo).. A case of no-uveitis under ABA was observed after 5 mo of
therapy in a girl previously treated with infliximab. 1 boy with early
JIA onset (in age of 18 mo) developed no-uveitis after 71 mo of ADA
71 mo simultaneously with general response decreasing and success-
fully switched to ABA. JIA subtypes were as follows: RF-neg polyar-
thritis 6 (27%), persistent oligoarthritis 3 (14%), extended
oligoarthritis 11 (50%), enthesitis-related arthritis (ERA) - 2 (9%). Aver-
age age at JIA onset was 4.5 ± 3.9 yrs. 19/22 patients had high la-
boratory activity (CRP 54 ± 23 mg/l; ESR 41 ± 19 mm/h) and severe
arthritis before BA initiation. However most of pts (18/22) achieved
90-100% ACRpedi-response by the uveitis development. 14/22 pts
were ANA-positive, 11/22 pts had HLAB27, including 3 pts who had
the both features. Uveitis was occurred earlier in ANA plus HLAB27
positive pts (mean exposure - 10.7 mo) than in only ANA-positive or
HLAB27-positive pts (27.4 mo and 21.6 mo accordingly). 19/22 (86%)
of pts received methotrexate (MTX) in mean dosage 11.5 mg/m2/
week. There are no differences in time of uveitis development de-
pending of MTX. In all cases of no-uveitis BA was switched.
Conclusion: Our study suggested that new onset of uveitis is rare ad-
verse event during BA therapy in JIA without any known predispos-
ing risk factors.. Such paradoxical effects may reflect not so much
therapy complications, but the delayed implication of natural charac-
ter of disease. Development of no- uveitis is more often observed in
pts receiving ETA, especially in pts with early age of JIA onset. High
activity aggressive manifestations at the disease onset and good ini-
tial response to BA are typical features for all pts, who developed this
paradoxical effect under BA therapy.
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Introduction: Microparticles (MPs) are irregularly shaped submicron
vesicles, which are released from plasma membrane upon cell activa-
tion and during the early phase of apoptosis. Increased levels of circu-
lating MPs (mainly of endothelial cell origin, but also platelet derived)
correlates with autoinflammatory disease activity, such as anti-
neutrophil cytoplasm antibody (ANCA) – associated vasculitis (AAV).
Objectives: To evaluate levels of activity markers expressed on sur-
face of MPs, during active disease and remission, compared to
healthy control subjects.
Methods: Our study included 48 AAV patients (24 with active and 24
with inactive disease) and 23 healthy control subjects (age and gen-
der matched). We analyzed the number and phenotype of MPs in
plasma identified by flow cytometry, via labeling with following
monoclonal antibodies: CD142 (tissue factor-TF), anti-H3cit (citruli-
nated H3 directed against neutrophil extracellular traps-NETs), anti-
pentraxin3 (pentraxin3), HMGB1 (high mobility group box 1 protein-
HMGB1), anti-TWEAK (tumor necrosis factor-like weak inducer of
apoptosis-TWEAK), anti-plasminogen (plasminogen), anti-C3a (C3a)
and anti-C5a (C5a). The assessment of vasculitis disease activity was
performed using the Birmingham Vasculitis Activity Score (BVAS),
while active disease was defined as BVAS ≥1 and inactive (remission)
as BVAS = 0. Statistical analysis was performed using GraphPed
software.
Results: Half of the patients group (24) had active vasculitis (mean
BVAS 6,69 ± 8,76) and 24 had inactive disease. Plasma levels of MPs
expressing TF, NETs, pentraxin3 and HMGB1 in active patients were
significantly higher than in those in remission and healthy controls
(p < 0.01, p < 0.0001, respectively). MPs expressing C5a and C3a
were significantly higher in both patients groups compared to controls
(p < 0.001). Additionally, levels of MPs expressing C5a stronglycorrelated with BVAS (r = 0.78, p < 0.0001), while there was no signifi-
cant correlation between other explored markers and BVAS. Data pre-
sented in Table 4.
Conclusion: Our results support recently postulated potential role of
complement system in AAV pathogenesis and disease activity. Evalu-
ated proteins expressed on MPs, especially C5a, could be used as po-
tential biomarkers which might reflect inflammation and disease
activity in AAV patients. Further investigations are necessary to con-
firm our preliminary results and to validate the most promising bio-
marker in AAV.
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Introduction: The endothelial protein Plasmalemma Vesicle-associated
protein 1 (PV-1) is the main component of stomatal and fenestral dia-
phragms of blood vessels. It regulates permeability, leukocyte migration
and angiogenesis [1]. Considering the central role of the endothelium
in vasculitis pathogenesis and the lack ofspecific biomarkersfor the clin-
ical diagnosis and management of this group of complex disorders, we
have investigated the levels of PV-1 among children with vasculitis and
their association with disease activity or remission.
Objectives: To determine, for the first time, serum levels of endothe-
lial protein PV-1 in a population of patients with vasculitis and
healthy controls and possibly to assess the role of PV-1 to serve as a
diagnostic biomarker in vasculitis disorders in childhood and/or to
monitor disease activity and severity.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 13 of 191Methods: A case-control matched for age study was conducted includ-
ing 62 healthy young people and 35 children with active vasculitis and
other inflammatory diseases with vascular involvement: 18 patients
with Pediatric Systemic Lupus Erythematosus (pSLE), 9 with Juvenile
Dermatomyositis (JDM), 2 with Kawasaki Disease, 2 with leukocytoclas-
tic vasculitis, 2 glomerulonephritis, 1 Central Nervous System Vasculitis,
1 Henoch-Schönlein Purpura (HSP). PV-1 serum levels were also mea-
sured in 9 children in clinical remission (2 SLE, 2 JDM, 3 HSP, 1 Kawasaki
disease, 1 Hughes-Stovin Syndrome). Measurement of PV-1in blood
serum (expressed in ng/ml) was performed using ELISA assay following
the manufacturer’s (Biomatik) instructions.
Results: Patients with active disease showed significantly higher con-
centrations of PV-1 than healthy controls (p < 0.001) and patients
with inactive disease (p < 0.001) (Table 5). Optimal serum PV-1 cut-off
to identify patients with active vasculitis was found to be 0.78 ng/ml,
which achieved on receiver operating characteristic (ROC) curve ana-
lyses an accuracy of 0.90, with 74% sensitivity and 92% specificity.
Different diseases did not show significant differences regarding
levels of PV-1.
Conclusion: PV-1 could represent a specific marker of disease activity
in vasculitis disorders in childhood.
1. Guo L, Zhang H, Hou Y, et al. Plasmalemma vesicle–associated pro-
tein: A crucial component of vascular homeostasis (Review). Exp Ther
Med 2016; 12:1639–44.
Disclosure of Interest: None Declared.Table 5 (abstract O23). See text for description
Patients Controls N = 62 Acute Vasculitis
N = 35
Remission vasculitis
N = 9
PV – 1 (ng/ml) Median
(interquartile range)
0.221 (0.082 –
0.436)
1.818 (0.746–
3.970)
0.316 (0.203 –
0.606)
p value < 0.001 < 0.001O24
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Introduction: Takayasu arteritis (TAK) is an idiopathic large-vessel
vasculitis affecting the aorta and its major branches. Although the
disease rarely affects children, it does occur, even in infants. The un-
treated inflammation often leads to narrowing or ectasias of aorta
and its direct branches with or without pulmonary and coronary in-
volvement. It’s a rare medical condition but we in our tertiary care
center have collected the second largest single center series of pa-
tients over the past 16 years.
Objectives: To evaluate the clinical features, disease activity, treat-
ment and outcome of childhood TAK in a tertiary center in South
India
Methods: We analyzed a retrospective case series of children fulfill-
ing the TAK classification criteria of the European League against
Rheumatism and the Paediatric Rheumatology European Society.
Data has been collected in a retrospective manner from our insti-
tute’s electronic medical records (EMR) for childhood onset TAK. Data
regarding demographics, clinical features, treatments, and outcomes
were recorded. Baseline data including age, gender, disease duration,
angiographic type, the extent of clinical disease using DEI.Tak, CRP,and ESR were collected. Disease activity was assessed by a composite
clinical score namely ITAS-A (CRP). At each visit, active disease was
defined as
1. Clinical activity by the presence of any one of the following:
1a. ITAS ≥ 2 (not attributable by in-stent restenosis) or
1b. ITAS-A (CRP) ≥ 3, but at least one point should be contributed by
clinical criteria as in ITAS proforma
2. Activity by imaging by presence of de Novo lesion on follow-up
angiography or stenosis of the same vessel extending beyond stent
margins
3. Laboratory criteria of activity were defined by persistently raised
CRP as well as ESR on 2 consecutive visits without any alternative ex-
planation like infection
Results: 100 children with juvenile-onset TAK were included in this
study over the past 16 years. Out of 100 children with TAK, 30 were
male and 70 were female. Median age at onset was 14 years and
mean duration of delay in diagnosis was 7 months (4-24 months).
The most common clinical features at presentation were pulse abnor-
mality (67%) followed by arterial hypertension (62%), claudication
(40%) and systemic symptoms like fever and fatigue (36%).
Past, present history of tuberculosis or tuberculosis after treatment
was seen in 6 patients while 2 patients had been treated empirically
for TB. At presentation, median ITAS 2010 score was 9 (4-15), DEI. Tak
was 9 (6-13) and TADS was 7 (4-11).
The full angiographic profile was performed for 97 patients. Rest of
the patients had limited area imaging. Type 5 was the commonest
followed by type 4 and type 1. Aneurysms or ectasias with or without
stenosis seen in 7 patients
Treatment included corticosteroids (85%), combined with MMF in
most cases (51), azathioprine(15), methotrexate (9) and tocilizumab
(5) were reserved for severe and/or refractory cases. Mean follow-up
duration was 33 months (12-61). Delta TADS calculated in 75 patients
was 0 (0-1) and last visit ITAS and ITAS-A CRP was 0 (0-1). Disease
course was persistently stable in 39, relapsing in 16, persistent active
in 5 children. 1 child expired during follow-up.
Conclusion: Improved awareness of TAK is essential to secure a
timely diagnosis. The initial symptoms and signs are non-specific,
and a high index of suspicion is needed if the diagnosis is to be
made. The investigation and management of Takayasu’s disease can
prove difficult.
Disclosure of Interest: None Declared.
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Introduction: Macrophage activation syndrome (MAS) is a life-
threatening complication of systemic juvenile idiopathic arthritis
(SJIA), characterized by activation and expansion of cytolytic lympho-
cytes and macrophages with hemophagocytic properties. Recent
work by us and others has shown that emergence of MAS is associ-
ated with a surge in IFN-gamma and IFN-induced chemokines; how-
ever, previous gene expression studies failed to demonstrate this
IFN-induced signature in peripheral blood cells. However, prior stud-
ies in SJIA and MAS have been limited by a failure to examine key
myeloid effector cells, specifically activated macrophages or histio-
cytes which traffic to tissue including bone marrow during MAS.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 14 of 191Objectives: Utilize single-cell RNA-sequencing to identify specific
gene expression signatures of bone marrow macrophage populations
in SJIA and MAS.
Methods: Cell sources include unused portions of bone marrow aspirates
obtained as part of a diagnostic workup and interpreted as normal were
obtained from the Cincinnati Children’s Hospital Immunopathology lab,
as well as cells obtained from a bone marrow biopsy from a newly diag-
nosed SJIA patient. Macrophage single cell suspensions were obtained
using cell sorting for populations expressing the monocyte and macro-
phage surface markers CD14 and CD163 while excluding cells expression
the granulocyte/monocyte marker CD15, prior to loading onto the Flui-
digm C1 Single-Cell Auto Prep System. Extracted RNA was converted into
cDNA and sequenced as a pooled library, and aligned to the human
Ensembl transcriptome using Kallisto through AltAnalyze version 2.1.1.
Results: Three independent control samples yielded 180 single cells
which passed quality-control filtering. While there was substantial inter-
individual variability, using principle component analysis and Iterative
Clustering and Guide-gene Selection, a core set of approximately 1400
genes were identified that contributed to the heterogeneity of normal
bone marrow macrophage population. Control macrophages formed at
least three primary cellular clusters, which were distinguished based on
expression of genes associated with inflammatory responses, GM-CSF sig-
naling, and aurora B signaling. 61 single bone marrow macrophages were
captured from a patient with newly diagnosed SJIA with active systemic
features, arthritis, marked anemia and relative thrombocytopenia, but
lacking other overt signs of MAS, who underwent bone marrow biopsy
as part of the diagnostic evaluation. Expression profiles were broadly
similar to control macrophages by PCA, and all macrophage clusters were
represented. However, a distinct subpopulation of bone marrow macro-
phages from the SJIA patient was identified that exhibited markedly
altered transcriptional profiles. Compared to other macrophages within
the cluster, this SJIA macrophage population showed alterations in
gene pathways including cellular response to interferon gamma
(adjusted p = 1.35e-14), endocytic vesicle membranes (p = 8.44E-14),
phagosome (p = 2.98e-9) and vesicle-mediated transport (p = 1.05E-07).
These cells showed a proinflammatory gene expression signature, in-
cluding significant enrichment for genes regulated by NF-kB and STAT1.
This included S100A12, which is highly expressed in patients with SJIA
and MAS and was markedly elevated in serum from this patient.
Conclusion: We identify a distinct subpopulation of bone marrow
macrophages in an SJIA patient with features associated with emer-
gence of MAS, including interferon response, phagocytosis and ves-
icular transport. This demonstrates the importance of studying these
effector cells at the sites of inflammation, and suggests that tissue
macrophages may be a key source of IFN-induced products during
MAS. Together, these data show that single cell gene expression pro-
filing of bone marrow macrophages can identify reproducible cellular
clusters as well as potential biologically relevant subpopulations and
pathways perturbed during inflammatory disorders.
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Pediatric Rheumatology 2017, 15(Suppl 2):O26Introduction: Pharmachild is a pharmacovigilance registry on chil-
dren with JIA treated mainly with biologics ±methotrexate (MTX). Lit-
tle evidence exists in literature about the role of JIA or its
immunosuppressive therapy in determining infections, especially
caused by opportunistic pathogens.
Objectives: To provide an update on opportunistic infections (OI) re-
vised by an independent Safety Adjudication Committee (SAC) (3
pediatric rheumatologists and 2 pediatric infectious disease
specialists).
Methods: The participating centres were asked to report all infec-
tions encountered by their JIA patients. PRINTO and the medical
monitor (MM) classified events based on MedDRA dictionary. Moder-
ate/serious/severe/very severe infections were then revised blindly
by the SAC, who were asked to answer 6 questions. The events with
consensus of at least 3/5 experts on the first 3 questions (‘Is this an
infection?’, ‘Is it common?’, ’Is it opportunistic?’) were retained for the
analysis. With referral to the recommendations by Withrop et al.1, for
the first time a list of opportunistic infections in children with JIA on
immunosuppressive therapy was elaborated and approved by con-
sensus, through three Delphi steps.
Results: A total of 772 safety events related to 634 patients were
submitted to the Safety Adjudication Committee. 689 (89.2%) events
received consensus among the experts on the 3 questions and, of
these, 682 (99.0%) were considered as infections, corresponding to
53 High Level Term (HLT) including 153 different Preferred Terms
(PT), according to MedDRA dictionary. Among the 682 infections, 603
(88.4%) were defined by the experts as common and 119 (17.4%) as
opportunistic. For 92 (60%) of the 153 PT, the MM and SAC used the
same PT, while the remaining 40% was adjudicated by a third exam-
iner, who analyzed again the case reports and assigned the PT which
was the most appropriate taking into account the experts’ opinion. A
final number of 52 HLT emerged and, among them, herpes viral in-
fections, tract respiratory infections and EBV were the most frequent
(Table 6). Analyzing the infections by PT, 151 different PT resulted. Of
them, the experts adjudicated: 22 as OI, 117 as not OI, 8 discordant
and 4 not evaluable. Comparing the experts’ adjudication with the
approved list of OI by PT, there was full agreement for the 22 PT clas-
sified as OI, while 26/117 (22.2%) PT resulted in the list, but were not
classified as OI by the experts.
Conclusion: Our preliminary analysis showed a significant number of
opportunistic infections in JIA patients on immunosuppressive ther-
apy, which was mostly confirmed in the list of opportunistic infec-
tions approved by the experts. Further analysis on the correlation
with medications is ongoing.
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with agreement of at least 3/5 experts on the first 3 questions.
(N: number of infections)
HLT N %
Herpes viral infections 265 38.9
Lower and upper respiratory tract and lung infections 93 13.6
Epstein-Barr viral infections 38 5.6
Abdominal and gastrointestinal infections 32 4.7
Tuberculous infections 29 4.3
Candida infections 17 2.5
Influenza viral infections 14 2.1
Streptococcal infections 14 2.1
Salmonella infections 9 1.3O27
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Introduction: Whole-body magnetic resonance imaging (WBMRI) is a
fast and accurate method to detect diseases throughout the entire
body without exposure to ionizing radiation. Possible emerging
applications for this technique include rheumatologic field and evalu-
ation of fever of unknown origin (FUO).
Objectives: To evaluate the ability of WBMRI to identify significant
potential diagnostic clue(PDC) in patients presenting a non specific
inflammatory clinical picture.
Methods: We retrospectively collected cases of pediatric patients
followed in a single pediatric rheumatology center who underwent
WBMRI between January 2010 and December 2015 for the following
indications: i) FUO(temperature greater than 38.3 °C for more than
three weeks or failure to reach diagnosis after one week of investiga-
tions), iii) recurrent fever, iii) persistent low grade fever with evidence
of elevation of acute phase reactants and/or other clinical symp-
toms.WBMRI studies were acquired with coronal and sagittal planes
(slice thickness 5 mm) with acquisition of several image sets with
automatic direct image realignment after acquisition creating a
whole-body scan.Sequences include short τ inversion recovery (STIR)
and T1-weighted. All studies have been evaluated twice, the second
time according to a predefined checklist, defined by an experienced
radiologist, considering systematically single/multifocal bone lesion,
bone marrow, joint effusion, soft tissues, adenopathies, parenchymal
and vessels looking for PDC.
Results: We collected 105 patients who underwent WBMRI; 24 (23%)
of them presenting FUO, 29 (28%) presenting recurrent fever and 52
(49%) presenting persistent low grade fever.The mean age of onset
symptoms was 7 years and seven months (range: 2 weeks old-
17 years and 6 months). The mean age of execution of WBMRI was
9 years (range: 5 months old- 19 years and one month). After the
whole diagnostic work-out a final diagnosis was achieved in 34 pa-
tients (32%).
PDCs were identified at the first evaluation in 72/105 cases (68.5%) and
in 29/105 cases (39%)the identified PDC was useful to the achievementof the diagnosis (7 JIA, 8 systemic infections, 4 monogenic inflamma-
tory diseases, 3 ALPS, 2 Goldbloom’s Syndrome,2 Vasculitis,1 eosino-
philic fasciitis, 1 hystiocytosis, 1 neuroblastoma).
Blind re-evaluation of WBMRI allowed the identification of additional
PDCs in 51 patients (14 of them previously negative).In 8 cases the
PDC found after re-evaluation were consistent with the final diagno-
sis (2 JIA, 2 infectious diseases,,1 neuroblastoma, 1 ALPS, 1 mono-
genic inflammatory disease, 1Takayasu arteritis).
Conclusion: WBMRI can be a powerful diagnostic tool in patients
with FUO. A predefined checklist increase sensitivity of WBMRI in the
identification of PDC.
Disclosure of Interest: None Declared.
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Introduction: Low back pain (LBP) is a common complaint in adults
that often begins in childhood. Despite the increasing frequency, it is
estimated only 24% of children with LBP visit a doctor. Nevertheless,
those patients are often seen in pediatric rheumatology clinic. Al-
though most of the LBP cases after exclusion of trauma are caused
by benign musculoskeletal disease, a history of sacroiliac (SI) joint
tenderness and/or inflammatory lumbosacral (LS) pain is one of the
ILAR classification criteria for enthesitis related arthritis (ErA), a form
of juvenile idiopathic arthritis (JIA) that includes most of the patients
with juvenile spondyloarthritis (jSpA). Recognition of jSpA particularly
early in the course of the disease represents a unique set of chal-
lenges and therefore all of the patients with inflammatory back pain
(IBP) and arthritis or enthesitis should be suspected for jSpA with
possible involvement of SI and other vertebral joints. Since magnetic
resonance imaging (MRI) is the preferred method of assessment both
for axial inflammation and other possible musculoskeletal, infectious
and malignant causes of LBP in children, it might be advisable to use
it in the initial assessment of suspected IBP in children.
Objectives: To evaluate the usefulness of early MRI in discovering in-
flammation of spinal joints and other possible causes of LBP in chil-
dren with suspected IBP not fulfilling ILAR classification criteria for
ErA at the time of investigation.
Methods: Thirty five children referred to our pediatric rheumatology
clinic due to LBP lasting for more than three months, who meet
ASAS criteria for IBP and had SI joint tenderness and positive FABRE
test on physical examination, participated in the study. Their average
age was 14.2 years (6-18) and 11 (31.4%) of them were boys. Five
study participants (14.3%) had arthritis and 19 (54.3%) had enthesitis
confirmed by physical examination and ultrasound, but none of
them meet ILAR criteria for ErA at the time. Twelve (out of 15) were
HLA-B27 positive and 13 (37.1%) had a history of SpA related disease
in a first degree relative. One of the patients had a diagnosis of ul-
cerative colitis (UC), and one of psoriasis. All of the participants had
normal CBC and CRP values, with negative ANA and RF. None had
neurological symptoms. Contrast enhanced MRI of SI joints and
thoracolumbar spine was performed according to recommended
protocols for the assesment of inflammatory changes within one
week after initial visit on a 1.5 T machine and interpreted by experi-
enced musculoskeletal radiologist.
Results: Nineteen (54,3%) patients had various pathological findings
detected by MRI. Four (11,4%) had signs of inflammation with one
having an active sacroiliitis according to ASAS criteria. Schmorl nodes
were discovered in six patients and three of them, including one
with the signs of inflammation, had Scheuermann disease. Two
patients had stress reaction in LS region. Five patients had incipient
degeneration of intervertebral discs. Three patients had disc protru-
sion without and one with radial nerve compression. After three
Table 7 (Abstract O29). Efficacy results and summary of safety
PBO N
= 35
CAN 150 mg
q4w N = 37
p-value
Proportion of responders at Wk 16
(E2), n (%)
2 (5.7) 13 (35.1) <0.002*
Proportion of patients with no new
flare at Wk 40 (E3), n (%)
PBO N
= 7
CAN 150 mg
q8w N = 6
p-value
1 (14.3) 3 (50.0) 0.2168
Safety
PBO N
= 35
Any CAN*, E2
N = 68
Any CAN*, E2
+ E3 N = 71
Exposure to CAN, pyr 3.2 19.1 51.0
Number of AEs (AE rate/100 pyr) 59
(1818.5)
251 (1313.6) 613 (1201.2)
Number of SAEs (SAE rate/100 pyr) 4
(123.3)
11 (57.6) 20 (39.2)
*Indicates statistical significance (one-sided) at the 0.025 level. #Any patient
who received a dose of CAN during E2 or E3
n = number of patients who responded; N = number of patients evaluated for
response. AE, adverse event; CAN, canakinumab; E, epoch; PBO, placebo; q4w,
every 4 weeks pyr, patient-years; SAE, serious AE ; Wk, week
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 16 of 191months of follow up, 19 patients (54.3%) meet ILAR criteria for ErA,
one for psoriatic arthritis and one, who also had UC, meet criteria for
undifferentiated arthritis.
Conclusion: Differential diagnosis of LBP in children is very wide and
it is difficult to distinguish inflammatory and other causes upon the
first encounter with pediatric rheumatologist based on history and
physical examination alone. In our study, all of the patients with LBP
had some characteristics of IBP and ErA, while definite diagnosis of
jSpA was subsequently established in almost 60% of the patients.
Interestingly, 20% of them already had inflammatory changes of LS
and SI joints discovered by MRI, while many others had signs of
other LBP causes. Therefore, MRI performed early after referral to
pediatric rheumatologist, in all children with suspected IBP, can be
very useful in elucidating the cause of LBP and differentiation of
those who need only symptomatic relief, orthopedic consultation or
further follow up in pediatric rheumatology clinic. High cost of this
approach can be justified with the benefit of early therapeutic inter-
vention in those with established axial inflammation and the avoid-
ance of unnecessary treatment in those with other causes.
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Introduction: Canakinumab (CAN), a fully human, specific, anti-
interleukin-1β monoclonal antibody, has been shown to be effica-
cious in reducing the frequency of flares and improving clinical
symptoms in patients (pts) with hyper immunoglobulin D syndrome/
mevalonate kinase deficiency (HIDS/MKD)1.
Objectives: Primary objective was to demonstrate that CAN 150 mg
every 4 weeks (q4w) was superior to placebo (PBO) in resolving flare
by Day 15 with no new flares over 16 weeks (wks). Secondary objec-
tives included: proportion of pts who maintained optimal control of
disease activity (absence of new flares) between Wk 16 and Wk 40
after dose prolongation; evaluation of pharmacokinetics (PK),
pharmacodynamics (PD) and safety of CAN in the HIDS/MKD pts.
Methods: The study comprised 4 epochs (E1-4): The study design
has been reported earlier2. In E2, HIDS/MKD pts were randomised
(1:1) to CAN 150 mg every 4 wks (q4w) or PBO. Pts who did not flare
in E2 in the CAN group were rerandomised to CAN 150 mg q8w or
PBO/CAN withdrawal in E3. In E3, dose could be escalated up to
300 mg q4w for pts with a flare. For PK/PD assessments, CAN con-
centrations and total IL1β at baseline (Day 1), and trough concentra-
tions at Wk 16 were assessed. Safety assessments included adverse
events (AEs) and serious AEs (SAEs).Results: Of the 72 HIDS/MKD pts randomised to CAN 150 mg
q4w (n = 37) or PBO (n = 35) in E2, 3 discontinued the study (2 PBO, 1
CAN). The proportion of responders at Wk 16 was significantly higher
with CAN vs PBO (`). In E3, 13 (CAN E2 responders) were re-randomised
to CAN 150 mg q8w or PBO while 53 pts completing E2 received open-
label CAN treatment. In E3, the proportion of pts who did not present
new flares was numerically higher in the CAN vs PBO group (Table 7).
22.7% of the HIDS/MKD pts, including pts treated in open-label main-
tained disease control with a prolonged dosing interval (q8w) till Wk
40. 22.7% required uptitration back to original dose 150 mg q4w while
28.8% pts required uptitration to 300 mg q4w. No new safety findings
or deaths were reported in CAN treated pts through E3 (Table 7). The
serum clearance and steady state volume of distribution of CAN (liquid
in vial) varied according to body weight, and were estimated to be
0.14 ± 0.04 L/day and 4.96 ± 1.35 L, respectively. The estimated half-life
of CAN was 25 ± 6.4 days. Total IL-1β serum concentrations showed
dose proportional increase.
Conclusion: CAN (150 mg q4w) was efficacious in resolving flare by
Day 15 and preventing new flares in HIDS/MKD patients over
16 weeks. Approximately 23% pts did not flare with a prolonged
dose interval (q8w) at the end of E3 compared to 14% pts who did
not flare when CAN was completely withdrawn. No new safety issues
were reported over 40 weeks of treatment; the safety profile was not
distinct from previous controlled studies. The PK/PD results observed
with the liquid-in-vial form of CAN were similar to those observed in
CAPS and SJIA.
1. Arostegui JI, et al Arthritis Rheumatol. 2015;67(S10). 2. De Benedetti
F, et al. Ann Rheum Dis. 2016;75(Suppl2):615.
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Table 8 (Abstract O30). Efficacy and summary of safety
CAN 150 mg
q4w N = 22
PBO N = 24 p-value
Proportion of responders at Wk
16 (E2), n(%)
10 (45.5) 2 (8.3) 0.005*
Proportion of patients with no
new flare at Wk 40 (E3), n(%)
CAN 150 mg
q8w N = 4
PBO N = 5 p-value
3 (75.0) 2 (40.0) 0.3571
Safety
PBO (N = 24) Any CAN*,
E2 (N = 43)
Any CAN*, E2
+ E3 (N = 61)
Exposure to CAN, pyr 2.0 12.1 39.2
Number of AEs (AE rate/100 pyr) 34 (1698.8) 112 (925.7) 265 (676.2)
Number of SAEs (SAE rate/100
pyr)
1 (50.0) 3 (24.8) 5 (12.8)
*Indicates statistical significance (one-sided) at the 0.025 level. #Any patient
who received a dose of CAN during E2 or 3.
n = number of patients who responded; N = number of patients evaluated for
response. AE, adverse event; CAN, canakinumab; E, epoch; PBO, placebo; q4w,
every 4 weeks pyr, patient-years; SAE, serious adverse event; W, week
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 17 of 191O30
Efficacy, safety, pharmacokinetics and pharmacodynamics of
Canakinumab in patients with traps: results from the pivotal phase
3 cluster trial
Marco Gattorno1, Ryoki Hara2, Anna Shcherbina3, Laura Obici4,
Segundo Bujan5, Gerd Hoerneff6, Anette Jansson7, Riva Brik8,
Itzhak Rosner9, Alberto Tomassini10, Yankun Gong11, Eleni Vritzali12,
Guido Junge12, Fabrizio De Benedetti13, Helen Lachmann14
1Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy; 2Yokohama
City University, Yokohama, Japan; 3Clinical immunology Department,
Center of Children's Hematology n.a. D. Rogachev, Moscow, Russian
Federation; 4Amyloidosis Research and Treatment Centre, Biotechnology
Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia,
Italy; 5Vall d'Hebron Hospital, Barcelona, Spain; 6Asklepios Clinic, Sankt
Augustin, Munich, Germany; 7Department of Rheumatology &
Immunology, Dr. von Hauner Childrens Hospital, Ludwig-Maximilians-
University, Munich, Germany; 8Meyer Children's Hospital, Rambam
Medical Center, Haifa, Israel; 9Rheumatology, Bnai-Zion Medical Center,
Rappaport Faculty of Medicine. Technion, Haifa, Israel; 10Institute for
Maternal and Child Health- IRCCS “Burlo Garofolo”, Trieste, Italy;
11Novartis Pharma, Shanghai, China; 12Novartis Pharma AG, Basel,
Switzerland; 13IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy;
14UK National Amyloidosis Centre, University College London, London,
United Kingdom
Correspondence: Marco Gattorno
Pediatric Rheumatology 2017, 15(Suppl 2):O30
Introduction: Interleukin (IL)–1β is known to be a key cytokine in the
pathogenesis of tumour necrosis factor receptor associated periodic
syndrome (TRAPS).1 Canakinumab (CAN) is a fully human monoclonal
antibody that specifically neutralises the activity of IL–1β.
Objectives: The primary objective was to demonstrate that canakinu-
mab (CAN)150 mg every 4 weeks (q4w) is superior to placebo (PBO)
in achieving a clinically meaningful response [resolution of flare at
Day 15 and no new disease flares over 16 weeks (wks) of treatment]
in TRAPS patients (pts). Secondary objectives included: the propor-
tion of pts who maintained optimal control of disease activity (ab-
sence of new flares) between Wk 16 and Wk 40 after dose reduction;
evaluation of pharmacokinetics (PK), pharmacodynamics (PD) and
safety of CAN in TRAPS pts.
Methods: The study comprised 4 epochs: a 12-wk screening epoch
(E1), a 16-wk randomised treatment epoch (E2), a 24-wk randomised
withdrawal epoch (E3) and a 72-wk open-label treatment epoch (E4).
TRAPS pts with a flare during E1 were randomised in E2 to receive
CAN 150 mg q4w or PBO. Pts who did not flare in E2 in the CAN
group were re-randomised to CAN 150 mg q8w or PBO/CAN with-
drawal in E3. In E3, for pts with a flare, dose could be escalated up to
300 mg q4w. For PK/PD assessments, CAN concentrations and total
IL-1β at baseline (Day 1), and trough concentrations at Wk 16 were
assessed. Safety assessments included adverse events (AEs) and ser-
ious AEs (SAEs).
Results: Of the 46 TRAPS pts randomised to CAN 150 mg q4w (n = 22)
or PBO (n = 24) in E2, 2 pts in the PBO group discontinued the study. The
proportion of responders at Wk 16 was statistically higher with CAN vs.
PBO (Table 8). In E3, 9 (CAN E2 responders) were re-randomised to CAN
150 mg q8w or PBO while remaining pts completing E2 received open-
label treatment. In E3, the proportion of pts with no new flare was nu-
merically higher in the CAN vs PBO group (Table 8). 53.3% of the TRAPS
pts, including pts treated in open-label maintained disease control with a
prolonged dosing interval (q8w) till Wk 40. While 8.3% pts were up-
titrated to 300 mg q4w. No new safety findings or death were reported
in CAN treated pts through E3 (Table 8). The serum clearance and
steady-state volume of distribution of CAN varied according to body
weight, and were estimated to be 0.14 ± 0.04 L/day and 4.96 ± 1.35 L, re-
spectively. The estimated half-life of CAN was 25 ± 6.4 days. Total IL-1β
serum concentrations showed dose proportional increase.
Conclusion: CAN (150 mg q4w) was efficacious in resolving flare by
Day 15 and preventing new flares in TRAPS patients over 16 weeks.
The prolonged dose interval (150 mg q8w) was sufficient to maintain
disease control in approximately 50% TRAPS patients at the end of
epoch 3. No new safety issues were reported over 40 weeks oftreatment; the safety profile was not distinct from previous con-
trolled studies. The PK/PD results observed with the liquid-in-vial
form of CAN were similar to those observed in CAPS and SJIA.
1.Gattorno M, et al. Ann Rheum Dis. 2016;76(1):1738
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Introduction: At present no clear evidence based guidelines exist to
standardize the tapering and discontinuation of corticosteroids (CS)
in juvenile dermatomyositis (JDM).
Objectives: To provide evidence-based recommendations for CS ta-
pering/discontinuation through the analysis of the patients in the
PRINTO new onset JDM trial. Secondary objective of the study was to
identify predictors of clinical remission and CS discontinuation.
Methods: New onset JDM children were randomized to receive ei-
ther prednisone (PDN) alone or in combination with MTX or CSA. All
children were given initially intravenous methylprednisolone, and
then PDN starting with 2 mg/kg/day. Gradual tapering according to a
specific protocol could lead to the safe dose of 0.2 mg/kg/day by
month 6, then discontinued at month 24. Major therapeutic changes
(MTC) were defined as the addition or major increase in the dose of
Table 9 (Abstract O31). Logistic regression model for the outcome:
achievement of remission (n/tot: 28/130; 21.5%)
OR (95% CI) P#
Responder at 2 months:
Printo-50 (vs. not responder/Printo-20)
5.41 (1.37 - 21.32) 0.0076
Printo-70 (vs. not responder/Printo-20) 6.90 (1.91 - 24.99)
Printo-90 (vs. not responder/Printo-20) 4.46 (1.08 - 18.38)
Age at onset > 8.53 years (£ 8.53 years) 4.64 (1.69 - 12.71) 0.0017
Treatment group: PDN +MTX (vs. PDN/PDN + CSA) 3.63 (1.30 - 10.09) 0.0116
AUC of the model: 0.80
OR: Odds Ratio; 95% CI: 95% Confidence Interval; P#: Likelihood Ratio test
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dropped from the trial. Patients were divided according to clinical re-
mission (CMAS = 52 and MD global = 0 for 6 continuous months) into
two major groups. Group 1 included those on clinical remission, who
could discontinue PDN, with no MTC, and represented the reference
standard for the best clinical outcome. Group 1 was compared with
those who did not achieve clinical remission, without or with MTC
(group 2 and 3, respectively). JDM core set measures (CSM) were
compared in the 3 groups. We also calculated the gold standard
group (group 1) median change in the CSM in the first 6 and over
24 months and applied a logistic regression model to identify the
predictors of clinical remission with PDN discontinuation.
Results: 139 children were enrolled in the trial: 47 on PDN, 46 on
PDN + CSA and 46 on PDN +MTX. We identified 30 (21.6%) patients
for group 1, 43 (30.9%) for group 2 and 66 (47.5%) for group 3. At
baseline all 3 groups had a high level of disease activity with no dif-
ferences in the CSM. Already in the first 2 months a clear differential
trend in disease activity measures, according to clinical remission sta-
tus and PDN discontinuation, could be identified. From the observa-
tion of the median change in the CSM of group 1 in the first
6 months, the following recommendations could be extrapolated: de-
crease corticosteroids from 2 to 1 mg/kg/day in 2 months if the MD-
global, parent-global, CHAQ, DAS, CMAS, MMT or Phs measures have
a change of at least 50%; from 1 to 0.5 mg/kg/day in the following
2 months if the MD-global, CHAQ, DAS, CMAS have a change of at
least 20%; in the following 2 months (month 4-6) corticosteroids can
be tapered up to the safe dose of 0.2 mg/kg/day, if the disease activ-
ity measures remain at low/normal values. We finally ran a logistic re-
gression model that showed that the achievement of PRINTO criteria
50-70-90 at 2 months from disease onset, an age at onset >9 years
and the combination therapy PDN +MTX, increase the probability of
clinical remission from 4 to 7 times. (Table 9).
Conclusion: We propose evidence based specific cut-offs for cortico-
steroid tapering/discontinuation based on the change in JDM CSM of
disease activity, and to identify the best predictors for clinical remis-
sion and corticosteroid discontinuation.
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Introduction: In immunocompromised patients, varicella zoster virus
(VZV) infection can have a very severe clinical course. There is scarce
evidence that in adult and paediatric population with rheumatoid or
juvenile idiopathic arthritis and other rheumatic diseases the treat-
ment with biologic agents may impair the antibody response to vac-
cines. However, there is no evidence on whether the use of biologic
agents affects in children the VZV IgG levels acquired after natural
infection.
Objectives: The aim of the study is to investigate whether children
with a rheumatic condition treated with biologic agents have a
change in their VZV immune status.
Methods: We performed retrospective case notes review of children
presenting with any rheumatic diagnosis requiring treatment with a
biologic agent to the Paediatric Rheumatology services at Great
Ormond Street Hospital NHS Foundation Trust between 2009 and
2017, identified from the biologic database. We included in the study
the children with positive VZV IgG prior to the treatment with a bio-
logic agent and with a minimum of one repeat VZV IgG measure-
ment post initiation of the treatment. A sensitive VaccZyme
VZV glycoprotein IgG Low Level Enzyme Immunoassay Kit (Binding
Site) was used to measure VZV IgG.
Results: Sixty four patients treated with biologic agents and with two
measurements of VZV IgG prior and post biologic were identified.
Forty three patients had positive VZV IgG acquired prior to treatment
and were included in the study. None had received the VZV vaccine,
which is not part of the routine childhood vaccination schedule in
the United Kingdom. After initiation of treatment with biologics, 10/
43 (23%, 2 males and 8 females) had a change in VZV IgG, of which
5/43 (11.6%) had negative VZV IgG, and 5/43 (11.6%) equivocal. Four
had a diagnosis of JIA, 2 systemic vasculitides, and 4 other rheumatic
conditions. Seven patients were treated with anti-TNF agents, 2
patients with Tocilizumab and 1 received Abatacept. Nine patients
received concomitant treatment with other disease-modifying anti-
rheumatic drugs (7/9 Methotrexate, 2/9 Azathioprine). For the 10 pa-
tients, the median age at the measurement of a positive VZV IgG
pre-biologic was 7 years (range 1-12), median time between the two
assessments was 40.5 months (range 9-105), and the median time
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 19 of 191between the initiation of the biologic agent and the post-biologic
measurement of VZV IgG was 24 months (range 11-68).
Conclusion: We describe the changes in the VZV immune status post
treatment with biologics in the first cohort of paediatric patients with
initial seroconversion following natural infection. Although limited by
the size of the study population, observational nature and other con-
comitant medications, our results indicate that biologic agents can
affect the VZV immune status of patients with rheumatic conditions,
making them susceptible to re-infection. Therefore we suggest that
all patients on biologic agents should have the VZV IgG levels re-
tested regularly to identify whether the VZV IgG levels are protective
and give prophylaxis as required in the event of varicella contact.
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Introduction: Aerobic fitness may serve as an important health-
related outcome measure in Juvenile Idiopathic Arthritis (JIA). Re-
duced aerobic fitness is associated with cardiovascular morbidity,
mortality and osteoporosis in adult patients with chronic diseases.
However, in adolescents and young adults, long-term outcome of
aerobic fitness is unknown. Reduced aerobic fitness was described
previously in cross-sectional studies in children and adolescents with
JIA and was more impaired in active disease.
Objectives: Our objectives are to describe the course of aerobic fit-
ness in a longitudinal cohort of adolescents and young adult JIA-
patients who are intensively treated and to identify the association
of clinical variables.
Methods: In a longitudinal cohort, all consecutive patients aged 10-
24 years were included after informed consent. Annual examinations
were obtained from demographic and disease-related items. At base-
line and at study-end, aerobic fitness (VO2peak) was assessed using a
graded cardiopulmonary exercise test (CPET) to volitional exhaustion
performed on a cycle ergometer. Absolute and relative VO2peak
values were measured and related to reference values of healthy
controls (Z-scores), using one-sample T-tests. Non-parametric tests
were used to evaluate results.
Results: Paired Z-scores were available from 35 patients. 40% were
male, median age at baseline was 13,0 yrs (IQR 4,1), disease duration
7,8 yrs (6,4), JADAS27 3,7 (6,4), DAS28 1,8 (1,0). 79% of the patients
were in DAS28-remission. 17% had systemic JIA, 6% persistent oli-
goarticular and 74% had a polyarticular course. Baseline and end Z-
scores were reduced compared to healthy controls (ZAbs_base -0,68,
IQR2,3 p = 0,01; Zrel_base -1,33, IQR 2,0, p < 0,01; Zabs_end -1,33, IQR
1,7, p < 0,01; Zrel_end -0,70, IQR 1,8, p = 0,01) and did not change
significantly over time (change Zabs_change 0,65, p = 0,34; Zrel_-
change 0,63, p = 0,31). At baseline, a higher DAS28 (p = 0,01), higher
JADAS27 (p < 0.01), ESR (p < 0,01), higher thrombocytes (p < 0.01)
and the use of MTX (p = 0.01) were associated with a worse outcome
of aerobic fitness. The greatest improvement of aerobic fitness overtime was seen in male patients (p < 0.01) at baseline. Multivariate
analysis showed that a higher DAS28 and male gender were the
most important variables for worse aerobic fitness at baseline, a
higher ESR at baseline was the most important predictor for improv-
ing aerobic fitness over time.
Conclusion: Aerobic fitness is significantly reduced in adolescents
and young adults with JIA and does not improve over time, despite
intensive treatment. Be aware of a reduced health outcome into
adulthood due to a persistent reduced aerobic fitness during disease
course of JIA, despite low disease activity.
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Introduction: Periodic fever, aphthosis, pharyngitis, and adenitis
(PFAPA) syndrome is an auto-inflammatory condition of unknown eti-
ology. It is the second most common auto-inflammatory disease in
our country, following familial Mediterranean fever. The strong
familial clustering suggest a potential genetic origin of the syndrome
but none of single genetic variants seem to be relevant for the dis-
ease etiology. Previous studies showed that tonsillectomy represents
efficient treatment options.
Objectives: Our aim was to explore the main clinical features, re-
sponse to tonsillectomy and long–term outcome of PFAPA pediatric
patients in a single cohort. We assessed association of MEFV gene
mutation with disease characteristics and treatment response.
Methods: We reviewed medical records of patients who were diag-
nosed with PFAPA syndrome between the January 2010 and June
2016. All of the recorded 562 patients were called by the telephone
and 359 (64%) of them were reached. Demographic, clinical and
therapeutically features were taken from the patients’ medical re-
cords. Data on clinical course and the disease outcome were col-
lected by using a structured questionnaire, which was fulfilled during
the phone conversation between investigator and patient’s parents.
Results: A total of 359 patients with PFAPA were examined: 155
(43%) of them were female. The mean age at disease onset, at
diagnosis and at the investigation was 22.79 ± 18.8, 41.7 ± 21.7 and
77.14 ± 31.35 months, respectively. The most common disease fea-
ture at the disease onset was: recurrent fever in 359 (100%), cryptic
tonsillitis in 359 (100%) and aphtous stomatitis in 317 (88%). Sixty-
three (17%) patients met the criteria for both PFAPA and FMF. MEFV
gene mutation analysis was performed in 93 (25%) patients and 51
of them (54%) had a heterozygous mutation in exon 10. Surgical
treatment was performed in 158 (43%) patients. Complete clinical
remission was achieved in 127 (80.3%) patients. Six (3%) showed no
response to surgical treatment while 25 (15.8%) patients had a partial
response. In patients with partial clinical response, frequency of
fever attacks decreased significantly from 17.5 to 7.3 attack per
year (p < 0.05). Among patients who did not respond to tonsillectomy,
11 (52.4%) were carrier of MEFV heterozygous mutation in exon 10.
There was a statistically significant difference between patients with
and without coexistence of FMF features, according to surgical treat-
ment response (p < 0.05). The mean age of resolution of PFAPA
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 20 of 191symptoms in patients who underwent tonsillectomy was 52 ±
22.4 months and in patients without tonsillectomy 66 ± 22.6 months
(Table 10).
Conclusion: Although PFAPA symptoms usually resolve before age of
eight, some patients’ complaints persist. FMF should be considered
in tonsilloadenoidectomy unresponsive PFAPA patients, especially in
endemic regions like Turkey. Tonsilloadenoidectomy seems to be an
effective treatment option for pediatric PFAPA patients.
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Disclosure of Interest: None Declared.Table 10 (Abstract P1). Clinical characteristics of patients according to
coexistence of FMF
Patients with
coexistence of FMF
(n = 63)
Patients without
coexistence of FMF
(n = 296)
p
Mean age at disease onset
(months ± SD)
27 ± 23 22 ± 16.6 0.562
Mean age at diagnosis
(months ± SD)
44 ± 23 43 ± 21 0.274
Male/Female ratio 36/27 168/128 1.0
Mean time interval between
fever episodes (weeks ± SD)
3 ± 0.9 3.2 ± 1.4 0.61
Mean duration of fever
(days ± SD)
3.6 ± 1.4 3.9 ± 3.6 0.94
Cryptic tonsillitis 63 (100%) 296 (100%) 1.0
Abdominal pain 20 (31.7%) 83 (28%) 0.54
Response to colchicum
treatment
18/27 (66%) 6/18 (33%) 0.03
Clinical response to surgical
treatment
18/36 (50%) 113/146 (77.4%) 0.002P2
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Introduction: Provisional Eurofever evidence-based classification cri-
teria for inherited periodic fever (TRAPS, FMF, MKD and CAPS) have
been recently developed and other diagnostic criteria are available
for FMF, CAPS and PFAPA. However, no consensus on how to com-
bine clinical criteria and results of molecular analysis has been
reached so far. We have recently identified, through a process based
on the Delphi techniques (2 subsequent Delphi surveys), thosevariables the expert, clinicians and geneticists, consider as important
for the diagnosis of each monogenic periodic fever syndrome and
PFAPA. We also obtained, trough a web-based evaluation a
consensus >80% among clinicians and geneticists on the diagnosis
for 269 over 360 patients with monogenic periodic fever, PFAPA and
undefined periodic fever (UPF) randomly selected from the Eurofever
Registry.
Objectives: To identify candidate set of classification criteria for
monogenic periodic fever and PFAPA and to test their sensibility and
specificity on the subset of patients having reached a consensus
among experts. To select the best sets of criteria for each disease to
be discussed in a Consensus Conference
Methods: We selected for each disease the clinical variables corre-
sponding to the 3rd quartile considering the total score obtained
after the second Delphi survey. Performing univariate statistical ana-
lysis, we subsequently assess the ability of these variables to classify
individual patients as having or not FMF, MKD, TRAPS, CAPS, PFAPA
or UPF according to consensus classification of experts. These vari-
ables could be associated both in a positive or negative way to each
disease. At the same time we assigned to each genotype presented
by our patients a score from 5 to 1 on the basis of the evaluation
done by the experts to be able to include the results of genetic test-
ing in the statistical analysis. In a second step, multivariate statistical
analysis has been performed to obtain different sets of criteria in-
cluding only positively associated or positively and negatively associ-
ated clinical variables with and without genetic data. For each
criteria the sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV) and area under the curve (AUC) were
calculated. The best performing criteria for each disease have been
selected and presented to the expert for voting in a consensus
Conference held in Genova in march 2017.
Results: A total of 98 clinical variables derived from the second
Delphi survey has been tested. The univariate analysis identified 15
variables significantly associated with FMF (6 positively and 9 nega-
tively), 20 with CAPS (12 positively and 8 negatively), 9 with TRAPS (6
positively and 3 negatively), 13 with MKD (11 positively and 2 nega-
tively) and 15 with PFAPA (5 positively and 10 negatively). 193 cri-
teria derived from the statistical analysis have been selected (45 for
FMF, 50 for CAPS, 44 for TRAPS, 32 for MKD and 22 for PFAPA) to be
discussed and voted at the consensus. In addition criteria already
published in the literature and criteria directly proposed by experts
were included for discussion.
Conclusion: Our process led to the identification of the best variables
to be included in the multivariate analysis for the identification of
the candidate criteria for monogenic periodic fever and PFAPA. Next,
the ability of candidate criteria to classify individual patients as hav-
ing FMF, MKD, TRAPS CAPS or PFAPA have been assessed by evaluat-
ing the agreement between the classification yielded using the
criteria and the consensus classification of the experts. The best clas-
sification criteria for each disease in term of sensibility and specificity
have been shown and voted by a panel of Experts during the Con-
sensus Conference held in Genoa. For CAPS, FMF and MKD a consen-
sus >80% has been reached for the best genetic/clinical criteria and
for the best clinical criteria while for TRAPS the consensus has been
reached only for the best clinical/genetic criteria. A new round of
web-based evaluation is now ongoing to try to reach a consensus on
the clinical criteria for TRAPS as well. Moreover a consensus has been
reached for PFAPA clinical criteria.
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Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 21 of 191Introduction: Chronic recurrent multifocal osteomyelitis (CRMO), also
known as chronic nonbacterial osteomyelitis, is a rare, noninfectious
inflammatory disorder that causes multifocal lytic bone lesions with
swelling and pain characterized by periodic exacerbations and remis-
sions of unclear/unknown pathogenesis.
Objectives: To describe a case of CRMO in a 10 years old girl.
Methods: A 10 years old girl came to our department because of
pain in her right shoulder since the age of 9 years. She did not recall
a precipitating event or a trauma, reported no fever or weakness.
There was no relevant personal or family history. Before coming to
our observation an X-ray of her right shoulder revealing an osteolytic
lesion and a PET-CT showing the presence of a pathological high-
uptake of the lesion were performed, and a biopsy of the lesion of
the right shoulder was done to exclude a neoplastic lesion, a bone
infection, or a Langerhans cells histiocytosis (LCH). Patient’s bone bi-
opsy showed infiltration by lymphocytes and neutrophils. No neo-
plastic cells were identified. All cultures were negative. LCH was
excluded since immunohistochemical evaluation of bone marrow for
CD1a and S100 expression was negative. When she was admitted to
our department she had pain in her right arm and shoulder. Labora-
tory results showed a modest increase of inflammation parameters
(ESR 34 mm/h, CRP 0,88 mg/dL) with normal complete blood count,
liver and renal function. The abdominal ultrasound and the chest X-
ray were normal so we performed an MRI. On MRI the lesion was
hypointense in T1 and hyperintense in T2 and STIR, suggesting an in-
flammatory process.Suspecting a CRMO, anti-inflammatory treatment
with naproxen was prescribed and the symptomatology disappeared.
Five months later the patient came back to our department because
of pain and swelling in her right clavicle. The physical examination
showed a painful swelling of the sternal end of the right clavicle. La-
boratory results indicated a modest increase of inflammation param-
eters (ESR 29 mm/h, CRP 0,98 mg/dL). Clavicle X-ray showed an
osteolytic lesion, ultrasound of sternoclavicular joint revealed articu-
lar effusion. On MRI this lesion was hyperintense in T2 and STIR.
Results: Clinical history, physical signs, instrumental investigations
and histopathological pattern were highly suggestive of CRMO. Anti-
inflammatory treatment with naproxen was started again and the
symptoms disappeared. After six months was performed a whole-
body MRI to evaluate the status of disease. The MRI did not show
new lesions and previous bone lesions disappeared.
Conclusion: In a patient with recurrent bone pain CRMO should be
considered. The diagnosis is of exclusion and it is based on the clin-
ical and radiological data. Biopsy is needed to exclude infectious
osteomyelitis, malignancy, LCH. Some authors suggest that biopsy is
not necessary if a patient has classical radiological findings of CRMO,
or comorbidities, such as Crohn's disease. Skeletal manifestations are
unifocal or multifocal, and the involvement of clavicle, sternum or
mandible suggest a CRMO diagnosis. Extra-articular manifestation are
gastrointestinal and skin involvement (acne, pustolsis, psoriasis).The
SAPHO syndrome seems to be an advanced state of CRMO. The
treatment of CRMO has been mostly empiric; NSAIDs are the first
choice for CRMO treatment. When disease activity is high or there
are complications therapy with bisphosphonates or biologic drugs
such as TNF antagonists (etanercept) or inhibitors of IL-1 (anakinra)
should be considered.
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Pediatric Rheumatology 2017, 15(Suppl 2):P4Introduction: Blau syndrome, or early-onset sarcoidosis, is a juvenile-
onset systemic granulomatosis associated with a mutation in nucleo-
tide-binding oligomerization domain 2 (NOD2). The underlying mecha-
nisms of Blau syndrome leading to autoinflammation are still unclear,
and there is currently no effective specific treatment for Blau
syndrome.
Objectives: To elucidate the mechanisms of autoinflammation in
Blau syndrome, we sought to clarify the relation between disease
associated-mutant NOD2 and the inflammatory response in human
samples.
Methods: Blau syndrome-specific induced pluripotent stem cells
(iPSCs) lines were established. To precisely evaluate the in vitro
phenotype of iPSC-derived cells, the disease-associated NOD2 muta-
tion of iPSCs was corrected using a CRISPR-Cas9 system. We also in-
troduced the same NOD2 mutation into a control iPSC line. These
isogenic iPSCs were then differentiated into monocytic cell lineages,
and the status of NF-κB pathway and proinflammatory cytokine se-
cretion were investigated.
Results: IFN-γ acted as a priming signal through the up-regulation of
NOD2. In iPSC-derived macrophages with mutant NOD2, IFN-γ treat-
ment induced ligand-independent, NF-κB activation and proinflam-
matory cytokine production. RNA-seq analysis revealed distinct
transcriptional profiles of mutant macrophages both before and after
IFN-γ treatment. Patient-derived macrophages demonstrated a simi-
lar IFN-γ-dependent inflammatory response.
Conclusion: Our data support the significance of ligand-independent
autoinflammation in the pathophysiology of Blau syndrome. Our
comprehensive isogenic disease-specific iPSC panel provides a useful
platform for probing therapeutic and diagnostic clues for the treat-
ment of Blau syndrome patients.
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Introduction: Clavicular cortical hyperostosis (CCH) is a rare inflam-
matory bone disorder of unknown aetiology represented by pain
and swelling of the clavicle. Although similar to chronic nonbacetril/
recurrent multifocal osteomyelitis (CNO/CRMO), due to lack of recur-
rence and additional inflammatory sites, it can be considered separ-
ate disease in the spectrum. In our previous study microarray gene
expression profiling of CCH patients revealed 974 differentially
expressed genes involved in various inflammatory processes (1). Sub-
sequent qRT-PCR in additional number of patients confirmed signifi-
cantly lower expression of ERBB2 gene and higher expression of
TRPM3 and TPRM7 transient receptor potential (TRP) channel genes.
Additionally, immunofluorescence microscopy showed high signal of
TRPM3 in blood cells of one CCH patient. Based on described find-
ings and other studies which showed TRP channels are involved in
inflammasome activation, while ERBB activation promotes protective
cellular outcomes during inflammation, we hypothesized CCH could
be autoinflammatory disease, but the mechanisms responsible for
observed expression alterations remained unclear.
Objectives: Identify possible disease causing gene variants in CCH
patients using whole exome sequencing (WES).
Methods: Genomic DNA was extracted from peripheral whole blood
samples of three CCH patients. Targeted exome sequencing was
performed using the Nextera Rapid Capture Exome Kit (Illumina). The
sequence library was constructed with 50 ng of genomic DNA and
100-bp paired-end reads were sequenced on HiSeq 2000 next-
generation sequencer (Illumina). The extracted variants were
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 22 of 191annotated and filtered using the Variant Studio software (Illumina)
and Variant Interpreter (Illumina).
Results: WES analysis identified 428 shared identical variants among af-
fected individuals. Thirty of these variants were not associated with a
gene, 121 were in ZNF717 gene and 277 were distributed in 63 other
genes. One heterozygous variant in CTBP2 gene, one in HYDIN gene
and six in ZNF717 were classified as likely pathogenic (Table 11).
Conclusion: In this comprehensive study “bottom-up” approach was
used in order to elucidate the molecular disease mechanisms of what
we believe could be a new disease entity. Previously performed dili-
gent transcriptome analysis and proof-of-concept experiment which
confirmed the results on a protein level indicated CCH could be in-
duced by sternoclavicular joint overuse, TRP channel overexpression,
inflammasome activation and reduced protection during inflamma-
tion. Interestingly, WES analysis identified majority of likely patho-
genic variants in ZNF717 gene. This gene encodes a Kruppel-
associated box (KRAB) zinc-finger protein, which belongs to a large
group of transcriptional regulators and is therefore involved in the
regulation of crucial physiological and pathological processes (2).
Many aspects of these proteins are still essentially unknown, as is
their role in the inflammation, yet it is speculated they increase DNA
accessibility and inflammatory gene transcription (3). Together with
possible influence on observed expression patterns, all of these pro-
cesses could contribute to CCH evolution.
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pathogenic
Gene Variant Coordinate Transcript Consequence dbSNP ID
CTBP2 T > T/A 126727602 rs76555439
HYDIN GA >
GA/G
70896015 NM_032821.2 frameshift_variant,
feature_truncation
rs77276171
ZNF717 A > A/
T
75786827 NM_001128223.1 stop_gained rs79635065
ZNF717 C > C/
A
75786916 NM_001128223.1 stop_gained rs78906544
ZNF717 G > G/
T
75787127 NM_001128223.1 stop_gained rs74740396,
rs148624740
ZNF717 T > T/
TA
75787352 NM_001128223.1 frameshift_variant,
feature_elongation
ZNF717 GAA >
GAA/G
75787645 NM_001128223.1 frameshift_variant,
feature_truncation
rs67117547,
rs141065192
ZNF717 G > G/
C
75788028 NM_001128223.1 stop_gained rs77971486,
rs150689808P6
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Pediatric Rheumatology 2017, 15(Suppl 2):P6Introduction: ADAM17 is an important shedding enzyme that regu-
lates the response to tissue injury and inflammation. Only 2 cases of
ADAM17 mutations in humans have been described thus far: siblings
with a homozygous ADAM17 deletion resulting in a severely trun-
cated protein causing autosomal recessive neonatal inflammatory
bowel and skin disease.
Objectives: The aim of this study was to discover the genetic cause
affecting a child with a novel inflammatory phenotype.
Methods: Whole Exome sequencing was performed using DNA ex-
tracted from peripheral blood for a trio analysis. The Nextera Exome
Capture and Hiseq sequencing platforms were used in this process.
Results: A four-year- old girl presented with extreme photophobia,
bloody diarrhoea, anal fissures from the first weeks of life, and inter-
mittent fevers. Examination revealed blepharitis, perioral rash and
gingival inflammation with hyperthrophy. Feeding difficulties attrib-
uted to gastro-oesophageal reflux led to oral aversion and poor
weight gain. Inflammatory markers were moderately elevated (mean
CRP-22 mg/L and ESR-32 mm/h) in between fevers, and higher
(CRP > 150 mg/L) during fevers. Upper gastrointestinal endoscopy at
10 months of age showed gastritis and duodenitis. Brain MRI showed
cerebellar hypoplasia; corneal biopsy revealed an abnormal cornea
and conjunctival epithelium. Extensive neuro-metabolic investiga-
tions performed were normal. Whole exome sequencing revealed 2
rare heterozygous missense mutations in the ADAM17 gene (p.I50V
and p.R215V). Sanger sequencing confirmed these results, and carrier
status in the parents. Both these mutations were absent from our in-
house exome database of 120 exomes; were not seen in homozy-
gous state in population databases; and were predicted damaging in
silico. Biopsies of oral mucosa, tonsillar and skin tissue were then
assessed by electron microscopy showing patchy structural changes
in hemidesmosomes.
Conclusion: We describe the third case of human disease associated
to ADAM17, but with a novel phenotype, similar to conditional
knock-out mouse models with severely reduced ADAM17 sheddase
activity, which develop opaque eyes, skin and heart defects as well
as increased susceptibility to dextran sulfate induced colitis. This is
in-keeping with the mutations found in our proband, since they are
unlikely to result in the complete absence of the protein described in
the other human cases.
Ongoing functional work will provide further information on how
these mutations affect ADAM17 activity and impact on hemidesmo-
some structure.
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Introduction: The spectrum of autoinflammatory diseases (AID) is
continuosly expanding and significant delay in diagnosis may occur
if those rare entities are not promptly identified.
Objectives: To assess the impact and significance of gastrointestinal
(GI) clinical manifestations in a broad cohort of AID patients.
Methods: The web-based international Eurofever registry containing
data retrospectively collected about patients enrolled by 108
partecipating centres from November 2009 to June 2016 was evalu-
ated. When present, each GI manifestation was ranked as occasion-
ally or persistently present during flares. Development of severe GI
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 23 of 191complications was also assessed. To then identify subsets of patients
featured by homogeneous patterns of clinical features, the unsuper-
vised Latent Class (LC) analysis was applied to the cohort featured by
GI manifestations (GI cohort) in the attempt to assign mutually exclu-
sive class membership based on latent patterns among the observed
variables.
Results: The cohort included 1655 patients with confirmed diagnosis
of AID. At least 1 GI manifestation was reported in 52.32%. Interest-
ingly, the latter had earlier onset compared to cohort that did not
show GI involvement (5.18 ± 8.18 vs 9.11 ± 10.25, mean years ± SD).
As expected, the majority of FMF, MVK and TRAPS were affected by
GI symptoms whereas CAPS and CRMO were mainly represented in
the subset lacking GI involvement. In the GI cohort (Table 12), during
flares LC1 (13%) displayed persistent abdominal pain together with
prolonged diarrhea, and it mainly included majority of MVK. LC2
(7%) was affected by occasional abdominal pain together with occa-
sional vomiting, diarrhea and hepatosplenomegaly. LC3 represented
the majority of GI cohort (72%) and presented only occasional ab-
dominal pain while LC4 (8%) was characterized by persistent abdom-
inal pain occasionally associated with vomiting, diarrhea, and
sometime developing complications such as septic peritonitis and
peritoneal adhesions. As expected, the latter was mostly represented
by FMF.
Conclusion: These data unveiled the unforeseen significance of GI in-
volvement in AID with implications in the daily clinical management.
GI specialists should be aware of these rare diseases in order to avoid
delayed diagnosis and joined work-up protocols should be devel-
oped in order to monitor these signs and prevent potential compli-
cations. A prospective analysis is needed in order to delineate the
disease history and potential evolutions (if any) into more defined GI
diseases in the contest of autoinflammation.
Disclosure of Interest: None Declared.Table 12 (abstract P7). See text for description
n= LC1 LC2 LC3 LC4 Tot GI Cohort Total not GI Cohort Total AID
Total 87 52 666 61 866 789 1655
CAPS 4 7 31 2 44 134 179
CRMO 0 0 28 1 29 323 352
FMF 17 15 274 43 349 28 378
MVK 39 15 56 8 118 4 122
PFAPA 11 2 99 0 112 158 271
TRAPS 7 7 101 5 120 37 158
Undefined 9 5 57 1 72 63 135
Others 0 1 20 2 23 38 60P8
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Introduction: Monogenic autoinflammatory disorders (AID) and some
primary immunodeficiencies can present early in life with Behçet-likesymptoms, and may be mistaken for Behçet’s disease (BD). Most of
these monogenic conditions require alternative treatments than typ-
ically required for BD, and are associated with high morbidity and
mortality if diagnosis and appropriate treatment are delayed. Next
generation sequencing (NGS) undoubtedly offers the opportunity to
screen for these diseases more efficiently, and greatly facilitates diag-
nosis in this context.
Objectives: To retrospectively describe the clinical and laboratory
features, and molecular diagnoses of 11 paediatric cases referred for
suspected BD.
Methods: Retrospective, two-centre, case series. A combination of
NGS or conventional candidate gene screening approaches were uti-
lised to ascertain genetic diagnoses, facilitated in some cases by
functional immunological screening assays. NGS approaches utilised
included targeted exome sequencing (the “Vasculitis and Inflamma-
tion Panel”, VIP); or whole exome sequencing (WES).
Results: Eleven children referred with suspected BD underwent fur-
ther molecular testing because of incomplete or atypical BD features,
and presentation under the age of 5 years. Seven/11 patients (58%)
were Caucasian; the remaining 4/11 were Asian; 64% were female.
Two cases were siblings from a consanguineous kindred with “famil-
ial” BD; and another had a maternal history of BD. The median age
of disease onset was 1.0 (range 0.5-3.0) years. All had systemic in-
flammation and oral ulceration; 4/11 had genital ulceration; 4/11 had
ocular involvement; and 8/11 had cutaneous manifestations. Nine
out of 11 were considered to have a monogenic cause: the final gen-
etic diagnoses were: A20 haploinsufficiency (n = 1); Hyper IgE syn-
drome (n = 1); LYN associated AID (n = 1); TRAPS (n = 1), Chronic
Granulomatous Disease (n = 2), Periodic Fever Immunodeficiency and
thrombocytopenia Syndrome (PFIT; n = 2), and pustular psoriasis
caused by mutation in AP1S3 (n = 1). The remaining two cases had a
suspected atypical AID caused by a novel variant in MEFV (n = 1);
and a STAT1 variant, as the suspected but as yet unproven mono-
genic cause (n = 1).
Conclusion: Rare monogenic disorders can mimic BD, particularly
when the presentation is under the age of 5 years. These data are
now informing a strategy to begin to explore screening for genetic
mimics of BD in a UK cohort of children and adults to better under-
stand the proportion of UK BD patients who may in fact have an
underlying genetic diagnosis.
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Introduction: Autoinflammatory diseases are a group of inherited
diseases characterized by early onset and systemic inflammation,
often manifesting with unexplained fevers. These pathologies are
usually caused by mutations in genes involved in the regulation of
innate immune response with consequent inflammatory phenotype.
The mechanism that lead to the development of this diseases are
not still clear and part are however genetically undefined.
Objectives: Our aim is to evaluate the differences in the expression
of proteins or pathway in monocytes, and plasma metabolites of pa-
tients with some of the best-known autoinflammatory diseases
(CAPS, TRAPS, FMF and MKD) and healthy subjects. The purpose is
clusterize the different disorders to better characterize each path-
ology and try to distinguish the genetically undefined pathologies.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 24 of 191Methods: Monocytes (purified form peripheral blood and incubated
for 4 hours with or without LPS) and plasma were collected from pa-
tients and healthy donors. The samples were processed and proteins
or metabolites expression evaluated by an High Resolution/Mass
Accuracy Liquid Chromatography Tandem Mass Spectrometry (HR/
MA LC MS/MS). PCA analysis and Person’s correlation were used as
quality control of experimental design, while the statistical analysis
was performed with the Perseus software.
Results: We analyze the monocytes and plasma of patients with
CAPS, TRAPS, FMF and MKD. We identified about 4000 proteins of
each 3500 are quantified by LFQ approach. PCA analysis and Person’s
correlation show a good reproducibility of data and a good separ-
ation between the different groups. In synchronous way using a clus-
ter analysis and heatmap, based on a machine learning protein
selection, we observed a protein signature specific for each group of
pathology and for each condition of monocytes treatment. Further-
more we used a supervised multivariate analysis to try to identify a
more specific list of proteins for each pathology: at the moment we
obtained a list of about 40 protein per disease, significantly modu-
lated if compared with healthy controls and comparing each path-
ology with the other.
Conclusion: Here, we addressed how an high resolution proteomics
approach could be used to better understand the biology of autoin-
flammatory diseases. The characterization of a broad spectrum of
proteins and metabolites and their interaction network will allow us
to identify new biomarkers for the different pathologies and better
comprehend and recognize the genetically undefined disorders.
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Introduction: Provisional evidence-based classification criteria for
inherited periodic fever (TRAPS, FMF, MKD and CAPS) have been re-
cently developed. However, no consensus on how to combine clin-
ical criteria, laboratory test and results of molecular analysis has been
reached so far. Moreover, no validated evidence based set of classifi-
cation criteria for PFAPA has been established so far. We conducted
a multistep process, based on a combination of expert consensus
and analysis of real patient, to develop new criteria for inherited peri-
odic fevers and PFAPA syndrome.
Objectives: To obtain a consensus > 80% among experts on the diag-
nosis of a group of patients with inherited periodic fevers, PFAPA
and undefined periodic fevers.
Methods: A panel of experts (25 clinicians and 8 geneticists) was
asked to evaluate, via a web-based system on the basis of clinical
and laboratory data, 360 real patients affected by AIDs (60 FMF, 60
TRAPS, 60 MKD, 60 CAPS, 60 PFAPA and 60 undefined periodic fever)
randomly selected from the EUROFEVER Registry. PFAPA patient were
evaluated only by clinicians. Experts were asked to classify each pa-
tient as having FMF, TRAPS, MKD, CAPS, PFAPA or undefined periodic
fever syndrome. The criterion for agreement used was 80% consen-
sus among raters.
Results: After four round of evaluation, 281 over 360 patients (78%)
were classified with a consensus > 80% for a specific disease: 36 as
FMF, 32 as CAPS, 56 as MKD, 39 as TRAPS, 37 as PFAPA and 81 as un-
defined periodic fever. In 50 cases the diagnosis changed respect to
the diagnosis of the enrolling center. 25 over 36 FMF patients werehomozygous or compound heterozygous for high penetrance vari-
ants while 4 over 36 patients were compound heterozygous with
one high penetrance mutation associated with E148Q variant. 6 over
36 were heterozygous for high penetrance mutations and 1over 36
patients carried only the E148Q variant. Over the 32 CAPS patients,
28 had a genotype consistent with the disease while 4 patients car-
ried a variant of unknown significance (V198M). None of the patients
showing the Q703K variant or with negative genetic test was classi-
fied as CAPS by the experts. Regarding TRAPS only 1 over 15 patients
carrying a low penetrance variants (R92Q, P46L) reached the consen-
sus; none of the 2 patients with negative genetic analysis reached
the consensus. Among MKD patients, 4 carried the V377I variant in
heterozygous date and among these 2 reached the consensus.
Conclusion: Our process led to a consensus on the diagnosis for 281
patients affected by inherited periodic fevers and PFAPA. In the sub-
sequent phase we had performed statistical analysis in which vari-
ables coming from the EUROFEVER Delphi survey will be tested on
these patients, to identify the best sets of classification criteria (in
term of sensitivity and specificity) for inherited periodic fever and
PFAPA that have been discussed in the consensus conference held in
Genoa in March 2017.
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Introduction: Familial Mediterranean fever (FMF) is an autosomal re-
cessive autoinflammatory disease characterized by irregular periodic at-
tacks of serosal inflammation. The gold standard in treatment is
colchicine and it is very potent both in preventing attacks and subsid-
ing inflammation and by that way avoiding emergence of amyloidosis.
Objectives: There is a hypothesis pointing out to the negative influ-
ence of colchicine on the intestinal absorption of vitamin B12. As col-
chicine treatment should be used lifelong, vitamin B12 deficiency
due to malabsorption may ensue during the course of treatment. Al-
though there is an adult study, there is no data for children with
FMF under colchicine treatment.
Methods: Forty-six children with newly diagnosed FMF were enrolled to
this prospective study. They were all started colchicine according to their
age (0-5 years:0.5 mg, 5-10 years:1 mg, >10 years: 1.5 mg - maximum
2 mg). Vitamin B12 and folic acid levels were obtained at the first day of
colchicine treatment, 3rd month and 6th month of the treatment. Muta-
tion analysis of the patients and their clinical findings were also reported.
Results: Of 46 children involved to the study 18 (39.1%) were
females and 28 (60.9%) were males. The mean age of beginning of
the symptoms was 65.3 ± 45.5 months, the mean age of diagnosis
was 97.13 ± 50.2 months. There was family history of FMF in 25 pa-
tients (54.3%). Fever was present in 40 (86.9%), peritonitis was in 35
(76%), pleuritis was in 11 (23.9%), arthritis was in 6 (13%) patients.
The mean vitamin B12 values and folate values were significantly
decreased during colchicine treatment. Vitamin B12 levels were
436.28 ± 174.43, 411.63 ± 196.70, 361.67 ± 142.58 at the beginning,
on the 3rd and 6th months of the colchicine treatment respectively.
Folate levels were 10.91 ± 3.45, 9.29 ± 4.37, 9.76 ± 5.64 at the begin-
ning, on the 3rd and 6th months respectively.
Conclusion: There was significant vitamin B12 and folate level de-
crease on the 6th month of colchicine therapy in the children with
newly diagnosed FMF. This may be related to ileal malabsorption of
vitamin B12 and jejunal malabsorption of folate. Although the study
was performed among a small number of children with FMF and a
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 25 of 191limited time period was reported, prolonged periods may show more
significant decrements in the levels of vitamin B12 and folate.
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Introduction: Familial Mediterranean Fever (FMF) is an autosomal re-
cessive autoinflammatory disease, characterized by recurrent fever
and self-limited paroxysmal attacks of serosal inflammation.
Objectives: The aim of this study was to evaluate whether iron
homeostasis parameters in patients with AAA was improved by treat-
ment with colchicine or not.
Methods: Forty-six pediatric patients with newly diagnosed FMF were
included into the study. All patients were assessed in the attack-free pe-
riods for hemoglobin, hematocrit, platelet, serum amyloid A, iron, total
iron binding capacity, and ferritin before the colchicine treatment, and
on the 3rd and 5th months of colchicine treatment.
Results: We have found that there was a significant increase in mean
hemoglobin values when compared the results of hemoglobin levels be-
fore the treatment and on the 5th month of the treatment (p = 0,048;
<0,05). Also, we have observed the same increase in iron levels
(p═0,004). We have seen that there was a significant decrease in ferritin
and SAA levels and platelet counts, reflecting the control of ongoing in-
flammation. However, no significant difference was found between mean
total iron binding capacity value, mean hematocrit values (Table 13).
Conclusion: In conclusion, we think that colchicine may be effective
in balancing the iron homeostasis that is disturbed by chronic inflam-
mation in FMF.
Disclosure of Interest: None DeclaredTable 13 (abstract P13). See text for description
Before treatment 3th month of
treatment
5th month of
treatment
p*
HGB 12,11 ± 1,16 (12,08) 12,20 ± 1,03 (12,05) 12,38 ± 1,02 (12,31) 0,027*
HCT 38,05 ± 3,19 (38,02) 38,63 ± 3,45 (38,30) 38,82 ± 2,81 (38,27) 0,135
PLT 350.932 ± 110.096
(334.600)
310.671 ± 85.475
(309.850)
303.202 ± 81.570
(296.700)
<0,001*
SAA 192,19 ± 295,14
(38,95)
20,26 ± 46,58 (3,85) 9,68 ± 25,81 (3,30) <0,001*
IRON 53,47 ± 29,56 (50,85) 66,76 ± 35,61
(56,50)
67,41 ± 31,15
(64,00)
<0,001*
TIBC 361,09 ± 52,93
(362,50)
364,78 ± 55,12
(365,00)
372,91 ± 48,92
(366,00)
0,163
FERRITIN 56,63 ± 42,46 (45,00) 34,69 ± 21,34
(30,55)
32,74 ± 23,80
(25,55)
0,002*P14
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Pediatric Rheumatology 2017, 15(Suppl 2):P14Introduction: The Familial Mediterranean fever (FMF; OMIM 249100)
is the most common autoinflammatory syndrome in the group of
hereditary periodic fever syndromes, widespread in Armenia. The
existing information on frequency of carrying the mutations of FMF
gene is hospital based data with subsequent recalculations. To our
best knowledge this is first epidemiological population based study
in Armenia.
Objectives: The objective is revealing the frequency of MEFV gene
mutations and genotypes in Armenian female population in Republic
of Armenia.
Methods: The proportionate random sampling technique was per-
formed to select 173 females aged 18-19 years from Yerevan and all
marzes (regions) of Armenia. Absence of history or clinical manifest-
ation of FMF or any autoimmune inflammatory disease/syndrome
was the premium inclusion criteria. Venous blood samples were
taken in EDTA containing vials. Genomic DNA was isolated by means
of “Puregene kit” (Gentra System, USA). Molecular-genetic testing
performed in the laboratory of auto inflammation diseases of the
Center of Medical Genetics and Primary Health Care that has an
international certificate and is the best in the region. The most com-
mon for Armenian ethnicity 12 mutation were analyzed: M694V,
M694I, M680I (G/C), M680I (G/A), V726A, E148Q, K695R, F479L,
R761H, A744S, P369S, 1692del.
Results: 53 (30.6%) of females from total 173 carry at least one muta-
tion of FMF gene. From tested 12 mutations only 9 were detected:
M694V, M680I, V726A, E148Q, K695R, F479L, R761H, A744S, and
P369S. The most frequent finding was M694V: 19 cases (38.8%),
followed by V726A: 11cases (22.4%) and E148Q: 9 cases (18.4%).
These three mutations cumulatively comprised almost 80% of all.
Out of 53 carriers 49 were heterozygous and four carries two muta-
tions. No homozygous were observed. E148Q mutation was pre-
sented in all four compound heterozygote carriers, two in
combination with V726A and two with P369S.
Conclusion: The frequency of carrying of FMF gene mutation in Ar-
menian non-symptomatic female population is 30.6%. The most
common mutations are M694V, V726A, and E148Q. The M694V re-
ported as the most frequent mutation in hospital settings as well,
causing the most sever course of disease. Asymptomatic carrier of
compound heterozygous genotype is rare, 2.3% only.
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon hereditary auto-inflammatory disease in the world. Although
FMF is inherited autosomal recessively, some heterozygotes may ex-
press disease phenotype and require therapy. On the other hand,
some of the patients presenting manifestations evocative of FMF
might happen to be heterozygotes coincidentally due to the high
frequency of MEFV variants in at-risk populations.To date, there is no
study in the literature about how to follow-up MEFV heterozygotes
who do not fulfil FMF criteria.
Objectives: To share a single-center experience of the long-term clin-
ical and laboratory follow-up of paediatric MEFV carriers.
Methods: The hospital charts of 240 children who were heterozygous
for MEFV variants were retrospectively reviewed. Among them, 119
heterozygous patients fulfilled paediatric FMF diagnostic criteria and
were started colchicine in the first 6 months of follow-up. Ten pa-
tients who fulfilled PFAPA syndrome with one MEFV mutation were
excluded. 42 patients did not continue to be followed-up at our unit.
So, the rest 69 heterozygotes were included in this study. Families
were advised to record an FMF diary; including presence of fever, ab-
dominal pain, chest pain, arthritis, arthralgia, myalgia, and erysipelas
like erythema and also were asked to record the duration of these
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 26 of 191symptoms. Patients were asked to admit to hospital in case of any
advocative FMF symptom lasting at least 6 hours in order to check
acute phase reactants. The children were also followed-up with their
routine analysis and serum amyloid A (SAA) levels every 6 months.
The data of the visits in which an infection was reported were not in-
cluded. The averages of all laboratory parameters were then
calculated.
Results: 39 children had pathogenic mutations and 30 children had
MEFV variants of unknown significance. The most common MEFV
variants were M694V (n = 24) and E148Q (n = 16). The mean age at
admission was 7.3 ± 3 years. The mean follow-up was 3.2 ± 1.6 years
(min:2 max:6 years).
The median of average SAA level was 3.5 (3-38) mg/L and the
median of average CRP level was 0.1 (0.01-1.8) mg/dl and mean
of average ESR was 11.3 ± 5.4 (5-27) mm/hour. The children with
pathogenic mutations had significantly higher mean SAA levels
than the children with variants of unknown significance (p =
0.018), however; the mean CRP and ESR were similar. Besides, the
children with pathogenic mutations had significantly more fever
episodes than the children with variants of unknown significance
(p = 0.04). None of the children had persistent proteinuria in the
follow-up. We started colchicine in only 2 patients who were
M694V heterozygous because of initiation of typical disease
symptoms accompanied by at least one increased acute phase
protein during an attack. Both patients had family history for
FMF and fulfilled the disease criteria after 2 years of follow-up.
Neither of these patients had persistently elevated acute phase
reactants in their routine follow-up.
Conclusion: The results of this study suggested that routine clinical
follow-up is useful; however, routine periodic laboratory work-up is
not necessary among MEFV carriers. To the best of our knowledge,
this is the first study about the long-term periodic clinical and labora-
tory follow-up of MEFV carriers in the literature.
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Introduction: Familial Mediterranean fever (FMF) is a periodic fever
syndrome caused by MEFV mutations. FMF may be associated with
psoriasis in some cases. The prevalence of psoriasis in normal Turkish
population is 0.40%.
Objectives: We aimed to investigate the prevalence of psoriasis
among FMF patients and their relatives.
Methods: FMF patients followed at Hacettepe University Adult
and Pediatric Rheumatology Departments between January and
August 2016 were included. FMF patients/their relatives were ac-
cepted to have psoriasis if the diagnosis was made by a
dermatologist.
Results: 351 FMF patients (177 adults; 174 children) were in-
cluded. The median (min-max) age of adult and pediatric pa-
tients was 35 (19-63) and 10 (2-18) years, respectively. Thirteen
(3.7%) FMF patients (11 adults, 2 children) had psoriasis.Psoriasis was more common in adult than pediatric patients (p =
0.02). Psoriasis was present in 22 (12.4%) of adult and 9 (5.2%)
of pediatric patients’ relatives (p = 0.023). The frequency of psor-
iasis in ≥1 relatives of FMF patients was found to be 8.8%. Ab-
dominal pain and fever were significantly higher and arthralgia,
arthritis, pleural chest pain, pericarditis, and erysipelas-like ery-
thema were significantly less frequent in the pediatric group
than adults (p < 0.05).
Conclusion: In our study, psoriasis was more common in FMF pa-
tients than the normal population. Thus, FMF patients should be
questioned and carefully examined for psoriasis lesions and psoriasis
family history. Prospective multicenter studies may be important to
find the incidence of psoriasis in FMF.
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Introduction: Periodic fever, aphthous stomatitis, pharyngitis and
cervical adenitis (PFAPA) syndrome is a fairly common autoinflamma-
tory disease. Still, knowledge of the effects of the recurrent fever epi-
sodes on the child and its family situation are limited.
Objectives: To examine the experiences of parents regarding the
impact of the disease on the child's general well-being, the
family's situation and how the family handles the associated
challenges.
Methods: A qualitative approach was used, applying a modified ver-
sion of Grounded theory for design, data collection and analysis.
Data was collected from two different sources:
· Face-to face interviews with one of the parents of children diag-
nosed with PFAPA (n = 10, 6 mothers and 4 fathers)
· Communication between parents of children with PFAPA in a closed
Facebook group
Results: The child´s well-being was highly affected by the symptoms
during episodes. Parents experienced increased stress with constant
fatigue, social constraints of family life and restricted career oppor-
tunities. Hope of a recovery was constantly present. Parents de-
scribed a lengthy process, depicted in the following Grounded
Theory core category: From uncertainty to gradually managing and
awaiting recovery.
Subcategories (below) describes illness trajectory, illness representa-
tion and the experiences/impacts of the periodic condition:
Uncertainty (Harmlessness - severity)
·Worries · Fear · Frustration
Assurance (Establishment of diagnosis)
·Relief · Reassuring · Explaining · Guilt reducing
Gradually managing (Regularity - unpredictability)
·Suffering · Exhaustion · Isolation · Work-related limitations
Recovery
·Outgrowing PFAPA · Surgery (tonsillectomy)
Conclusion: Getting a diagnosis becomes very important for parents
since this reduces uncertainty and feelings of guilt
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Introduction: Type I interferonopathies are a clinically heterogeneous
group of Mendelian disorders characterized by constitutive upregula-
tion of type I interferon activity. Aicardi-Goutières syndrome (AGS)
manifests as an early-onset encephalopathy and sometimes mimics a
congenital viral infection. Over time, as many as 40% of patients de-
velop chilblain skin lesions on the fingers, toes, and ears. Classical
AGS phenotype was associated with mutations in seven genes en-
coding proteins involved in nucleotide metabolism and/or sensing:
TREX1 (AGS1), RNASEH2A (AGS2), RNASEH2B (AGS3), RNASEH2C
(AGS4), SAMHD1 (AGS5), ADAR1 (AGS6), and IFIH1 (AGS7). Mutations
in these genes result in the induction of type I interferon production
and upregulation of interferon stimulated genes. However, the true
extent of the phenotype associated with pathogenic variants in the
AGS-related genes is not yet known.
Objectives: To identify the genetic cause for a phenotype associating
severe encephalopathy and chilblain skin lesions in a twenty years
old male.
Methods: A twenty years old male presented since early infancy with
violaceous, scaling lesions of the fingers and toes, resorption of distal
phalanges, dystrophic nail changes and, violaceous lesions on the
nose that worsened during the cold season. He was diagnosed at
the age of 7 years with Cornelia de Lange syndrome (CdLS) based on
the phenotype associating severe somatic and psychomotor retard-
ation, microcephaly, hypertrichosis, synophrys, arched palate, strabis-
mus, hearing loss, cryptorchidism and unilateral vesicoureteral reflux
with kidney scarring. Laboratory investigations showed mild
thrombocytopenia and positive anti-thyroid antibodies. No cerebral
imaging was ever performed. The patient consulted in our Clinic be-
cause of his severe peripheral vasculopathy. The interferon type I sig-
nature was determined in the peripheral blood of the patient and
four age/sex matched healthy controls by quantitative PCR for 3
interferon-stimulated genes (ISGs) (MX-1, IFIT-1 and IFI44); a type I
interferon score was calculated as previously described (Nezos et al.
J. Autoimmunity, 2015). For disease gene identification, a next-
generation sequencing (NGS) panel followed by Sanger sequencing
were performed.
Results: The type I interferon score was markedly higher (98 times
higher) in our patient compared to healthy controls. Using a next-
generation sequencing panel, followed by Sanger confirmation, the
patient was found to be homozygous for a novel c.66delC/
p.SerGlnfs*43 variant in SAMHD1. Although not seen before, consid-
ering that this lesion is predicted to act as a biallelic nonsense muta-
tion, and in light of the clinical features, this result confirmed the
diagnosis of an Aicardi-Goutières syndrome. A cerebral MRI will be
performed to evaluate the cerebrovascular involvement in this pa-
tient, considering the risk of intracerebral large vessel involvement
with catastrophic cerebral vascular accidents associated with muta-
tions in SAMHD1.Conclusion: We describe a novel mutation in SAMHD1 in a patient
with AGS, previously diagnosed with CdLS. It is important to consider
the diagnosis of AGS in patients with neurologic symptoms in the
presence of chilblain lesions.
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Introduction: Chronic Atypical Neutrophilic Dermatosis with Lipody-
strophy and Elevated temperature (CANDLE) is a rare recessively
inherited autoinflammatory syndrome, characterized by early-onset
recurrent fevers, skin lesions, periorbital swelling, lipodistrophy, arth-
ritis, myositis, short stature and hepatomegaly. It is caused by defects
in assembly of the proteasome complex. Thus far, mutations have
been identified in 5 genes although most commonly they are found
in the PSMB8 gene.
Objectives: We present a 4 year old boy with a genetically confirmed
diagnosis of CANDLE after presenting to our clinic with the typical
clinical and laboratory features of the syndrome.
Methods: The patient was born at full-term and after uneventful
pregnancy, to unrelated parents. At 20 days postnatal age a
maculopapular rash appeared, initially confined to the extremities,
and accompanied by fever. Over the next two years the rash
spread to involve the face and body. He developed periorbital
swelling, splenomegaly, leucocytosis, iron-deficiency anemia and
thrombocytopenia. Fever, reaching up to 40 °C, was a consistent
features of disease flares. Three skin biopsies were performed
and showed evidence for perivascular and periadnexial infiltra-
tions, consisting mainly of neutrophils. Bone marrow biopsy and
immunologic investigations were unremarkable. Treatments with
Hydroxychloroquine, Methotrexate and short courses of cortico-
steroid were tried with little to no effect.
At the age of 2 years and 10 months, the boy presented to our
Clinic. Lipodystrophy, short stature (-4 SDS), typical facial features,
longer IV-th and V-th fingers of both hands and hepatomegaly
were noted in addition to the above features and a clinical diag-
nosis of CANDLE syndrome was made. Blood samples from the
child and both parents were sent to NIH for genetic testing, re-
vealing compound heterozygous mutations in the patient’s
PSMB8 gene. The two mutations, p.A92V and p.K105Q, were pre-
viously associated with CANDLE. Each parent is heterozygous for
one mutation.
Results: The patient has since been on treatment with oral Methyl-
prednisolone that proved to be effective in controlling his skin rash
and systemic inflammation at the cost of systemic side effects. Regu-
lar follow-up during the next two years showed nephrocalcinosis,
which resolved with symptomatic therapy, and arterial hypertension,
controlled by dual antihypertensive therapy. Preliminary reports in
the literature showed that JAK-inhibitors might be very effective in
controlling the disease activity and we hope to obtain this therapy
for our patient.
Conclusion: CANDLE should be considered in patients who present
with early-onset severe inflammation, typical skin rash, and lipody-
strophy. Genetic testing is already available and although therapy is
currently challenging, treatment with JAK-inhibitors holds promise
for the future.
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Introduction: The complement system represents a major part of the
innate immune system, consisting of more than 30 different proteins
in plasma and on cell surfaces and can be activated through three
different pathways. Inflammasomes are also part of the innate im-
mune system. A group of disorders in inflammasomes have been as-
sociated with autoinflammatory diseases (AIDs). Familial cold
autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS)
and chronic infantile neurological, cutaneous and articular syndrome/
neonatal onset multisystem inflammatory disease (CINCA/NOMID)
were originally described as three distinct diseases. After the identifi-
cation of their common genetic origin, i.e. mutations in the NLRP3
gene on chromosome 1q44, they are perceived as a continuum of
one disease entity and labelled cryopyrin-associated periodic syn-
dromes (CAPS). Aim of this preliminary study in a patient with MWS
was to find a correlation between the complement system and a dis-
order of autoinflammation.
Objectives: Aim of this preliminary study in a patient with MWS was
to find a correlation between the complement system and a disorder
of autoinflammation.
Methods: PBMCs (peripheral blood mononuclear cells) were isolated
from blood of a healthy donor and of an individual suffering from
MWS by density gradient centrifugation using a Ficoll Paque Pre-
mium (GE Healthcare). After washing, PBMCs were incubated with
anti-human CD14 Magnetic Beads (BD) to obtain CD14+ monocytes.
These were stimulated by addition of cytokines (IL-4 and GM-CSF) for
five days to generate immature moDCs (iDCs), which were used for
cytokine ELISAs and flow cytometric analyses. IL-6 and IL-1β cytokine
ELISAs were performed according to the manufacturer (Biolegend)
following stimulation of cells using either LPS or differentially com-
plement opsonized HIV-1. Phenotypical characterization of pathogen-
exposed DCs was performed by analyzing characteristic surface
markers (CD11c, DC-SIGN (C-type lectin receptor on DCs, characteris-
tic marker for iDCs), CD86) by multi-color flow cytometry.
Results: IL-1β production of iDCs is higher in the patients cells than
in the cells of the healthy donor. However, the most significant dif-
ference was shown in complement opsonized iDCs. DC-SIGN is
higher expressed in complement opsonized iDCs in patient cells
compared to cells of a healthy donor (37,12% v28,64%). DC-SIGN is
also higher expressed in the iDCs of the MWS patient after stimula-
tion with LPS.
Conclusion: The complement system may play an important role in
the development of an proinflammatory milieu in patients with disor-
ders of autoinflammation. The phenomenon shown in a patient with
MWS has to be reproduced in more MWS patients a well as in pa-
tients with other disorder of autoinflammation.
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Pediatric Rheumatology 2017, 15(Suppl 2):P21Introduction: Recurrent pericarditis is a common complication of
acute pericarditis and affects 15-30% of patients after an initial at-
tack. The etiology is poorly understood and about 80% of these re-
current pericarditis are "idiopathic". However, some data suggest an
autoimmune or autoinflammatory mechanism. Colchicine associated
with nonsteroidal anti-inflammatory drugs (NSAIDs) is the treatment
of choice and the use of other treatments remains exceptional.
Objectives: To analyze the clinical findings, course and treatment of
pediatric patients with recurrent pericarditis.
Methods: Retrospective monocentric study. Inclusion Criteria :1) pa-
tients with at least twice recurrence of recurrent pericarditis (RP) ; 2)
followed at Necker hospital between 2006 and 2016. Exclusion Cri-
teria : 1)Known history of autoimmune or autoinflammatory disease.
Results: Thirteen patients (10 F and 3 M) with recurrent pericarditis
were included. The median age at disease onset (first episode of
pericarditis) was 11.3 years (range 8 - 17). Two groups of patients
could be identified: In group 1 (6 patients), the recurrent pericarditis
occurred after surgical correction of cardiac malformations; in group
2 (7 patients), there was no history of cardiac disease. During the epi-
sodes of pericarditis, all patients showed fever, chest pain, electrocar-
diographic changes and increased white blood cell counts and C
reactive protein (CRP median 181 mg/l, polymorphonuclear cells
13619 g/l,) without differences between the two groups. A family his-
tory of recurrent pericarditis was noted in 2 patients from the first
group. Six patients had pleuritis and/or pneumonia with concomitant
pleural effusion (3 patients in each group). Patients in group 1 had
more recurrences than in group 2 (median 2.8 vs 1.5) during the
same follow-up period (one year). ANA > 1/640 (Anti-nuclear auto-
antibodies) and anti-DNA were present in 2 patients of each groups.
The pericardial biopsy was performed in 5 patients and displayed fi-
brosis and showed[an inflammatory tissue with predominance of
neutrophils. Initial treatments was aspirin with anti-inflammatory
dose, alone (5 patients) or in combination with Colchicine (4 pa-
tients), colchicine alone (1 patients) or in combination with ibuprofen
(1 patient) and antibiotic therapy (2 patients). To prevent recurrence,
six of patients were treated with NSAIDs associated to colchicine or
indomethacin alone. Corticotherapy was required in 2 patients in
group 2 . Anakinra was introduced in one of them because of corti-
codependence. Clinical remission was obtained in all patients after
discontinuation of the treatment (10 patients) or under treatment
(3patients). A heterozygous mutation of R92Q for the TRAPS gene
was found in 1 of the 6 patients studied. No mutation in the MEFV
gene was found.
Conclusion: Recurrent pericarditis can develop after cardiac surgery
or can be isolated. The presence of fever, inflammatory syndrome,
pericardial neutrophilic infiltrate, and the efficacy of anti-IL1 in some
patients suggests that some recurrent pericarditis could be consid-
ered as auto-inflammatory disease. Furthermore the existence of fa-
milial cases in two patients suggests a genetic susceptibility. In
conclusion early anti inflammatory treatment should be considered
in recurrent pericarditis associated with an inflammatory syndrome,
after rulling out an infection.
Disclosure of Interest: None Declared
P22
Sinogenic subdural empyema in two girls treated with
Adalimumab for chronic recurrent multifocal osteomyelitis (CRMO)
Anne Estmann Christensen, Peter Toftedal
Hans Christian Andersen Children's Hospital, Odense University Hospital,
Odense, Denmark
Correspondence: Anne Estmann Christensen
Pediatric Rheumatology 2017, 15(Suppl 2):P22
Introduction: Sinusitis is a rare cause of intracranial infection in chil-
dren. The morbidity and mortality remains high in reported series.
Objectives: We report two cases of sinusitis complicated with intra-
cranial empyema in patients treated with tumor necrosis factor-alfa
monoclonal antibody (Adalimumab) for CRMO.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 29 of 191Methods: Case report
Results: The two girls were 11 years old when the infectious compli-
cation developed.
Patient 1 had been treated with adalimumab for 15 months, as she
developed fever, acute pansinusitis and orbital cellulitis and ab-
scesses during vacation. She was treated with intravenous antibiotics
and drainage. The treatment was continued after returning home,
and clinical improvement and normalisation of C-reactive protein
(CRP) was achieved. Mild and unspecific symptoms of headache,
double vision and swelling of the forehead remained and was ini-
tially thought of as sequela after surgery. Upon further investigation
papilloedema was recognised and a CT scan of the brain showed
subdural empyema, intra cerebral oedema located in the frontal lope,
abscesses intra orbital and in the forehead, continued sinusitis and
subperiosteal abscess and osteomyelitis (Potts puffy tumor). An ag-
gressive rhino- and neuro-surgical approach combined with long-
term broad-spectrum antibiotic treatment was initiated. Despite this,
osteomyelitis in the frontal bone reoccurred several times, latest 1½
year after the initial infection. Immunosuppressive drugs have been
discontinued at the beginning of the infectious period.
Patient 2 was treated with methotrexate for a year and received ada-
limumab for a period of 3 months. In these months she developed
chronic rhinitis and allergy was suspected but not confirmed. When
psoriasis appeared adalimumab was stopped, but the chronic sinus-
itis persisted. Two months later she was admitted with high fever
and convulsions. She had discrete increased white cell count in the
spinal fluid and a CT scan showed pansinusitis but no ostitis or intra
cerebral changes. Broad-spectrum antibiotic treatment was started
together with drainage of the sinuses. She improved clinically but
CRP remained elevated. A MRI of the head was planned, but before
it was performed another convulsion occurred. MRI showed pansinu-
sitis, osteitis and subdural empyema. Functional endoscopic sinus
surgery (FESS) was performed and the girl is now improving on long-
term antibiotic treatment. Methotrexate treatment was stopped at
the initial symptoms of meningitis.
Conclusion: Tumor necrosis factor-alfa monoclonal antibody is an ef-
ficient anti-inflammatory drug used in treatment of several inflamma-
tory diseases. The increased risk of infections is well known. Special
attention should be drawn towards symptoms of chronic rhinitis/si-
nusitis, as severe intra cerebral complications, such as subdural em-
pyema, may develop. Children with sinusitis and any neurologic
finding, signs of complicated sinusitis such as Pott's puffy tumor or
orbital cellulitis, or persistent headache, fever, or nausea and vomit-
ing should have additional evaluation for sinogenic subdural
empyema.
Written consent for publication has been obtained from the parents.
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Introduction: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is a
rare auto-inflammatory disorder, characterized by recurrent episodes
of bone pain. Diagnosis can be challenging and is based on exclu-
sion. Laboratory investigations, radiology and histology are necessary
to make a differential diagnosis with malignancy, infectious osteo-
myelitis and juvenile idiopathic arthritis.
Objectives: To document clinical characteristics of pediatric patients
diagnosed with CRMO. To collect data on outcome and management
of the disease.Methods: We reviewed clinical characteristics, radiological data and
treatment in pediatric CRMO patients, followed at the pediatric
rheumatology department of the University Hospital of Leuven.
Results: Twenty-five patients were enrolled, with a mean age of
10.1 years at onset of the disease. The mean age at diagnosis was
11.2 years, with a mean diagnostic delay of 14 months. Bone pain
was the leading symptom (24/25 patients). On imaging, 148 lesions
were identified with an average of 5,9 lesions per patient. The most
common sites of involvement were the vertebrae (37%) and lower
limbs (31%), followed by the pelvis (10%) and clavicle (9%). In almost
half of patients (12/25) monotherapy with NSAIDs was sufficient to
obtain remission. The remaining 13 patients received bisphospho-
nates as 2nd-line therapy. Methotrexate was prescribed in 5 patients.
Two patients needed further therapy with biologicals: etanercept (n
= 2) and tocilizumab (n = 1). Disease was in remission in 15/25 after a
mean time of 22.7 months. The prognosis was worse in patients with
spinal involvement, resulting in more long-term sequelae
Conclusion: We present a unique pediatric cohort of 25 CRMO pa-
tients. A typical pattern of bone involvement could be found on MRI.
Lesions presented as areas of bone marrow edema, with an abnor-
mal hyperintensity on STIR images and/or abnormal hypointensity on
T1-weighted images and/or areas of contrast enhancement. NSAIDs
were administered as first-line treatment. Second-line strategies in-
cluded bisphosphonates, glucocorticosteroids, methotrexate, etaner-
cept and tocilizumab
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon autoinflammatory disease in the world. It is an autosomal reces-
sive disease caused by mutations in MEFV.
Objectives: The aim of this study is to evaluate the clinical character-
istics of FMF patients in relation with their MEFV mutations.
Methods: 378 patients (0-18 years), who were followed up at the
Department of Pediatric Rheumatology in Hacettepe University,
Ankara, Turkey, between January 2005 and October 2016, were
included in the study. Mutations in MEFV were evaluated in all of
the patients. The clinical characteristics, disease activity, need for
additional treatment and acute phase reactants were compared
according to the mutations of the patients. We have also com-
pared after dividing patients into two groups as patients with
high-risk mutations (M694V/M694V, M680I/M680I, M694V/M680I)
and others.
Results: 36.7% of the patients were homozygous for M694V. 14.3%
M694V/M680I, 10% M694V/V726A, 9% M694V/-, 6% M694V/E148Q,
3.7% M680I/V726A, and 2.9% were M680I/M680I. The patients with
M69V/M694V were significantly younger at disease onset than other
patients (3 years vs 4 years, respectively; p = 0,021). In addition, the
disease duration, disease activity, acute phase reactants, and
AIDAI(auto-ınflammatory disease activity index) values were higher
and need for additional therapy was more frequent among patients
with M694V/M694V compared to others.The disease activity, acute
phase reactants were higher and need for additional therapy was
more frequent in patients with high-risk mutations than others
(Table 14).
Conclusion: The disease phenotype is more severe in patients with
high-risk mutations. Therefore, close follow-up is critical for these
patients.
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Table 14 (abstract P24). Clinical characteristics and laboratory findings
of M694V homozygote patients
Others
(n = 240)
M694V-Homozygote
(n = 138)
p
Age of diagnosis (years), 5 (0-17) 4 (1-15) 0,098*
Disease duration (years), 6 (0-17) 7 (1-17) 0,004*
Attack status in last 6 months,
n (%)
72 (30,0) 65 (47,1) 0,001**
Attacks frequency in last 6 months 2 (1-19) 2 (1-15) 0,722*
Disease activity score 0 (0-5) 1 (0-6) <0,001*
AIDAI, 0 (0-14) 1 (0-9) <0,001*
Regular drug use (n = 192), n (%) 86 (64,7) 38 (64,4) 0,973**
Need for addditional treatment
(n = 192), n (%)
7 (5,3) 13 (22,0) <0,001**
n: number of patient; %: Column percentage; *Mann-Whitney U Test;
Table 15 (abstract P26). See text for description
Onset age p
≤5 yaş (n
= 261)
6-11 yaş
(n = 98)
≥12 yaş
(n = 19)
Age (year), median (min-max) 10 (2-18) 13 (7-18) 17 (14-18) <0,001*
Sex, n (%) Male
Girl
143 (54,8)
118 (45,2)
56 (57,1)
42 (42,9)
10 (52,6)
9 (47,4)
0,897**
Attack Status in Last 6 Months
n (%)
100 (38,3) 29 (29,6) 8 (42,1) 0,237**
Attack frequency in the last
6 months median (min-max)
2 (1-19) 2 (1-6) 1,5 (1-3) 0,226*
ISSF, median (min-max) 1 (0-6) 1 (0-5) 1 (0-4) 0,103*
Treatment compliance (n = 192),
n (%)
84 (66,7) 31 (57,4) 9 (75,0) 0,363**
Need for additional treatment
(n = 192), n (%)
12 (9,5) 7 (13,0) 1 (8,3) 0,764**
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon auto-inflammatory disease which is characterized by recurrent,
self-limited flares of fever associated with polyserositis. The associ-
ation with infectious disease is not clear except for the association
with helicobacter pylori infection.
Objectives: In this study, the aim was to assess whether there was a
tendency to infections.
Methods: 197 children with FMF who were followed at the Depart-
ment of Pediatric Rheumatology in Hacettepe University, Ankara,
Turkey between May 2016 and October 2016 were included in the
study. In immunodeficiencies, the tendency for infections are defined
as acute otitis media, sinusitis and pneumonia frequencies in a year,
intravenous antibiotic requirement, presence of abscess, presence of
recurrent urinary tract infections and acute gastroenteritis. We have
assessed these frequencies in our patient groups according to muta-
tions and attack frequencies.
Results: 30.4% of the patients were in the M694V homozygote group
and 42.1% were in high-risk mutation(M694V/M694V, M680I/M680I,
M694V/M680I) group. When examining M694V homozygous patients;
3% of patients had more than 4 acute otitis media per year, 6.7%
had sinusitis more than 4 per year, and 1.7 had more than 4 per
month of upper respiratory tract infection. All of the patients had less
than 2 pneumonia per year. Only 6.7% of patients needed intraven-
ous antibiotics. Recurrent urinary tract infection was present in 3.3%
and abscess was 1.7% of patients. 13.4% of the patients had a history
of acute gastroenteritis.
When examining high-risk mutations patients; 3.6% of patients had
more than 4 acute otitis media per year, 4.8% had sinusitis more than 4
per year, and 2.4% had more than 4 per month of upper respiratory
tract infection. All of the patients had less than 2 pneumonia per year.
4.8% of patients needed intravenous antibiotics. Recurrent urinary tract
infection was present in 3.6% and abscess was 1.2% of patients. 14.4%
of the patients had a history of acute gastroenteritis.
There was no statistically significant difference in the incidence of in-
fection between mutation groups.
When the patients who had an attack in the last 6 months were ex-
amined, there was no significantly difference in infection status.
**Pearson chi-Square TestWhen the patients, who had increase in any infection frequency, were
evaluated according to the mutation groups and attack status in the last
6 months, there was no significantly difference between the groups.
Conclusion: FMF patients are not inclined to develop infections as in
immunodeficiencies. It may be speculated that the abnormality in the
innate immune system in these patients does not significantly inpair
host defense. More extensive work on this issue may be needed.
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon autoinflammatory disease in the world. The disease course
could be different in different age groups.
Objectives: In this study, we aimed to study the disease characteris-
tics, treatment compliance and need for additional treatment accord-
ing to age groups of FMF patients.
Methods: 378 FMF patients (0-18 years) followed at the Department of
Pediatric Rheumatology in Hacettepe University, Ankara, Turkey, be-
tween January 2005 and October 2016 were included in the study. The
patients were evaluated in three groups according to their age at dis-
ease onset; 0-5, 6-11, 12-18 years. The treatment compliance was evalu-
ated in 199 out of 378 patients according to their present ages.
Results: The disease onset was ≤5 years in 69%, 6-11 years in 26%, and
≥12 years in 5% of patients. Fever symptom was significantly less fre-
quent in the ≥12 years group than the other age groups. The characteris-
tics of patients according to age groups (at symptom onset) are
presented in Table 15. The disease onset was significantly younger in pa-
tients homozygous for M694V mutation than patients who were negative
for M694V (p = 0.021). 64,6% of 199 patients were compliant to colchicine
treatment. When we grouped these patients according to their present
age, ≤5 years group was the most compliant and the adolescent patients
(≥12 years of age) was the less compliant to treatment (p < 0.05).
Conclusion: The disease course may be different in different age
groups in FMF. FMF may present with less typical phenotype when
the symptoms start at an older age (less fever symptom in adoles-
cent. Treatment compliance is very critical in FMF patients and our
results have emphasized that poor compliance is an important prob-
lem in especially adolescent patients.
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon auto-inflammatory disease which is characterized by recur-
rent, self-limited flares of fever associated with polyserositis. Oral
apthosis and periodontitis may be seen in the course of the dis-
ease. However we lack studies on the dental care in pediatric
FMF patients.
Objectives: In this study, the aim was to report the oral findings and
to check the effects of tooth decay on disease course in children
with FMF.
Methods: 199 children with FMF who were followed at the Depart-
ment of Pediatric Rheumatology in Hacettepe University, Ankara,
Turkey between May 2016 and October 2016 were included in the
study.
Results: The characteristics of patients are presented in Table 16. The
mean age of patients was 11.24 ± 4.04 years. Tooth decay was ob-
served in 182 (91.5%) patients. Tongue abnormalities in 65 (32.8%),
lip abnormalities in 13 (6.6%), buccal abnormalities in 6 (3%). Oral
aphthosis occured in 21 (10.6%), and recurrent oral aphthosis in 67
(33.8%) patients. The median (min-max) dental plaque index was
1.26 (0-2.25), and the median gingival index was 0.87 (0-1.81).
Erythrocyte sedimentation rate and the attack frequency at the last
six months were both higher in the patients with tooth decay than
patients who did not have decay. Tooth decay was more common
away M694V homozygous patients (98.3% vs 88.6%, p = 0.025;
respectively).
Conclusion: The frequency of the tooth decay was higher in our pa-
tient group compared to previously reported Turkish figures(91.5%
vs 69.8-73.1%; respectively). The attack frequency at the last six
months was higher away patients with tooth decay. Our results may
suggest that dental problems may be a trigger for inflammatory at-
tack in FMF. On the other hand, the chronic inflammation itself may
be a risk factor for tooth decay in FMF.
Disclosure of Interest: None DeclaredTable 16 (Abstract P27). The demographic and laboratory features of
the patients
All patients
(n = 199)
Patients with
tooth decay
(n = 182)
Patients who did not
have tooth decay
(n = 17)
median
(minimum-
maximum)
The status of attack at the
last six months, n (%)
115 (57.7) 75 (97.4) 2 (2.6)
The frequency of attacks at
the last six months (n = 115)
0.96 ± 2.08/0
(0-19)
2 (1-19) 2.5 (2-3)
n (%)
Deciduous tooth decay 166 (83,4)
Permanent tooth decay 104 (52,3)
Tooth decay 182 (91,5)
Dental plaque index 1.26/198 (0-
2.25)
Gingival index 0.87/198 (0-
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Introduction: In 2008 the Paediatric Rheumathology European Soci-
ety (PReS) promoted an International Project (EAHC, Project
No2007332) for the study of Autoinflammatory Diseases (AIDs)
named Eurofever, whose main purpose is to create a web-based
registry for the collection of clinical, laboratory, instrumental and re-
sponse to treatment information in patients with AIDs.
Objectives: To implement the Registry with the new recently de-
scribed AIDs and to increase the collection of longitudinal data, par-
ticularly regarding treatment and safety.
Methods: The data analysed in the study were extracted from the
Eurofever registry, which is hosted in the PRINTO website (http://
www.printo.it). From February 2015 we started the longitudinal col-
lection of follow-up data for the patients already included in the
Registry with particular focus on treatment, modification of the clin-
ical picture, onset of complication/sequelae/adverse events.
Results: Up to date 3648 patients (M:F = 1799:1849) have been en-
rolled in the Registry from 60 different countries (all of them with
available baseline demographic information). In 3183 pts (87%)
complete clinical information and response to treatment data from
disease onset to diagnosis are also available. For each disease the
number of enrolled patients is: FMF 1012 pts (877 with complete
clinical data); CAPS 289 pts (268 with complete clinical data); TRAPS
272 pts (254 with complete clinical data); MKD 203 pts (188 with
complete clinical data); Blau’s disease 50 pts (26 with complete clin-
ical data); PAPA 35 pts (all of them with complete clinical data);
NLRP-12 mediated periodic fever 13 pts (10 with complete clinical
data); DADA2 10 pts (6 with complete clinical data); SAVI 3 pts (all of
them with complete clinical data); DIRA 3 pts (all of them with
complete clinical data); Majeed 3 pts (all of them with complete clin-
ical data); CANDLE 1 pt (with complete clinical data). Among multi-
factorial autoinflammatory diseases: PFAPA 653 pts (530 with
complete clinical data); CRMO 535 pts (513 with complete clinical
data); 340 pts with undefined periodic fever (269 with complete clin-
ical data); Bechet disease 215 pts (186 with complete clinical data)
and Schnitzler syndrome 11 pts (all of them with complete clinical
data).
Longitudinal data are available for 393 pts (11%, M:F = 190:203). For
each disease, the number of patients with at least one follow-up visit
is: FMF 72 pts, CAPS 36 pts, TRAPS 32 pts, MKD 29 pts, PAPA 6 pts,
DADA2 3 pts, SAVI 1 pt, DIRA 1 pt. Among multifactorial diseases:
CRMO 99 pts, Bechet disease 67 pts, undefined periodic fever 29 pts,
PFAPA 14 pts, Schnitzler syndrome 4 pts.
Conclusion: The enrolment in Eurofever Registry is still ongoing. The
longitudinal collection and analysis of data coming from the Registry
will improve our knowledge both on the natural history of the single
disease and on the efficacy/safety of treatment commonly used in
the clinical practice.
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Introduction: CAPS is a rare autoinflammatory disease associated
with mutations in the CIAS1 gene, encoding for NLRP3 that result in
overactivation of the inflammasome and systemic inflammation.
Muckle-Wells syndrome (MWS) is a rare autosomal dominant disease
which causes episodic fever attacks, sensorineural deafness, recurrent
hives, arthritis and eye involvement.
Objectives: Here we present the findings of eye involvement in a
family whose 11 members have MWS.
Methods: Clinical data was collected during the course of ongoing
patient care.
Results: We evaluated the clinical features of 11 patients who were
referred to a tertiary care center. The median age of the patients was
25 years (range: 9-65). The ratio of females/males was 1.2 (6/5). All
patients had arthritis with exacerbation on exposure to cold and re-
current episodes of pink eye. The median age of onset of ocular in-
volvement was 8 years (2-45). We observed severe eye involvement
in 27% of our cases, including band keratopathy, severe damage of
corneal stroma and neovascularization. Corneal involvement and
clouding was detected in four patient. Two of those had the diagno-
sis of keratoconus as well. Patients with keratoconus had corneal
scarring due to corneal hydrops verified with corneal topography.
The other two patients with corneal clouding had bant keratopathy.
One of those patient was a 17 year old girl who had recurrent uveitis
with hypopyon which necessiated the use of intravitrealdexamethasone implant. She also had posterior synechia of the iris
to the lens. The other eye of that patient had signs of phthisis bulbi.
The other patient with bant keraopathy was 46 years old male who
had optic atrophy and tractional fibrovascular membranes at the
posterior pole of the eye. Anakinra was used for treatment of 5 cases,
and canakinumab of 3 cases. It was observed that the frequency of
conjunctivitis decreased after anti IL-1 therapy. There was no muta-
tion detected in the study of MEFV (all exons), TNFRSF1A (exons 2 to
7), MVK (all exons), NLRP3 (all exons), NOD2 (exons 4, 8 and 9) and
PSTPIP1 (exons 10 and 11) genes.
Conclusion: In this study, it has been shown that eye findings related
to MWS can vary from conjunctivitis to severe uveitis. We want to
emphasize that ocular involvement in MWS should be carefully
assessed, since it can lead to visual impairment.
Trial registration identifying number:
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is an
auto-inflammatory condition primarily affecting children with an esti-
mated prevalence of 1 per 106. The umbrella term CRMO includes
patients unifocal and multifocal disease that meet the diagnostic
criteria.
Objectives: To describe clinical phenotype of an Irish cohort of pa-
tients with CRMO and compare those with unifocal and multifocal
disease.
Methods: This study was a retrospective chart review of a prospect-
ively gathered cohort of patients attending a single paediatric
rheumatology centre.
Results: Since 2006, 42 patients have been diagnosed with CRMO at
the National Centre for Paediatric Rheumatology (NCPR) and 5 of
these have unifocal disease. Patients with unifocal disease had a sin-
gle site involved throughout the disease. Three patients with unifocal
disease had a single symptomatic episode. All patients met the diag-
nostic criteria proposed by Jansson et al and are ethnically Irish.
Overall the mean age at diagnosis was 10.4 years, diagnostic delay
was 0.78 years and number of physicians seen prior to referral to
paediatric rheumatology was 3.5. All patients with unifocal disease
and 68% of patients with multifocal disease were female (overall F:M
= :1). The distribution of lesions was similar in both groups. In pa-
tients with unifocal disease, all underwent biopsy to confirm the
diagnosis, none had systemic symptoms at presentation, synovitis at
any stage or a personal history/first-degree relative with an associ-
ated autoimmune disease. In patients with multifocal disease, 81%
underwent biopsy, 24% had systemic symptoms at presentation,
21% had synovitis and 38% had a personal history/first-degree rela-
tive with autoimmune disease. 1 patient (20%) with unifocal disease
was refractory to NSAID treatment and received methotrexate. 14 pa-
tients (38%) with multifocal disease were refractory to NSAID
treatment and received methotrexate, corticosteroids, anti-TNF, pami-
dronate or a combination of these.
Conclusion: The clinical phenotype of patients with unifocal CRMO
appears to be different to those with multifocal disease. It may be
less frequently associated with other autoimmune or autoinflamma-
tory conditions and more frequently responsive to NSAID treatment
alone. However, the number of patients with unifocal disease in this
cohort was low.
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Introduction: Bone marrow oedema in a child is a rare and uncom-
mon condition associated with joint and bone pain exacerbated by
weight bearing.
Objectives: We re-evaluated in the period of 2015-2016 seven
pediatric patients referred to our Rheumatology Clinic for persistent
foot pain with MRI oedema of the feet bones (interpreted commonly
as algodystrophic syndrome manifestation); they had all been mis-
diagnosed in other institutions as affected by algodystrophy of the
ankle/feet or complex regional pain syndrome (CRPS).
Methods: All the patients were re-evaluated with clinical examin-
ation, blood samples of bone turnover and vitamin D levels.
Results: Mean age of the 7 patients (F:M 6:1) was 11 years. 3 of the pa-
tients (43%) had a previous diagnosis of oligoarticular juvenile idiopathic
arthritis ANA+ with the disease in complete remission at the moment of
the clinical evaluation; 4 patients did not suffer from any chronic disease.
Physical examination did not reveal any skin color change (rubor)
but intense pain limited to the skeletal sites of feet and ankles; only
two patients (28%) had a slight swelling of the feet.
6 of the patients suffered from joint hypermobility with recall of
minor ankle strain prior to the symptoms onset as precipitating event
after meticulous history; 1 was a football player and reported recur-
rent feet microtrauma.
1 patient had been treated in another institution with bisphospho-
nates without any improvement. Bone turnover markers were normal
in the 6 patients not treated previously with bisphosphonates; vita-
min D was below the lower limits in all patients (72% < 20 ng/mL).
All Patients were treated with an adequate daily vitamin D intake and
symptomatic pain relief was achieved with low dose NSAIDs (ibupro-
fen) or a short course of steroid treatment (prednisone); rest and phys-
ical therapy were recommended; vitamin C was added when diet
intake was too low according to minimal daily diet recommendations.
Clinical improvement appeared within a 2 to 3 month treatment period
in all patients; MRI performed in the 3 patients with over 6 month of
treatment documented complete regression of bone marrow oedema.
Conclusion: Symptoms and disability out of proportion to the clinical
findings is a clinical key feature of MRI bone oedema of painful skel-
etal sites in children; differential diagnosis with the multifacet
pediatric CRPS is possible when bone oedema is associated with lim-
ited clinical findings; it may be secondary to underestimated articular
microtraumatisms in a bone turnover milieu of vitamin D deficiency;
we underline the importance of supplementing vitamin D until the
age of 18 as daily drops, in order to avoid its deficiency, which, in
combination with other environmental and predisposing factors,
could be the cause of invalidating clinical complaints.
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non-infectious inflammatory bone disorder that affects young chil-
dren and adolescents. It usually affects multiple sites and most com-
monly the metaphyseal regions of long bones in the lower limbs,
pelvis and clavicles.
There is presently no approved guideline for evaluation of bone in-
flammation in chronic non-bacterial osteomyelitis (CNO) or chronic
recurrent multifocal osteomyelitis (CRMO). Bone scan (BS) has been
the conventional imaging modality used to evaluate this rare inflam-
matory bone disease. While recent literature suggests whole body-
magnetic resonance imaging (WB-MRI) as the imaging modality of
choice, limited resources and high costs are often prohibitive.
Objectives: We aimed to compare the diagnostic yield of bone scan
to WB-MRI in CRMO in relation to clinical symptoms and location of
lesions on imaging.
Methods: A retrospective review of clinical notes of children with
CNO/CRMO was performed. 7 patients with paired BS and WB-MRI
performed less than 9 weeks apart between September 2009 and
October 2015 were analysed. Patients were excluded if both scans
were done more than 9 weeks apart or if there was treatment
change between scans.
Results: Four sets of scans were performed at diagnosis and 3 sets
after initiation of treatment. BS and WB-MRI detected a total of 29
and 40 lesions respectively. 6 out of 7 patients had asymptomatic le-
sions. 17/29 (58.6%) and 27/40 (67.5%) were found on BS and WB-
MRI respectively.
Symmetrical lesions were detected in 4/7 patients with no significant
difference between both modalities (BS 43% vs MRI 57%). All sym-
metrical lesions occurred in the pelvis and lower limbs. BS was super-
ior in detecting lesions in the spine (85.7% vs 57.4%) and feet (42.8%
vs 14.29%), whereas WB-MRI was better for upper limb (0% vs
14.29%) and lower limb (57.1% vs 71.4%) lesions. Both performed
equally in detecting lesions in the pelvis and clavicles, with an inci-
dence of 85.7% and 28.6% respectively.
None of the differences in results reached statistical significance but
our cohort of patients was small.
Conclusion: Whole body bone scan performs comparably to MRI in
detecting inflammatory bone lesions in CRMO, both symptomatic
and asymptomatic. Bone scan remains an appropriate and accessible
imaging modality in the evaluation of CRMO, particularly in institu-
tions where resources are limited.
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Introduction: The decrease in mineral bone density (BMD) is one of
the main manifestations of juvenile idiopathic arthritis (JIA).
Objectives: To evaluate indicators of bone metabolism in patients
with articular JIA.
Methods: The study included 66 patients with articular variant of JIA
(36 oligoarticular variant of the disease, 30 - with polyarticular),
whose average age of 9.74 + 3.56 years, boys – 28, girls - 38. All pa-
tients by ELISA in the serum was assessed level: beta crosslaps c-
terminal telopeptide (CL), osteoprotegerin (OPG), a membrane pro-
tein RANKLand 25-hydroxycholecalciferol (25(Oh)D), carried out ultra-
sonic densitometry. The obtained data were compared with the
results defined in the group of children without signs of inflamma-
tory diseases (comparison group).
Results: The results of densitometry showed a reduction in BMD in
the range Z = -1,1 -2,6 SD up to 40% of cases with oligoarticular the
form of JIA and in 57,7% of cases, polyarticular JIA variant. Deficiency
Table 17 (Abstract P37). Comparison between JATA single-item scores
and JATA TMJ-GA before and after TMJ intraarticular corticosteroid injec-
tion (IACI); VAS 0-10 (0 = worst;10 = best). Values are expressed as me-
dian (IQ). Wilcoxon test; statistical significance: p < 0.05.
Pre-TMJ IACI Post-TMJ IACI p
Ability to bite a sandwich/an
apple/a “bombolone”
5,0 (4,8-6,0) 9,0 (8,0-10,0) 0,022
Ability to eat a pizza or a steak 5,0 (4,0-7,0) 9,0 (8,5-10,0) 0,036
Ability to accurately wash the
teeth
4,0 (4,0-7,3) 10,0 (9,5-10,0) 0,035
TMJ global assessment 5,0 (3,0-5,3) 9,0 (8,5-9,5) 0,022
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and polyarthritis detected at 23.3% and 50%, respectively, and the
failure is at 76,7% and 50%, respectively. In the control group, these
figures were 10% and 75%, respectively. The ratio of RANKL/OPG in
children with oligoarthritis were 0.17 and polyarthritis - 0,22 in the
control group - 0,07. Indicators of CL, indicating bone resorption in
the group of oligoarthritis was increased at 93.3%, in the group of
polyarthritis in 100%.
Conclusion: Thus, in patients with JIA is a decrease in BMD, with
changes in biochemical parameters outstrip the capabilities of the
method of instrumental diagnosis (densitometry) and can be recom-
mended for research on early stages of osteopenia providing for
timely correction of bone metabolism.
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Introduction: Several studies investigated the accuracy and efficacy
of IACI for the treatment of TMJ involvement in JIA. However, the im-
pact on patients’ daily activities and patients’ acceptance of TMJ IACI
has been scarcely studied.
Objectives: To detect variations in daily activities involving TMJs in
patients with JIA, before and after TMJ IACI, through a Juvenile Arth-
ritis TMJ self-reported Assessment (JATA) questionnaire, developed
for the purpose. Second aim: to assess the patients’ acceptance of
the TMJ IACI procedure at the study center.
Methods: Patients with JIA and clinical involvement of TMJ consecu-
tively seen at the study center in September-December 2016, with at
least 8 years of age, were asked to identify the daily activities most
affected by TMJ arthritis. From the collected items, we asked them to
select the most relevant and representative of “TMJ well-being/wors-
ening” in their daily life. We included in the JATA the items most fre-
quently selected and a patient’s global assessment (GA) of their TMJs
(VAS 0-10; 0 = worst; 10 = best). Then, a subgroup of patients, who
underwent to intraarticular corticosteroid injection (IACI) of one or
both TMJ, was asked to complete the questionnaire (VAS 0-10; 0 = to-
tally unable, 10 = fully able) and TMJ-GA, before and after the thera-
peutic intervention. Further, we asked the patients to provide a
global assessment of the TMJ IACI procedure performed at the study
center (VAS 0-10; 0 = worst; 10 = best). Statistical analysis was per-
formed using GraphPad Prism 5 software. Scores of each item and
JATA-score were compared between pre- and post-TMJ IACI (Wil-
coxon matched pairs test, statistical significance: p <0.05).
Results: Twenty (77%) out of the 26 eligible JIA patients identified
daily activities most relevantly affected by TMJ involvement. There-
after, the items most frequently selected were included in the JATA:
1.ability to bite a sandwich/an apple/a “bombolone”; 2.ability to eat a
pizza or a steak; and 3.ability to accurately wash the teeth. Eight pa-
tients (100% female, 62.5% with persistent oligoarthritis and 12.5%
with extended oligoarthritis, polyarticular RF-negative, and polyarticu-
lar RF-positive, respectively) filled the JATA questionnaire, reporting
their abilities and global assessment of TMJ before and after TMJ
IACI. Each questionnaire was completed in about 3-5 minutes. We
observed a statistically significant improvement in the scores, both ofthe single items and the TMJ-GA, prior and after TMJ IACI (Table 17).
The procedure was evaluated with a median score of 8 (IQR: 7.8-10).
Conclusion: The JATA questionnaire demonstrated to be easily ap-
plicable and showed significant improvement of each item, after TMJ
IACI. TMJ IACI procedure at the study center was well accepted. Fur-
ther studies are planned to confirm these results and investigate the
applicability of JATA in clinical practice and research.
Disclosure of Interest: None DeclaredP38
Early pain report in oligoarticular juvenile idiopathic arthritis is
related to long-term outcome
Ellen D. Arnstad1,2, Veronika G. Rypdal3,4, Suvi Peltoniemi5, Ellen Nordal3,4,
Lillemor Berntson6, Kristiina Aalto5, Anders Fasth7, Troels Herlin8, Susan
Nielsen9, Marek Zak9, Pål R. Romundstad10, Marite Rygg2,11 and Nordic
Study Group of Pediatric Rheumatology (NoSPeR)
1Department of Pediatrics, Levanger Hospital, Levanger, Norway;
2Department of Laboratory Medicine, Children’s and Women’s Health,
NTNU - Norwegian University of Science and Technology, Trondheim,
Norway; 3Department of Pediatrics, University Hospital of North Norway,
Tromsø, Norway; 4Department of Clinical Medicine, UIT The Arctic
University of Norway, Tromsø, Norway; 5Department of Pediatrics,
Children’s Hospital, Helsinki University Hospital, Helsinki, Finland;
6Department of Women`s and Children`s Health, Uppsala University,
Uppsala, Sweden; 7Department of Pediatrics, University of Gothenburg,
Gothenburg, Sweden; 8Department of Pediatrics, Århus University
Hospital, Århus, Denmark; 9Pediatric Rheumatology Department,
Pediatric Clinic II, Copenhagen University Hospital, Rigshospitalet,
Copenhagen, Denmark; 10Department of Public Health and General
Practice, NTNU - Norwegian University of Science and Technology;
11Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway
Correspondence: Ellen D. Arnstad
Pediatric Rheumatology 2017, 15(Suppl 2):P38
Introduction: Persistent course oligoarticular juvenile idiopathic arth-
ritis (JIA) has the best prognosis of all JIA categories. One third of
children with oligoarticular onset will, however, develop oligoarticular
extended JIA or other JIA categories during the course of the disease
with outcome similar to polyarticular disease (1). Therefore it is im-
portant to look for early predictive factors to define long-term out-
come for these children. Pain is a frequent complaint, and
knowledge of pain and its relevance for disease outcome is limited.
Objectives: To study if self-reported pain early in disease course can
predict long-term disease outcome among children with oligoarticu-
lar JIA.
Methods: Consecutive cases of JIA from defined areas of Norway,
Denmark, Sweden and Finland with onset in 1997 to 2000 were pro-
spectively included in a population-based cohort study (1). Self-
reported pain was measured on a 10 cm visual analogue scale (VAS-
pain). The Finnish participants were excluded due to lack of pain
scores. Remission at 8 years follow-up was defined according to Wal-
lace (2). We used binomial regression in STATA for multivariable
analyses.
Results: The final study population consisted of 243 children, and of
these 120 (49%) had oligoarticular disease 6 months after disease
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 35 of 191onset. Median age at onset in the oligoarticular group was 5.0 years,
73% were girls and 67% reported VASpain >0 six months after disease
onset. At 8 years follow-up 43% had developed oligoarticular ex-
tended or other JIA categories, 49% reported VASpain >0 and 53%
were not in remission off medication.
In the oligoarticular onset group, we analyzed associations between
early pain reports and outcome at 8 years follow-up. Children report-
ing pain 6 months after disease onset developed oligoarticular ex-
tended or other JIA categories more often compared to those
reporting no pain at 6 months (percent point difference 19%, 95% CI
[1-37%]). Among those reporting pain at 6 months, a higher propor-
tion reported pain also at 8 years, compared to children with no pain
at 6 months (percent point difference 35%, 95% CI [16-53%]. Pain at
6 months was associated with not being in remission off medication
at 8 years compared to no pain at 6 months (percent point differ-
ence 36%, 95% CI [19-54%]. After adjustments for age and sex, the
results were similar.
Conclusion: Early pain report among children with oligoarticular JIA
seems to predict development into prognostically more unfavourable
JIA categories, more pain persistence and more severe long-term dis-
ease outcome.
References:
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Introduction: Temporomandibular joint (TMJ) involvement with both
active and chronic signs of arthritis is seen very often (17-87%) in
children with juvenile idiopathic arthritis. Contrast enhanced MRI is
the golden standart for diagnosis of TMJ arthritis. There are data that
specific HLA II class alleles can be asociated with more severe disease
course and radiologic progression in patients with rheumatoid
arthritis.
Objectives: To identify HLA II class alleles of risk and protection in
JIA patients with chronic arthritis signs in temporomandibular joints
evaluated with contrast enhanced MRI.
Methods: We performed retrospective study with 72 JIA patients
treated at Childrens university hospital in whom TMJ MRI was per-
formed and acute or chronic or both signs of arthritis were detected.
Patients were genotyped for HLA- DRB1; DQB1; DQA1- using RT-PCR
with sequence-specific primers. Associations of DRB1; DQB1; DQA1
alleles in patients were examined individually using the Chi-square
test and Cochran-Mantel-Haenszel test.
Results: 72 JIA patients with mean age of 13.9 years (range 6.0-
17.9 yr); 48 (77%) girls and 14 (23%) boys. The mean duration of the
disease from the time of diagnosis till performing TMJ MRI was
1.5 years (range 0.2-8.0 yr). JIA subtypes were as follows: seronega-
tive polyarthritis 60%, seropositive polyarthritis 8%, peristant olygoar-
thritis 2%, arthritis with enthesitis 9%, undifferentiated 3% and 2%for
systemic arthritis.
Two groups were separated on the basis of presence of chronic arth-
ritis signs (n = 62) or absence of them (n = 10). Alleles DRB1*14 (OR =
0.19, 95% CI from 0.04 to 0.92, p = 0.039) and DQA1*05:01 (OR = 0.29,
95% CI from 0.11 to 0.80, p = 0.016) were less often observed in the
group with chronic arthritis signs than in the group without them.There were no longer duration of disease in the group with chronic
arthritis signs (1,47 ± 1,98) compared with 2nd group (2,71 ± 3,30) (p
= 0,173).
Conclusion: Alleles DRB1*14 and DQA1*05:01 are possibly protective
for development of structural damage in temporomandibular joints
in JIA patients and is not dependent on duration of the disease.
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Introduction: Juvenile idiopathic arthritis (JIA) consists of an auto-
immune condition with several subgroups with distint clinical, la-
boratory features and therapy response. Although antinuclear anti-
body (ANA) positivity can be found in all subtypes, a higher
prevalence in the oligoarticular form is well known. Recently, its asso-
ciation with the remission rate has been studied, but few data are
available.
Objectives: To evaluate the clinical response based on ANA status in
JIA patients.
Methods: We performed an observational retrospective study with
all children diagnosed with JIA followed in our Rheumatology
Pediatric Unit until april 2017. Demographic and clinical data were
colleted from medical records. JIA subtypes were categorized accord-
ing to the classification of the International League of Associations
for Rheumatology 2001. ANA were considered positive when at least
2 titers were ≥ 1/100. Remission status at follow-up was defined using
the Wallace preliminary criteria. Parametric and non-parametric test
were used for statistic analysis (SPSS 20.0). P-values <0.05 were con-
sidered statistically significant.
Results: A total of ninety-four patients were enrolled. Sixty-three
were female (67%). The mean age at time of diagnosis was
7.2 years (SD 4.4) and the mean follow-up was 8.9 years (SD 6.6).
The most common subgroup was oligoarticular persistent JIA
(38.3%), followed by polyarticular (25.5%), systemic (13.8%), psori-
atic (10.6%), enthesitis-related arthritis (7.4%) and oligoarticular
extended JIA (4.3%). Extra-articular manifestation as uveitis was
seen in 14 patients. Both rheumatoid factor and anti-citrullinated
peptide antibody were positive in 37.5% of the polyarticular JIA.
ANA positivity was presented in 41.5% of all patients, in which
was found a significant predominance of the oligoarticular form,
female gender, earlier onset of disease and increased risk of de-
veloping chronic anterior uveitis during the course of the disease
(p = 0.001, p = 0.025, p = 0.001, p = 0.015, respectively). The mean
joint count at diagnosis was 3.9 (SD 5.0). At the last follow-up
evaluation the mean joint count was 0.32 (SD 0.7), almost 59% of
the patients were in remission (25.5% on medication for at least
6 months and 33% off medication for ≥ 12 months) and 41.5%
had active disease. 6.4% of the patients were treated with bio-
logic monotherapy, 37.2% were receiving classic DMARDs while
14.9% were under combination therapy. In the group of patients
in remission on medication >6 months, 8.3% and 45.8% of the
patients were treated with biologic and classic DMARDs respect-
ively, and combination therapy was observed in 37.5% of them.
In the group with active disease, biologic monotherapy, classic
DMARDs or combination therapy use was seen in 10.3%, 61.5%
and 12.8% of the patients, respectively. No significant diferences
were found in what concerns clinical outcome when comparing
ANA-positive and ANA-negative patients (p = 0.091).
Conclusion: Our study demonstrates once again the association be-
tween the ANA positivity and the oligoarticular subtype, female pre-
dominance and the presence of uveitis. It also supports the late
literature that didn’t find a relationship between the remission rate
and ANA status.
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Introduction: Juvenile idiopathic arthritis (JIA) is the childhood disabil-
ity from a musculoskeletal disorder. It generally affects large joints such
as the knee and the ankle. JIA combine with muscle weakness, poor
flexibility, atrophy, pain, and decreased proprioception of the affected
joints, abnormal biomechanics, articular cartilage damage.
Objectives: We aimed to observe the effects of knee Q deformity on
postural stability of children with pes planovalgus having JIA.
Methods: Twenty participants as age range 4-16 years (4 female,16
male) were enrolled this study. New York Posture Rating Scale were
used to evaluate the posture of participants. Hand held dynamometry
was used to assess the strength of the lower extremity muscles. Their
static balance evaluated with Flamingo balance test. Their dynamic bal-
ance evaluated with Prokin balance system. Q angle was calculated by
Universal desktop ruler. Universal Desktop Ruler allows you to measure
not only a straight-line distance but any curved distance on the screen.
For statistical analysis SPSS Version 21.0 program was used.
Results: For our statistical evaluations, abduction, adduction, knee
flexion and extension negatively, knee flexion angle and addiction
angle positively may affect static balance(p < 0,05). In addition to
that, dynamic balance related to power of plantar flexion positively,
knee extension, inversion, abduction angle positively. The results of
this study showed that knee flexion angle and plantar flexion angle
may affect Q angle negatively. There is statistically significant effect
between Q angle and posture deformity (p < 0.05).
Conclusion: In this study, power of hip flexion structure and function of
the foot and ankle, and there is preliminary evidence that foot problems im-
pair balance. Balance has often been used as a measure of lower extremity
function and is defined as the process of maintaining the center of gravity
within the body's base of support. These results are supported by evaluat-
ing more children with juvenile idiopathic arthritis with pesplanovalgus.
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Introduction: Pediatric immune-rheumatologic diseases are rare, char-
acterized by chronic course and significant impact on patient’s life. Re-
cent developments have significantly improved the prognosis of these
diseases, but a close follow-up of patients’ cohorts is essential to evaluate
the long- term outcome. The JIRcohorte is an international platform de-
veloped to follow pediatric immune- rheumatologic diseases, andevaluate the long-term tolerance and efficacy of immunosuppressive
and biological therapies. The challenge was to develop a tool with items
both common for all patients and specific for each disease.
Objectives: Describe the multi-module tool implemented in the JIRcohorte
platform and the collective of patients included in the different modules.
Methods: For each of the eCRF, an expert group has defined the items
to be collected for prospective follow-up of patients with a specific dis-
ease. A first comparison was done to highlight the identical items from
the different eCRF and the items specific to each one. For all the items
reported in more than one module in a similar but not identical way, a
negotiation between the experts made it possible either to find a com-
mon item or to clearly define the difference between them. We de-
scribe the patients of 45 centers (in Belgium, France, Maroc and
Switzerland) included in the JIRcohorte between 2014 and 2017.
Results: Thanks to the development of a multi-module tool, we were able
to reduce the number of items to insert in the JIRcohorte from 3860 to
2188, by keeping the same level of information. A total of 3266 patients
and 10733 visits were collected. The number of patients and visits per mod-
ule are as follows: Juvenile Idiopathic Arthritis (1371 patients, 4782 visits),
Temporomandibular Arthritis (64, 156), Juvenile Dermatomyositis (18, 61),
Juvenile Systemic Lupus (121, 369), Juvenile Periodic Fever Syndrome (450,
803), Still Disease (54, 176), Uveitis (142, 1409) and Vaccination (2251, 6924).
Conclusion: JIRcohorte collects follow-up data on pediatric patients
with different immuno- rheumatologic pathologies. Thanks to its
structure, with both common and specific items in each module, it
can be used as a valuable tool to compare pediatric patients with dif-
ferent inflammatory rheumatic diseases.
Disclosure of Interest: None Declared
Genetics and environment
P43
Progressive pseudorheumatoid dysplasia resolved by whole exome
sequencing: a novel mutation in WISP3 and review of the literature
Aviva Eliyahu1,2, ben pode-shakked3,4,5, Asaf Vivante5,6, Ortal Barel7, Shai
Padeh8,9, Dina Marel-Yagel9,10, Alvit Veber11, Shachar Abudi12, Irit
Tirosh2,13, Shiri Shpilman2,14, Shirlee Shril15, gideon rechavi7,16,17,
Friedhelm Hildebrandt18, Mordechai Shohat7,19, yair anikster3,20,21
1 Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital,
Sheba Medical Center, tel hashomer, Israel; 2Sackler Faculty of Medicine,
Tel-Aviv University, Tel Aviv, Israel; 3Metabolic Disease Unit, Edmond and
Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel;
4Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel; 5The Dr.
Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical
Center, Tel-Hashomer, Israel; 6Division of Nephrology, Department of
Medicine, Boston Children's Hospital, Harvard Medical School, Boston,
MA, United States; 7Sheba Cancer Research Center, Sheba Medical
Center, Tel Hashomer, Israel; 8Pediatric Rheumatology Unit and
Department of Pediatrics, Edmond and Lily Safra Children's Hospital,
Sheba Medical Center, Tel-Hashomer, Israel; 9Sackler Faculty of Medicine,
Tel-Aviv University, Tel-Aviv, Israel; 10Metabolic Disease Unit Israel,
Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-
Hashomer, Israel; 11Metabolic Disease Unit, Edmond and Lily Safra
Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel;
12Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital,
Sheba Medical Center, Tel-Hashomer, Israel; 13Pediatric Rheumatology
Unit and Department of Pediatrics, Edmond and Lily Safra Children's
Hospital, Sheba Medical Center, Tel Hashomer, Israel; 14Pediatric
Rheumatology Unit and Department of Pediatrics, Edmond and Lily
Safra Children's Hospital, Tel Hashomer, Israel; 15Division of Nephrology,
Department of Medicine, Boston Children's Hospital, Harvard Medical
School, Boston, MA, United States; 16Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel; 17The Wohl Institute for Translational Medicine,
Sheba Medical Center, Tel Hashomer, Israel; 18 Division of Nephrology,
Department of Medicine, Boston Children's Hospital, Harvard Medical
School, Boston MA, United States; 19Sackler Faculty of Medicine, Tel-Aviv
University, Tel-Aviv, Israel; 20Sackler Faculty of Medicine, Tel-Aviv
University, Tel-Aviv, Israel; 21The Wohl Institute for Translational Medicine,
Sheba Medical Center, Tel-Hashomer, Israel
Correspondence: Aviva Eliyahu
Pediatric Rheumatology 2017, 15(Suppl 2):P43
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 37 of 191Introduction: Progressive pseudorheumatoid dysplasia (PPRD) is a
rare autosomal-recessive, non-inflammatory arthropathy, shown to
be caused by mutations in the WNT1-inducible signaling pathway
protein 3 (WISP3) gene. Although several hundred cases were re-
ported worldwide, the diagnosis remains challenging. Subsequently,
the syndrome is often unrecognized and misdiagnosed, leading to
unnecessary procedures and treatments.
Objectives: We present here a multiply affected consanguineous
family of Iraqi-Jewish descent with PPRD. The proband, a 6.5 years
old girl, presented with bilateral symmetric bony enlargements of
the 1st interphalangeal joints of the hands, without signs of synovitis.
Methods: Molecular analysis by Whole Exome Sequencing and
homozygosity mapping was performed on the proband and other af-
fected and non affected relatives.
Results: Molecular analysis by Whole Exome Sequencing and homo-
zygosity mapping identified a novel homozygous missense mutation
(c.257G > T, p.C86F) in the WISP3 gene. Following this diagnosis, an
additional 53 years old affected family member was found to harbor
the mutation. Two other individuals in the family were reported to
have had similar involvement however both had died of unrelated
causes.
Conclusion: The reported family underscores the importance of rec-
ognition of this unique skeletal dysplasia by clinicians, and especially
by pediatric rheumatologists and orthopedic surgeons.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children and an important cause of
short-term and long-term disability [1]. It is essential to know the
prognosis for the individual patient early in the course of disease
and preferentially at the time of diagnosis in order to start the right
treatment immediately [2].
Objectives: The goal of the study was to determine whether the
TNFA gene -308A > G, IL1B gene -511C > T and IL6 gene -174G > C
single nucleotide polymorphisms (SNPs) are associated with the dis-
ease severity in patients with JIA.
Methods: The study included 255 patients with JIA who were divided
into 4 subgroups according to the severity of the disease course:
mild (N = 33), moderate (N = 58), severe (N = 68) and very severe (N
= 96). The grouping was performed depending on the number of af-
fected joints, the presence or absence of high laboratory activity, sys-
temic features, uveitis, early radiologic progression, functional
disability and the need for early "aggressive" therapy. Genotyping
was performed using real-time PCR method. Statistical analysis was
performed using two-tailed Fisher's exact test (p), odds ratio (OR)
and 95% confidence interval (CI).
Results: The IL6 -174G allele was significantly more frequent in pa-
tients with a very severe disease course, than in other patients (p =
0.040, OR = 1.498, 95%CI 1.033-2.167). At the same time, there was a
significantly higher proportion of the IL1B -511CT genotype in a mild
disease course subgroup in comparison to other subgroups (p =
0.024, OR = 2.427, 95%CI 1.109-5.160). Then the analysis was per-
formed separately for girls and boys. The association mentioned
above for the IL6 -174G allele was confirmed only for boys (p = 0.026,
OR = 2.108, 95%CI 1.131-3.883) and for the IL1B -511CT genotype –
only for girls (p = 0.0004, OR = 10.079, 95% CI 2.656-44.857). In
addition, it was found that the IL1B -511 T allele marks a very severe
JIA course in boys (p = 0.019, OR = 2.231, 95% CI 1.135-4.215) andthat the TNFA -308A allele marks a mild JIA course in boys (p = 0.007,
OR = 4.778, 95% CI 1.731-14.256).
Conclusion: In this study we revealed gender-specific associations of
the IL6 gene -174G > C, IL1B gene -511C > T and TNFA gene -308A >
G SNPs with an altered risk of a very severe or mild JIA course.
References. [1] Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet.
2007 Mar 3;369(9563):767-78.
[2] van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile
idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015
Nov;74(11):1996-2005.
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Introduction: Survivin is an anti-apoptotic protein and its circulating
levels were associated with joint destruction and erosions in rheuma-
toid arthritis (RA). Recently it was suggested to be a marker of severe
disease course in adult patients with RA as well as juvenile idiopathic
arthritis (JIA). Three single nucleotide polymorphisms (SNPs) can
affect the normal protein and its concentration. Methotrexate (MTX)
is an important drug in treating JIA, but markers to predict its effi-
cacy are needed.
Objectives: To evaluate the effect of SNPs in survivin gene on
methotrexate efficacy in JIA.
Methods: The data of 119 consecutive patients with JIA treated
with MTX at the University Children’s Hospital Ljubljana from
June 2011 to January 2015 have been retrospectively reviewed.
The disease activity was measured using JADAS 71 score. Non-
responders were defined as patients not reaching 30% improve-
ment in JADAS 71 score 6 months after the beginning of treat-
ment with MTX. Genotyping of SNPs in the genes for survivin
was performed using real time PCR methods. The following SNPs
were analyzed: BIRC5 G692C rs8073069, BIRC5 T241C rs17878465
and BIRC5 G692C rs8073069. Two-tailed Fisher exact test was
used for statistical analysis.
Results: A total of 119 patients were included in the analysis, 91
(76.5%) girls and 28 (23.5%) boys. Ten (8.4%) patients had systemic
arthritis, 41 (34.5%) RF negative polyarthritis, 5 (4.2%) RF positive
polyarthritis, 24 (20.2%) persistent oligoarthritis, 24 (20.2%) extended
oligoarthritis, 11 (9.2%) juvenile psoriatic arthritis, 2 (1.7%) patients
suffered from enthesitis related arthritis and 2 (1.7%) had undifferen-
tiated arthritis. Mean time of disease duration before MTX was
started was 13 months in the whole cohort and 6.9 months in the
subgroup of patients with polyarticular disease (RF positive and RF
negative). Mean starting dose of MTX was 10.3 mg/m2 and mean
dose at 6 months was 12.0 mg/m2. Forty-two (35%) patients were
switched to subcutaneous MTX to achieve higher efficacy. At
6 months 30/116 (25.8%) of patients were defined as non-
responders. BIRC5 rs17878465 (p < 0.0001) and BIRC5 rs9904341 (p =
0.0272) were associated with achieving 30% improvement in JADAS
71 after 6 months. BIRC5 rs9904341 was also associated with 70% im-
provement in JADAS 71 score (p < 0.0001) after 6 months of
treatment.
Conclusion: Our results suggest that SNPs in survivin gene, BIRC5
rs17878465 and BIRC rs9904341 could be markers of MTX response
in JIA.
Disclosure of Interest: None Declared
Table 18 (Abstract P47). MRI score (CE: contrast enhancement)
TMJ ACTIVITY PARAMETERS
Right Left Total
score
Joint effusion YES □ NO □ YES □ NO □ 0-2
Contrast enhancement
(CE)
YES □ NO □ YES □ NO □ 0-2
Bone edema/bone
marrow CE
YES □ NO □ YES □ NO □ 0-2
Total activity score 0-3 0-3 0-6
TMJ DAMAGE PARAMETERS
Erosions/irregularities of
the condyle
YES □ NO □ YES □ NO □ 0-2
Disc abnormalities YES □ NO □ YES □ NO □ 0-2
Flattening of condyle MODERATE/SEVERE
□ MILD□
NO□
MODERATE/SEVERE
□ MILD□
NO□
0-4
Mandibular asimmetry YES □ NO □
IF YES: RIGHT < □ LEFT < □
0-1
Total damage score 0-5 0-9
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Introduction: European League Against Rheumatism/Paediatric Rheuma-
tology International Trials Organisation/Paediatric Rheumatology European
Society (EULAR/PRINTO/PRES) proposed validated classification criteria for
Henoch-Schönlein purpura (HSP). However, there are rare studies report-
ing initial risk factors to HSP nephritis (HSPN) and outcomes using these
new criteria. In addition, these studies generally included small samples,
and none of them were evaluated in Latin American population.
Objectives: To evaluate risk factors associated with HSPN and out-
comes in children and adolescents of a tertiary center in Latin America.
Methods: Two hundred ninety six patients with HSP were retrospect-
ively assessed by demographic data, and initial clinical manifesta-
tions, laboratory exams and treatments evaluating in the first three
months of disease. All of them fulfilled validated EULAR/PRINTO/PRES
criteria for HSP. They were also divided in two groups: with and with-
out nephritis. Additional, persistent non-nephrotic proteinuria, neph-
rotic proteinuria and renal insufficiency were also evaluated at 1, 5,
10 and 15 years after diagnosis.
Results: Nephritis was detected in 139/296 (47%) at first 3 months. The
median of age at diagnosis was significantly higher in HSPN patients
compared to those without this complication [6.6(1.5-17.7) vs. 5.7(0.9-
13.5) years, p = 0.022]. The frequencies of persistent purpura (31% vs.
10%, p < 0.0001), recurrent abdominal pain (16% vs. 7%, p = 0.011),
gastrointestinal bleeding (25% vs. 10%, p < 0.0001) and corticosteroid
use (54% vs. 41%, p = 0.023) were significantly higher in the former
group. In the multivariate analysis, logistic regression demonstrated that
the independent variables that predicted HSNP were persistent purpura
(OR = 3.601; 95%CI 1.605-8.079; p = 0.002) and gastrointestinal bleeding
(OR = 2.991; 95%CI 1.245-7.183; p = 0.014). Of 139 HSPN, further analysis
revealed that persistent non-nephrotic proteinuria, nephrotic proteinuria
and renal insufficiency occurred during follow-up: at 1 year [46/88 (52%),
1/88 (1%) and 2/88 (2%)], at 5 year [25/47 (53%), 1/47 (2%) and 1/47
(2%)], at 10 year [9/20 (45%), 1/20 (5%) and 1/20 (5%)] and at 15 years
[1/6 (17%), 0/6 (0%) and 0/6 (0%)]. In addition, in patients without HSPN
at disease onset: 29/118 (25%) had persistent non-nephrotic proteinuria
and/or hematuria only at 1 year of follow-up, 19/61 (31%) at 5 years, 6/
17 (35%) at 10 years and 4/6 (67%) at 15 years of follow-up.
Conclusion: Persistent purpura and gastrointestinal bleeding were
initial predictors for HSPN. Persistent non-nephrotic proteinuria and/
or hematuria may occur during the disease follow-up, even in pa-
tients without previous HSPN, and rigorous monitoring of renal in-
volvement should be performed.
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Pediatric Rheumatology 2017, 15(Suppl 2):P47Introduction: Arthritis of the temporo-mandibular joint (TMJ) is often
responsible for severe osteo-articular damage in patients with juvenile
idiopathic arthritis (JIA). Early diagnosis of TMJ involvement remains dif-
ficult, due to the lack of reliable clinical or imaging parameters. How-
ever, magnetic resonance imaging (MRI) is regarded as the most
sensitive tool for the detection of TMJ involvement in JIA.
Objectives: To develop and validate a MRI score for early detection
of TMJ disease activity and damage in children with JIA.
Methods: After a review of the most recent literature on MRI of the TMJ
in JIA and based on their experience, three specialists in different fields
(a rheumatologist, a dentist and a radiologist) devised the score for the
assessment of activity and damage of TMJ shown in Table 18. The score
consists of 3 parameters of arthritis activity (joint effusion, contrast en-
hancement (CE) and bone edema), and 4 parameters of joint damage
(erosion/irregularities of the mandibular condyle, disc abnormalities, flat-
tening of the condyle, mandibular asymmetry). The activity score ranges
from 0 to 6 and the damage score from 0 to 9. After a series of training
sessions aimed to reach consensus on the definition of the score fea-
tures, each specialist assigned independently the MRI score to an unse-
lected sample of TMJ MRIs of JIA patients followed at our center. The
inter- and intra-observer reliability were calculated through the weighted
kappa. The CE parameter was also compared with a recently validated
score calculated on a specific region of interest (ROI) of the TMJ MRI in
JIA patients1. Agreement was considered acceptable for a k value > 0.60.
Results: A total of 35 TMJ MRIs performed between December 2013
and December 2016 were evaluated. The analysis of the absolute
agreement in score assignment among specialists revealed substantial
agreement, with greater concordance between the dentist and the
radiologist. The rheumatologist tended to assign lower scores. Among
disease activity parameters, the lowest agreement was seen for bone
edema, whereas the most challenging joint damage parameter was
disc abnormalities. There was a moderate agreement between the CE
recorded by the study assessors and that obtained through the ROI cal-
culation, especially for the rheumatologist and the dentist.
Conclusion: We have developed a new simple and feasible MRI score
for the detection and quantification of disease activity and damage
of the TMJ in children with JIA. Although the overall score proved re-
liable across different specialists, further work is needed to increase
concordance for assessment of bone edema and disc abnormalities.
Reference: 1. Resnick CM et al. Quantifying Temporomandibular Joint
Synovitis in Children With Juvenile Idiopathic Arthritis. Arthritis Care
Res (Hoboken). 2016;68:1795-1802.
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Table 19 (Abstract P49). Salivary gland US-scores according Hocevar´s
classification
pjSS
(n = 9)
sjSS other
(n = 8)
sjSS in MCTD
(n = 8)
All
(n = 25)
Decrease in echogenity 3 (33,3%) 3 (37,5%) 2 (25%) 18 (72%)
Inhomogenous
parenchyma
9 (100%) 7 (87,5%) 6 (75%) 22 (88%)
Hypoechoic areas 9 (100%) 8 (100%) 7 (87,5%) 24 (96%)
Hyperechoic reflexes 7 (77,7%) 6 (75%) 6 (75%) 19 (76%)
Disturbed border 4 (44,4%) 2 (25%) 0 6 (24%)
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Introduction: Phagocyte recruitment and migration to the site of in-
flammation are key events in the early phase of inflammation. They
are indispensable for pathogen elimination, tissue repair and restor-
ation of tissue homeostasis. However, dysregulated phagocyte infil-
tration and a subsequently overwhelming immune response can also
cause severe inflammatory disorders. Therefore, targeting and modu-
lation of phagocyte infiltration represents a promising new approach
to fight inflammatory disorders and diseases, such as rheumatoid
arthritis. Furthermore, non-invasive tracking of phagocyte migration
to the site of inflammation could extend both scientific knowledge
as well as the repertoire of diagnostic strategies in clinical use.
Objectives: Within this study we aimed to establish a Fluorescence
reflectance imaging (FRI) based system to visualize and analyze mi-
gration properties of different cell populations in inflammatory dis-
ease models, like experimental arthritis, in vivo.
Methods: Immortalized murine myeloid progenitor ER-HoxB8 cells
were differentiated to neutrophils or monocytes (Wang et al., 2006).
Differentiated cells were labeled in vitro with the membrane-selective
fluorescent dyes DIR (Eisenblätter et al., 2009) or DID, respectively.
Viability and functionality of labeled cells were confirmed by in vitro
assays. In several mouse models - particularly in a collagen induced
arthritis (CIA) mouse model - we investigated the ability and specific
properties of different cell populations to migrate to sites of inflam-
mation in vivo via fluorescence reflectance imaging (FRI). Using
CRISPR-Cas9 technology we introduced targeted gene deletions for
main adhesion molecules.
Results: ER-HoxB8 monocytes and neutrophils could effectively be la-
beled with DIR or DID. In vitro assays confirmed that viability and
functionality of ER-HoxB8 cells was not affected by cell labeling. Sub-
sequent in vivo imaging experiments allowed the visualization of mi-
grated labeled phagocytes in different murine disease models,
thereby cells could be detected at sites of inflammation with high
sensitivity and specificity. In a CIA mouse model the amount of immi-
grated cells could even be associated closely to disease score and
disease severity. Thus, the detection of immigration of labeled cells
might also give hints about new inflammatory spots that are about
to settle up before they can be detected macroscopically. Further-
more, differential cell labeling allowed direct quantitative comparison
of differences in migration rates of wildtype and CD18 or CD49d
knockout cells in vivo.
Conclusion: Specific and distinguishable labeling of diverse cell types
allows in vivo tracking and subsequent quantification of migrated
cells within the same animal. Targeted gene deletion allows analysis
of molecular mechanisms relevant for leukocyte recruitment during
different stages of arthritis. Correlation of the amount of immigrated
cells to disease severity offers new opportunities to non-invasively
detect and monitor inflammatory sites in vivo.
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Introduction: Diagnosis of juvenile Sjögrens syndrome (jSS) although
rare seems to be underestimated in pediatric patients. Especially inpatients with undifferenciated mixed connective tissue disease
(MCTD) secondary jSS is frequently present but missed in the diag-
nostic work-up.
Objectives: Our intend was to characterize distinct, ultrasonographic
(US) findings in a cohort of primary- and secondary jSS patients, the
latter with a focus on MCTD and attribute these findings to US scores
defined in adult SS.
Methods: A single-center study collected data from clinical charts of
jSS-patients admitted to the GCPAR. According the EULAR/ACR cri-
teria 8 patients with primary jSS, 8 patients with secondary jSS and
MCTD and 9 patients with secondary jSS and other collagenoses
were included. All ultrasonographic (US) findings were performed by
two experienced investigators between 5/2014 and 3/2017 using a
GE logic 8 system. Different scoring systems from the literature were
compared for accuracy for gland echostructural abnormalities.
Results: A total of 25 patients (22 females, 3 males) with a mean age
of 15,8 years have been included. All 9 pjSS patients had sicca symp-
toms, this was present in only 56,3% of sjSS. Swelling or pain in
major salivary glands occurred in 7 of 9 pjSS but only 5 of 16 sjSS (in-
cluding MCTD). US scoring of salivary glands according to Hocevar
[1] which had been proven to be accurate in jSS as well [2] showed a
mean score of 26 in pjSS and 18,28 in sjSS patients. We could not
correlate US score (Hocevar) with the duration of the disease (Pear-
sons r =0.197) (Table 19).
Conclusion: In patients with pjSS and sjSS salivary gland ultrasound
is a helpful, first-line tool not only to detect salivary gland involve-
ment but to score the severity of inflammation as well. As sjSS is sup-
posed to be underestimated in collagenoses and MCTD, screening of
salivary gland by US is usefull even in patients without sicca-
symptoms to identified typical, inhomogeneous parchenchymal ap-
pearance with hypoechoic lesions suggestive for jSS.
References:
1. Hocevar A. et al;. Rheumatology 2005; Vol 44; pp 768
2. Krumrey-Langkammerer M. et al. 2015: Ultraschall in Med 2015; 36 - A349
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Introduction: The ankle is a complex anatomical structure owing to
the multiple joint recesses and surrounding tendons. The clinical
examination of this joint is a challenging task even for the expert
physician. Ultrasound (US) is becoming a useful adjunctive tool to
clinical evaluation for the assessment of children with juvenile idio-
pathic arthritis (JIA). Disagreement between clinical and US
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 40 of 191examinations in the assessment of the ankle region has been shown
in some studies.
Objectives: The aims of the study were: 1) to assess the frequency of
clinical signs of articular and periarticular involvement and of US ab-
normalities in the different joint recesses and tendon compartments
of the ankle region; 2) to investigate the correlation between clinical
signs of articular involvement and US abnormalities in the different
joint recesses of the ankle region.
Methods: Twenty-seven ankles of 19 patients with JIA with a clinical
suspicion of disease involvement were included in the study. At the
same consultation, the ankles were scanned by a physician with ex-
perience in the US assessment of children with JIA, who was blinded
to clinical findings. Clinical and US evaluations focused on tibiotalar
and subtalar joints, the tarsal area and on tendon compartments. For
each of the joint recesses the presence of swelling, pain on motion
and restricted motion and the detection of joint effusion (JE), syn-
ovial hypertrophy (SH) and power Doppler (PD) signal inside the area
of SH were recorded on clinical and on US evaluation, respectively.
US abnormalities were graded on a 4-point semiquantitative scale.
Correlation between clinical signs of articular involvement and US
abnormalities in the different joint recesses of the ankle region was
estimated using the Kendall’s tau (τ) coefficient.
Results: Overall, on clinical assessment swelling was found more fre-
quently in the tibiotalar joint (52%), whereas both pain and restricted
motion were documented more commonly in the subtalar joint (44%
and 41%, respectively). On US assessment JE and SH were detected
more frequently in the tibiotalar joint (56% and 67%, respectively);
PD signal was displayed more commonly in the subtalar joint (44%).
Among tendon compartments, both clinical and US assessments doc-
umented a more frequent involvement of flexor tendons (11% and
52%, respectively). Correlation was found between presence of pain
or restricted motion on clinical evaluation and detection of PD signal
on US in the tibiotalar joint (τ = 0,58, p = 0,002 and τ = 0,57, p = 0,002,
respectively). In the tarsal area correlation was found between pres-
ence of restricted motion on clinical assessment and detection of PD
signal on US (τ = 0,43, p = 0,024) and between presence of pain on
clinical assessment and detection of SH on US (τ = 0,41, p = 0,033).
No correlation was found in the subtalar joint between any clinical
sign of articular involvement and US abnormalities.
Conclusion: Tibiotalar and subtalar joints are more commonly af-
fected than the tarsal area on both clinical and US assessment in
case of ankle involvement in JIA. Flexor tendons are more frequently
inflamed than the anterior and lateral tendon compartments. On clin-
ical examination, pain or restricted motion, but not swelling, in the
tibiotalar joint and in the tarsal area seem to correlate with the pres-
ence of synovitis on US in these joint recesses of the ankle region.
The assessment of the subtalar joint remains a challenging task for
the physician without the use of US.
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Introduction: Kawasaki disease (KD) is an acute febrile systemic vas-
culitis that affects blood vessels of small and medium calibre. With
the availability of intensified treatments for most severe patients, it is
crucial to early identify patients at high risk for coronary artery aneu-
rysms (CAA). However, the available risk scoring systems from Japan
have not been validated in European populations. There is little data
concerning the link between initial echocardiogram findings and car-
diac prognosis.Objectives: To investigate the first echocardiogram can predict resist-
ance to conventional therapy and/or subsequent development of
CAA
Methods: We retrospectively analysed demographic, clinical, bio-
logical, echocardiographic and therapeutic data from children diag-
nosed with KD between 2006 and 2016 at the Robert-Debré
University Hospital, Paris, France.
Results: A total of 157 children with KD were included. Initial echo-
cardiogram was performed after a median of 6 days of fever and was
abnormal in 48 cases (31%). The initial presence of any echocardio-
graphic abnormality was strongly associated with resistance to intra-
venous immunoglobulin (p = 0.005) and development of coronary
artery lesions within the first six weeks of disease (p = 0.01). All pa-
tients (n = 7) with persistent coronary abnormalities at one year
already had an abnormal initial echocardiogram. In contrast, severity
scores had low sensitivity (24-33%) and low specificity (72-81%) to
predict immunoglobulin resistance or cardiac involvement.
Conclusion: Abnormalities in the initial echocardiogram can be used
to early identify patients with severe Kawasaki disease in populations
with mixed ethnic backgrounds.
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Introduction: Takayasu arteritis is a chronic granulomatous vasculitis
that effects primarily aorta and its main branches and rarely seen be-
fore the age of 18. Delay in diagnosis and treatment is a common
feature due to the nonspecific systemic features. There is limited data
on clinical features and long-term outcome of Takayasu arteritis. Also,
there is need to evaluate efficacy of current therapies, since the
spectrum of treatment options have been increased compared to
the past.
Objectives: We aimed to report our referral center experience on the
clinical features and treatment options of Takayasu arteritis. In
addition, we have evaluated the correlation of various activity and
damage scores with eachother
Methods: We performed a retrospective chart review for Takayasu ar-
teritis between October 2002 and October 2017 at our tertiary refer-
ral pediatric rheumatology center. In addition to the current cases
that are followed-up, we have comprehensively searched the hospital
database for the ICD-9 code 446.7 and ICD-10 code M31.4 to identify
Takayasu arteritis patients.
Results: Overall, 16 patients (12 female) have been diagnosed with
Takayasu arteritis in last 15 years. Mean age of the patients at disease
onset and diagnosis were 10.9 ± 4.8 years and 11.5 ± 4.7 years, re-
spectively. While the median duration from the onset of first symp-
tom until the diagnosis was 2.4 months (range 0.1-65 months), the
mean disease duration was 6.1 ± 5.9 years. The most frequent mani-
festation at admission was nonspecific systemic features (fever, fa-
tigue, anorexia, weight loss) (n = 13, 81.2%) followed by hypertension
(n = 10, 62.5%) and neurologic findings (n = 4, 25%). Tuberculosis dis-
ease was also detected in 4/16 subjects (25%) at disease onset and
anti-tuberculosis therapy initiated concomitantly with immunosup-
pressive drugs. All patients had met the ACR 1990 criteria for the
classification of Takayasu arteritis. The most common angiographic
type was Numano’s type IV seen in 5 patients, followed by type V in
4, type III in 4, type IIa in 2, type IIb and type I one patient each. Sub-
jects had extensive disease at presentation with mean DEI.Tak (±SD)
of 13.8 (±6); All of the subjects had elevated acute-phase reactants,
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(±7.1) and mean PVAS score (±SD): 14.0 (±4.4)). These three activity
scores correlated with each other both at disease onset and last visit
(p < 0.05). The most frequently used immunosuppressive drug in
therapy was corticosteroids (n = 16/16, 100%), followed by azathio-
prine (n = 15/16, 93.7%), cyclophosphamide (n = 10/16, 62.5%),
methotrexate (n = 6/16, 37.5%) and tocilizumab (n = 6/16, 37.5%). The
rate of angioplasty and/or bypass was not rare (n = 7/16, 43.7%). Des-
pite the high frequency of surgical procedure, there was no deceased
patient with Takayasu arteritis in the last 15 years.
Conclusion: There is no deceased Takayasu patient in the last
15 years. Fairly good clinical outcomes compared to the past may be
due to new biologic drugs and/or improved surgical techniques.
Three different disease activity scores were in a great concordance
with each other.
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Introduction: Development of coronary artery abnormalities (CAA) is
the hallmark of Kawasaki disease (KD) and accounts for most of the
morbidity and mortality associated with the disease. Concerns have
been raised as to whether patients with KD are really at risk for pre-
mature atherosclerosis later in adulthood. With advancements in
technology, dual-source computerized tomography (DSCT) coronary
angiography can be developed as a low radiation imaging paradigm
for patients with KD. Advantages over echocardiography include the
ability to visualize middle and distal coronary segments with little or
no inter-observer variability. Unlike catheter angiography, DSCT angi-
ography is non-invasive and clearly delineates calcification and intra-
luminal abnormalities.
Objectives: This study is designed to evaluate whether KD is a risk
factor for premature atherosclerosis by calcium scoring (Agatson’s al-
gorithm) and to detect the CAA (aneurysm/thrombus/stenosis/ecta-
sia) using DSCT with low radiation protocols.
Methods: In this prospective study, 21 patients (male: female- 15:6)
with KD in convalescence for more than 10 years were enrolled
(mean: 15.76 years). Diagnosis of KD was based on the 2004 Ameri-
can Heart Association (AHA) Criteria for KD. Written informed consent
was taken from all the patients prior to the enrolment. Patients were
scanned during a single breath-hold with a customized protocol de-
signed to minimize the administered radiation dose. Non-ionic con-
trast (Omnipaque 350, GE Healthcare, Ireland) 2-4 ml/kg was injected
at a rate of 4-5 ml/s (through 20G cannula), in the right antecubital
vein, followed by a saline push (1-2 mL/kg at a rate of 1.5 mL/sec-
ond) with a dual head power injector. An 128 slice SOMATOM Defin-
ition flash DSCT scanner (SIEMENS HEALTH CARE; Germany) was used
for coronary angiography. The data acquisition parameters were 80-
100 KVp voltage, tube current (mAs) (care dose 4D), detector config-
uration 128x0.6 mm, gantry rotation time 0.28 seconds, and the scanlength was adjusted from the scout image to encompass the entire
heart. The scan was taken from carina till the apex of heart. Images
were analyzed on dedicated work station using proprietary soft ware
(Syngovia). Coronary arteries was evaluated using the 13 segment
model proposed by the AHA. The calcium score was calculated by
determining the density of the highest density pixel in each plaque
taking the threshold of 130 HU and applying a weighting factor to
each plaque, depending upon the peak density in the plaque. Heart
rate at which data was acquired, was recorded along with electrocar-
diogram tracing.
Results: Mean age of the patients at the time of diagnosis was
3.21 years and mean time interval time interval between diagnosis
and imaging 12.59 yrs. At the time of data acquisition the mean
heart rate of the patients were 80 beat/min, mean tube current
2417.66 mAs, median scan time 2.5 seconds and median effective
dose 2.52 mSv. CAAs are seen in the form of aneurysms and ectasias
in two patients (9.52%) in our study. No patient with significant sten-
osis was seen. The aneurysms were detected in proximal segments
of RCA (Saccular, medium sized) and LAD (fusiform, small sized). The
ectasias were detected in one patient (4.76%) in LAD and LCx. Raised
calcium score is seen only one (4.76%) patient with abnormal coron-
ary arteries. The calcium deposition is seen in only in abnormal
segments.
Conclusion: Our study suggests that KD itself may not be a cause for
premature atherosclerosis unless the coronary arteries are involved
in form of aneurysms. However, the results of this preliminary study
done in a small population size has to be replicated in larger cohorts
to make a firm conclusion.
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Introduction: Coronary artery abnormalities (CAA) develop in 20-25%
of untreated cases and 3-5% of treated cases of Kawasaki disease
(KD), that accounts for most of the morbidity and mortality associ-
ated with the disease. Although, transthoracic 2-D Echocardiography
(2DE) is the initial preferred modality for imaging coronary arteries, it
has several inherent limitations- unclear views of middle and distal
segments of coronaries, chances of inter-observer variation, and poor
acoustic windows in older children to view the coronaries. Dual
source CT (DSCT) coronary angiography has recently emerged as an
non-invasive tool that has low radiation exposure and can accurately
demonstrate the coronary wall anatomy and intraluminal abnormal-
ities like thrombosis, stenosis, calcification. It has several advantages
over echocardiography including the ability to visualize middle and
distal coronary segments with little or no inter-observer variability.
Objectives: To evaluate the role of DSCT coronary angiography in de-
tecting CAAs in children with KD who were not treated with intraven-
ous immunoglobulin during acute stage and its comparison with 2DE.
Methods: Nineteen (19) children (M:F = 15:4) with KD who did not re-
ceive intravenous immunoglobulin and are on regular follow up in
Pediatric Rheumatology Clinic were enrolled (median age: 11.03 years;
range: 3.7-23 years). Diagnosis was based on diagnostic criteria given
by AHA. All of the patients were the cases of incomplete KD and
were not given IVIg because they either presented late in convales-
cent phase or when then presented to us, they were afebrile and
ESR, CRP were not raised. Mean duration since diagnosis of KD to the
time when study was conducted was 3.84 ± 2.27 years. The study
was approved by the Ethics Committee of the Institute. A written in-
formed consent from the parents was obtained prior to enrolment.
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coronary angiography (SIEMENS HEALTH CARE; Germany) and 2DE
on the same day. Diameters of major coronary arteries were mea-
sured and presence of any coronary artery lesions was looked for. Re-
sults of 2DE carried out at the time of diagnosis were also taken into
account. Student paired T test was used to compare the average
diameter of coronaries obtained by two imaging modalities.
Results: None of the patients showed any coronary artery abnormal-
ities by both DSCT and 2DE. All coronary arteries were well visualized
by DSCT and even LCX branches and distal RCA was also well visual-
ized. However, coronary artery could not be visualized in 7 patients
out of 19 by 2DE. In 3 patients, even main arteries were also not seen
due to poor acoustic window. However, in 4 cases, RCA and LMCA
were well visualized, but it was difficult to visualize left circumflex ar-
tery clearly. The 2DE and DSCT had almost the same results of prox-
imal coronary artery especially LMCA, proximal RCA, and LAD.
However, DSCT provided the more accurate visualization of distal
coronary artery than 2DE. The average diameter of coronary artery
measured by 2DE and CT angiography was almost similar. 2DE at the
time of diagnosis showed dilatation of coronaries in 3 children (2
LMCA, 1 LAD) which were not seen in current echo and DSCT.
Conclusion: DSCT coronary angiography more accurately delineated
the anatomy and lumen of coronary arteries especially in older chil-
dren with KD when compared with 2DE. DSCT is superior to echo for
distal coronary artery visualization. It can reveal coronary artery le-
sions in patients with KD in timely manner and help with therapeutic
decision making to improve the prognosis.
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Introduction: Kawasaki disease (KD) is usually considered as an
acute, self-limited vasculitis of childhood. However, of late, several
long-term complications including development of major coronary
events and premature atherosclerosis have been recognized in pa-
tients with KD. The evaluation of vascular endothelial function is im-
portant in predicting several long-term complications in patients
with KD. Flow mediated dilatation (FMD) of the brachial arteries is
considered one of the non-invasive ways to study the vascular endo-
thelial dysfunction.
Objectives: To study the FMD of brachial artery (BA) and evaluate for
endothelial dysfunction in children with KD in both acute and conva-
lescent phases.
Methods: Sixteen (16) children with KD and an equal number of con-
trols were enrolled. The diagnosis of KD was based on the standard
clinical diagnostic criteria enunciated by the 2004 American Heart As-
sociation (AHA). FDA approved automated edge detection software
program (Brachial artery analyserTM) combined with high resolution
ultrasound images were used to study the BA. Ultrasonography
(USG) on a standard Philips Medical system was performed by a
trained and expert radiologist. The software provided the diameter
measurement every second. A 10-MHz multifrequency linear array
probe attached to a high-resolution ultrasound machine was used to
acquire images of the right BA. Baseline images of the right brachial
artery were obtained for 2 minutes. A forearm cuff was positioned
1 cm under the antecubital fossa and inflated to 250 mm Hg for 5 mi-
nutes to induce forearm-reactive hyperemia. The cuff was then re-
leased and images of BA were recorded continuously for next5 minutes. The basal diameter was taken as the average of measures
collected during the first minute, and FMD was calculated as the
maximum percentage change in the brachial artery diameter com-
pared with the basal value. The USG was repeated in convalescent
stage, at least three months later the diagnosis.
Results: Mean age of the study population was 4.8 years in cases (n
= 16; M:F- 12:4) and 5.75 years in control population (n = 16; M:F-
10:6). The baseline BA diameter in acute phase of KD children is 2.3
± 0.34 mm and that of convalescent phase is 2.49 ± 0.35 mm. Healthy
control population had a mean baseline BA diameter of 2.35 ±
0.46 mm. Maximum dilatation was 2.56 ± 0.36 mm in the group of
acute KD, 2.93 ± 0.31 mm in the group of convalescent KD and 2.95
± 0.56 mm in healthy controls (p- 0.02). Children with KD had FMD of
12.32 ± 6.2% in acute phase and 17.99 ± 8.13% in convalescent
phase, whereas, the control population had FMD of 26.88 ± 12.76%
(p <0.01).
Conclusion: Our results suggest that FMD is significantly reduced in
children with KD in acute phase and convalescent phase as com-
pared to healthy controls. To the best of our knowledge, ours is the
first study done in both phases of KD and suggests that endothelial
dysfunction starts as early as in the acute phase of KD.
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Introduction: With the increased use of imaging as a supportive tool
for starting or intensifying treatment in JIA patients, discrepancy be-
tween the MR imaging and clinical assessment will pose a dilemma.
Objectives
To evaluate patient characteristics and disease activity parameters in
a single tertiary center cohort of JIA patients, both with and without
synovial hypertrophy upon MRI, in order to explore frequency of mis-
matching results.
Methods
Clinical, laboratory, and contrast-enhanced MRI data of the knee of
prospectively enrolled JIA patients from 2008-2014 were analyzed.
JIA was diagnosed according to the ILAR criteria. The Wallace criteria
for inactive disease were used. The validated Juvenile Arthritis MRI
Scoring (JAMRIS) system for the knee was used to evaluate the pres-
ence of synovial hypertrophy (1). Clinically active and inactive pa-
tients were, as separate groups, divided into two groups based on
the JAMRIS (four groups in total): JAMRIS score ≥1, meaning synovial
hypertrophy, or JAMRIS score 0. Patient characteristics and disease
activity parameters were then compared using the Chi-square and
Fishers exact test if data were categorical and with the Mann–Whit-
ney U if continuous.
Results
The MRI showed contradictory findings with reference to the clinical as-
sessment in 43 of 124 patients (34.7%) (Table 20). The clinically active
patients with discordant findings ((i.e. no synovial hypertrophy seen on
MRI; n = 25) were significantly older and had been more often diag-
nosed with polyarticular JIA, compared to the clinically active patients
with concordant findings (n = 47) (median age 13.2 years vs 10.9; p =
0.006 and 72% vs 34%; p = 0.003, respectively). The clinically inactive
patients with discordant findings (i.e. synovial hypertrophy seen on
MRI; n = 18) were significantly younger than the clinically inactive pa-
tients with concordant findings (median age 10.7 years vs 14.4; p =
0.008). Other clinical parameters, including CHAQ, laboratory results
and medication usage were, however, not significantly different be-
tween the discordant and concordant groups (Table 20).
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 43 of 191Conclusion
Nearly 35% of the JIA patients showed discordant findings between
clinical assessment and MRI. Clinically active patients without syn-
ovial hypertrophy on MRI were significantly older at the time of MRI
than the clinically active patients with synovial hypertrophy on MRI.
In the clinically inactive JIA patients, the discrepancy between clinical
assessment and MRI was especially seen in younger patients. The
meaning of synovial hypertrophy in the clinically inactive patient is
still unknown, but it might indicate an incomplete disease remission.
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Disclosure of Interest: None DeclaredTable 21 (Abstract P57). See text for description Median percentage
values of MPA (CD14 + CD41+) in children with KD in follow-up: at
diagnosis, 24 hour after completion of IVIg infusion and 3 months after
diagnosis
S no Category Median MPA% (IQR) P value
1 At enrolment (n = 14) 41.31 (26.6, 52.69) <0.001*
2 24 hours after IVIg (n = 14) 18.55 (9.2, 22.99)
3 Follow-up at 3rd month (n = 11) 7.55 (4.15, 14.6)
Table 20 (Abstract P56). See text for description
Clinically Active Clinically Inactive
Variable Concordant
n = 47
Discordant
n = 25
p-
value
Concordant
n = 34
Discordant
n = 18
p-
value
Female
gender, n(%)
26 (55.3) 18 (72.0) 0.209 23 (44.2) 10 (19.2) 0.389
Age, years 10.9 (8.6-
13.7)
13.2 (11.3-
15.6)
0.006 14.4 (12.1-
16.3)
10.7 (9.3-
13.6)
0.008
Oligoarticular
JIA, n(%)
21 (44.7) 2 (8.0) 0.001 11 (32.4) 11 (61.1) 0.076
Polyarticular
JIA, n(%)
16 (34.0) 18 (72.0) 0.003 19 (55.9) 4 (22.2) 0.038
Other
subtypes, n(%)
10 (21.3) 5 (20) 1.000 4 (11.8) 3 (16.7) 0.682P57
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Introduction: The acute phase of Kawasaki disease (KD) involve
endothelial damage and activation of platelets. Markers of platelet
activation were found to be elevated in adults with coronary artery
disease (CAD) and venous thromboembolism. The actual evidence
for platelet activation in KD, however, is limited to platelet aggrega-
tion studies and few studies on platelet activation markers and circu-
lating microparticles. Monocyte-platelet aggregates (MPA), one of the
most sensitive markers for activated platelets has not been studied
in the acute phase of KD.
Objectives: To assess platelet reactivity by flow cytometry based
measurement of MPA in children with KD.
Methods: Fourteen (14) children with KD, 15 age-matched febrile
controls, and 13 age-matched healthy controls were enrolled in this
prospective study. Diagnosis of KD was based on the American Heart
Association (AHA) 2004 criteria. Samples were collected at three dif-
ferent phases of illness in patients with KD- acute stage prior to ad-
ministration of IVIg and aspirin, 24 hours after administration of IVIg,
and 3 months after onset of illness. Immediate fixation of the sample
and lysis of red blood cells (RBC) were carried out at the room
temperature with the use of BD FACS lysing solution. The washed
samples were immunolabeled with a saturating concentration of
PerCP-conjugated CD14 (lipopolysaccharide-protein receptor, BD
PharmingenTM, Catalogue no. 555398) and fluorescein isothiocyanate
(FITC) conjugated GP IIb (CD41, BD PharmingenTM, Catalogue no.555466). Following incubation for 20 minutes at room temperature,
the cells were acquired on the flow cytometry (Beckman coulter,
Navios). The monocytes were gated from the lymphocyte side scatter
plot and MPAs was identified from the monocyte population that
had expressed both CD14 (monocyte marker) and CD41 (platelet
marker) using the Kaluza software.
Results: The median age group (inter-quartile range) in the cases, fe-
brile controls, and normal controls were 6 (3.0, 7.25), 5 (3.6, 9.0), and
5.5 years (4.15, 6.5), respectively. Male to female ratio among the
groups were 12:2, 13:2, and 11:2 respectively. Echocardiographic ab-
normalities were detected in 3 children (2- transient abnormalities
such as coronary wall brightness and coronary ectasia, 1- giant cor-
onary aneurysms). Percentage of MPA% values were significantly
high in children with KD [Median (IQR)- 41.3% (26.6, 52.7)] compared
to the febrile [Median (IQR)- 5.98% (2.98, 9.72)] and normal controls
[Median (IQR)- 4.48% (2.57, 5.59)], p < 0.01. A consistent drop in serial
MPA% was observed from the diagnosis of KD to the end of third
month follow-up [Table 21]. The MPA% values at 3 months post
diagnosis of KD [Mean (SD)- 9.59% (7.65)] were significantly higher
compared to the normal controls [Mean (SD)- 4.3% (2.03)], p-0.004.
*p < 0.05 considered significant
Conclusion: MPA% as an objective measure of platelet activation
was significantly elevated in children with acute stages of KD when
compared with age and sex-matched febrile and normal controls. El-
evated levels of MPA% in patients with KD 3 months post diagnosis
suggest that the endothelial inflammation or damage in KD persists
for a longer duration even after control of symptoms and signs of
systemic inflammation. Long-term studies on platelet activation
markers in a larger multicentric cohort would conclusively establish
the role of platelets in acute and long-term cardiac morbidity in KD.
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Introduction: Chronic active EBV (CAEBV) infection is a rare condition
associated to a chronic activation of Epstein Barr virus and therefore
to a chronic and potentially life-threating lymphoproliferation. The
prognosis is poor: most of the patients not treated with bone mar-
row transplantation die for lymphatic malignancies and the common
immunosuppressive and antiviral therapy are usually not effective.
Even if with a wide heterogeneity, most of the patients with CAEBV
present severe clinical manifestations with early onset and poor
prognosis; the presence of an underlying immunodeficiency causing
an unusual EBV replication is therefore reasonable.
Objectives: To describe the clinical course and the genetic
characterization of a patient with CAEBV mimicking PFAPA at disease onset.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 44 of 191Methods: In a patient with CAEBV infection a whole exome sequen-
cing (WES) approach was undertaken and variants were prioritized
with a custom pipeline to identify the genetic cause of his condition
that was validated through Sanger Sequencing in the trio.
Results: The patient, born of consanguineous parents, at the age of
15 months presented, in complete wellbeing, a not-complicated in-
fectious mononucleosis; in the following months he presented recur-
rent episodes of high fever with exudative tonsillitis, adenitis,
splenomegaly and sweating, lasting 3-5 days and treated with
NSAIDS or antibiotics. Blood examinations revealed neutrophilic
leukocytosis and elevation of acute phase reactants; plasmatic immu-
noglobulins were within the normal range. An autoinflammatory con-
dition with periodic fever was suspected and therefore on-demand
steroidal treatment was suggested, with good response. The child
continued to present periodic fever, associated to the occurrence of
respiratory infections requiring antibiotics, and recurrent episodes of
cheratitis. Several destructive dental caries were found as well as
hyper sensibility to mosquitoes bite.
Immunologic test revealed then a reduction in the level of plasmatic
immunoglobulins. The detection of EBV DNA with quantitative PCR
revealed 21935 copies for 100000 leucocytes with prevalence of in-
fection in the B cells. Whole body positron emission tomography re-
vealed a retroperitoneal formation of about 35 mm with an
increased metabolism that, at biopsy, revealed a reactive lymphaden-
opathy with paracortical involvement associated with EBV infection.
Genetic conditions associated to chronic EBV infection and immuno-
deficiency were ruled out: the genetic tests for SAP, XIAP, BAFF-R
and ICOS were negative and the cytofluorimetric analysis of perforin,
CD107 and 2B4 receptor were normal. In light of these findings a
CAEBV was suspected.
Being the patient in good general conditions and in light of the
prevalent involvement of CD20+ lymphocytes, on demand treatment
with rituximab was started. The clinical response to treatment was
initially very satisfying; however after two years the child presented
severe infections requiring prolonged hospitalisation; stem cell trans-
plantation was then performed with a complete normalization of
both clinical and immunological features.
Among variants identified through a WES analysis of the patients
and his parents, a homozygous mutation of the CD70 gene appeared
to fit the recessive model of inheritance. The variantc.163-2A > G af-
fects the exon2AG-acceptor splice site of the CD70 gene
(NM_001252) leading to a deficiency in CD70, the ligand of CD27, a
gene involved in isolated immunodeficiency. In the meantime our
analysis was ongoing, CD70 mutations were reported in a few pa-
tients with a similar condition.
At the protein level, the anti-CD70 antibody failed to detect CD70 by
flow cytometry at the cell surface of PHA-stimulated T and EBV-
trasformed B cells of the patient. In contrast, expression of CD70 was
detectable on cells from healthy donors.
Conclusion: This case describe a new case of a newly identified gen-
etic cause of CAEVB presenting with recurrent periodic fever.
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We report the case of a 6-year-old boy with pain in the right knee
and both ankles after a 10-day course of oral amoxicillin-clavulanate
completed three weeks earlier; at the same time he developed diar-
rhea with positive culture for Clostridium difficile (CD). Three days
later the knee and ankles arthritis resolved spontaneously but ap-
peared in the right shoulder and homolateral hip with a migratory
pattern and with fever. Synovial fluid and blood cultures, rheumatoidfactor, ANA and HLA-B27 antigen were negative. The improvement
of colitis and the negativity of fecal calprotectin at follow-up allowed
to exclude an inflammatory bowel disease. Nonsteroidal anti-
inflammatory drugs (NSAIDs) and metronidazole completely resolved
pain, joint swelling and diarrhea. After 24 months of follow-up there
has been no recurrence.
Reactive Arthritis (ReA) is an aseptic acute inflammatory arthritis occur-
ring after an intercurrent infection in which the causative organism is
outside from the joint. It is typically an asymmetrical oligo/polyarthritis
predominantly in the lower limbs large joints (knee, ankle, hip) and
present approximately 2-4 weeks following infection. Several patients
present a migratory pattern and acute arthritis is often characterized by
severe pain and sometimes erythema over the affected joints; enthesi-
tis/tenosynovitis may occur. Most frequent causes are Salmonella, Shi-
gella, Yersinia, C. jejuni, group A Streptococcus and C. trachomatis.
CD is the most common cause of diarrhea after antibiotic therapy
but CD ReA is rare and its pediatric epidemiology is poorly known; it
was generally migratory and polyarticular, involving large joint and
tipically with a good outcome and self-limiting course.
For the diagnosis of ReaA following CD enterocolitis there are criteria
established by Putterman and Rubinow [1], but basically a history of
diarrhoea after a course of antibiotic with the exclusion of other
causes of gastroenteritis or noninfectious arthritis is essential.
Jacobs et al [2] documented until 2001 35 cases of CD ReA in adults;
epidemiology in child instead is rare and unknown, but incidence of
CD infection has increased among children. We performed a literature
search of MEDLINE, Google Scholar, and Cochrane Reviews computer-
ized databases using the keywords “Clostridium difficile”, “arthritis”, and
“child” to identify all papers reporting CD enterocolitis-associated ReA
in childhood. Six papers met our review's inclusion criteria with a total
of 32 pediatrics cases of CD ReA. The most recent study identified, from
2004 to 2013, 26 cases with acute arthritis/tenosynovitis after CD infec-
tion and authors estimate that CD ReA affected 1.4% of child with CD
infection; only 35% of CD ReA were correctly diagnosed, occasionally
misdiagnosed as septic arthritis [3].
Conclusion: CD infection should be suspected in children presenting
with an acute inflammatory arthritis following an episode of diarrhea,
especially when culture for common enteric infection are negative and
the patient has received antibiotic therapy before the onset of diarrhea.
Written informed consent for the publication of patient details was
obtained.
Disclosure of Interest: None Declared
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Table 22 (Abstract P61). Frequencies of five most important daily
activities of patients with JIA
Activity % Activity % Activity % Activity %
Carrying
something
66 Using a
knife
20 Drinking 8 Gripping
small objects
4
Writing 50 Buttoning 18 Cutting nail 8 Using a
scissors
4
Opening a bottle
cap
48 Taking a
bath
16 Washing dishes 6 Stirring a
soup
2
Dressing 38 Peeling a
fruit
14 Pushing
something
6 Opening a
zipper
2
Opening a door
with handle/knob
38 Washing
hair
14 Removing a sock 4 Acclaiming 2
Combing 28 Tying a
shoelace
12 Reaching to grab
something
4 Using a fork 2
Unlocking 28 Brushing
teeth
10 Unpacking 4
Tapping 26 Eating 10
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 45 of 191Introduction: Juvenile idiopathic arthritis (JIA) is most common
chronic rheumatic disease in childhood. The upper extremity in-
volvement in JIA causes muscle imbalance, joint destruction,
pain, stiffness and limitations on activities of daily living (ADL) in
varying degrees. However, the information about prevalence of
symptoms, disorders, ADL limitations, participation restriction
and options of treatments for upper extremity involvement in
JIA are limited. It has been reported that improvements of upper
extremity functions were achieved by video-based games (VBG)
in various disease groups. However, in the literature, no study
has been found about effectiveness of VBG in children with
arthritis.
Objectives: The aim of the study was to investigate the effects of
two different task-oriented activity training to activity perform-
ance and participation in children who have involved upper limb
with JIA.
Methods: 62 patients included in the study were randomized into
two groups as group I (patient-centered task-oriented activity train-
ing in daily living conditions) and group II (patient-centered task-
oriented activity training with VBG). The patients’ pain, by “Numeric
Rating Scale (NRS)”, range of motion (ROM) by “goniometer”, muscle
and grip strengths by “dynamometer”, activity performance and par-
ticipation by “Childhood Health Assessment Questionaire (CHAQ)”,
“Duruoz Hand Index (DEI)”, “Jebsen-Taylor Hand Function Test
(JTHFT)” and “Nine Hole Peg Test (NHPT)” were evaluated. In group I,
ADL were trained with real materials used in daily life and various re-
habilitation products. In group II, ADL were trained with VBG. We
have created training protocol with Xbox 360 games for patient-
centered task-oriented activity training with VBG. We prefered ‘Dance
Central2’, one of the Xbox 360 games, for warming (macerana dan-
cing, 10 minutes). Other games, ‘Fruit Ninja’, ‘Table Tennis’, ‘Boxing’,
‘Volleyball’, ‘Darts’ and ‘Bowling’ were selected appropriately accord-
ing to patients performance. All the patients completed 8 weeks
(45 minutes for every session, 3 times in a week) of client-centered
treatment.
Results: After treatment in both groups, significant changes were
found in NRS, ROM, muscle strength, grips strength, CHAQ, DEI,
JTHFT and NHPT (p < 0,05). Table 1 shows comparison between the
groups for the activity performance, pain severity, hand grip and
pinch grip strengths. After the treatment, group II was statistically
more superior than group I in changes of wrist extension ROM and
DEI (p <0.05). In addition to, almost all changes of muscles strength
in group II were statistically more superior than changes of group I
(p < 0.001).
Conclusion: In our study, two different task-oriented activity training
provided significant changes in pain, ROMs of upper extremity,
muscle strength, grip strength, activity performance and participation
and patient-centered task-oriented activity training with video-based
games has been proved as an alternative treatment in children who
have involved upper limb with JIA.
Trial registration identifying number: Clinical Trial Number: NCT02954718
This work was supported by Research Fund of Istanbul University.
Project No: 51144
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children and is an important cause of
short-term and long-term disability. Many children appeared to have
elbow, hand- and/or wrist-related symptoms and impairments, withresulting moderate to severe levels of activity limitations and partici-
pation restrictions at daily living. However, in the literature, no study
has been found about variety of activity performance problems in
patients with JIA. The Canadian Occupational Performance Measure
(COPM) is a client-centered, patient reported outcome measure with
which clients evaluate their activity performance and satisfaction
with performance in areas of self-care, productivity and leisure.
COPM is generally used for analyzing activity performance problems
in many chronic diseases.
Objectives: The aim of the study was to analyze the activity perform-
ance problems of patients with JIA.
Methods: 50 patients with JIA (42 Female, 8 Male) were included
in the study. Inclusion criteria consisted of a diagnosis of JIA ac-
cording to the International League of Associations for Rheuma-
tology criteria, being aged between 6–18 years, having at least
one affected joint in upper extremity (shoulder, elbow, wrist, and
finger joints). Activity performance problems as perceived by the
individual were measured using face to face interview by the
Canadian Occupational Performance Measure (COPM). During the
interviews, the patients were encouraged to identify any daily ac-
tivity that they would like or need to do but found difficult to
complete because of their rheumatic diseases. Patients then iden-
tified the five most important daily activities and rated, first, their
current level of performance, and then, how satisfied they were
with this current level of performance. These performance and
satisfaction scores were rated by on a 10-point scale, with higher
scores indicating better performance and satisfaction. The statis-
tical software SPSS 21.0 was used for the analyses.
Results: The mean age was 12,76 ± 3,16 and the mean disease dur-
ation was 5,92 ± 3,82 years. 8% of patients had involvement shoulder
joint, 74% of them had involvement elbow joint, 88% of them had
involvement wrist joint and also 64% of them had involvement fin-
ger joint. The patients with JIA described 36 different types of prob-
lematic activities and identified 30 of them as the five most
important daily activities. Table 22 shows frequencies of five most
important daily activities of patients with JIA. The five most identified
problems were “carrying something” (66%), “writing” (50%), “opening
a bottle cap” (48%), “dressing” (38%) and “opening a door with han-
dle/knob” (38%) according to COPM. The mean of COPM-
performance scores was 3,99 ± 1,72 and the mean disease COPM-
satisfaction scores was 2,56 ± 1,70.
Conclusion: Our results showed that patients with JIA, who have at
least one affected joint in upper extremity, reported problems with a
wide range of activities. We suppose that the COPM can be a useful
tool for identifying activity performance problems as a patient-
focused outcome measure and also, it could provide information
about patient centered management for patients with JIA.
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Introduction: The evidence of vaccine safety and efficacy in patients
with rheumatic diseases is increasing. However, the data on vaccin-
ation status in children with rheumatic diseases remain scarce. So far,
only few smaller studies were published that found suboptimal vac-
cination coverage in patients with rheumatic diseases.
Objectives: To assess vaccination status in a cohort of children with
rheumatic diseases followed at the University Children's Hospital
Ljubljana and to evaluate the most common reasons for vaccination
dropout.
Methods: All consecutive patients with rheumatic diseases evaluated
at the rheumatology outpatient clinic between 1 January 2015 and
15 January 2017 received a questionnaire about their vaccination sta-
tus and reasons for potential vaccination dropout. Descriptive statis-
tics were used to analyse the proportion of children with full
vaccination status at 5, 10, 18 years and at their last clinic visit. The
study was approved by the national ethics committee.
Results: By May 2017 the data were received from 125 out of 422 en-
rolled patients (29.6%). Among included patients 64.8% were female,
median age was 12.3 (1.5-22.9) years and median age at diagnosis
5.8 (0.7-16.6) years. The majority of included children had JIA (n =
114), followed by SLE (n = 5), CRMO (n = 2), JDM (n = 2), MCTD (n = 1)
and systemic sclerosis (n = 1). Vaccination coverage was complete in
92.1%, 81.3%, 72.2% and 71.2% of patients at 5, 10, 18 years and at
their last clinic visit, respectively. Most commonly omitted vaccines
were Hepatitis B (22.9%) and second dose of Measles, Mumps and
Rubella vaccine (18.3%). Most common additional vaccine was
against tick-borne encephalitis (26.4%), which is an endemic disease
in Slovenia. Most common reasons for vaccination dropout were sug-
gestion of the treating rheumatologist and active disease.
Conclusion: We experienced a low initial response rate of 30%,
which might be due to increasing parents' vaccine hesitancy. In our
sample we found an approximately 10% decrease in complete vac-
cination coverage between consecutive age cohorts. Overall vaccin-
ation coverage in children with rheumatic diseases is lower than in
general population in Slovenia. Parent and patient education on vac-
cination remains crucial and when possible, vaccination catch-up
plans and booster vaccinations should be advocated on an individual
basis.
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Pediatric Rheumatology 2017, 15(Suppl 2):P64Introduction: Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease of childhood (4/1000 children) and untreated, can
lead to significant morbidity including joint deformities, loss of func-
tion and blindness (uveitis). Guidelines for the management of JIA
have been created for use in the developed world. Challenges in
diagnosis and management arise when these guidelines are applied
in low-resource settings given different endemic diseases, access to
care, and sociocultural practices.
Objectives: We performed a needs assessment of clinicians man-
aging JIA in low-resource settings with a view to applying our find-
ings to recommendations for JIA management in developing
countries.
Methods: An anonymous needs assessment regarding the manage-
ment of JIA in developing countries was developed based on four
areas of attention identified by rheumatologists in the developing
world: patient management (access to care and medications, clinical
work-up, transition); education (to the health professions and the
public); advocacy, networks and policy; and research. The survey
(available in English and Spanish) was tested, validated and electron-
ically circulated to healthcare practitioners who see children with JIA
in developing countries. Contacts were acquired through pediatric
rheumatology professional networks
Results: The survey was distributed to 502 practitioners, with 116 re-
sponses from clinicians in South America (50%), Africa (28%), Asia
(12%), the Middle East (1.5%), Central America (1.5%) and other
countries (7%). Respondents were pediatric rheumatologists (66%),
adult rheumatologists (22%), allied health professionals (7%), general
pediatricians (4%) and general practitioners (1%); median age 40-50
years, median 10-15 years in practice. The percentage of time de-
voted by these clinicians to pediatric rheumatology in their practice
was: <25% (29%), between 26-50% (19%), between 51-75% (13%),
>75% (17%) and 100% (22%).
Barriers to accessing care for children with JIA identified by respon-
dents were: insufficient training in JIA among pediatricians (74%),
lack of awareness of JIA in the healthcare community (73%), long re-
ferral pathways (67%) and few pediatric rheumatologists (63%). En-
demic diseases that complicate the management of JIA in
participants’ settings were: tuberculosis (84%), HIV (41%), sickle cell
anemia (31%), malaria (19%) and diarrheal disease (19%). Transition
planning was not a programmed strategy in >40%; and non-
adherence to uveitis screening guidelines was reported in >40%.
Education on JIA was available to 71% of pediatrics trainees, 50% of
adult rheumatology trainees and <50% of medical students in partici-
pants’ settings. Established pediatric rheumatology training programs
were unavailable to 40%; access to educational resources and edu-
cating the public on JIA was available to only one third of
respondents.
Policy and advocacy interventions felt to potentially improve access
to care for JIA patients were: increasing the availability of pediatric
rheumatologists (79%) and jobs for them (50%), better training on
managing JIA (74%), formulation of clear referral channels (65%), for-
mation of patient support groups (62%) and availability of manage-
ment guidelines (49%).
One third of participants were not involved in research. Epidemio-
logical and clinical research were felt to be research priorities in JIA
by 75% and 62% of participants to ascertain local burdens of disease.
Major barriers to performing research include: lack of funding (79%),
lack of time (58%), lack of support systems, e.g., laboratory (52%),
lack of trained personnel (46%) and lack of experience (26%).
Conclusion: Management of JIA remains a challenge in the develop-
ing world; is rooted in educational gaps in the medical and general
community; and complicated by endemic disease and insufficient ac-
cess to resources. Guidelines specific to low-resource settings, and in-
formed by research exploring the local burdens of disease and
experiences of stakeholders, may serve as a powerful educational
document to advocate for policy change and best practices.
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Introduction: Many studies in pediatric rheumatology underline the
concept of « window of opportunity », early in the disease course to
prevent joint or ocular damage in the context of juvenile idiopathic
arthritis (JIA). In Europe, despite facilitated access to health care, chil-
dren with JIA are referred to pediatric rheumatology centres with sig-
nificant delay. This delay is closely linked to the organization of the
country’s health care delivery system. In France and Switzerland
nothing is known about diagnostic delay and little about access to
remission in JIA.
Objectives: To assess the diagnostic delay and the rate of remission
at one year and 2 years in JIA patients of the JIR cohorte.
Methods: The JIRcohorte is an international network dedicated to col-
lect prospective and retrospective data on juvenile inflammatory
rheumatic diseases. Data collection started in 2013. We included all
French and Swiss JIA patients according to the ILAR classification. We
focused on the relationship between (i) diagnostic delay (defined by
the number of weeks between the first symptoms and the diagno-
sis), (ii) distance between parent’s home and the place of the diagno-
sis, and (iii) remission rate at one year, two years and treatments.
Results: We included 709 JIA patients (50% oligoarthritis, 17% RF–
polyarthritis, 15% enthesitis-related arthritis [ERA], 10% systemic JIA
[sJIA], 3% RF+ polyarthritis, 3% psoriatic arthritis, and 2% undifferen-
tiated arthritis).
The median diagnostic delay of the whole cohort was 17 weeks
(interquartile range (IQR) 9-48). The patients with ERA had the lon-
gest delay: 45 weeks (13-104), whereas children with sJIA had the
shortest delay: 9 weeks (4-21). The median diagnostic delay was not
correlated with parents’ home distance from the diagnostic center.
59% and 57% of the patients were in remission and 57% at 1 and
2 years of follow-up, respectively.
The median delay between diagnosis and treatment onset was
3 weeks (IQR 0-34) for oral corticosteroids, 8 weeks (IQR 0.3- 30) for
intra-articular corticosteroids, 9 weeks (IQR 0-52) for DMARDS and
52 weeks (IQR 19-147) for biologics.
The diagnostic delays for the whole cohort and for the different JIA
subtypes are in line with the international literature. JIA with indolent
symptoms as ERA had the longest diagnostic delay whereas sJIA as-
sociated to overt manifestations including fever had the shortest
delay. In France and Switzerland, there are no guidelines about diag-
nostic delay but UK guidelines advocate a diagnostic delay inferior to
10 weeks. According to these guidelines, 68% of our patients exceed
this delay, which is shlighly lower than previous studies. The absence
of correlation with parents’ home distance from the diagnostic center
is also described in other countries. Our remission rate at 1 year is
higher than described in other studies but it decrease at 2 years. The
treatment delay is longer in our cohort than in other studies.
Conclusion: The diagnostic delay and treatment delay in France and
Switzerland are too long. Strong efforts have to be made to under-
stand the underlying factors to suggest improvements in care path-
way organization and practices by the elaboration of care course
management guidelines. The JIR network permit to design a pro-
spective study to identify these factors and improve the short-termprognosis of JIA, in the context of national and European rare disease
health programs.
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Introduction: The transition from pediatric to adult healthcare is a
vulnerable time for adolescents and young adults (AYA) with chronic
conditions. Thie year the European League Against Rheumatism
(EULAR) and the Pediatric Rheumatology European Society (PReS)
jointly offered expert-opinions regarding transitional care of AYA
with juvenile-onset rheumatic diseases and the American College of
Rheumatology (ACR) developed a toolkit. For these guidelines to be
implemented or for these resoures to be utilized, adult and pediatric
rheumatologists need to understand their application. Nevertheless,
there are no published curricula for teaching transition skills to
rheumatologist-in-training.
Objectives: We sought to develop and assess the impact of a work-
shop designed to help adult rheumatology fellows learn key skills for
providing effective transition care to transferring young adult
patients.
Methods: A 1-hour skills-based workshop on transition and transfer
best practices was developed alongside an objective standardized
clinical examination (OSCE) station in which trainees were given
12 minutes to welcome a young adult with lupus – and her parent –
to a first visit in an adult clinic and perform a full history. The OSCE
evaluation rubric assessed five transition/transfer skills (skills 1-5) and
one “control skill” (skill 6), on a Likert scale of 1-5, with 5 being the
best performance. Adult rheumatology fellows (n = 19) from 5 institu-
tions were evaluated with the OSCE; 12 were tested with the OSCE
de novo, whereas 7 were tested with the OSCE after participating in
the workshop. Unpaired, aggregated OSCE scores were complemen-
ted with unpaired pre- & post-survey data in which fellows reported
their self-assessed level of preparation for 12 transition and transfer
skills.
Results: Fellows’ self-assessed proficiency with 12 key transition/trans-
fer skills increased significantly with participation in the workshop and
accompanying OSCE, including fellows’ confidence in their ability to dis-
cuss the needs of the transferring patient with the pediatric rheuma-
tologist (p < 0.01). In addition, OSCE performance (see Table 23) was
greater in the group of fellows that participated in the workshop prior
to the OSCE (“post-workshop” - average score of 4.3) than in the group
that took the OSCE de novo (“pre-workshop” - average score of 3.3, p =
0.01). The skills demonstrating statistically significantly higher scores
post-workshop were: skill 1) highlighting differences between adult
and pediatric care and setting expectations (p < 0.01); skill 2) placing
the patient in the primary role and utilizing the parent for corrobor-
ation (p < 0.05); and skill 4) performing a confidential adolescent social
history. There was a trend towards improved performance for skill 3,
assessing self-management skills, whereas there was no significant
change in skill 5, assessing barriers to transition and medication adher-
ence. Performance on skill 6, the control skill of assessing patient and
parent understanding of the disease process, was lower in the group of
fellows’ that participated in the workshop prior to being tested with
the OSCE (p = 0.01).
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 48 of 191Conclusion: A brief educational intervention successfully increased
adult rheumatology fellows’ perception of their proficiency with key
transition/transfer skills. In addition, fellows who participated in the
educational intervention had significantly higher scores on their
OSCE performance. It is likely that the “control skill” score was lower
in the post-workshop group owing to more time being spent on
newly acquired peri-transfer skills: during the 12-minute OSCE sce-
nario, discussing disease pathogenesis took a backseat to conversa-
tions about expectations in the adult care model, self-management
skills, and goal setting. Making this curriculum available to all
rheumatologists-in-training would likely improve the care young
adult rheumatology patients receive when transferring from pediatric
to adult rheumatology. A complementary curriculum for pediatric
rheumatology fellows could further improve the care of AYA rheuma-
tology patients.
Disclosure of Interest: None DeclaredTable 23 (Abstract P67). See text for description
Skill 1 Skill 2 Skill 3 Skill 4 Skill 5 Total/Avg Skill 6
Pre-workshop (n = 12) 3.5 4.3 3.8 2.8 2.3 16.7/3.3 3.5
Post-workshop (n = 7) 4.6 5.0 4.4 4.7 2.6 21.3/4.3 2.0
p-value <0.01 <0.05 0.18 0.01 0.86 0.01 0.01P68
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Introduction: Juvenile idiopathic arthritis (JIA) is characterized by
chronic inflammation of the joints which can lead to structural bone
damage.
Objectives: The primary objective of this study was to evaluate re-
sponse of newly diagnosed JIA patients to an early aggressive treat-
ment by conventional radiography. Secondary objective was to
compare Poznanski and BoneXpert methods to evaluate presence
and progression of radiological damage in wrists of JIA patients.
Methods: JIA patients participating in the BeSt for Kids study (NTR
1574) were eligible in case of wrist involvement at inclusion if con-
ventional radiographs were available at baseline or within 6 months
before/after study inclusion. Follow-up radiographs after 12-36
months were available for comparison. Radiographic bone damage
as reflected by carpal length was assessed using Poznanski score.
BoneXpert method was used to determine bone age and bone min-
eral density (BMD).
Results: Forty JIA (27 female) patients were evaluated for Poz-
nanski score and BMD (mean age 7.2 ± 3.4 years), 26 patients (15
female) were evaluated for bone age (mean age 9.3 ± 2.2). At
baseline mean Z-score of RM/M2 was 0.047. At follow-up mean
Z-score changed to 0.055 (p = 0.937). Baseline and follow-up Z-
scores were not different from a healthy population. Bone age
did not significantly differ at baseline (Z-score 0.08) and follow-
up (Z-score 0.25). At baseline BMD was significantly diminished
compared to healthy controls (Z-score -0.71) and improved sig-
nificantly (Z-score -0.44 (p = 0.032)).
Conclusion: In this cohort of JIA patients treated early and aggres-
sively we have detected no radiographic damage in the wrist at
baseline or follow up. BMD was significantly diminished at baseline
but improved significantly after follow-up.
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Introduction: Juvenile idiopathic arthritis, JIA, is classified into
seven categories; systemic-onset type, persistent and extended
oligoarthritis, polyarthritis with rheumatoid factor negative, poly-
arthritis with rheumatoid factor positive, psoriatic arthritis,
enthesitis-related arthritis and undifferentiated arthritis classified
by the International League of Associations for Rheumatology. As
each category of JIA has different features in clinical phenotypes,
precise subtyping is required for research and management. Due
to inclusion and exclusion criteria, some patients is ended up in
the undifferentiated category. Undifferentiated arthritis includes
patients who do not meet criteria for any category. Or, they meet
the criteria for more than 1 category but with either a close rela-
tive who has psoriasis or the presence of RF. The prevalence of
subtypes of JIA was reported; Oligoarticular JIA occurs most fre-
quently (50% to 60% of cases), followed by polyarticular JIA.
However, there is not enough information in the literature about
the undifferentiated arthritis group.
Objectives: We aimed to analysis the characteristic findings of the
undifferentiated arthritis group in JIA patients.
Methods: This was a retrospective longitudinal cohort study of pa-
tients with JIA at a tertiary care pediatric rheumatology clinic. Sub-
jects were included if they were evaluated at our pediatric
rheumatology clinic between June 2016 and May 2017, had a diag-
nosis of JIA according to ILAR criteria.
Demographics (sex, age at diagnosis, ANA, RF, HLA B27 status),
clinical disease elements (active joint count, tender enthesis
count) and current medication use at each visit were identified
by querying the electronic medical record. All available visits
were included in the analysis. All analyses were performed using
SPSS 16.0
Results: During the study period there were 215 JIA patients eval-
uated at 640 visits. 180(84%) of patients had newly-diagnosed
JIA.
There were 21 (84%) girls and 4 (16%) boys. Mean age at dis-
ease onset was 13.4 ± 2.2 years.The median duration of disease
was 8 years.The median duration prior to treatment was
1 months. Among 25 patients with undifferentiated arthritis, 11
(48%) patients had enthesitis, 15 (60%) had sacroiliitis. Joints
mainly affected in the undifferentiated arthritis group with were
knees (16, 64%) and 2 patients were RF-positive and 7patients
had positive ANA had undifferentiated arthritis. 6 patients (24%)
of undifferentiated JIA patients used more than one DMARD.-
Methotrexate was the mainstay of treatment (52%), with an ini-
tial dose of 10–15 mg/m2/week and a maximum dose of 20–
25 mg/m2/week or 25 mg/week. Sulfasalazine was used in36 %
of undifferentiated JIA patients. 2 of the patients received bio-
logic agents.
Conclusion: Since distribution of the JIA category is different
upon ethnicity, this study showed that percentage of undifferenti-
ated JIA patients in our cohort was found higher reported from
other studies in the literature. This is a single center, referral-
based cohort study. As such, it might not represent the entire
population of Turkey. In our conclusion, to clarify characteristics
of undifferentiated JIA patients, need large cohort and multicen-
ter study.
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Introduction: Uveitis is the most common form of extraarticular
organ involvement in juvenile idiopathic arthritis (JIA). The onset
of chronic anterior uveitis in JIA is insidious and often entirely
asymptomatic. Children with JIA must be subjected to periodic
eye examinations with slit lamp according to the different risk
of developing this complication. The decision to undertake a
screening program depends on the cost-benefit balance. To
date, however, there is uncertainty about the optimal frequency
of eye examinations. Although guidelines for ophthalmologic
surveillance have been proposed, none of them is universally
embraced.
Objectives: To evaluate the time of the occurrence of uveitis after
the onset of arthritis in children with JIA
Methods: The clinical charts of 1425 patients with JIA by ILAR
criteria followed at study centers from January 1987 to October
2016 and with a follow-up of at least 6 months after disease on-
set were reviewed to identify those who had uveitis. In all pa-
tients, the diagnosis of chronic anterior uveitis was confirmed by
an ophthalmologist and was defined according to the
Standardization of Uveitis Nomenclature Working Group criteria.
Children with systemic arthritis, rheumatoid-factor positive poly-
arthritis and enthesitis-related arthritis were excluded. Patients
who developed uveitis before the onset of arthritis were also ex-
cluded. Patients who developed uveitis at the same time of the
arthritis onset were included. Through the construction of a cu-
mulative frequency curve, we defined the risk of developing
uveitis for each year of disease, starting with the onset of
arthritis.
Results: A total of 336 patients (23.6%) had uveitis a median of
1.1 years after onset of arthritis. The cumulative frequency curve
showed that 47.6% and 67.3% of patients developed uveitis in the
first 1 and 2 years of illness, respectively, and that less than 5% of all
instances of uveitis occurred after 7 years from the onset of arthritis
(Table 24).
Conclusion: Our study shows that nearly half of JIA patients
with uveitis developed this complication in the first year after
onset of arthritis and around two-third within two years. Less
than 5% of patients had uveitis after 7 years from disease on-
set. These findings underscore the need for tight ophthalmo-
logic monitoring in the first 2 years of disease and support the
recommendation of current guidelines to lengthen ophthalmo-
logic screening after 7 years of disease without ocular
involvement.
Disclosure of Interest: None DeclaredTable 24 (Abstract P70). Cumulative frequency of uveitis
Follow-up (years) 0 to 1 1 to 2 2 to 4 4 to 6 6 to 8 8 to 9 > 9
N. 160 66 51 31 15 6 7
Cumulative % 47.6 67.3 82.4 91.7 96.1 97.9 100P71
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Introduction: A Phase 3b, open-label (OL), multicenter study (CLIP-
PER) has shown efficacy of etanercept (ETN) in pediatric patients
(pts) with extended oligoarticular (eo) juvenile idiopathic arthritis
(JIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA).
CLIPPER2 is an ongoing OL extension study assessing long-term
safety and clinical benefits of ETN in this population.
Objectives: Describe safety and clinical benefit of 6 yr of ETN treat-
ment in CLIPPER (2 yr) and CLIPPER2 (4 yr) studies.
Methods: 127 pts with eoJIA (2–17 yr), ERA, or PsA (12–17 yr) who re-
ceived ≥1 ETN dose (0.8 mg/kg QW [max, 50 mg]) in CLIPPER were
eligible to enter CLIPPER2. Efficacy endpoints included proportions of
pts achieving JIA ACR30/50/70/90/100 and Wallace/Juvenile Arthritis
Disease Activity Score (JADAS) inactive disease/clinical remission cri-
teria. Time to disease flare for pts who met predefined study criteria
for withdrawing from ETN treatment was assessed by Kaplan-Meier
(KM) analysis. Safety was assessed from CLIPPER baseline (BL) to
month (m) 72.
Results: 109/127 (86%) pts entered CLIPPER2. At m72, 46/127 (36%)
were taking ETN (39 [31%] ongoing, 7 [6%] restarted treatment), 44
(35%) had stopped ETN treatment, and 37 (29%) had discontinued
the study. Improvements in disease activity seen in CLIPPER (m0–24)
were largely maintained at m72 (Table; observed cases). Proportion
of pts achieving JIA ACR30/50/70 responses at m24 (% = 99/98/93)
was maintained to m72 (% = 96/96/88). Proportion of pts achieving
JIA ACR90/100/Wallace inactive disease at m24 (% = 65/54/34) was
maintained to m60 (% = 71/51/31) but afterwards decreased (% = 50/
26/10 at m72). Sustained remission (≥12 continuous months) was
achieved by 7/98 (7%) pts. 22/127 (17%) pts withdrew from ETN
treatment due to low/inactive disease; 13/22 (59%) experienced dis-
ease flare (median time to flare [KM] = 190 days).
Most frequently reported treatment-emergent adverse events (TEAEs)
were (no. events [N], events per 100 pt-yr [EP100PY]), headache (28,
5.34), arthralgia (24, 4.58), and pyrexia (20, 3.81) (Table 25). Number
and frequency (N, EP100PY) of TEAEs (excluding infections/injection
site reactions [ISR]) decreased over the 6-yr study period from 193,
173.81 in yr1 to 37, 61.34 in yr6. Most commonly reported treatment-
emergent (TE) infections were (N, EP100PY) upper respiratory tract in-
fection (66, 52.0), pharyngitis (58, 45.7), and gastroenteritis (31, 24.4).
1 case of malignancy (Hodgkin’s lymphoma) and no cases of active
tuberculosis, demyelinating disorders, or deaths were reported.
Conclusion: OL ETN treatment to m72 was effective and well toler-
ated in pts with eoJIA, ERA, and PsA. Majority of pts who withdrew
from ETN treatment experienced disease flare. TEAE frequency de-
creased over time.
Trial registration identifying number: NCT00962741/NCT01421069
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Clinical Outcomes
Mean (95% CI)
Safety Summary (to m72)
N (EP100PY) unless otherwise stated
BL1(n =
127)
m241(n
= 109)
m482(n
= 64)
m722(n
= 47)
eoJIAEXP
= 245.607
PY
ERAEXP
=
158.888
PY
PsAEXP
=
119.945
PY
TotalEXP
=
524.441
PY
PtGA 4.96
(4.6,5.4)
0.97
(0.7,1.2)
1.32
(0.9,1.8)
1.29
(0.9,1.7)
TEAEs* 244
(99.35)
151
(95.04)
90
(75.03)
485
(92.48)
PGA 5.02
(4.7,5.3)
n = 108
0.62
(0.5,0.8)
n = 63
0.67
(0.5,0.9)
0.76
(0.5,1.0)
TE infections 351
(142.91)
93
(58.53)
117
(97.54)
561
(106.97)
CRP,
mg/L
8.26
(5.7,10.8)
n = 103
2.76
(1.7,3.8)
2.85
(1.6,4.1)
n = 46
1.58
(1.2,2.0)
TEAEs*
causing
withdrawal, n
(%)
5 (2.04) 8 (5.03) 0 13 (2.48)
JADAS
73
joints
n = 119
17.16
(15.9,18.4)
n = 102
2.28
(1.7,2.9)
n = 61
2.48
(1.8,3.1)
n = 29
3.12
(2.2,4.1)
TE infections
causing
withdrawal, n
(%)
2 (0.81) 0 1 (0.83) 3 (0.57)
No.
active
joints
6.74
(5.9,7.6)
0.61
(0.2,1.0)
n = 63
0.49
(0.3,0.7)
n = 30
0.60
(0.2,1.0)
Serious TEAEs 11 (4.48) 17
(10.70)
4 (3.33) 32 (6.10)
No.
active
joints
(LOM)
5.72
(5.0,6.5)
1.06
(0.5,1.6)
n = 63
1.02
(0.6,1.4)
n = 30
1.10
(0.5,1.8)
Serious TE
infections
5 (2.04) 4 (2.52) 4 (3.33) 13 (2.48)
Opportunistic
infections†
0 1 (0.63) 1 (0.83) 2 (0.38)
Data from patients taking ETN (full analysis set)
1CLIPPER study
2CLIPPER2 study
*Excluding infections/ISR
†All herpes zoster
CRP, C-reactive protein; EXP, exposure to ETN; LOM, limitation of motion; PGA, physician’s global assessment;
PtGA, patient/parent global assessment; PY, pt-yrP72
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Introduction: Methotrexate (MTX) is commonly used in the treat-
ment of children with juvenile idiopathic arthritis (JIA). Frequently it
is discontinued due to intolerance with anticipatory and associative
gastrointestinal symptoms. Eye Movement Desensitization and
Reprocessing (EMDR) is a therapy where non-processed and dysfunc-
tional experiences and memories are reprocessed by intensive recall
combined with eye movements. This leads to selective processing of
the negative affect.
Objectives: Objective of this study was to investigate effectiveness of
EMDR in the treatment of MTX intolerance in JIA patients, with the
underlying hypothesis that intolerance occurs due to dysfunctional
memories and expectations.
Methods: An open prospective study on consecutive JIA patients with
MTX intolerance was performed. Intolerance was determined using the
Methotrexate Intolerance Severity Score (MISS) questionnaire andhealth-related quality of live was determined using the PedsQL, at 3
time points: directly before and after treatment (after treatment: MISS
only), and 4 months after treatment. Patients were treated using a stan-
dardized EMDR protocol with 8 sessions over a time period of 2 weeks.
Changes in MISS and PedsQL were compared using descriptive and
non-parametric methods.
Results: 14 patients with MTX intolerance (median MISS at inclusion:
13.5, range: 6-26) were included. Directly after treatment, all patients
reported marked improvement of MTX intolerance symptoms (me-
dian MISS: 0.5, range: 0-3, p = 0.001). After 4 months, lasting reduc-
tion of MTX intolerance symptoms was observed (n = 5, median
MISS: 5, range: 0-10, p = 0.068). However, 2/5 patients (40%) showed
MISS >6. The health-related quality of life showed a trend towards
improvement 4 months after treatment (n = 5, median pedsQL prior
to treatment 84.4%, 4 months after treatment 92.4%, p = 0.46).
Conclusion: MTX intolerance in children with JIA can effectively be
treated using an EMDR protocol, with lasting effect over 4 months.
This intervention could potentially increase quality of life in affected
patients and enable continued treatment with MTX.
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Introduction: Juvenile idiopathic arthritis with systemic onset (soJIA)
is the most striking form of JIA with combination of arthritis and sys-
temic features. The acute lung involvement (ALI) is not frequent
manifestation of soJIA but often influence on disease course, out-
comes and treatment. The mechanisms of lung involvement are still
unclear.
Objectives: The aim of our study was to compare clinical and labora-
torial features of patients with soJIA with and without ALI.
Methods: In the study were included retrospective data of 82 chil-
dren with soJIA. ALI was described if patient had at least one: dys-
pnoe, shortness of breath, signs of respiratory distress syndrome,
interstitial lung disease, pulmonary arterial hypertension.
Results: ALI was detected in the onset of soJIA in 18 (22.0%) of pa-
tients. Patients with ALI had more severe soJIA disease course (data
in Table 26).
Patients with ALI more frequently had MAS (p = 0,0006), pericarditis
(p = 0,0006), transient proteiunuria, attributed to MAS (p = 0,015),
concomitant sepsis (p = 0,005) and morphological evidence of hemo-
phagocytosis in bone marrow (p = 0,02).
The main predictors of development ALI were presence of macro-
phage activation syndrome (OR = 6.6 [2.1; 21.0], p = 0.0006), bone
marrow hemophagocytosis (OR = 13.9 [0.7; 269.2], p = 0.02), heart in-
volvement (OR = 6.4 [2.1; 19.7], p = 0.0006), kidney involvement (tran-
sient proteinuria) (OR = 6.1 [1.2; 30.3], p = 0.0015), evidence of
concomitant sepsis (OR = 21.2 [1.0; 466.0], p = 0.005), albumin ≤
25.6 g/l (OR = 73.3 [10.9; 495.0], p = 0.0000001), AST > 37.3 U/l (OR =
5.3 [1.4; 20.2], p = 0.008), CRP > 125.0 g/l (OR = 5.6 [1.7; 18.6], p =
0.003), ferritin > 690 ng/ml (OR = 22.7 [2.7; 191.4], p = 0.0002),
hemoglobin ≤ 89 g/l (OR = 7.1 [2.3; 22.6], p = 0.0001), LDH > 882 U/l
(OR = 4.8 [1.4; 16.4], p = 0.002), platelets ≤ 211x109/l (OR = 10.1 [3.1;
32.9], p = 0.00002), prothrombin ≤ 74.6% (OR = 12.6 [2.8; 57.3], p =
0.0003), total protein ≤ 65.0 g/l (OR = 8.7 [2.7; 27.8], p = 0.00008).
Conclusion: The identified predictors of ALI in soJIA have to check to
evaluation of prognosis and choosing treatment plans.
Disclosure of Interest: None Declared
Table 27 (Abstract P74). See text for description
Before 1997
(n = 211)
1997-2005
(n = 602)
After 2005
(n = 612)
number of Uveitis 60 (28,4%) 149 (24,8%) 127 (20,8%)
Age at onset <3 96 (45,5%) 273 (45,3%) 302 (49,3%)
Age at onset 3-7 80 (37,9%) 203 (33,7%) 169 (27,6%)
Age at onset >7 35 (16,6%) 126 (20,9) 141 (23,0%)
Extended oligoarthritis 35 (16,6%) 84 (14,0%) 97 (15,8%)
Persistent oligoarthritis 117 (55,5%) 317 (52,7%) 348 (56,9%)
FR-negative poliarthritis 35 (16,6%) 139 (23,1%) 138 (22,5%)
Psoriatic arthritis 11 (5,2%) 21 (3,5%) 10 (1,6%)
Undifferentiated arthritis 13 (6,2%) 41 (6,8%) 19 (3,1%)
Table 26 (Abstract 73). See text for description
Parameter ALI (n = 18) W\o ALI (n = 67) p
Hemoglobin, g/l 86,5 (80,0; 108,0) 105,0 (94,0; 116,0) 0,003
Platelets, x109/l 201,0 (95,0; 492,0) 454,0 (361,0; 588,0) 0,006
CRP, mg/l 104,8 (37,5; 154,0) 47 (18,0; 104,0) 0,07
LDH, U/l 1042,0 (543,0; 1230,0) 516,0 (395,0; 676,0) 0,012
Ferritin, ng/ml 1759,0 (1144,0; 11300,0) 321,0 (139,0; 1278,0) 0,0009
Prothrombin, % 71,1 (63,0; 79,0) 91,0 (79,0; 98,0) 0,0009
Fibrinogen, g/l 1,8 (0,8; 4,0) 4,7 (3,2; 5,7) 0,012
Total protein, g/l 64,6 (55,0; 70,3) 71,2 (67,0; 77,0) 0,002
Albumin, % 24,1 (23,0; 25,6) 39,0 (31,8; 43,2) 0,00001
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Introduction: Uveitis is the most common extra-articular mani-
festation of juvenile idiopathic arthritis (JIA). In recent years,
there has been a major advance in the management of both
JIA and of uveitis. Non-controlled studies have suggested that
some medications, particularly methotrexate and anti-TNF
antibodies, are potentially capable to prevent the occurrence
of uveitis. However, whether the recent therapeutic progress
had led to a reduction in the prevalence of uveitis is
unknown.
Objectives: To investigate the temporal trend in the prevalence of
uveitis in JIA patients seen over a 30-year period.
Methods: A retrospective analysis of the medical records of all chil-
dren with JIA by ILAR criteria who were seen at authors’ units be-
tween January 1987 to October 2016 was carried out. The prevalence
of uveitis in patients with onset of JIA in different time periods (be-
fore 1997, between 1997 and 2005 and after 2005) was evaluated.
Patients without uveitis who had a disease duration of less than
6 months were excluded.
Results: A total of 1.425 patients with JIA, 336 (23.6%) of whom
had developed uveitis were identified. The prevalence of uveitis
was 60/211 (28.4%) among patients with onset before 1997, 149/
602 (24.8%) among patients with onset between 1997 and 2005,
and 127/612 (20,8%) among patients with onset after 2005. The
follow-up of patients seen in the three time periods was compar-
able (Table 27).
Conclusion: Our study shows a decrease in the prevalence of
uveitis over time, which might be, at least partially, related to
the increased tendency toward earlier use of methotrexate and
the introduction of biologic agents. This finding should to be
confirmed in patient series seen in other pediatric rheumatology
centers.
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon autoinflammatory disease manifesting with self-limited recur-
rent febrile attacks and polyserositis. Acute recurrent monoarthritis is
the most common form of musculoskeletal involvement in FMF;
however, up to 5% of FMF patients may develop chronic joint dis-
eases including sacroileitis. It is difficult to distinguish whether sacroi-
liitis is a musculoskeletal finding of FMF or whether this is the
coexistence of two diseases; FMF and SpA.
Objectives: In this study, we aimed to evaluate FMF patients with
sacroiliitis, and compare their features with juvenile spondyloarthro-
pathy (SpA) patients all of whom had sacroiliitis.
Methods: 15 pediatric FMF patients with sacroiliitis and 30 patients
with juvenile SpA followed between 2014-2016 at the Department of
Pediatric Rheumatology at Hacettepe University, Ankara, were in-
cluded in the study.
Results: The median (min-max) age at diagnosis of sacroiliitis was
11 (7-15) for FMF + sacroiliitis, and 11.5 (7-16) years for juvenile
SpA patients. All patients suffered from hip pain and morning
stiffness. Only two FMF + sacroiliitis patients had enthesitis, while
nearly half of juvenile SpA patients (46.7%) had enthesitis. Four
FMF patients suffered from lower back pain, although none of
them had spinal involvement. On the other hand, approximately
one third of juvenile SpA patients had spinal involvement. The
median white blood cell count, erythrocyte sedimentation rate,
and C reactive protein values in FMF + sacroiliitis patients were
higher (10.1x103/mm3 vs 7.8x103/mm3, p = 0.002; 41 vs 28 mm/h,
p < 0.001; 4.6 vs 1.3 mg/dl, p < 0.001; respectively) than juvenile
SpA patients. HLA B27 positivity was more common in juvenile
SpA than FMF + sacroiliitis patients (86.6% vs 26.7%, respectively,
p = 0.001). The most common MEFV (MEditerranean FeVer) muta-
tion was M694V in FMF patients. All juvenile SpA patients but
one were negative for MEFV mutations. One juvenile SpA patient
was heterozygous for E148Q.
Table 28 (Abstract P77). See text for description
Genes MEFV MEFV MEFV TNFRSF1A NLRP3 NOD2 NOD2 NOD2 PSTPIP1
Mutation E148Q I591T M694I P46L V198M D925G N289S E778K G258a
JIA
Patients
7/101
6,9%
4/
101
3,9%
3/101
2,9%
1/101
0,9%
4/101
3,9%
1/101
0,9%
4/101
3,9%
1/101
0,9%
1/101
0,9%
Iberian
Population
0/107
0%
2/
107
1,8%
18/
69.706
0,03%
0/107 0% 1/107
1,8%
1/107
1,8%
1/107
1,8%
0/107
0%
1/6498
0,01%
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 52 of 191Conclusion: We demonstrated that pediatric patients with FMF +
sacroiliitis showed different characteristics (higher inflammatory
markers, less frequent spinal and enthesitis involvement and HLA-
B27 positivity) from patients with juvenile SpA. The jury is out to de-
cide whether FMF is a triggering factor for SpA or whether this is a
feature of FMF per se.
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Introduction: Systemic-onset juvenile idiopathic arthritis (SoJIA) is a
rare paediatric rheumatic condition with unclear pathogenesis, chal-
lenging diagnosis and treatment.
Objectives: The aim of our study is to describe the epidemiology,
clinical presentation and biologic treatment of SoJIA patients regis-
tered in the JIRcohorte.
Methods: This is a multicentre, observational, retrospective and in-
ception cohort study, through an international platform: JIRcohorte.
Patients with SoJIA, diagnosed and followed in one of the participat-
ing centres in the JIRcohorte project in Switzerland, France, Belgium
and Morocco are enrolled in the registry.
Results: 212 patients with SoJIA have been included; 119 were girls
with a female: male ratio of 1.3:1. The median age at diagnosis was
5.4 years and the median diagnostic delay was 40 days. Data for ini-
tial systemic manifestations were available in 57 patients: 96% pre-
sented with typical fever (55/57), 56% with rash (32/57), 32% with
lymphadenopathy (18/57), 21% with splenomegaly (12/57), 21% with
hepatomegaly (12/57), and 16% with serositis (9/57). Data for joint in-
volvement were available in 46 patients: arthritis was reported in
only 61% of them during the first year of disease evolution, with a
poly-articular predominance (61%). 169 out of 212 patients (80%)
had a biologic treatment at least once during their disease course.
Before 2008, anti-TNFa agents were more frequently used (69%),
followed by anti-IL-1 agents (30%), with a very few patients receiving
anti-IL-6 agent (1%). Since 2008, anti-IL-1 agents became the most
common biologic treatment (46%), followed by tocilizumab (36%),
with fewer patients under anti-TNFa agents (18%). Higher rate of in-
fectious adverse effects was reported with Tocilizumab, while Ana-
kinra was associated with skin and administration site effects.Conclusion: We describe here the main epidemiologic and clinical
characteristics, as well as the treatment of patients with SoJIA in-
cluded in our international JIRcohorte platform. Biologic therapies, in
particular anti-IL1 agents, are widely used in the treatment of this
disease throughout the last years. Further prospective data analysis is
required to evaluate the long-term efficacy and the safety of these
treatments.
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Introduction: Classification criteria of Juvenile Idiopathic Arthritis (JIA)
are clinical and of exclusion. Autoinflammatory Inherited Diseases (AID)
are innate immune system disorders with clinical similarity with JIA that
have been considered in differential diagnosis of this disease. Patients
with AID previously wrongly diagnosis as JIA has been described
Objectives: To evaluate presence of variations on genes implicated
in AID in a group of JIA patients attended at our center between
January 2000-2015. To compare clinical and laboratory data between
patients with and without variations on these genes.
Methods: Transversal (January 2000-2014) and prospective (January
2014-2015) study. Clinical, demographics and laboratory (erythrocyte
sedimentation rate (ESR), C reactive protein (CRP), ANA, blood cell
count) data were collected. Next-generation sequencing test of MEFV,
TNFRSF1A, MVK, NLRP3, NOD2 and PSTPIP1 were done.
Results: One hundred and one patients were included (76 girls). 61 oli-
goarticular JIA, 20 rheumatoid factor (RF) negative polyarticular JIA, 19 ex-
tended oligoarticular JIA and 1 RF positive polyarticular JIA. Fifty patients
were ANA positive. At least one variation was identified in 26.7% of our
patients. Accumulated probability of having some variation in these
genes in our JIA series was statistical significant greater than healthy Iber-
ian population (20 vs 8.2% respectively, p = 0.01). Table 28 describes iden-
tified genetic variations. Variations in all searched genes were detected
except for MVK. Oligoarticular extended JIA was the more affected sub-
type (47.4%, p = 0.082). We did not find differences according to ANA.
Based on the presence of a genetic variation we did not find differ-
ences in age at onset disease, presence of extra-articular symptoms,
laboratory parameters at diagnosis.
Conclusion: Variations on all AID studied genes were detected ex-
cept for MVK. We found greater prevalence of genetic variations in
JIA patients than described in healthy Iberian population. We did not
find differences according ANA. We did not find clinical nor labora-
tory predictors of presence of a genetic variation
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Introduction: Temporomandibular joint (TMJ) arthritis is common in
children with Juvenile Idiopathc Arthritis (JIA); it confers significant
functional and psychological morbidity to young people suffering
with pain, functional impairment and facial asymmetry, as a result of
TMJ destruction. Gadolinium-enhanced MRI is the gold-standard im-
aging modality for detection of synovitis, however early recognition
of TMJ arthritis is challenging: clinical assessment is insensitive and
early findings on MRI overlap with non-inflammatory synovial en-
hancement of normal children. With the expense and relative scarcity
of MRI, coupled with challenging interpretation of results in early dis-
ease, there is an absence of international consensus with regard to
screening in TMJ arthritis. Reducing the burden of deforming TMJ
disease in young people would undoubtedly be aided by effective
early detection of joint involvement.
Objectives: This observational study aims to understand the charac-
teristics of the JIA patient cohort undergoing TMJ MRI in our centre.
It aims to identify opportunities for improved clinical practice with a
view to early detection of TMJ arthritis, and to contribute to discus-
sion regarding development of consensus based local guidance for
TMJ surveillance in children with JIA.
Methods: The electronic clinical records of 30 consecutive patients
undergoing TMJ MRI between March 2014 and April 2016 were retro-
spectively reviewed. They were split into two age groups, 0-4 years
(n = 15) and 5-12 years (n = 15). Baseline characteristics including
age, sex, JIA subtype, time lag between JIA diagnosis and MRI-TMJ
involvement, indications for MRI, MRI reports and whether the MRI
changed clinical management were assessed. All TMJ MRIs (n = 56)
performed on these 30 patients were assessed.
Results: Children developed TMJ involvement aged 8-10 years old, re-
gardless of age of onset of JIA. Following diagnosis of JIA, TMJ involve-
ment was identified after 6.75 years (median, range 1.25–9.33 years.
Mean 5.92 years) in 0-4 age group, and 1 year (median, range 0-9year.
Mean 1.83 years) in 5-12 group. 40% (6 children, aged 7-11years) in 5-
12 group had TMJ involvement at diagnosis. Most common indications
for MRI were pain and restriction (0-4 group), with deviation and asym-
metry (5-12 group). The 5-12 group had more bony erosions on MRI re-
port (13/15) and more unilateral disease compared to 0-4 group. The
burden of TMJ disease occurs predominantly over the age of 5 (28/30).
MRI changed clinical management (18/30).
Conclusion: Irrespective of age of onset of JIA, children developed
TMJ involvement between 8-10 years of age. This indentifies a group
upon which to focus targetted MRI surveillance with the aim of de-
tecting early TMJ disease. This is a small study, but it contributes to
the ongoing discussions regarding formation of pragmatic consensus
guidance in TMJ surveillance in asymptomatic children with JIA. Fur-
ther study is required.
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Pediatric Rheumatology 2017, 15(Suppl 2):P79Introduction: Introduction: The subspeciality of pediatric rheumatol-
ogy is the newest discipline established at child health institution in
Alain hospital, in 2013. The service provides tertiary care for children
with rheumatic diseases from all over United Arab Emirates. Currently
there are no data that describe the epidemiology of rheumatic dis-
eases in children.
Objectives: The aim of this study is to describe the demographics
and diagnostic classification of children with rheumatic conditions
followed up in the clinic.
Methods: Methods: a retrospective cohort was conducted. All the
files from August 2013 to July April 2017 were reviewed. Case de-
scription and diagnosis were captured. Standardized description of
diagnosis was used. All patients were screened for uveitis by ophthal-
mologist using slit lamp examination
Results: Results: rheumatic conditions were diagnosed in 130 subject.
JIA was the most frequently encountered rheumatic condition 44%
(n = 58), followed by FMF 10% (n = 14) and SLE 9% (n = 12). Among
JIA group oligoarticular JIA was the most common subtype 60% (n =
35), 10% (n = 10) of the cases were complicated by anterior uveitis.
The remaining 37% of patients had a variety of other conditions.
MTX was used to treat 38% (n = 51) of the cases. Biologics were
started in 20% (n = 25) cases.
Conclusion: Conclusion: this is the first cohort that describes the epi-
demiology of rheumatic conditions among UAE children, it highlights
the rheumatologist conditions and their frequencies among pediatric
population, however continuos prospective data is needed to con-
firm our initial observation.
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Introduction: The ankle-foot complex (AFC) is a commonly involved
joint site in children with Juvenile Idiopathic Arthritis (JIA) that re-
quires special attention from clinicians due to the complexity of its
anatomical structure and the recognized association with a more se-
vere disease course. Some patients experience recurrent, treatment
refractory involvement of this region, posing unique challenges for
therapeutic management. Little information concerning the longitu-
dinal course of AFC arthritis in relation to treatment and its predic-
tors is available to date to guide treatment strategies for JIA patients.
Objectives: To describe trajectories of AFC involvement in a cohort
of JIA patients in relation with received treatments, and identify sub-
groups of patients at risk of recurrent or treatment resistant AFC
arthritis over time.
Methods: Records of oligoarticular and polyarticular RF-negative JIA
patients followed in a single tertiary center and diagnosed between
2005 and 2012 were retrospectively evaluated for the occurrence of
clinically assessed tibiotalar, subtalar and tarsal arthritis. 143 patients
with at least one episode of AFC involvement in the first 5 years from
disease onset and complete records were identified. Data collected
during a total of 2288 visits - at baseline and at intervals of 3-4
months during the first 5 years of follow-up - were included in the
analysis. Specifically, time-varying variables such as disease status,
patterns of joint involvement, and current treatments including intra-
articular steroid injections were analyzed. Probabilities of AFC arthritis
and of being treated with methotrexate (MTX), etanercept (ETN),
other TNFa inhibitors or systemic steroids at each evaluation from
the second to the fifth year of follow-up were evaluated through
multistate Markov modeling, which allows detecting transitions
among different clinical states. The relationship between the
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 54 of 191identified states and clinical-demographical features at onset and in
the first year of follow-up was then assessed through regression
modeling.
Results: The model identified 6 latent states, defined by the combin-
ation of AFC activity and treatment status at each time point: ab-
sence of AFC involvement in patients currently off medication (State
1, 906 observations); absence of AFC involvement while receiving
MTX treatment (State 2, 622 observations); low probability of AFC
arthritis and during treatment with both MTX and ETN (State 3, 316
observations); AFC arthritis in patients currently off medication (State
4, 158 observations); State 5 (197 observations) and State 6 (89 ob-
servations) are associated with AFC arthritis during MTX therapy but
with high and low probability respectively. After adjusting for active
joints count, the number of relapses involving the tibiotalar joint dur-
ing the first year from onset predicted the transition from State 1 to
State 4 - relapse off therapy - and were inversely correlated with
probability of transition from State 3 to State 1, namely maintaining
remission after therapy withdraw (p = 0.014 and p = 0.035, respect-
ively). Tarsal joints arthritis in the first year of disease was negatively
associated with transition from State 5 to State 2, namely AFC re-
sponse to MTX therapy (p = 0.030). A negative correlation between
the occurrence of subtalar involvement in the first year of disease
and State 1 was also observed (p = 0.021).
Conclusion: Analysis of longitudinal data provides insight for the
identification of patients at risk of recurrent AFC involvement and
their clinical management. Further studies are needed to assess the
potential value of such information in guiding therapeutic strategies
for JIA patients.
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Introduction: Camptodactyly-Arthropathy-Coxavara-Pericarditis (CACP)
syndrome is a rare autosomal recessive disorder caused by muta-
tions in the PRG4 (proteoglycan 4) gene located on chromosome
1q31.1 (OMIM:*604283). Hallmarks of the syndrome include con-
genital or early-onset camptodactyly and arthropathy with syn-
ovial hyperplasia, progressive coxa vara deformity and non-
inflammatory pericarditis. Patients affected by CACP syndrome
lack the glycoprotein lubricin, a major lubricant expressed mainly
in joints and in pericardial and pleural cavities. Features of CACP
syndrome mimic juvenile idiopathic arthritis (JIA) and children
with CACP are often misdiagnosed as JIA. To date, twenty-two
homozygous mutations and 1 case of CACP syndrome resulting
from uniparental disomy of chromosome 1 have been reported
in different ethnic populations, none from Greece.Objectives: To report the mutations in the PRG4 gene in 2 siblings
with CACP syndrome in one family from Greece.
Methods: A 6 years old boy suffered from congenital camptodactyly
and progressive non-inflammatory arthropathy from the age of
2 years (knees, ankles, elbows, wrists, and cervical spine). Radio-
graphs, ultrasound and MR images revealed features of CACP syn-
drome. He was diagnosed with juvenile idiopathic arthritis at the age
of 3 years and received corticosteroids, methotrexate, and anti-TNF
treatment without efficacy. The patient's younger brother, aged
2 years, had a similar history, albeit more severe, starting at the age
of 2 months. The family consulted in our Clinic for a second opinion
at the age of 6 years. Molecular genetic studies were done for all
coding exons and the exon-intron boundaries of the PRG4 gene.
NGS was performed on hybridization-captured region of interest. All
variants were confirmed by Sanger sequencing.
Results: The 2 siblings were found to be compound heterozygotes
for c.[957del];[3254_3260del] p.[(Asp320Ilefs*2)];[(Ser1085*)]. These
rearrangements lead to a shift of the reading frame and the appear-
ance of a premature stop codon. This type of mutations is likely to
lead to the synthesis of a non-functional truncated protein.
Conclusion: To our knowledge, this is the first report of PRG4 muta-
tions from Greece as well as the first case of CACP syndrome pheno-
type caused by novel heterozygous mutations. The presence of
arthropathy with camptodactyly, especially if familial, should alert the
clinician to the possibility of CACP syndrome and avoid misdiagnosis
of JIA and unnecessary treatment with potentially harmful drugs.
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Introduction: Previous studies suggest that children with Juvenile
Idiopathic Arthritis (JIA) have poorer oral health compared to their
healthy peers despite adequate knowledge of appropriate dental
care. We hypothesised that this may be due to dental anxiety and
that there may be specific dental and/or disease related factors
which predict dental fear in this population
Objectives: We aimed to determine the prevalence and predictors of
dental fear in a single centre population of JIA patients.
Methods: JIA patients aged 5–18 years attending the rheumatology
clinic at the Women’s and Children’s Hospital in Adelaide, South
Australia completed a questionnaire regarding dental visit frequency,
past dental experiences, oral health behaviour, self-rated dental
health, assessment of dental anxiety using the Modified Child Dental
Anxiety Response Scale (MCDASf), their cognitive vulnerability-related
perceptions of dental treatment-related events and the degree of
pain and reduced movement in upper limb and temporo-mandibular
joints (TMJs). Clinical data relating to JIA subtype, medications, arth-
ritis activity in upper limbs and TMJs and JADAS score on the day of
questionnaire completion were also documented.
Results: Ninety four patients, (24 boys, 25.5%) participated. Average
age was 12.3 years (SD = 4.3), average disease duration 5.6 years (SD
= 4.3) and median JADAS score 1 (range 0–17.2). Thirty eight (40.4%)
had oligoarticular and 33 (35.1%) had polyarticular onset disease.
Nine (9.6%) had examination findings of TMJ involvement and four
(4.3%) had active arthritis in upper limb joints of the dominant hand.
Mean MCDASf score (Cronbach’s alpha = 0.93) was 2.97 with 50.5% of
children having a score above the cut point for classifiable high den-
tal fear. While dental fear was not related to having received any
specific previous dental treatment, those who had not received any
treatment had higher dental fear than those who had experienced at
least one treatment (3.61 cf 2.87, p = 0.002). There was no statistically
significant association between having had a previously unpleasant
Table 29 (Abstract P83). Clinical characteristics of patients with JIA by
subtypes
All
N =
342
Oligoarthritis
N = 91
Polyarthritis
N = 120
Systemic
N = 28
Enthesitis
related –
Psoriatic
N = 83
Un
classified
N = 20
p-
value
Age at
onset
(median)
7 8 10 6 10 9 <.0001
Duration of
disease
(median)
4 3 7 6,5 3 33 <.0001
Gender
Male:Female
4:6 4:6 2:8 4:6 7:3 4:6 <.0001
N % N % N % N % N % N % p-
value
RF (+) 92/
252
36,5
17/63 26,9 62/112 55,3 3/15 20 5/50 10 5/12 41,6 <.0001
HLA-B27 26/
126
20,6
7/34 20,5 3/23 13,1 0/4 0 15/61
24,6
1/4 25 0,648
Bone
erosions
33/
147
22,4
4/38 10,5 17/66 25,7 4/7 57 2/27 7,4 6/9 66,6 0.0002
Axial
involvement
60
17,5
10 10,9 14 11,6 4 14,2 30 36,4 2 10 <.0001
Peripheral
involvement
285
83,3
80 87,9 103 85,8 22 78,5 72 86,7 8 40 <.0001
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tal fear was associated with anxiety related to receiving blood tests
(r = 0.32, p = 0.002) and injectable medications (r = 0.34, p = 0.001).
Vulnerability-related cognitions, ie perceptions of the dental visit as
dangerous, disgusting, uncontrollable and unpredictable were signifi-
cantly correlated with dental fear (r = 0.44, p < 0.001) and in a multi-
variable stepwise regression model accounted for a statistically
significant amount of variance in dental fear (adjusted R2 = 31.1%)
after controlling for participant demographics, medically-related
fears, and having received a past dental treatment.
Conclusion: In a single-centre cohort of JIA, approximately 50% re-
ported high levels of dental fear associated with procedures related
to their arthritis care rather than a previously unpleasant dental ex-
perience. Those who had not yet visited a dentist had higher dental
fear with vulnerability-related cognitions of the dental visit contribut-
ing most significantly to dental fear. These results may explain poorer
dental health reported in JIA patients.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatologic disease in children (1). Artmedica is one of
the main medical facilities specialized in pediatric rheumatology.
Objectives: To describe a large cohort of patients with JIA from several re-
gions of Colombia that are followed in a specialized private medical center.
Methods: A cross-sectional study was conducted in 366 patients who
were enrolled in the registry between December of 2011 and August
of 2016. There were 342 patients who met the International League
of Statistical Associations for Rheumatology criteria who were in-
cluded in the analysis. Association was examined by means of Chi-
square tests, Kruskal-wallis test, and logistic regression analyses (to
adjust for possible confounders).
Results: Analysis of clinical characteristics by subtypes showed differ-
ences in gender, rheumatoid factor positivity, bone erosions, axial
and peripheral involvement (Table 29). Hand and/or feet deformities
were present in 21,3% of the patients, bone ankylosis of the wrist in
9,6%, asymmetric extremities in 2,9%, and ankylosis of the hip in
1,2%. Complications such as uveitis, delayed growth and osteopor-
osis presented in 4,7%, 7,9% and 5,5%, respectively. Three cases of
avascular necrosis and one case of macrophage activation syndrome
were registered during follow up. No significant differences in
DMARD and biologic therapy were found among groups, but less
use of steroid therapy in oligoarthritis (OR 0,24 95%CI 0,09-0,91) and
enthesitis related arthritis (OR 0,05 95%CI 0,02-0,16).
Conclusion: Polyarthritis was more common in preadolescent fe-
males while enthesitis related arthritis in preadolescent males. Bone
erosivity was particularly conspicuous in polyarticular and systemic
JIA, which implies a great risk of deformities and ankylosis, and could
justify a more agressive and early management. The definition of re-
gional epidemiological profiles in JIA helps to understand differences
in disease patterns, that allow both the development of personalized
interventions and resources optimization.
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Introduction: Tocilizumab, an anti-interleukin 6-receptor, its an ef-
fective treatment in the juvenile idiopathic arthritis, but there is not
so much date about the use in clinical practice in subcuteneous ad-
ministration and what happens when we optimize it.
Objectives: To study the effectiveness and safety of tocilizumab (TCZ
intravenous and subcutaneous) in JIA patients in clinical practice
Methods: Design:Case series. Population:Consecutive patients with
JIA treated with TCZ in HRUM. Inclusion criteria: Patients with JIA,
infant-juvenile and adult, followed in the Maternal and Child Hospital
and Civil Hospital respectively. Exclusion criteria: Missing data on pri-
mary outcome variable. Protocol: Patients with infant-juvenile AIJ
treated with TCZ. They are reviewed during every infusion of TCZ. Be-
fore age of 14 years old, patients are derived to Rheumatology Unit
to be reviewed in adult unit and then they are followed each time
they receive an infusion of the drug in day-hospital or every three
months if they are in sc therapy (sc biological therapy clinic). Out-
comes: Mean changes from baseline in DAS28, HAQ and activity level
at 3rd month from change to sc TCZ and at 6 months from the re-
duction; count and description of serious and non-serious side effects
during the follow-up. Other variables: Demographics, therapeutic and
clinical-analytical data: tenderness joint count (TJC), swollen joint
count (SJC), CRP, ESR, physician VAS, patient VAS, adverse events.
Statistical analysis: Paired t test or Wilcoxon signed rank between the
first and last TCZ administration, between the dose reduction and
after 6 months, and between switching to sc administration and after
3 months
Results: The main baseline characteristics of patients with JIA during
last administration of TCZ are shown in Table. The mean of DAS28
was higher in JIA adults in the last administration of TCZ (p =
0.028).During the exposure to TCZ three non-severe adverse events
Table 30 (Abstract P85). See text for description
VARIABLE n = 80
Age in years, median (±DE) 10,7 (3,3)
Sex, female; n (%) 56 (70)
BMI
Median en kg/m2 (±DE) 18,2 (4,2)
Percentile, median (±DE) 42,0 (29,9)
Index waist/hip (±DE) 0,84 (0,06)
Total fat (kg), media (±DE) 11,36 (8,9)
Total Lean (kg), media (±DE) 26,1 (8,9)
Total mass (kg), media (±DE) 38,8 (16,7)
MFI (%) media (±DE) 7,5(5,3)
MFFI (%) media (±DE) 17,8 (3,8)
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 56 of 191were recorded. Three patients switched to sc. At 3 months after to
start sc TCZ, no differences were observed in effectiveness outcomes
and any adverse effect with sc TCZ was recorded. There was not any
switch to sc TCZ in patients with infant-juvenile JIA, compared to pa-
tients older than 14 years where 70% of them changed to sc TCZ (p
= 0.022).Seven patients reduced doses: 6 with iv and 1 sc. Six months
after the reduction, no difference was observed in effectiveness out-
comes; only trend to fewer non-severe adverse effects in patient with
reduced doses (3 with full doses versus none patient in dose reduc-
tion;p = 0.07). Only one patient returned to full dose because
inefficiency.
Conclusion: Conclusions: TCZ in JIA patients seem an effective option
in daily clinical practice. The switch from iv to sc TCZ in JIA patients
seems effective in clinical practice. Reduction in TCZ dose in JIA may
possible, maintaining good control of the disease and possibly with
fewer side effects
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Introduction: Various studies have shown that the excess of adipos-
ity is a proinflamatory state that conditions worse response to treat-
ment. There are few studies on the subject in arthritis juvenile
idiopathic (JIA).
Objectives: OBJECTIVE: To describe the body composition and an-
thropometric parameters of patients with JIA, and evaluate the pos-
sible relationship with the activity of the disease.
Methods: PATIENTS and methods: Observational, cross-sectional, in chil-
dren aged 4-15 years with JIA (excluding forms monoarticular), study in
a tertiary hospital pediatric Rheumatology unit. It collected data an-
thropometric, clinical and of treatment. Also held dual absorptiometry of
x-rays (DEXA) body total with assessment of body composition.
Define the index of mass fat (MFI) as the mass fat divided by the
mass total and (MFFI) fat-free mass index as lean mass (kg)/height
(m2).
The JADAS27 index was used for the evaluation of the activity of the
disease.
Results: RESULTS: We analyzed 80 patients, whose characteristics are
shown in Table 30. The most frequent subtype was oligoarticular JIA
(16.3% extended, 47.5% persistent) followed by polyarticular JIA
(25.1%). Twenty-five percent had uveitis. Fifty percent had inactive
disease with treatment, 26% had activity and 23% were inactive
without treatment. 52.5% had methotrexate and 30% had a bio-
logical drug (22.5% antiTNFα, 5% antiIL-1, 2.5% antiIL-6), with an
average disease duration of 6.6 years (±3.7DE).They had mean scores
of JADAS27 of 2 (± 4DE), PCR of 4.7 mg/l (± 9,5DE), VSG of 8.7 mm
(± 7,2DE) and CHAQ of 0.17 (± 0,38DE). The anthropometric parame-
ters are shown in Table 30. The mean of JADAS27 in patients with
normal BMI, was lower than 1.7 (± 3.6 SD) for those who were over-
weight or with obesity 3.3 (± 6.0 SD), although not significant (p =
0.255). In simple linear regression, an increase of 0.3 JADAS27 was
observed for each unit of IMG increase (p = 0.03). This relationship
was maintained in the multivariate analysis (B 0.015; p 0.01) inde-
pendently of the JIA subtype and the treatment received during the
evolution.
Conclusion
CONCLUSION: In JIA patients, there is a linear relationship between
IMG and disease activity measured by JADAS, but most patients had
a normal BMI. The establishment of this relationship (fat-inflamma-
tory activity) would be transcendental because of the need to
optimize the recommendations in the JIA approach
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Introduction: 25hydroxi-vitamin D has antiinflammatory and immu-
nomodulatory properties. Hypovitaminosis D prevalence in Juvenile
Idiopathic Arthritis (JIA) patients ranges from 6% to 30%
Objectives: Evaluate hypovitaminosis D in JIA pediatric patients in
Spain and assess involved factors.
Methods: Observational cross-sectional study in JIA Spanish patients
from 4 to 15 years old, monitored by a Pediatric Rheumatology Unit.
Monoarticular forms and patients with other chronic diseases were
excluded.
Anthropometric, clinical and treatment data were recorded. Blood
test with bone metabolism parameters and validated diet (KIDMED-
Mediterranean Diet Quality Index) and exercise (PAQ-C/PAQ-A-Phys-
ical Activity Questionnaire for Children) questionnaires were
obtained.
Hypovitaminosis D was defined as 25hydroxi-vitamin D plasma levels
lower than 30 ng/ml
Results: 76 children were enrolled. Their characteristics are included
in Table 31.
The population's prevalence estimation of hypovitaminosis D was 16
- 35% (CI 95%).
We found no relationship between 25 hydroxi vitamin D levels and
sex, JIA subtype nor duration or dose of systemic glucocorticoids.
In bivariate analysis we found direct association between hypovitami-
nosis D and Body Mass Index percentile (BMIp)(p = 0,05), received
dose of prednisone (p = 0,03) and clinical activity duration (p = 0,04);
and an inverse relation with physical activity level (p = 0,04).
In multivariate analysis, relationship between hypovitaminosis D and
BMIp (B 0,024; p 0,016) and with disease activity (B 0,015; p 0,01)
were maintained. Moreover, we found an inverse association with
biological disease-modifiying antirheumatic drugs (B-4,69; p 0,048),
specifically with anti tumoral necrosis factor α (antiTNFα) (B -4,7; p
0,042)
Conclusion: Hypovitaminosis D prevalence in our population is simi-
lar to previously described.
JIA patients with higher BMIp have more hypovitaminosis D, as it has
been reported in other inflammatory diseases.
A direct relationship exists between inflammatory activity and hypo-
vitaminosis D, but we need more studies to asses if one is cause or
consecuence of the other.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 57 of 191Patients treated with antiTNF have higher plasma levels of 25 hydroxi-
vitamin D, this can be explained because these drugs may increase 25
hydroxi-vitamin D levels or due to a better response to antiTNF of those
patient with higher plasma levels of 25 hydroxi-vitamin D.
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PATIENTS` CHARACTERITICS (N = 76)
Gender (Male), 23 (30,3)
Age (years), median (IR) n (%) 10,83 (8,52-13,54)
25OH-Vitamin D (ng/mL), mean (+/-SD) 34,04 ng/mL (8,90 ng/
mL)
DISEASE CHARACTERISTICS (N = 76)
JIA subtype, n (%) Systemic 9 (11,8)
Oligoarticular 47 (61,9)
Polyarticular 20 (26,3)
Inflammatory activity duration (days), median (IR) 385,0(246,75-761,25)
RECEIVED TREATMENTS (N = 76)*
Systemic GC, n (%) 61 (80,2)
Synthetic DMARDs treatment, n (%) 39 (51,3)
Biological DMARDs treatment subtype,
n(%)
Anti-TNFα 15 (19,7)
Anti-IL1 4 (5,2)
Anti-IL6 2 (2,6)
JIA: Juvenile idiopathic arthrtis; RF: Rheumatic factor; GC: glucocorticoids;
DMARD: Disease-modifying antirheumatic drug; Anti- TNFα: anti- tumoral
necrosis factor α;
Anti-IL1: anti-interleukin 1; Anti-IL6; anti-interleukin 6P87
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Introduction: Juvenile idiopathic arthritis (JIA) is one of the most
common pediatric chronic illnesses. A remarkable number of patients
need long term or lifelong treatment. In ‘biological era’ many publi-
cations have strengthened the safety and effectiveness of TNF inhibi-
tors and some of them noticed psychological or neuropsychological
(NP) adverse events (AE). The relationship of these AEs with the treat-
ment is unclear. There is no evidence available if these skills vary in
different therapy and change during JIA therapy.
Objectives: Our aims are to estimate NP state in JIA treatment
groups and specify NP state influencing factors. The next step was to
compare NP state in different treatment groups.
Methods: Descriptive statistics and exploratory analysis were com-
pleted. 120 patients were examined at the Paediatric Rheumatology
Unit (Semmelweis University, Budapest) between 01.01.2015 -
31.12.2016. 68 patients received combined therapy (TNF inhibitor +
methotrexate (MTX) and/or salazopyrin (SSZ)), 42 patients received
DMARD: MTX +/-SSZ, 18 patients were on only TNF inhibitor therapy.
After a formal psychological assessment, all patients were tested with
age specific questionnaires as well: Infant Behaviour Questionnaire,
Children’s Behaviour Questionnaire, Child Behaviour Checklist. Fur-
thermore, by using Woodcock Johnson III Tests of Achievement,
three NP variables were compared in treatment groups: attention,
learning, and working memory. In addition, current and baseline dis-
ease activity, duration of therapy and demographic parameters were
assessed in each group. These parameters were stratified, and NP
variables were compared in these strata. Comparison of NP variablesof different treatment groups were age-, age at diagnosis-, gender-,
duration of treatment-, current and baseline JADAS disease activity-
matched.
Results: In the analysis of each treatment groups we did not observe
any significant deviation of all NP variables based on age, gender,
duration of treatment, current JADAS disease activity. All NP variables
were the highest in patients whose JIA was diagnosed between 3,1-
5,25 years of age. In combined therapy group attention was signifi-
cantly (p < 0,05) higher in patients whose baseline disease activity
was low. In the analysis of comparison of treatment groups the fol-
lowing differences were observed: learning score was significantly
lower (p < 0,05) in male patients in MTX group than in the combined
therapy group. Working memory score was significantly (p < 0,05)
higher in patients whose JIA was diagnosed between 3,1-5,25 year of
age, and whose treatment duration was longer than 3 years in com-
bined therapy group. Attention score remained stable in age-, age at
diagnosis-, gender-, JADAS disease activity-matched treatment
groups. There was no significant discrepancy in all three NP variables
between disease activity-matched treatment groups.
Conclusion: We have not observed any clinically significant differ-
ence in the neuropsychological state in different treatment groups
assessed only at a definite date. Age, age at diagnosis, gender, dur-
ation of treatment, current and baseline JADAS disease activity were
not clinically influencing factors of NP variables in this study. The
analysis of cognitive function has already been assessed, but has not
been analysed yet. In a prospective study we will follow patient’s psy-
chological changes before and during therapy in order to observe if
different therapies have any effect on psychological functions in JIA
patients.
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Introduction: TNF inhibitors have been widely used in the therapy of
juvenile idiopathic arthritis (JIA) since the early 2000s.
Objectives: We assessed the efficacy, change in efficacy, reason for
treatment discontinuation, relapse rate of TNF inhibitor treatments
for JIA started between 2012-2016 at the Unit of Pediatric Rheuma-
tology, Semmelweis University, Budapest.
Methods: 146 treatments were started for 116 patients with polyarti-
cular course JIA. The following variables were assessed: Giannini im-
provement and JADAS-71 score every 3 months, the time for
achieving at least 90% Giannini improvement, reason for treatment
discontinuation, relapse rate. We estimated the alteration of Giannini
improvement and JADAS-71 disease activity in patients treated for at
least 24 months. Finally, we analysed the features of patients
achieved inactive disease. Paired Wilcoxon test, Kaplan-Meier survival
analysis, log rank test, chi square test, Fisher’s test, T test were used
with SPSS statistics program.
Results: Statistically significant (p < 0,05) alteration was detected in
achieving ever higher improvement of the Giannini’s criteria in the
first 12 months of treatment, afterwards this alteration remained in
tendency but not statistically. The JADAS-71 disease activity signifi-
cantly decreased in the first 6 months of the treatment, afterwards
the decline remained in tendency. Giannini 90% improvement was
achieved significantly more frequently in those who received etaner-
cept treatment, first-line TNF inhibitor treatment and any first-line
biological. Among those who achieved inactive disease, there were
significantly more of those, who started treatment with fewer active
joints, lower JADAS score and CHAQ values, and were significantly
younger at diagnosis. Biological therapy was discontinued due to in-
efficacy in 50,8%, remission 28% and adverse events 10,5% of cases.
In addition, 37,5% of patients had relapse whose treatment was
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 58 of 191discontinued due to remission, all within the first 3 months on off-
medication.
Conclusion: Giannini’s criteria improved significantly over the first
12 months, the disease activity decreased significantly in the first
6 months, afterwards these observations remained in tendency in
our cohort. Approximately one-third of treatments were discontinued
due to remission almost two-third of these patients have not experi-
enced relapse during our observation period.
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Introduction: Juvenile Idiopathic Arthritis (JIA) is the most frequent
disease in pediatric rheumatology. There are few studies about body
composition in these population, most of them suggest they have
excess fat.
Sarcopenia in children and young adults is pathologic and constitute
a risk factor of morbi-mortality due to its association with alteration
in immunologic function, decrease strength muscle and thermoregu-
lation capacity, exercise tolerance and functionality, all of them affect
articular function and preservation. Additionally, bone mass accretion
and bone mineral density are related proportionally direct to muscle
mass.
Also patients with sarcopenia could present an increase in the fat
mass known as sarcopenic-obesity.
Objectives: To describe body composition alterations in a cohort of
children diagnosed with JIA in Bogota, Colombia.
Methods: Cross-sectional study where a cohort of children with
JIA was assessed the anthropometry and densitometry measured
by dual-energy X-ray absorptiometry (LUNAR iDXA). It was evalu-
ated stature and weight. The fat mass was evaluated through Fat
Mass Index (FMI): Kg/m2, subtotal percentage body fat for age
and gender, and subtotal trunk fat mass. To measure lean mass
was used: lean mass index (LMI): Kg/m2, appendicular lean mass
(arm and leg lean): Kg/m2, and total bone mineral density less
head (TBLH)
The statistical analysis was only descriptive where it involved meas-
urement of central tendency and dispersion.
Results: Thirty children were included in the study. Fifty three per-
centage were female with average age of 13.8 years (ranked from 5
to 22 years).All subtypes of arthritis were included, 56% had systemic
and polyarticular subtypes.
The average of onset of the disease was 5 year (ranked from 2 to
14 years).
In this cohort 33% of the patients had short stature.
36% patients had compromise in fat mass. FMI median z-score was
-0.57 (ranked from -1.66 to 1.11), 26% of children presented fat defi-
ciency (12.5% of them had severe fat deficit), and 10% excess fat -
obese. In 20% of patients the percentage of fat was above of ex-
pected and trunk fat mass was higher in 16% of the studied children;
the last measure is related to cardiovascular risks.
80% of the patients had low LMI z-score that is considered as low
lean mass- sarcopenia. LMI z score median was -2.17 (ranked from
-4.56 to 0.36). 58.6% presented low appendicular lean mass.
30% of patients had compromise in two compartments (FMI and
LMI). 100% of patients with Fat deficit had low lean mass –sarco-
penia, while 33% of patients had sarcopenic-obesity (fat excess
with sarcopenia) which is associated to decrease in life-
expectancy.The median z score for Total bone mineral density less head (TBLH)
was -1.25 (ranked from -3,8 to 1,5 . The TBLH density was low in a
30% of patients, from which 100% had low lean mass-sarcopenia.
Conclusion: The included children diagnosed with JIA presented
high percentage of disorders of body compositions characterized by
sarcopenia 80% followed by fat mass compromise in 36% (low fat
mass 26% and excess fat 10%) and low bone density in 30%.
The abnormalities in the lean mass could be explained due to the in-
crease in metabolic rate and catabolism which lead to skeletal muscle
consumption. It has been described “rheumatic cachexia” in 67% of
adults with rheumatoid arthritis, affecting bone mineralization, strength
muscle loss, and is associated with cardiovascular risk increase, but
there is not any data in children with JIA.
This is the first study which measure sarcopenia by DEXA in this
population, additional studies including more patients are necessary
to validated these results and establish opportune interventions to
improve their nutritional status and quality of life.
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Introduction: Temporo-manidibular joint (TMJ) involvement in juven-
ile idiopathic arthritis (JIA) is the subject of many unanswered
questions.
Objectives: We here wonder if the ILAR categories might help identi-
fying JIA patients at risk of TMJ involvement.
Methods: In single cohort of consecutive JIA patients, TMJs were sys-
tematically examined at each follow-up visit of JIA patients according
to the European recommendations. Clinical involvement of TMJs over
time was longitudinally recorded during JIA follow-up. JIA categories
were defined according to ILAR definitions.
Results: There were 137 JIA patient, comprising 89 girls and 44 boys
aged 14.13 years +/- 4.99 at the time of the analysis. Mean age at
disease onset was 7.84 years +/- 4.89 and mean follow-up was
4.41 years +/- 3.83 [0.2-23.9 years]. There were 63 ERAs, 33 oligoarti-
cular JIAs with 26 persistent and 7 extended diseases, 27 polyarticu-
lar JIAs, 6 being RF positive, 10 psoriatic arthritis and 4 systemic JIAs.
44 JIA children had clinically detectable TMJ involvement (32%), but
the percentages were rather different across the ILAR sub-groups :
TMJs were symptomatic in 12 ERAs (19%), in 9 oligoarticular JIAs
(27.3%), in 18 polyarticular JIAs (66.7%), in 3 psoriatic arthritis (30%)
and in 2 systemics (50%) ; moreover, within the oligoarticular group,
the most affected category was the oligo-extended group with 6 out
of 7 patients having TMJs involved (85.7%).
Interestingly, the clinical manifestations were not the same since half
of the oligoextended JIA patients reported no pain, no chewing diffi-
culty, no evidence of mouth opening limitation but insidiously devel-
opped facial asymetry due to unilateral TMJ inflammation. In all
cases, the spreading of the arthritic process happened before 5 of
age. In contrast, ERA patients manifested pain and reduced mouth
opening much more frequently and at a later age, prompting to a
quick therapeutic answer.
Conclusion: In conclusion, TMJ arthritis might have severe conse-
quences in those patients starting agressive disease early in life, as
many extended-oligoarticular as well as part of polyarticular JIAs and
systemics. Detecting the patients at high risk for structural damage
in TMJs should be a major goal in the coming years. This preliminary
Table 32 (Abstract P91). Relationships between PGA and laboratory
parameters analyzed by linear regression
B 95% CI P-value R2
ESR 0.358 0.194 – 0.523 <0.001 18.3%
CRP 0.345 0.227 – 0.463 <0.001 28.7%
Leucocytes 1.387 0.064 – 2.710 0.040 4.9%
Neutrophils 1.849 -0.289 – 3.986 0.089 4%
MRP8/14 in serum 0.056 0.024 – 0.087 0.001 12.9%
MRP8/14 in plasma 0.075 0.056 – 0.094 <0.001 47.8%
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 59 of 191study also shows that a significant proportion of ERA patients suffer
from TMJ inflammation during the course of their disease. The lim-
ited number of patients is the drawback of this preliminary study
and larger prospective studies are required to validate these data.
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Introduction: Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory joint disease affecting children. In clinical practice it is occasion-
ally difficult to assess the real inflammatory activity. Physician’s
assessment of global disease activity (PGA) is a holistic assessment
and it is always available. The myeloid-related protein complex 8/14
(MRP8/14, calprotectin) secreted by infiltrating phagocytes in syn-
ovial inflammation has been suggested to function better than con-
ventional acute-phase reactants as a marker of low inflammatory
activity and to be more sensitive and reliable indicator of disease
activity.
Objectives: The aim of our prospective, observational cohort study
was to analyze whether the MRP8/14 levels in serum (S-MRP8/14) or
plasma (P-MRP8/14) and conventional inflammatory markers, such as
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), leuco-
cytes (leuc) and neutrophils (neutr), correlate with disease activity
assessed by physician.
Methods: Serum and plasma MRP8/14 concentrations from 88 conce-
cutive new-onset JIA patients collected before starting DMARDs were
measured by human calprotectin ELISA kit (Hycult biotech). Clinical
data of the patients with median age of 6.6 yrs (range 1 – 15.3 yrs)
were collected during the visits in the pediatric rheumatology out-
patient clinic in Oulu University Hospital between October 2011 and
November 2014. Median PGA was 21 with the scale 0-100 (range 3 –
85), median patients/parents global assessment of wellness 31 (range
0 – 88), median patients/parents assessment of pain 31 (range 1 –
45), and median number of joints with active arthritis (AJC) 3 (range
1 – 45). Correlations were analyzed by Spearman’s coefficient. Mul-
tiple linear regression was used to quantify the strength of the rela-
tionship between laboratory inflammatory markers and to assess
which parameter has the most powerfull coefficient of determination
of PGA.
Results: Median P-MRP8/14 concentration was 184.9 ng/ml (range
1.2 – 685.9 ng/ml) and in S-MRP8/14 255.0 ng/ml (67.4 – 553.5 ng/
ml). Median CRP was 1.5 mg/l (1.5 – 193 mg/l), ESR 13 mm/h (2 –
98 mm/h), leuc 7.4 x 10E9/l (3.4 – 15.2 x 10 E9/l) and neutr 3.9 x
10E9/l (1 – 10.5 x 10E9/l).
We found positive correlations between PGA and the laboratory pa-
rameters. PGA weakly correlated with leuc (Spearman’s Rho 0.281, P
= 0.008) and neutr (0.313, P = 0.007). Association was better with ESR
(0.432, P < 0.001), CRP (0.582, p < 0.001), P-MRP8/14 (0.682, P < 0.001)
and S-MRP8/14 (0.409, P < 0.001).
PGA has stronger association with P-MRP8/14 than with the other in-
flammatory parameters (Table 32.). Multiple linear regression analysis
showed leuc, ESR, CRP, neutr, S-MRP8/14 and P-MRP8/14 explaining
55% of PGA. When analyzed the standardized B the strongest rela-
tionship was found between P-MRP8/14 and PGA (B = 0.084 (95% CI:
0.045 – 0.123) P < 0.001, standardized B = 0.733), but association be-
tween S-MRP8/14 and PGA remained weak (B = -0.032 (95% CI: -0.074
– 0.010), P = 0.14, standardized B = -0.203).
R2 coefficient of determination, B regression coefficient
Conclusion: P-MRP8/14 seemed to be much better than the other
conventional inflammatory laboratory markers or MRP8/14 serum
concentration when assessing disease activity in JIA patients. P-MRP8/14 concentration might be useful indicator to be used in clin-
ical practice when making evalution of disease activity.
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Introduction: Familial Mediterranean Fever (FMF) is the most com-
mon inherited auto inflammatory disease, characterized by recurrent,
self–limited attacks of fever and aseptic polyserositis.FMF is wide-
spread in Armenia and there is a higher than expected frequency of
FMF-associated arthritis in children. Chronic arthritis can be the first,
and sometimes the only manifestation of FMF.
Objectives: To the importance of genetic investigation for MEFV gene mu-
tations in patients of high-FMF-prevalence ethnicities with chronic arthritis.
Methods: Case reports of two patients with chronic arthritis as their
first symptom of FMF.
Results: 1-st case: A 6 year-old boy was admitted to the hospital with
complaints of weakness and limping during the last 1.5 years. He had
also self- limited episodes of knee and foot pain. The physical examin-
ation revealed pain on flexion of the left knee, painful palpation of both
sacroiliac joints, but no visible or palpable changes of the joints. Initial la-
boratory examination showed elevation of ESR– 49 mm/h and CRP-
48 mg/l. WBC, RBS, PLT were in normal range. An extensive diagnostic
work up including biochemical examination, serology tests, urine test,
chest X-ray, Echo-CG revealed no changes. Splenomegaly was found on
abdominal sonography. MRI of the pelvic bones and hip joints indicated
signs of bilateral sacroiliitis. Chronic arthritis was diagnosed. Despite of
absence of clinical features of FMF, genetic analysis for MEFV gene muta-
tions was done and homozygous genotype for M694V mutation (M694V/
M694V) was found. Treatment with colchicine and sulfasalazine was
started and both his clinical condition and laboratory findings improved
significantly. Only occasionally the patient still has gait abnormalities.
2-nd case. A 1.8 year-old girl was admitted to the hospital because
of pain, swelling and deformity of the left wrist, which had started
5 months earlier. In her past history 2 episodes of unexplained fever
of 1 day duration were noticed. The physical examination revealed
swelling, pain and limitation of motions of the left wrist. ESR was ele-
vated within 53 mm/h, but CRP was negative. Thorough diagnostic
work up (CBC, biochemical examination, serology tests, urine test,
chest X-ray, Echo-CG, abdominal sonography) revealed no patholo-
gies. MRI of the left wrist indicated signs of arthritis. Chronic arthritis
was diagnosed. But also genetic analysis of MEFV mutations was
done and 2 mutations (M694V/R761H) in compound-heterozygous
state were found. Intraarticular injection of triamcinolone acetonide
to the left wrist was done and colchicine treatment was started with
significant improvement: during 4 months of follow up the girl had
no complaints and no inflammatory activity with normal level of ESR.
Conclusion: In ethnicities with high prevalence of FMF, screening for
MEFV gene mutations is recommended for patients with chronic
arthritis even in the absence of FMF symptoms.
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Introduction: Etanercept was the first biologic drug approved in chil-
dren. Russian rheumatologist received the access to etanercept only
in 2009 after infliximab, adalimumab, abatacept. Currently etanercept
reach the first position in the biologics, used in JIA in Saint-
Petersburg.
Objectives: The aim of our study was to evaluate the efficacy of eta-
nercept in the tertial hospital in Saint-Petersburg using the registry.
Methods: The data about all patient (n = 148) who received etaner-
cept were included into the registry. We evaluated all routine JIA
measures, ESR, CRP, achievement the remission every 6 months, dy-
namics of height, weight and side effects. The duration of study was
more than 30 months.
Results: The demographic of study population was: girls were 92/148
(62.2%), onset age - 4.9 (2.4; 9.6), age of etanercept initiation: 9.8
(5.9; 13.9) time between JIA onset and etanercept was 2.4 (1.2; 5.8).
Duration of etanercept treatment was 3.5 (2.3; 4.3) years. The distri-
bution of JIA categories was: persistent oligoarthritis 6/148 (4.1%), ex-
tended oligoarthritis 11/148 (7.4%), RF-negative polyarthritis 84/148
(56.8%), RF-positive polyarthritis - 3/148 (2.0%), enthesitis-related
arthritis - 32/148 (21.6%), psoriatic arthritis - 9/148 (6.1%), non-
differentiated arthritis 3/148 (2.0%). ANA-positivity was in 33/120
(27.5%), HLA B27 - 24/80 (30%) and RF-positivity - 5/148 (3.4%).
During the trial the etanercept shows high efficacy in the main JIA
measures and laboratorial tests (Table 33). Also we have observed
decreasing of WBC (p = 0.03), PLT (p = 0.000001), ESR (p = 0.03), in-
creasing the hemoglobin (p = 0. 006), body mass index (p = 0.02). Fre-
quency of morning stiffness decreased from 62.8% to 4.6% (p =
0.0001). The achievement of remission (ACRPedi100) reached 69.3%
patients.
Etanercept was discontinued in 12/148 (8.1%) due to primary or sec-
ondary inefficacy or new onset of uveitis, injection site reactions
were rare and lead to discontinuation of etanercept in 1/148 (0.7%).
No serious infections, tuberculosis, malignancy were observed during
the study.
Conclusion: Etanercept show high efficacy in non-systemic JIA pa-
tients. Serious side effects were rare and comparative to literature
data. Registry of biologics is a good tool for collection data about pa-
tients. Future investigations required.
Disclosure of Interest: None DeclaredTable 33 (Abstract P93). See text for description
Parameter Baseline End of study p
Morning stiffness, minutes 60.0 (30.0; 120.0) 20.0 (10.0; 20.0) 0.03
Global disease activity, mm 48.0 (35.0; 68.0) 0.0 (0.0; 28.0) 0.000001
MD VAS, mm 43.5 (30.0; 60.0) 0.0 (0.0; 18.0) 0.000001
Patient’s VAS, mm 20.0 (10.0; 20.0) 0.0 (0.0; 10.0) 0.000001
Painful joints, n 2.0 (1.0; 5.0) 0.0 (0.0; 0.0) 0.000001
Swollen joints, n 4.0 (2.0; 11.0) 0.0 (0.0; 0.0) 0.000001
Joints with LOM, n 4.0 (1.0; 9.0) 0.0 (0.0; 0.0) 0.000001
Active joints, n 7.0 (3.0; 15.0) 0.0 (0.0; 0.0) 0.000001
CRP, mg/l 1.9 (1.0; 5.5) 0.5 (0.2; 1.3) 0.000001P94
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Introduction: Juvenile idiopathic arthritis (JIA) – is a chronic inflam-
matory joint diseases, which affects the children under the age 16.
Methotrexate (MTX) is a basis of treatment of patients with polyarti-
cular JIA (pJIA). Patients, who fall or intolerance MTX required in bio-
logic treatment.
Objectives: The aim of our study was evaluate the efficacy and safety
of tocilizumab (TCZ) in children with pJIA.
Methods: In the present retrospective study with maximal duration
42 months were included 40 children (82,5% girls) with active pJIA,
resistant to previous therapy with MTX alone or combination with
others non-biologic DMARDs, whom were treated with TCZ every
4 weeks 8 mg/kg (weight ≥ 30 kg) and 10 mg/kg (weight < 30 kg).
Onset JIA age was 4,8 (2,9; 8,1) years, time between JIA onset and
start of TCZ was 5,7 (1,8; 8,5) years. Duration of TCZ treatment was
1109 (452; 1542) days. TCZ monotherapy was in 13,2% children.
Results: During TCZ course NSAID were discontinued in all studied
population, decreased part of children who were treated with com-
bination of non-biologic DMARDs from 37.5% to 2.5% and proportion
of whom were treated with MTX from 92.5% to 75.0%, and lefluno-
mide up to 2.5%. The discontinuation of the second DMARD, cortico-
steroids, cyclosporine and NSAIDs were due to achievement of
remission and rare due to intolerance. In first 6 months of therapy
was revealed impressed decreasing of ESR (p = 0.000002), CRP (p =
0.00002), WBC and (p = 0.001) PLT (p = 0.00002) up to normal ranges
during whole TCZ course. Number of active joints decreased grad-
ually (p = 0,00002), reached the median = 0 to 24th month, 15.3% ob-
tained inactive disease status in 6 months and 80% in 42 months.
During the study inactive disease status was reached totally in 60.5%
patients and in 3 patients TCZ was discontinued due to persistent re-
mission. The main predictors of achievement inactive disease were
WBC < 9.0 x 109/l (HR = 1,92, p = 0.16), absence of previous biologic
treatment (HR = 1.92, p = 0.16). The absence of previous biologic
treatment was also predictor of low disease activity status (HR = 2.4,
p = 0.01).
Among adverse effects were transient hypercholesterolemia and
hypertriglyceridemia and single episode of grade II neutropenia
which not lead to TCZ discontinuation infection side effects and anti-
biotic treatment.
Conclusion: The safety and efficacy of TCZ was demonstrated in chil-
dren with pJIA. Serious adverse events were not revealed.
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Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 61 of 191Introduction: Juvenile arthritis is a broad term that describes hetero-
geneous group of a chronic inflammatory joint disease which charac-
terized by progressive course leading reduced mobility and function.
Progressive chronic arthritis of an unknown cause lasting for at least
more than three months are the main diagnostic criteria of JIA. A
typical classic variant of oligoarticular JIA (oligo-JIA) is well known.
Monoarthritis of the elbow joint is atypical onset oligo-JIA. It’s diffi-
cult to differentiate of elbow chronic synovitis due to clinically het-
erogeneous. The instrumental and specific diagnostic tests are great
assistance to determine cause of synovitis.
Objectives: Chronic synovitis in children arises from several causes.
There are inflammatory, infectious, traumatic, reactive, hemorrhagic,
neoplastic and undifferent etiologies of synovial diseases. Usually
chronic elbow monoarthritis associated with tumor-like conditions (pig-
mented villonodular synovitis, synovial haemangioma and chondroma-
tosis), osteomyelitis, tuberculosis arthritis, osteochondropathy and rare
JIA. The aim of the present study was to determine diagnostic and
treatment strategies of elbow monoarthritis manifested like oligo-JIA.
Methods: We carried out a retrospective review of sixteen children
with chronic undifferentiated elbow monoarthritis which were hospi-
talized at Children Orthopedics Institute, Saint-Petersburg (rheuma-
tology department) between 2011 and 2016. The data of clinical,
serological, x-ray, ultrasound, MRI, arthroscopy and synovial fluid
were analyzed. Detected atypical/diffuse form synovial proliferation
or limited to a well-defined single nodule were recommended for
arthroscopy and biopsy. Six children were excluded from study due
to verification of cause elbow monoarthritis: 6-yr-old girl - PVNS, 10-
yr-old boy cavernous haemangioma and 17-yr-old boy - synovial
chondromatosis, 2 small girls and 1 boy - osteoid osteoma. Ten chil-
dren were study group (median age 5,8 ± 2,5, range 3-11 years; fe-
male 90%, male 10%). Children with post-traumatic elbow joint
transient effusion were controls.
Results: Trauma of elbow joint related to onset chronic arthritis, pro-
gressive flexure contracture with dry synovitis, low activity and the
long-term period absence of clinical involvement of other joints were
occurred in all children. Asymptomatic early-stage, progressive flex-
ure/combined contracture less joint effusion and morning stiffness
were cause of late diagnosis of oligo-JIA. Only seven children (all
girls) were ANF positive ≥ 1:160, two HLA-B27 positive. Radiographic
finding of early-stage JIA were accelerated cartilage model ossifica-
tion of distal humeral epiphysis and trochlear, osteoporosis with sub-
chondral bone sclerosis and cyst-like deformation. The MR imaging
were non-specific inflamed elbow synovium. Overgrowth of epiphy-
sis and trochlear with joint space narrowing, deformation articular
surfaces with erosive changes were radiographic findings of late-
stage JIA. MR imaging revealed significance multiple erosive synovitis
with bone cyst-like deformation. Ultrasound wasn’t show elbow
synovitis at half of the study children. 70% children were negative ef-
fect of monotherapy NSAID. Positive treated effect was achieved
after intra-articular triamcinolone injection (20-40 mgs) and metho-
trexate therapy (15 mg/m2/week) > 6 months, splinting and physio-
therapy. After 2-3 years 30% children were persistence oligo-JIA
(involved wrist or knee), 40% - extended oligo-JIA, 30% - isolated
monoarthritis. Children with post-traumatic elbow joint deformation
haven’t revealed chronic synovitis.
Conclusion: Monoarthritis of elbow joint are rare atypical manifest-
ation of pauciarticular JIA. Non-specific clinical signs and instrumental
imaging may contribute to diagnostic problems of elbow chronic
synovitis. Therapy of elbow chronic idiopathic monoarthritis must be
coincide treat-to-target strategy in juvenile arthritis. Ultrasound can’t
be the decisive diagnostic method of chronic elbow pathology.
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Pediatric Rheumatology 2017, 15(Suppl 2):P96Introduction: Juvenile idiopathic arthritis (JIA) encompasses a com-
plex group of disorders comprising several entities in children. Mul-
tiple biomarkers have been used to detect the disease activity.
Platelet Microparticles(PMP) are small vesicles released from plasma
membrane upon platelet activation. Several studies stated that PMP
has been associated with the thrombotic event and inflammatory
process in adults. This is the first study in literature to estimate PMP
in JIA.
Objectives: To estimate the level of plasma PMP in children with JIA
and to study the relationship with disease activity of JIA.
Methods: Study design: Cross-sectional study
Inclusion criteria: Children with JIA who fulfilled the International
League of Associations for Rheumatology (ILAR) classification criteria
for juvenile idiopathic arthritis were included.They were categorized
into active disease group and inactive disease as assessed by Wallace
criteria. Complete Blood count, ESR, CRP, and PMP were estimated in
all children. PMP level was calculated by Flow Cytometry.Blood inves-
tigations and baseline demographics were analyzed
Results: Out of 26 children with JIA, 12 had active disease group and
14 had an inactive disease as assessed by Wallace criteria. Mean PMP
level was 83507 cells/μland 34904 cells/μlin active and inactive dis-
ease respectively (p = 0.06). There was no significant correlation be-
tween PMP level in JIA patients with corresponding ESR, CRP, and
platelets
Conclusion: Our study states that level of PMP is significantly ele-
vated in disease activity of JIA and could represent a new biomarker
reflecting the state of cell activation in JIA. PMP role in the inflamma-
tory processes needs to be further elucidated
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Introduction: Paediatric Rheumatology in South Africa competes
with limited health care resources allocated to epidemic diseases.
Data on prevalence, incidence, disease categories, delay in diagnosis
and management are crucial for defining the need for specialized
services. Available literature is limited in South and sub-Saharan Af-
rica. Major challenges include lack of awareness; lack of trained staff,
facilities and support services.1 Education in Paediatric Rheumatology
is neglected at undergraduate and postgraduate levels with a short-
age of paediatric rheumatologists.1 Tygerberg Hospital offers a dedi-
cated clinical service since 1995 with an accredited subspecialty
training post since 2005.
Objectives: The primary aim is to document demography, disease
profile and medical management of patients attending the Tyger-
berg Paediatric Rheumatology clinic. The secondary aim, based on
these findings, will address the need of specialized services and sub-
specialty training posts.
Methods: Retrospective folder review, electronic data search and use
of bivariate and multivariate statistical tools used for analysis to out-
line the disease profile of JIA (Juvenile Idiopathic Arthritis), other
autoimmune (AI) or auto-inflammatory diseases and miscellaneous
musculoskeletal conditions and management thereof.
Results: 450 patients were reviewed between March 1995 and March
2017. Referrals were derived from secondary and tertiary hospitals
(68%), general and private practitioners (13%) and 8.2% by primary
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 62 of 191healthcare centers. 60% of referred patients resided in the greater
Cape Town region and 40% in rural-country regions, depending on
availability of public health transportation services. Most of the pa-
tients (74%) were from a family income bracket of less than 7700
USD per year.
Gender distribution reflected 56% female and 44% male. The most
common age of presentation was between 10-14 years (46%) with a
range of 0 to19 years. Racial distribution was Mixed Racial 79%,
Blacks 16%, Whites 4% and Asians 1%. JIA (38%) was most common
rheumatological condition. Reactive Arthritis (23%), autoimmune and
autoinflammatory conditions (11%), vasculitides (2%) and miscellan-
eous musculoskeletal conditions (39%) e.g. growing pains, Raynaud's,
infection related arthritis, malignancies etc. comprised the rest.
Common presenting symptoms were tender joints (71%), stiffness
after rest (46%) and swollen joints (44%). Uveitis was present in 9%
at initial diagnosis or during follow up. Delay in diagnosis was up to
9 years.
Ibuprofen (42%) was the most commonly used NSAID. Most fre-
quently used DMARD's were methotrexate and hydroxychloroquine.
Intra articular steroid injections were frequently indicated and bio-
logical therapy accessed by selected patients.
Referral to ancillary services included physiotherapy (51.6%), imaging
predominantly X-rays (41%), ophthalmology (47.1%), orthopedics
(37%), occupational therapy (27%) and dermatology (16.7%).
46.5% were offered social grants. 14.7% recorded, achieved remis-
sion. Remission could not be established in most patients due to
high rate of patients lost to follow up (50%). 3.5% transitioned to
adult Rheumatology services.
Conclusion: Patients reviewed were mainly of mixed racial origin
from low-income homes. JIA was the most common paediatric
rheumatological condition seen. Delay in diagnosis and late referrals
were frequent. Increased awareness, education and training, early
diagnosis of disease and appropriate funding for these neglected dis-
eases could dramatically improve outcome. Addressing challenges
unique to a developing country and resultant complexities of man-
agement are essential for advocacy and planning of such services.
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Introduction: Ear perichondritis can be caused by trauma, relapsing
polychondritis (RP), vasculitis, infections etc. Irrespective of etiology,
cartilage deformity and necrosis may occur. Chondrodermatitis nodu-
laris helicis (Winkler’s disease) is a localized cartilage inflammation,
often with crusting, resulting from trauma or bland vascular
impaiment.Objectives: Long-term assessment of recurrent unilateral perichondri-
tis in patients with systemic diseases, for the development of RP
diagnostic criteria.
Methods: We retrospectively identified the cases of unilateral re-
current ear perichondritis in the patients with suspected polychon-
dritis in the last 15 years in a tertiary referral adult Rheumatology
department. The patients then fulfilled a questionnaire and were
seen prospectively for two years. All chondritis episodes and the
Mc Adam and Damiani-Levine polychondritis criteria were
assessed. Laboratory tests for inflammation, immunology, uric acid,
ENT examination, cartilage biopsy whenever accepted and an ex-
tensive search for infection,vasculitis, hematologic malignancies,
as well as complications of other organs classically involved by
polychondritis were recorded, as part of the regular screening for
polychondritis.
Results: We identified 3 cases of recurrent unilateral chondritis, all
occuring in spondylarthritis patients, that were followed up for 3 to
12 years for other polychondritis features, without development of
RP criteria. None of these patients developed ulcerations or crusting
to suggest Winkler’s disease, either.
Case 1: A 26-years female patient with a juvenile extensive oligoar-
thritis since the age of 5 and psoriasis since 11, on methotrexate,
presented with recurrent episodes of right ear swelling and inflam-
mation, healing within three days, not altered by empiric antibiotic
short courses, accompanied by transient mild leukocytosis with neu-
trophilia. An active follow-up for 12 years did not reveal other chon-
dritis sites. NSAIDs helped to alleviate the attacks, which became less
frequent with time.
Case 2: A 48-year male patient with aseptic abscesses syndromes,
Crohn’s disease and spondylarthritis with bilateral coxitis diagnosed
for 3 years had a recurrent left ear upper lobe inflammation since
the first visit. The nodular chondritis, with low-level local inflamma-
tion generally lasting for one week, independent from the joint
flares, responded to the addition of NSAID and sulfasalazine to adali-
mumab and azathioprine. No progression to polychondritis was
noted in 3 years.
Case 3: A patient with undifferentiated spondylarthritis and a history
of treated medullar thyroid carcinoma presented with recurrent right
ear painful inflammation. No signs of tumoral dissemination or re-
lapse were detected in 6 years. The cartilage biopsy was normal. The
attacks' frequency decreased after leflunomide.
Conclusion: Unilateral recurrent ear perichondritis may not always
herald polychondritis, at least in spondylarthritides. It can be specu-
lated that local triggers (pressure on the ear, etc) may activate the
innate immunity through danger-associated molecular patterns, how-
ever, the progression to polychondritis probably requires activation
of certain Toll-like receptors. An active search for an RP is neverthe-
less worthed in the unilateral chondritis, as RP requires a more ag-
gressive therapy. Informed consent to publish has been obtained
from the patient/parent/guardian.
Funding:PN-II-RU-TE-2014-4-2708
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Introduction: Generalized joint hypermobility (GJH) is characterized
by deficiency of collagen and changes in the proportion of collagen
subtypes. It is a clinical feature associated with excessive laxity of
joints. Oral mucosa, teeth and temporomandibular joint (TMJ) can be
affected in these condition.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 63 of 191Objectives: It was aimed to evaluate the dental and temporoman-
dibular status in children with GJH.
Methods: Sixty two children with GJH and age-sex match sixty two
healthy children as a control group were enrolled to the study. The
GJH was assessed by the Beighton Hypermobility Score (BHS). The
subjects screened for dental and TMJ status. Assesment included
index for ‘Decayed’, ‘Missing’ and ‘Filled Teeth’ (DMFT), visual plaque
index (VPI) and gingival bleeding index (GBI) scores, tooth mobility
and TMJ evaluation. The Mann–Whitney U and chi-square tests were
used to evaluate the data.
Results: Mean BHS score was found 6.3 ± 1.2 in GJH group. VPI and
GBI scores were found significantly higher in children with GJH then
control group (p < 0.05). No differences were found regarding the
DMFT scores between GJH and control groups (p > 0.05). Temporo-
mandibular disease (TMD) frequency was significantly higher in chil-
dren with GJH compared to the control group (p < 0.001) (Table 34).
The most frequent TMD obtained as clicking while maximum active
mouth opening. By the way, combined TMJ problems observed in
approximately one third of the GJH children.
*Mann-Whitney U test and #Chi-square test was used for analysis.
VPI: Visual plaque index, GBI: Gingival bleeding index, DMFT:
decayed, missing and filled teeth, MT: Mobility of tooth, TMD: tem-
poromandibular disease.
Conclusion: High frequency of TMD in GJH group may demonstrate
that TMJ is also affected in GJH. The higher VPI and GBI scores indi-
cating the poor oral hygiene in children with GJH may point out that,
this children can not perform properbly toothbrushing.
Trial registration identifying number: Ethical approval was obtained
from the Ethics Committee of Karadeniz Technical University, Faculty
of Medicine (Approval number: 2016/102).
Disclosure of Interest: None DeclaredTable 34 (Abstract P100). Comparison of dental status, MT and TMD
between in GJH and control groups
GJH group Control group p
Age (median (min-max)) 8 (5-17) 9 (5-17) 0.43*
Gender (M/F) 36/26 36/26 0.57#
VPI positivity (%) 88.7 74.2 0.03#
GBI positivity (%) 64.5 45.2 0.02#
DMFT score (median(min-max)) 0.062 (0-0.23) 0.080 (0-0.23) 0.27*
MT positivity (%) 3.2% 1.6% 0.50#
TMD positivity (%) 48.4% 14.5% <0.001#P101
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Introduction: IgG4-related disease (IgG4-RD) is relatively a new grow-
ing entity of immune mediated origin, characterized by a unique
pathological feature that affect a wide variety of organs with infiltra-
tion of IgG4-positive plasma cells and occasionally elevated serum
IgG4. It is both a systemic inflammation and a sclerosing disease. The
most common manifestations are parotid (14-26%) and lacrimal
swelling (4-13%), lymphadenopathy and autoimmune pancreatitis.
Several studies have examined orbital adnexal IgG4-related disease
or IgG4-related orbital inflammation. The diagnosis should be proven
histopathologically but other conditions such as lymphoma should
be carefully excluded. Patients with IgG4-RD respond beneficially to
glucocorticoid therapy especially when administered at early onsetstages. In some cases, the combination of immunosuppressive
agents is required.
Objectives: To describe a pediatric clinical case with orbital IgG4 re-
lated disease with an excellent response after immunosuppresive
treatment.
Methods: We present a 16-year-old girl with IgG4-RD during one
year with left ocular pain and eye inflammation, diagnosed as bacter-
ial conjunctivitis and trated with ophtlamic antibioticoteraphy, with
no improvement. Weight loss and increased acute phase reactants
(erythrocyte sedimentation rate and C-reactive protein). On ocular
computed tomography. Histopathology clearly defined the mass to
be IgG4 related fibrosis with focally arranged fibrosis in a storiform
pattern, and positive CD20 deposit ++++, positive IgG4 +++ in plas-
matic cells and lymphocytes, positive CD38 deposit ++. Biopsy re-
port: Autoimmune Dacryoadenitis Associated with IgG4 Disease. IgG4
serum normal level 9 mg/dl.
Ocular Magnetic resonance imaging was performed in which volume
and lacrimal gland intensity is identified, which displaces the rectus
and oblique muscle causing proptosis, the lacrimal gland presented
an increase in it’s dimensions with measures of 23x8x10mm in its
posterior axes, posterior No abnormal reinforcement is identified in
the contrast medium. Infectious serological test were negative (EBV,
CMV, HBV, HCV, toxocara and toxoplasma).
Results: The patient was started on oral corticosteroids and myco-
phenolate mofetil, which resulted in significant clinical improvement
after 3 months of treatment, the mass became smaller and the pa-
tient was asymptomatic.
Conclusion: IgG4-RD remains a field not yet fully explored or under-
stood. Early and efficient therapies aiming to achieve a beneficial
outcome, and to improve prognosis are still required.
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Introduction: Rheumatic fever (RF) and post-streptococcal arthritis
(PSA) are characterized by autoantibodies secondary to beta
hemolytic streptococcus group A infection. In our country, the car-
diac sequelae acquired by the RF generate substantial costs for the
State and family, becoming a public health problem.
Objectives: To assess the clinical characteristics and outcome of pa-
tients with RF and PSA from a Paraguayan referral hospital.
Methods: Retrospective and descriptive study of patients under the
age of 18 years, diagnosed with RF and PSA between January 2009
and April 2017.
Results: 32 cases of RF and 8 PSA (all misdiagnosed as originally RF)
were found. The population is distributed similarly by all states of the
Eastern Region from Paraguay. The average monthly income per
household is 18% with 2 minimum wages, 37% with a minimum sal-
ary, 30% less than 1 minimum wage, and 15% without data. 62% of
children with RF sleeps with 3 or more family members in the same
room. Mean age at diagnosis: 10.5 (3-17) years. The female to male
ratio is 4:6. Only 5% are Native patients. During the acute phase, 52%
had polyarthritis, 43% had carditis, 13% had chorea, 2% had subcuta-
neous nodules, and 2% had erythema marginatum. Jones minor cri-
teria: arthralgia 20%, fever 14%, elevated ESR 21%, CRP positive 16%,
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(45%), followed by mitral and aortic simultaneously (10%), 8%
aortic and 5% tricuspid alone; 32% with no affected heart valves.
In 93% of patients not throat culture was done. ASO + in 21% of
cases, performed in all patients. Treatment: all received ben-
zathine penicillin G, 35% NSAID, 18% corticosteroids, 10% halo-
peridol, 14% valproic acid. Eleven patients discontinued
treatment. Only 10% of patients with RF has required heart sur-
gery (valve replacement), with one death.
Conclusion: RF remains a major cause of acquired heart disease in
our country, perhaps by inadequate management of streptococcal in-
fections, in addition to late diagnosis of the disease and household
overcrowding.
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Introduction: There has been increasing interest in the patient’s per-
spective on outcome of treatment. The Haemophilia Activity List
(HAL) has been developed as a disease-specific questionnaire for
haemophilia patients and is a validated self-report measure of func-
tion developed according to WHO’s International Classification of
Functioning, Disability and Health.
Objectives: In this study, we performed a cross-cultural adaptation
and linguistic validation of the HAL questionnaire to assess the
health-related quality of life in hemophilia patients in the future.
Methods: To validate HAL in Korean, the English versions of HAL
were translated into Korean using ‘the forward–backward translation’
method and merged into a final Korean version. Validation was per-
formed against the Korean version of the multidimensional health as-
sessment questionnaires (MDHAQ) as general tool and Routine
Assessment of Patient Index Data (RAPID3) as similar arthritis-specific
tool. All processes were done with permission of the developer and
according to WHO guidelines.
Results: Eighty-six patients with severe and moderate forms of
haemophilia A and B with haemophilic arthropathy were invited
to participate in the study. Spearman’s rank correlation test was
used for validation and internal consistency of the HAL was cal-
culated with Cronbach’s alpha. Seventy-five patients (86.2%) (15–
62 years old) answered the questionnaires. The internal
consistency of the Korean version of HAL was high, with Cron-
bach’s alpha being 0.80–0.95. Upper extremity function had the
highest consistency and leisure activities and sport had the low-
est. The correlation was good between the HAL overall score and
MDHAQ overall (r = 0.78), MDHAQ pain (r = 0.79), and RAPID3
physical function (r = 0.82).
Conclusion: The Korean version of HAL has both internal consistency
and convergent validity and may complement other functional tests
to gather information on the patient’s self-perceived ability. This
questionnaire of Korean version can be useful as a disease-specific
instrument for evaluation of the health-related quality of life in Ko-
rean patients with haemophilic arthropathy.
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Introduction: IgG4-related disease is a fibroinflammatory condition
characterized by tumefactive lesions, dense lymphoplasmacytic infil-
trate rich in IgG4-positive plasma cells, storiform fibrosis and often el-
evated serum IgG4 concentration. On microscopic examination,
presence of IgG+ plasma cells (>10-50/HPF), IgG4+/IgG+ plasma cell
ratio (>50%) and typical histopathologic pattern confirm the diagno-
sis. Inflammatory pseudotumor (inflammatory myofibroblastic tumor)
is a mass lesion composed of myofibroblasts, plasma cells, lympho-
cytes and eosinophils.
Objectives: The aim of this study is to analyze the pediatric patients
with inflammatory pseudotumor (inflammatory myofibroblastic
tumor) of various organs for the diagnosis of IgG4 related disease,
and to investigate the composition of T helper subsets.
Methods: 20 patients who were diagnosed as inflammatory pseudo-
tumor (inflammatory myofibroblastic tumor) of various organs at
Hacettepe University Faculty of Medicine, Department of Pediatrics,
Pathology Unit were included in the study. Immunohistochemical ex-
pression of IgG, IgG4, CD3, CD20, CD68, IL-10, IL-17, Foxp3, IFN-
gamma, IFN-alpha and IL-4 were studied from archived paraffin
blocks.
Results: The mean age of the patients at the time of biopsy was
7,36 ± 3.85 yr. The biopsies were taken from orbita (2 patients), medi-
astinum (7 patients; 3 from lungs, 3 from mediastinal wall, 1 from
bronchi), and abdomen (10 patients; 2 liver, 1 spleen, 2 intestinal, 4
intraabdominal, 1 retroperitoneal wall). Out of the 20 patients, 3 had
more than 50 IgG4+ cells per HPF but none of them did fulfil the
diagnostic criteria for IgG4-related disease. In terms of inflammatory
milieu, all the biopsies were positive for CD3, CD20 and CD68. As for
T helper cell subtypes, all of the biopsies were IL-10 positive, 85% of
the biopsies were IL-4 positive, 95% were IL-17 positive, 80% were
Foxp3 positive, 50% were IFN-alpha and 35% were IFN-gamma
positive.
Conclusion: In our cohort, none of the inflammatory pseudotumors
(inflammatory myofibroblastic tumors) fulfilled the diagnostic criteria
for IgG4-related disease. B cells, macrophages and T cells are present
in the inflammatory pseudotumor and all T helper cell subtypes such
as Th1, Th2, Th17 and Treg are included in the inflammatory milieu.
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Introduction: Livedoid vasculopathy is characterized disease with re-
current ulceration and thrombosis. Its pathogenesis has been found
to be related to occlusion of the cutaneous microcirculation leading
to thrombosis, ischemia and minimal inflammation in the vascular
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oxygen therapy (HBO) facilitates wound healing by affecting the fi-
brinolytic pathway. We used HBO in a patient resistant to other
treatments.
Methods: A girl aged 15 years was admitted to the Erciyes University
Faculty of Medicine Pediatric Rheumatology Department at the first time
in May 2016 complaining of painful ulceration in the ankles and foot.
Results: A fifteen-year old female presented with a one year- old his-
tory of recurrent multiple painful ulcer, purpuric macule and porcel-
ain – white stellate scars on the ankle and the foot. Patient did not
give any history of any other medical illness, or any systemic com-
plaints. There was no remarkable feature in baseline laboratory ex-
aminations. Doppler ultrasonography of the lower extremities did
not find any vascular insufficiency in the major vessels. Skin biopsy
from the lesion site revealed featured of focal necrosis of the epider-
mis, subepithelial focal hemorrhage, hyalinization of the capillary
walls and thrombosis in some vessels. The tests containing C3, C4,
RF, ANA, ANCAs, ACA IgM and IgG, lupus anti-coagulant, anti-
thrombin III, protein C, protein S, homocysteine were normal. Factor
V Leiden, prothrombin and methylenetetrahydrofolate reductase
(MTHFR) gene mutation analysis were performed. Heterozygous mu-
tation was detected in nucleotide region 1298 of the MTHFR gene.
Anti-platelet, immunosuppressive, immunomodulatory drugs and sys-
temic steroid were given to the patient with diagnosis of livedoid
vasculopathy. Hyperbaric oxygen therapy was applied on frequent
relapses with these treatments. The patient completely relieved from
pain and ulcers showed marked improvement.
Conclusion: Treatment of livedoid vasculopathy is very challenging
due to low incidence and unclear pathogenesis. Hyperbaric oxygen
therapy is well tolerated, with few side-effects compared with the
other treatment regime. We treated resistant livedoid vasculopathy
with hyperbaric oxygen therapy.
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Introduction: Osteogenesis imperfecta, an inherited connective
tissue disorder with remarkable clinical variability, is caused by a
quantitative or qualitative defect in collagen synthesis. Exact
prevalence of cardiac involvement in Osteogenesis imperfecta is
indistinct.
Objectives: The aim of this study was to determine the prevalence of
cardiac involvement in children with Osteogenesis imperfect by
Echocardiography.
Methods: During one year, Sixty five patients were referred to Out-
patient Clinic of Musculoskeletal and endocrinology in Mofid Chil-
dren’s Hospital. All of them were consulted with our Pediatric Cardi-
ologist and echocardiography was performed.
Results: Among 65 patients (60% male, 40% female), mean age
was 6.95 ± 4.36 year-old (ranging from 2 months to 17 years old).
Twenty percent of patients were belong to subtype one, 47.7%
to subtype III, and 32.3% to subtype IV according to silence
category.
Prevalence of aortic root dilatation, mitral valve prolapse (MVP), mi-
tral regurgitation (MR), and tricuspid regurgitation (TR) were 13.8%,
15.38%, 7.6%, and 15.38% respectively. We found a significant rela-
tionship between MVP and female gender, however, no relation with
patient’s subgroups.Conclusion: Because of the importance of cardiac involvement in our
study, we suggest to perform echocardiography in all children with
osteogenesis imperfecta.
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Introduction: Acid ceramidase deficiency (Farber disease; Farber lipo-
granulomatosis) is caused by mutations in both alleles of the ASAH1
gene, resulting in deficiency of acid ceramidase and accumulation of
the pro-apoptotic and pro-inflammatory sphingolipid, ceramide. It is
considered an ultra-rare disease, with only 109 cases reported in the
medical literature since 1952. However, since 2014, we have identi-
fied a cohort of 45 patients (some of whom are since deceased) from
30 countries on 6 continents, which indicates a much broader
phenotypic spectrum and potentially higher incidence than previ-
ously thought. The information collected from this cohort demon-
strates that there are patients diagnosed in late adulthood with
attenuated forms, as well as patients for whom years elapse between
the appearance of the three typical Farber symptoms: joint disease
(arthritis and/or contractures), subcutaneous nodules, and hoarseness
(due to laryngeal involvement). Moreover, there is wide intra- and
inter-patient variability of symptom severity.
Objectives: To develop a natural history study structure and design
that would enable systematic collection of information on deceased
patients using medical records, as well as on living patients who
have or have not undergone hematopoietic stem cell transplantation
(HSCT). In addition, the study will evaluate clinical assessment tools
used for other diseases with similar symptoms, as well as those de-
veloped specifically for Farber disease.
Methods: We designed a cross-sectional cohort study with a unique
data collection instrument, including sections for the collection of retro-
spective data on disease-specific and general medical history, as well as
data from clinical assessments to be performed at prospective visits.
Results: The pre-existing clinical assessment tools include (among
others) the Childhood Health Assessment Questionnaire (CHAQ), and
Wong-Baker Faces Pain Rating Scale, 6-minute Walk Test, Pulmonary
Function Testing, and Joint Range of Motion measurements. We also
developed a unique patient reported outcome measure related to
Farber disease symptoms including physical impairment, pain, and
emotional distress, and a method for the assessment of change in
size of subcutaneous nodules.
Conclusion: Consideration of the broad spectrum of ages and het-
erogeneous phenotypes in a small population of patients available to
participate in a study of the natural history of acid ceramidase defi-
ciency led to the design of a cross-sectional cohort study with retro-
spective and prospective components. By including deceased
patients and patients having undergone HSCT in the study design,
the amount of data that can contribute to the understanding of this
very rare disease is substantially increased. Furthermore, the specific
prospective assessments will allow us to follow disease progression
over time, and to evaluate the degree to which the assessment tools
and techniques may be appropriate measures to use to register
change in certain symptoms. It is our hope that this unique design
will provide data which is sufficiently robust to serve as the basis for
preventing misdiagnosis of acid ceramidase deficiency as JIA, provide
an indication of the most appropriate methods for measuring effi-
cacy in future therapeutic trials, and serve as a potential point of ref-
erence in the design of similar studies in rare disease populations.
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Introduction: The lived experiences and opinions of patients, par-
ents and carers (PPCs) living with rheumatic and musculoskeletal
diseases (RMDs) must inform and influence all aspects of re-
search, from prioritisation through to dissemination. For ex-
ample, contributing to grant applications, designing studies,
identifying the most suitable outcomes to include in a clinical
trial, facilitating study recruitment and sharing findings with the
wider community. In turn, it is possible that involving PPCs may
enhance expectations and subsequent levels of satisfaction with
research.
Objectives: The aim of the PPC representatives on the clinical studies
group is to provide strategic guidance for the paediatric rheumatol-
ogy community about the most effective ways of engaging and in-
volving PPCs in clinical and health services research.
Methods: To effectively represent PPCs living with RMDs, it is crit-
ical to have a means of ensuring that PPC representatives encap-
sulate the range of views within the PPC community. The
paediatric rheumatology clinical studies group PPC representa-
tives aim to do this through networking, linking with external
rheumatology stakeholder groups and through hosting consumer
research meetings. In addition, PPC representatives comment on
various documents as part of their role, including trial protocols,
ethics applications and and participant information sheets. They
have also been involved in formulating three research questions
as part of the clinical studies group research strategy. The top
three research priorities were informed by a patient-led research
study with young people and their families. With much delight,
one research priority has informed the current development of a
study to improve treatment tolerability for young people with
RMDs.
Results: Activities of PPC representatives include attendance several
face-to-face and teleconference meetings each year. This is an essen-
tial activity that enables researchers and healthcare professionals to
actively interact with PPCs as equal partners, in order to shape on-
going and future research activities. This approach also emphasises
the importance of physical meetings in fostering collaborative and
participatory approaches to research. In addition, PPC represenatives
bridge the gap between the research community, patient groups
and charities, facilitating communication between individuals and
teams.
Conclusion: By widely accepting and embracing the PPC voice as
a catalyst for high quality, young person- and family-focused re-
search, it is hoped that the often negative experiences of living
with an RMD can be used positively to shape research, so as to
be able to provide the best possible care, treatment and support
for young people and their families living with RMDs in the
future.
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Introduction: Acid ceramidase deficiency (Farber disease; Farber lipo-
granulomatosis) is considered an ultra-rare disease. Since 2014, Enzy-
vant has identified a cohort of 45 patients from 30 countries on 6
continents, with a much broader phenotypic spectrum and demon-
strating a potentially higher incidence than previously thought. The
cardinal symptoms of Farber disease are: arthritis, subcutaneous nod-
ules, and hoarseness. Over 70% of the moderate and attenuated
phenotype patients in the Enzyvant cohort were initially diagnosed
with a form of Juvenile Idiopathic Arthritis.
Objectives: Initiate a qualitative research study to understand the
symptoms and impact of Farber disease from the perspective of pa-
tients and caregivers by conducting one-on-one interviews for con-
cept elicitation, content validity, and patient interpretation of newly
developed patient-reported outcome tools.
Methods: This study consisted of two parts: semi-structured qualita-
tive interviews to understand Farber disease (FD) symptoms and to
evaluate new Farber-specific PRO measures to capture the impact of
FD symptoms on patients including: subcutaneous nodules, voice,
overall pain, arthritis, ability to move joints, ability to perform daily
tasks, and level of fatigue. Participants were asked to rate the symp-
toms’ impact on a scale of 0–10, with 0 meaning no impact and 10
meaning greatest impact. Additional PROs for benchmark assessment
were (among others): Childhood Health Assessment Questionnaire
(CHAQ), SF-36 in patients and caregivers.
Results: Eight interviews were conducted with 4 caregivers and 4 pa-
tients. Included were: 2 adult patients (attenuated phenotype); 1
caregiver of deceased child (severe phenotype); 1 transplanted adult
patient (moderate phenotype); 1 caregiver of transplanted pediatric
patient (moderate phenotype); 1 caregiver of a pediatric patient
(moderate phenotype); and 1 caregiver/patient dyad of a non-
transplanted pediatric patient (moderate phenotype). Interviews re-
vealed the symptoms of acid ceramidase deficiency have measurable
clinical impact across a broad spectrum of phenotypes and symptom
severity. In general, all participants found the questionnaires and as-
sessments relevant to their condition. Feedback was provided by the
participants to improve the formulation and scope of questions. With
regard to the relative impact of symptoms, the ability to move joints
had an average impact rating of 6.6 (range 1 to 10), followed by abil-
ity to perform daily activities and subcutaneous nodules with 5.9
(range 1 to 10 for daily activities and 3 to 9 for nodules), voice im-
pact was rated 5 (range of 3 to 9). The remaining symptoms (arthritis,
overall pain, level of tiredness, and other symptoms) all yielded lower
levels of impact. In the cases where the SF-36 and CHAQ were com-
pleted, scores demonstrated significant impact and disability in the
population of patients with acid ceramidase deficiency.
Conclusion: In spite of the small number of participants, the informa-
tion gathered provides a better understanding of methods useful for
measuring symptom impact, potentially in the context of future
therapeutic trials, and may allow better discussion of symptom im-
pact between physicians, patients and caregivers. This type of quali-
tative study can be particularly useful in rare disease populations,
and may also help interpret the utility of both new and established
patient reported outcomes in cases when the size and variability of
the available population prohibits traditional methods of validation.
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Introduction: Sjögren syndrome (SS) is a systemic autoimmune dis-
ease characterized clinically by sicca syndrome resulting from
lymphocytic infiltration of the exocrine glands.
Objectives: To identify genetic susceptibility factors in juvenile-onset
primary Sjögren syndrome through whole exome sequencing.
Methods: Paired-end sequencing was performed on genomic DNA
on an Illumina HiSeq 2500 (Genomics Core Facility). Burrows-Wheeler
Aligner software was used for alignment to Genome Build hg19,
GATK Haplotype Caller for base calling and ANNOVAR software for
annotation. Identified variants were confirmed by Sanger sequencing
(LGC Genomics Facility, Berlin, Germany).
Results: A girl (P1) aged 14 years was born the second of four chil-
dren to consanguineous parents of Moroccan origin. In the familial
history we note beta thalassemia minor in father and index patient
and type 1 diabetes in the father. Immunological screening was
prompted by two occurrences of ethmoiditis with orbital cellulitis
and progression to an orbital abscess in the first episode, before the
age of 4 years. However, no notable infectious episodes recurred. La-
boratory analysis revealed isolated IgG2 deficiency (0.55 g/L; 0.72-
3.40), very low memory B cells (1.8%) and a low response to 1/3
pneumococcal serotypes tested. At the age of 9 years, she presented
with recurrent transient episodes of fever and arthritis in her knees
and ankles. Laboratory analysis showed clear immune activation with
hypergammaglobulinemia (IgG 24.40 g/L; 5.30-13.06), mildly elevated
sedimentation (26 mm/h) and positivity for rheumatoid factor (RF)
(519 IU/ml; ≤40) and anti-Ro autoantibodies (>282.0; ≤7.0) (Table 1),
suggestive for SS. In addition, increased CD5+ B cells (31.4%), glu-
tamic acid decarboxylase (GAD) autoantibodies (4.2; ≤0.9), low total
complement levels (<20%; 70-140) and undetectable levels of C2
were found (<7 mg/L; 14 – 25). Symptoms persisted and at the age
of 10 years she developed cutaneous vasculitis of the legs, feet,
hands and eyelids. Furthermore, she developed sicca symptoms of
the eyes and mouth, secondary caries, hoarseness and a persistent
elevation of amylase (214U/L; 28-100). Magnetic resonance imaging
(MRI) demonstrated mild enlargement of the right parotid gland,
which appeared lightly inhomogeneous with T2-hyperintesive foci
and a limited number of intraglandular lymph nodes, suggestive for
parotitis. Due to persistent disease activity at the age of 12 years, she
was started on treatment with daily administration of 200 mg Pla-
quenil. While hypergammaglobulinemia and sicca symptoms persist,
sustained remission of vasculitis and arthritis ensued. Whole exome
sequencing revealed P1 is homozygous for the classic deletion in C2
causal for type I C2 deficiency.
Conclusion: The presentation of primary SS at this age is very rare
and P1 displayed both typical clinical (vasculitis, arthritis, parotitis)
and laboratory (hypergammaglobulinemia, anti-Ro autoantibodies, RF
positivitiy, low memory and high circulating CD5+ B cells) features.
To the best of our knowledge C2 deficiency, the most frequent her-
editary deficiency in the classical component pathway, was neverreported in association with SS. One study on adult pSS detected
low CH50 in 15% of patients and hypocomplementaemia correlated
with systemic symptoms1. Unlike deficiency for the C1 complex or
C4, the penetrance of C2 deficiency in SLE is merely 10%2. However,
since the majority of C2 deficient patients do not manifest auto-
immunity there are likely other genetic or environmental drivers for
disease. C2 deficiency may be a negative modulating factor on the
development and course of autoimmune disease and screening
should be considered in patients with primary SS.
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Introduction: RAiISE is a user-led research project inspired by the
negative experiences that young people face while studying and liv-
ing with an invisible illness. Many young people who live with
chronic illnesses look no different to their healthy peers. The invisible
nature of some illnesses can often lead to an invisible struggle, lead-
ing to misunderstandings, particularly in the case of young people. It
can be a huge burden on the chronically ill to make the invisible, vis-
ible to others.
Objectives: The main objective of RAiISE is to improve the standard
of care given to young people with invisible illnesses in school, col-
lege and university and to create a resource to teach education pro-
fessionals a series of strategies and techniques to support their
students. RAiISE will also offer support to young people with invisible
illnesses and aim to empower them to take control of their own
health.
Methods: A young patient of Alder Hey NHS Children's Foundation
Trust decided to raise awareness of living with an invisible illness. A
network of young people, parents, education and health profes-
sionals was created and a series of workshop and focus groups
allowed each stakeholder to share their experiences and expertise as
they inspired and advised the production of the RAiISE information
pack. It is important that young people are able to shape research
based on their lived experiences. Several international charities and
organisations have offered support and knowledge in advising the
process.
Results: At early workshop meetings, young people with invisible ill-
nesses and their parents were able to offer personal accounts and
experiences which highlighted that the most common themes were
problems with communication and trust, as well as difficulty in un-
derstanding the erratic nature of many chronic illnesses. From this re-
search, a draft information pack was written by the RAiISE
committee, which was later presented to young people, parents,
health and education professionals and charity representatives. All
stakeholders were able to offer their expertise from their respective
fields. Feedback was overwhelmingly positive and any adjustments
are to be made in the coming weeks. The final pack will be com-
pleted and ready for distribution by the end of summer 2017.
Conclusion: The project has been a successful example of young pa-
tient led research and highlights the importance of self-management
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 68 of 191in young people living with invisible chronic illnesses. The collabor-
ation between young people, parents, and education and health pro-
fessionals has highlighted the necessity for cooperation between all
stakeholders for the benefit of the young person.
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Introduction: Health related quality of life (HRQOL) can be severely
affected in children with juvenile idiopathic arthritis (JIA). Earlier stud-
ies have shown that, amongst other factors, school absence is one of
the main predictors of HRQOL in children with JIA[i]. HRQOL is also
related to pain intensity and coping strategies.[ii] In young JIA pa-
tients (aged 4–9 years) school functioning can be impaired due to
pain, fatigue and limited joint function. Adequately coping with
these symptoms of JIA during schooldays demands a shared man-
agement approach between the young child, parent(s), teacher and
health professionals. An instrument supporting young children with
JIA in managing their symptoms during schooldays in a structured
way was lacking.
Objectives: 1. To develop an instrument to support a young child
with JIA managing symptoms during schooldays.
2. Implementation and evaluation of the feasability of the developed
shared management tool in the rehabilitation program.
Methods: 1. Elements necessary in the instrument are elected after
consulting parents of young children with JIA and health profes-
sionals of Reade multidisciplinary team for children with JIA. With
help of a professional designer an instrument is developed to pro-
vide a shared management tool for managing symptoms during
schooldays.
2. Children with JIA (aged 4–9 years) with problems in school attend-
ance and their parents are informed about the instrument and in-
vited to use it during their rehabilitation program in Reade. Parents,
children and health professionals evaluate the feasability after using
the instrument by filling in a questionnaire.
3. Results of questionnaires are discussed in the multidisciplinary
team for evaluation.
4. Improvement points for the instrument are proposed.
Results: 1. A personal diary called “Back and Forth Booklet” is de-
signed which contains (1) education pages for the child, parents and
the teacher about JIA, pain and energy levels and how to manage
these, (2) a daily pain measure instrument for location and amount
of pain for the child (colour-in pain puppet), (3) a level of energy in-
strument for expressing fatigue (image of full/half full/empty glass)
(4) space for registration of appropriate alternatives for limited activ-
ities by the health professionals or parents, (5) daily feedback spaces
for the teacher and (6) a visual analogue (VAS) Likert smiley scale for
daily self-evaluation by the child.
2. 9 children and their parent(s), 3 occupational therapists, 3 physical
therapists, 1 social worker, 1 psychologist and 9 teachers have used
the Back and Forth Booklet. Two parents, two children, one teacher
and seven health professionals completed a questionnaire.
3. Evaluation of the questionnaires so far showed that the use of the
Back and Forth Booklet contributes in communication about the
child’s pain and fatigue among the child, parents, teachers and
health professionals. The Back and Forth Booklet facilitates school-
teachers in supporting a child with tailored pain and fatigue coping
strategies. All users were satisfied with the design. Children appreci-
ated the colour-in pain puppet for not having to explain verbally the
teacher about their pain.4. Items for improvement were: (1) Parents need open space for shar-
ing daily information with the teacher (2) Occupational therapists
suggest extra space for documentation of appropriate alternatives
for limited activities.
Conclusion: The “Back and Forth Booklet” is a promising shared man-
agement tool, supporting young children to cope with JIA symptoms
in school. Small adjustments can improve the feasability.
[i] Haverman et al A&R 2012; 64(5)694-703
[ii] Sawyer et al Rheumatology 2004;43:325-330
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Introduction: The Smiling Childhood project was launched by
APMAR Onlus, supported by the Valdese Church and their generous
8x1000 funds donation.
The project comes from a long journey undertaken by our associ-
ation in order to be closer to people affected by chronic pathologies
during their daily lives, defining strategies of inclusion in order to
create an understanding atmosphere about Rheumatic Pathologies,
who unfortunately are still not very well known nowadays.
Some of these pathologies are diagnosed at a later stage, resulting
in a late treatment and in some cases in a great degrade in self-
sufficiency.
Objectives: The aim of our project is to offer support for families and
develop empowerment over chronic and rare Rheumatic Pathologies
in children; giving easier access to information, promoting actions in
order to offer an early diagnosis, helping families face the new chal-
lenges they will be inevitably exposed to
Methods
The method is to create a partecipative process by involving all pos-
sible factors in an active process regarding chronic and rare rheum-
atic pathologies in children. We have involved, over the course of
the years and through the help of educational and informational
workshops, various family members, journalists and paediatricians.
Results: We have therefore been able to build a social window, in
collaboration with professional staff, that works overall to make the
journey that these families will have to face easier. With the use of
this social window, the family nucleus can find information as well as
a place to be heard and guided.
Moreover, available to them is also a psychotherapist psychologist,
both over the phone or in the form of a private meeting. The clinical
instrument used here is the meeting with our staff (both hearing and
empathy), and with the use of monitoring sheets, drawings and illus-
trations according to the age of the child. At the end of this forma-
tive journey, the family will be asked to fill out a survey in order to
rate our project.
Our social window is also available online in the form of a blog.
Other communication and participation activities take place in local
doctor’s surgeries, schools, and with the collaboration of Rheumatol-
ogy Paediatricians. We have also developed a comic, ‘A new chal-
lenge together’, in order to inform young adults and children on
these issues.
Conclusion: The presence of a Rheumatic Pathology can result in
heavy effect on the life of a child and its family. These impacts vary
depending on the resources that they might have available. May
these be ‘external’ (financial and economical, available treatments,
network support) or ‘internal’ (the possession of medical and bureau-
cratic information useful to the management of the problem, the re-
lationship between the members of each family and their degree of
flexibility).
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 69 of 191Our project, ‘A Smiling Childhood’ has kept many families informed,
emotionally supported and aware of their internal resources.
Disclosure of Interest: None Declared
P116
Anxiety, depression, and parental perception of uncertainty
among parents of children with juvenile idiopathic arthritis in
Bogota, Colombia.
Adriana Diaz-Maldonado1,2,3, Sally Pino2,4, Pilar Guarnizo2,5,6, Juan Manuel
Reyes2, Leonardo Ariza2
1Hospital de la Misericordia, Bogota, Colombia; 2Care for Kids, Bogota,
Colombia; 3Instituto Roosevelt, Bogota, Colombia; 4Hospital San Jose
Infantil, Bogota, Colombia; 5Fundacion Cardio Infantil, Bogota, Colombia;
6Cayre, Bogota, Colombia
Correspondence: Adriana Diaz-Maldonado
Pediatric Rheumatology 2017, 15(Suppl 2):P116
Introduction: Juvenile idiopathic arthritis (JIA) is a chronic illness
which affects among 2 – 150 children for 100.000 in Europe and
North America, most of them are cared by their parents (1). It has
been estimated that parents of a child with chronic illness can
present mood problems, cognitive problems, anxiety, high level of
distress and lower levels of quality of life (2).
Objectives: Describe the anxiety, depression, familiar functionality
and parental perceptions among parents of a child with JIA in
Bogotá, Colombia.
Methods: A cohort of parents of children with JIA were approached
for this study in Bogota, Colombia. The questionnaires Hamilton rat-
ing scale for anxiety (HAM-A), Beck depression inventory (BDI), family
APGAR scale, parental perception of uncertainty scale (PPUS), and
parental coping strategy inventory (PCSI) were self-administrated. De-
scriptive analysis was performed according to the nature of the
variables.
Results: Twenty two parents participated in the study characterized
by 16 women and 6 men. The average age of the parents was
43.86 years (ranged from 33 to 62 years). Most of them with mild to
high income and the 55% of the parents had graduate degrees. Age
of children with JIA was 14.95 years (8 to 20 years), 55% were female.
The most frequent type of JIA was polyarticular and enthesitis-
related arthritis (64%), followed by systemic (16%), oligoarticular
(16%) and psoriatic arthritis (5%).
In terms of anxiety, 46% of parents reported having moderate anx-
iety. Similar results related to stress were observed. Mild depression
symptoms were found in 18% of parents and moderate in 9%. Se-
vere and moderate familiar dysfunctionality were reported by the
parents in 14% and 36%, respectively. There was not association of
familiar dysfunctionality and the number of years living with the dis-
ease. However, those parents of children with more than two years
of disease present an increase in moderate symptoms of depression.
Perception of uncertainty was moderate with mean score of PPUS of
83.85 (SD 15.66). Parents of children with recent diagnosis(less than
2 years) presented higher scores than parents of children which had
been diagnosed longer than two years (mean score 88.5 (SD 8.70) vs
80.75 (SD 18.68), respectively). Among parents with higher PPUS
score: 89% reported severe or moderate anxiety, 66% reported mod-
erate symptoms of depression, and 44% informed moderate or se-
vere familiar dysfunctionality.
Being optimistic, learning about the diseases and treatment, and in-
teractions with their ill child were the most frequent coping strat-
egies used by the parents. However, parents of children with recent
diagnosis are more optimistic and interact more with their ill child
compared with parents of children which had been diagnosed lon-
ger than two years.
Conclusion: This study shows that anxiety and stress in parents of
children with JIA is present frequently. Perception of uncertainty,
anxiety, and familiar dysfunctionality were observed more frequent
and severe in parents of children with recent diagnosis(less than two
years). Considering the limitations of the study, in order to alleviate
anxiety and depression symptoms on parents, and prevent family
dysfunctionality, psychological intervention and participation ingroup support are recommended strategies for parents of children
with recent JIA diagnosis.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children and an important cause of
short-term and long-term disability.
Physiotherapy and occupational therapy, with the aim to keep or re-
store joint function and to achieve a normal pattern of mobility, are
important components of the therapeutic approach. In standard
physical therapy patients tend to lose interest in the treatment, due
to the monotony of the exercises, and as a consequence, patients ei-
ther perform their exercises irregularly or quit the physical therapy.
In recent years, the introduction of new gaming input devices, such
as Nintendo’s Wii Remote™ and Microsoft’s Kinect, and the develop-
ment of games that involve physical activity, induced the researchers
to consider the possibility of using videogames to perform physical
therapy.
Objectives: To design a set of rehabilitation games that could help
patients affected with Juvenile Idiopathic Arthritis performing their
physical therapy.
Methods: A multidisciplinary study group involving paediatric rheu-
matologists, physiotherapists and engineers of the Department of
Electronics, Information and Bioengineering of the Politecnico of
Milan was created.
During the first meeting, the rheumatologists explained the basic as-
pects of disease and the principal physical problem observed in pa-
tients with JIA; the therapists introduced how the physical therapy
for JIA works.
In order to improve the final outcome, engineers used an iterative de-
sign approach, that is, they designed the games, and then they
followed a cyclic process of prototyping, testing and analyzing designs.
The key points on which engineers focused were: the ability of the
game to adapt to the capabilities of the patient, the possibility for the
therapists to create custom game levels, the need to save every infor-
mation about how the patient performs during the exercises and the
possibility to see again the exercise carried out by the patient.
For this study, the attention was focused on hand and wrist.
Four different games to play were developed. For each game was
defined a rewarding system that increases the score when the player
does something good, but does not decrease it when he/she makes
a mistake. The scoring system was also a useful first qualitative feed-
back for the therapist about the patient’s performance.
The therapists were asked to create a custom level for the flight
simulator game, so she could simulate an exercise performed in a
typical training session.
Results: Three poliarticular JIA patients took part to the first experi-
mental session. Ten, fifteen and twenty-one years old respectively.
The first patient had ankle involvement, while the last two had wrist
and small joints of the hand involvement.
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Flappy Bird-like game. The flight simulator, in particular, was tested
both with the hands and with the feet.
The feedback from the subjects was quite good; The therapists’ feed-
backs were also good. The patients enjoyed the exercises much more
and “it did not look like they were doing exercises”. The subjects
were doing without complaint the same exercises that they found to
be boring and difficult during standard physical therapy.
Conclusion: The feedbacks received during the experimental sessions
validated the work. The patients liked the games and suggested
some additional changes to make them more appealing. The thera-
pists also were satisfied with the study design. They were glad to see
how easily the patients performed their exercises by playing the
games.
In future work it should be possible t dynamically adapt the difficulty
during the game in relation to the patients’ performances. It would
be consider also the possibility to use a webcam to see live the pa-
tients while they are playing and to record the patient’s performance,
giving the therapist a second visual feedback in addition to the
replay.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children and a cause of short-term and
long-term disability.
Physiotherapy is an important component of the therapeutic ap-
proach. The rehabilitation process is developed through a series of
simple, repetitive exercises to be performed frequently and for a long
time. Often patients lose interest and stop performing them before
the results have been accomplished.
Recently a new frontier in the design of videogames has been ex-
plored: the games for rehabilitation. The development of this re-
search field has been limited by the cost, technical limitations and
technical expertise needed to use the products and the sensors
needed.
The introduction of new gaming input devices and the development
of games that involve physical activity, induced the researchers to
consider the possibility of using videogames to perform physical
therapy.
Objectives: To design a set of rehabilitation games for children with
JIA, that would be considered amusing by the largest part of players,
while helping them in performing their rehabilitation exercises for
the mobility of knee and ankle.
Methods: The project was conducted in collaboration between
pediatric rheumatologists, physiotherapists and engineers researchers
of the Politecnico of Milan.
The specific rehabilitation principles were applied to the ones of the
common game design, to obtain games both medical relevant and
fun to play. The iterative design approach, a methodology based on
a cyclic process of prototyping, testing, analysing, and refining of the
games was applied by the researchers.
Four different games were designed, one for the ankle, three for the
knee. The third and the fourth games were redesigned to perform
two types of exercises.
The first exercise prescribe the use of a wobble board, a board
mainly used to perform equilibrium exercises. During the exercise
the patient had to tilt on all four different directions the board by
performing the deflection of the extension of the ankles, if thepatient is seated on a chair, or by changing the position of the whole
body.
The second exercise prescribed to perform the extension-deflection
movement of the knee while the patient was seated from the rest
position to the maximum angle reachable by the patient.
For each of this games the therapist could completely personalize
the parameters of the game in order to personalize the experience
of the patient and make it suitable for his/her clinical condition.
Experimental sessions were performed to validate the result of the
system.
The interaction of the patient with the games were tested, and it
was verified how they react to the different type of experience.
Results
Tuning session.
Tuning session was completed by testing the games with 2 JIA pa-
tients, 15 and 12 years of age respectively, with predominant in-
volvement of ankles (patient 1) and ankles and right knee (patient 2).
Therapeutic sessions.
Two therapeutic sessions were performed on 4 (3 female and 1 male)
and 3 (female) patients respectively. Median age 7 years (5-15 years)
Feedbacks received from patients and therapists were good, and all
the patients completed easily their sessions.
Conclusion: Four rehabilitation games for the mobility of knee
and ankle were developed. The feedbacks received from the pa-
tients and therapists were very good. The rehabilitative sessions
were easily controlled, the patients enjoied the sessions and the
therapists appreciated also the possibility to monitor the patient
even in remote.
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Introduction: Requests of rheumatologic visits for lims arthralgia are
more frequent in these last years, expecially in adolescents. Func-
tional Pain (without demonstrable organic cause), is often associated
with psychological problems.
Objectives: to differentiate organic articular pain from functional
pain;
to evaluate the real incidence of functional pain in healthy school
students;
to investigate the correlation between functional pain and psycho-
logical disagreement, in a series of school students.
Methods: A questionnaire was given to a group of students of pri-
mary school; the following data were collected: a) sex, age; b) func-
tional pain; c) relation with relatives, teachers and schoolfellows; d)
failure in school-studies.
Results: 809 students, 354 females, 455 males, median age 14 years,
participated to the study.
Functional Pain was referred from 537/809 students: 265 Females,
272 males: p = 0,155. Pain episodes showed a different incidence be-
tween females and males (p = 0,511).
Pain intensity vs. number of episodes in females showed a statisti-
cally significant correlation (p = -0,001). Most frequently abdominal
pain was recorded in females and limbs pain was selectively de-
scribed in males.
Psychological disagreement was referred from 513/809 students: 260
females, 253 males (p = 0,150).
Psychological disagreement was reported with: parents in 15; with
siblings in 59; with other relatives in 45; with teachers in 42, with
schoolfellows in 356.
The correlation disagreement vs. functional pain in all the students
included in the study was statistically significant (p < 0,001).
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pain. The most frequent cause of disagreement was schoolfellows’ be-
haviors. Limbs pain is a frequent record, especially in adolescent males.
Functional pain correlates significantly with psychological disagree-
ments: according to literature, it can lead to severe manifestations.
Psychological approach, supported by several studies, demonstrated
that it is mandatory to recognize such pain; to talk with the students
concerning the cause of their psychological disagreements, to know
their problems and to reassure them with the aim of gaining their
confidence. A confidence with parents and/or teachers and/or their
peers, may be useful for adolescents.
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Introduction: Juvenile Idiopathic Arthritis (JIA) is the more frequent
rheumatologic disease in paediatric age with a possible worsening
on posture in a vulnerable period of life. This condition can show a
negative impact on balance and on activities of daily life.
Objectives: The aim of the study is to evaluate the efficacy of regular
physical activity on posture and balance deficit in children and ado-
lescents affected by JIA.
Methods: We enrolled 56 patients (17 patients affected by JIA: JIA
group; and 39 healthy control subjects, of comparable age: CG). Fur-
thermore, JIA group was stratiphied in two subgroups: inactive (AIG-
SED) and active (AIG-ACT). All the patients were tested by a comput-
erized analysis of posturography, by a new-generation stabilometric
platform (Sensor Medica; Guidonia Montecelio, Roma).
Results: The group AIG-SED showed statistically significant differ-
ences vs. the group CG on the following indexes: ellipse surface (p <
0,05), ball length (p < 0,0001) e Y mean (p < 0,05). At the opposite, no
statistically significant difference was relieved between the AIG-ACT
and the CG, with the exception of the ball length (p < 0,05), which is
reduced respect the CG.
Conclusion: This pilot study confirms the relieve of regular physical
activity on the motor deficit, on balance and posture secondary to
JIA, especially in evolutive age.
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Introduction: Children’s experience of moving from children’s hos-
pital department to adult department in hospital care are often re-
lated to increased stress and anxiety. The transition period could also
be very demanding for the parents. Studies show that preparing the
children from early age could prevent most of the stress and anxiety.
By starting the transition process several years before the child’s
move to adult care we presume the parents gets educated and sup-
ported for letting their child take more responsibility for its own ill-
ness. At the pediatric reumatology department, Astrid Lindgrens
Childrens hospital we are working with a transition program inspired
by Janet McDonagh. The program consists three meetings with the
rheumatology nurse.Objectives: To prepare and facilitate the child and its parents for the
child’s transition to adult care.
Methods: The children and their parents are called to three meetings
over a period of 5 years. The first meeting are placed when the child
is 14 years old. Before the meeting the child and its parents filled in
different transition formula. To evaluate the child’s knowledge about
its disease and treatment we used the questionnaire MEPS abbrevi-
ation for medical issues, exercise, pain and social support.
Results: To evaluate if the child and its parents found it valuable to
participate in the transition program, we did a pilot study. After the
visit to the nurse the child got a evaluation formula. The results
showed that 86% of the participants should totally recommend this
to other children with rheumatic disease and the remaining 14% rec-
ommended it. Neither of the children found it embarrassing or hard
to fulfilled the transition formula.
Conclusion: Both the children and their parents found the first transi-
tion meeting with the nurse very educational and valuable. The
meeting with the nurse seems to facilitate the transition process for
the child and its parents. By offering a structured transition program
to the children and their parents the fear of moving to adult care
can be reduced.
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Introduction: Transition for patients with chronic diseases is defined
as the purposeful, planned movement of adolescents and young
adults from child-centered to adult oriented health care system.1
Rheumatic diseases of childhood extend to adulthood as active dis-
eases in 30-70%, which is the reason for requiring rheumatologic
care into adulthood.
First coordinated transition of pediatric rheumatologic patients in
Croatia was organized in 2012 as developmental type of transition,
where patient is gradually prepared for the transition by a
pediatrician rheumatologist throughout years preceding transfer. The
moment of final transfer to adult care is organized in the pediatric
rheumatology clinic, where patients and their parents are meeting
adult rheumatologist in known environment (pediatric rheumatology
ambulance). At the transfer, patient's history is being presented to
the adult rheumatologist and afterwards patient is examined by both
of the specialists. At the end of the examination, patient is given next
checkup date at adult rheumatologist clinic, where the patient will
continue with regular follow up visits.
Objectives: Our objective is to verify successfulness of organized
transition of pediatric rheumatologic patients to adult care.
Methods: We have conducted a retrospective research of patients’
databases at Departments of Pediatric Rheumatology and correlated
them with data from adult Clinical Immunology and Rheumatology
Department in order to verify number of pediatric patients that have
continued with regular follow up in adult care after coordinated
transition.
Results: During 5 year period (2012.-2017.) 78 patients have been
transferred to adult rheumatologist. There were 50 JIA patients, 18
SLE patients, and 10 patients with other rheumatic diseases (8 pa-
tients with mixed connective tissue disease, 1 with Wegener's granu-
lomatosis, 1 with fever of unknown origin). Median age at the time
of transfer was 19,6 years (14,6-26,6). Patients with SLE were older at
the time of transfer than two other groups of patients (SLE 21,29 ±
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of 63 patients (80,8%) have continued with regular follow up at adult
rheumatologist and 15 patients never showed up at adult rheuma-
tologist clinic, probably due to remission of the disease or possible
follow up by other chosen adult rheumatologist.
Conclusion: Young adults with rheumatic diseases have complex
medical and psychological needs and transition to adult care is a crit-
ical component of care. In order to maintain adequate level of follow
up and prevent additional flares in turbulent adolescent period, con-
tinuity of rheumatologic care is essential. By organizing coordinated
transition to adult rheumatologist, a most of the pediatric patients
with rheumatic disease (80,8%) are continuing with regular follow up
in the adult care. Each transition should be an individually tailored
process according to needs and psychological maturity of patients.
1Blum RW et al. Transition from child-centered to adult health-care
systems for adolescents with chronic conditions. A position paper of
the Society for Adolescent Medicine. J Adolesc Health. 1993.
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Introduction: According to the Referral Center’s policy regarding the
patients’ psychomotor rehabilitation, a summer camp program is an-
nually offered to children with Chronic Rheumatic Diseases (CRD) in
clinical remission and ability for self-care.They attend a sport camp
addressed to healthy children, where the CRD group participates in
various camp activities (handicrafts, arts, games, sports and swim-
ming), accompanied by a specialized physiotherapist and a pediatric
rheumatologist. During their 2-week camp life, they additionally re-
ceive education and practice on maintaining group and personalized
physiotherapy.
Objectives: To evaluate the psychomotor impact of organized sum-
mer rehabilitation program on children with CRD, in a setting away
from the caregiver protection, for 5 consecutive years.
Methods: A 28-item questionnaire was created pertaining 5 domains:
physical activity, self-care, pain, socialization and psychology and a
score range 1-4 (4 the best). The questionnaire was annually com-
pleted by the children after the end of the camp and the responses
were evaluated in respect to the participants’ age and their experi-
ence in the camp setting.
Results: Replies of 69 campers with a mean age of 11 yrs were ana-
lyzed. A mean total score of 54/65 was found, which was positively
correlated with the participants age (p < 0.001). Campers with no pre-
vious experience had a significantly median lower score (48), after
age adjustment (p = 0.05). The domains of physical activity and
psychology had the worst scores for the naive campers (p = 0.018,
and p = 0.027, respectively). Socialization was positively correlated
with age (p = 0.008) and especially among the naïve young partici-
pants (p = 0.005). There was no correlation between pain and activ-
ities’ restriction. Home sickness regarding either the family, or peers
or TV watching was reported by 82%, 74% and 37.5%, respectively.
Noteworthy, 88% expressed the desire to become future camp team-
leaders.
Conclusion: These findings indicate that the aforementioned kind of
camp life offering a rehabilitation program for children with CRD has
a beneficial impact on their quality of life. The valuable effect was
found to be correlated with the campers’ age and was more promin-
ent, in those with the least experience. The reported home sickness
by the majority of children did not affect their active participation inthe program. Moreover, they expressed the wish to gain more camp
experiences and take future camp responsibilities as leaders.
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Introduction: Lupus nephritis (LN) is one of the most frequent com-
plications of juvenile-onset systemic lupus erythematosus (JSLE). LN
can cause serious renal damage due to formation of a highly inflam-
matory environment inside the kidneys, eventually leading to glom-
erular destruction, proteinuria and end-stage renal failure. The
specific role of the resident renal cells in LN is still largely unknown.
Objectives: To investigate the role of the human glomerular endo-
thelial cells (GEnCs) in renal inflammation, by measuring the produc-
tion of pro-inflammatory factors under various stimuli.
Methods: Human conditionally immortalized GEnCs (ciGEnCs) were
treated for 24 hours with 10 ng/ml of human recombinant cytokines
previously identified to play a prominent role in juvenile-onset LN;
Interferon (IFN) -alpha and -gamma (IFN-α, IFN-γ), interleukin (IL) -1β,
IL-6 and IL-13, tumour necrosis factor-alpha (TNF-α) and vascular
endothelial growth factor (VEGF). The effect of bacterial endotoxin in-
flammation was tested via lipopolysaccharide (LPS) treatment (1 μg/
ml).
Real-time PCR, ELISA and Luminex multiplex assays were performed
to assess changes in expression and secretion of pro-inflammatory
cytokines and chemokines: TNF-α, IFN-γ, IL-6, IL-8, IL-10, soluble vas-
cular cell adhesion molecule-1(sVCAM-1), monocyte chemoattractant
protein-1 (MCP-1), monocyte inducible protein-1α (MIP-1α), IFN-γ in-
duced protein-10 (IP-10), macrophage- and granulocyte macrophage-
colony stimulating factors (M-CSF, GM-CSF). Flow cytometry was used
to assess surface expression of intercellular adhesion molecule-1
(ICAM-1) and VCAM-1. Data were analysed by Kruskal-Wallis test with
Dunn’s post-hoc test. All measurements were compared to untreated
ciGEnCs.
Results: At 24 hours, TNF-α and IL-1β upregulated MCP-1, MIP-1α
and GM-CSF protein secretion. IL-1β stimulated IL-6 and TNF-α secre-
tion whereas IFN-γ promoted IP-10, IL-10 and TNF-α secretion. The
combined cytokine treatment enhanced M-CSF secretion. IL-13 up-
regulated sVCAM-1 secretion whereas IL-13 and TNF-α increased sur-
face expression of VCAM-1. TNF-α upregulated surface ICAM-1. LPS
stimulated IL-6, IL-10, MIP-1α, IP-10, GM-CSF, IFN-γ and TNF-α secre-
tion. The outcome of the real-time PCR assays reflected the protein
assay results.
ELISA, Luminex and flow cytometry results of protein secretion and
surface expression are presented in the table below.
Conclusion: This study provides evidence for a prominent role of
GEnCs in the propagation of inflammation in LN. Four pro-
inflammatory cytokines (TNF-α, IL-1β, IFN-γ and IL-13) and LPS were
identified as key players in GEnC activation in vitro.
During a renal flare in LN, these cytokines together with LPS could
stimulate inflamed GEnCs to produce other pro-inflammatory cyto-
kines, chemokines and adhesion molecules which, in turn, would fur-
ther enhance the glomerular inflammatory microenvironment by
increasing the recruitment of immune cells inside the glomerulus.
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Table 35 (Abstract P124). See text for description
ciGEnC treatment Pro-inflammatory
factors
Protein concentration (pg/ml)/surface
expression
Median/GeoMean Fluoresecence; IQR,
n = 6)
Untreated Stimulated
TNF-α · GM-CSF (0; 0-0) (197.7; 189.7-272.3,
P = 0.049)
· MIP-1α (208.5; 207-209) (222.3; 221-223.3,
P = 0.048)
· ICAM-1 (247.5; 211.5-279) (443; 353.3-472.3,
P = 0.009)
IL-1β · IL-6 (30.55; 16.9-108.5) (3479; 1815-5243,
P = 0.0004)
· GM-CSF (0; 0-0) (950.5; 464.9-1128,
P = 0.0004)
· TNF-α (4.484; 3.717-4.383) (10.60; 7.048-12.71,
P = 0.011)
· MIP-1α (208.5; 207-209) (221.5; 215.8-225.8,
P = 0.049)
IFN-γ · IL-10 (0.514; 0.370-0.610) (18.19; 15.69-19.77,
P = 0.004)
· TNF-α (4.484; 3.717-4.383) (8.381; 7.270-8.825,
P = 0.029)
· IP-10 (2.387; 2.279-3.688) (3015; 2642-3114,
P = 0.008)
IL-13 · sVCAM-1 (191.8; 88.54-559.1) (1539; 1033-1646,
P = 0.022)
Combined cytokine
treatment
· MCP-1 (800.1; 446-1705) (3755; 3359-3911,
P = 0.008)
· M-CSF (192.4; 85.19-1427) (3461; 2093-5098,
P = 0.021)
· VCAM-1 (59.60; 49.65-69.58) (119; 85.13-163.3,
P = 0.005)
LPS · IL-6 (30.55; 16.9-108.5) (3323; 2083-4886,
P = 0.0007)
· IL-10 (0.514; 0.370-0.610) (17.32; 9.014-20.25,
P = 0.009)
· GM-CSF (0; 0-0) (312.2; 125.5-576.5,
P = 0.017)
· IFN-γ (0; 0-0) (28.47; 12.14-40.44,
P = 0.003)
· TNF-α (4.484; 3.717-4.383) (14.60; 10.38-20.15,
P = 0.0005)
· IP-10 (2.387; 2.279-3.688) (2870; 1042-3147,
P = 0.013)
Table 36 (Abstract P125). See text for description
Juvenile NPSLE Adult NPSLE p-value
N° of patients 28 (41%) 41 (59%) -
Women:men 20:8 39:2 0.0060*
Time of disease (months) 19.8 232.5 0.0001*
NP manifestations at onset 7 (25%) 11 (27%) 0.8651
Lupus nephritis 16 (57%) 9 (22%) 0.0028*
Anti-DNA ab (IU/ml) 178.9 39.4 0.0005*
ESR (mm/h) 53.8 35.7 0.0199*
C3 low (< 80 mg/dl) 22 (79%) 16 (39%) 0.0012*
C4 low (< 16 mg/dl) 22 (79%) 13 (32%) 0.0001*
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Introduction: Neuropsychiatric (NP) manifestations are a main cause
of morbidity and mortality in juvenile-onset systemic lupus erythe-
matosus (jSLE). Some studies suggest that they are more frequent
and severe in jSLE than in adult-onset SLE (aSLE).
Objectives: To compare the clinical and serological profile of
pediatric and adult patients with neuropsychiatric lupus (NPSLE)
treated in a Spanish tertiary center.Methods: A retrospective study of patients with jSLE (age of
onset: 0-18y) and aSLE (age of onset: >18y) seen in our center
during the period 1988-2016 was performed. Case definitions
of the American College of Rheumatology were used to iden-
tify NPSLE manifestations. Demographics, clinical and sero-
logical data were obtained through a review of their medical
records.
Results: A total of 69 patients with NPSLE were included, aSLE 41
(59%) and jSLE 28 (41%), the comparison of groups is presented
in the table. Most of them were Caucasian (92%), mean age at
diagnosis in adults was 36.4 years (range: 19-68) and 13.9 years
(range: 8-18) in children. The proportion of males was higher in
the latter group. The mean duration of the disease was signifi-
cantly greater in adults, as well as the time from SLE diagnosis
to NP manifestation onset, although without significant differ-
ence. Central NP manifestations were the most frequent in both
groups (aSLE 93%, jSLE 96%) regarding to the peripheral manifes-
tations (aSLE 12%, jSLE 11%). The most frequent manifestations
in aSLE were headache (29%), cerebrovascular disease (27%), sei-
zures (17%) and myelopathy (15%), whereas in jSLE were seizures
(46%), headache (29%), mood disorder/depression (25%), psych-
osis (18%) and autonomic disorders (18%). A significant group of
patients presented ≥ 2 central manifestation during their evolution
(aSLE 32%, jSLE 41%), with the mean number of manifestations
in adults being 1.36 (range: 1-3) and in children 1.44 (range: 1-4).
Patients with jSLE developed lupus nephritis with a significantly
higher frequency, as well as higher titres of anti-DNA antibodies,
erythrocyte sedimentation rate (ESR) and hypocomplementemia.
During the study period there was mortality in 2 cases of aSLE
and 2 jSLE (5% and 7%, respectively).
Conclusion: Our results corroborate that juvenile patients with NPSLE
present higher disease activity compared to adults. There was no sig-
nificant diference in the time from SLE diagnosis to NP manifestation
onset, but tended to be shorter in jSLE. The spectrum of NPSLE was
varied both groups and an important proportion of them devel-
oped ≥ 2 manifestation. Mortality continues to be important in NPSLE
in both age groups.
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chronic autoimmune disease with variable clinical and laboratory
manifestations. Characteristic hyperactivity of the immune system in
patients with SLE is reflected in dysregulation of proteins of various
signaling pathways as well as in aberrant concentrations of pro- and
anti-inflammatory plasma cytokines.
Objectives: In this study, we focused on STAT1 and STAT5 basal ex-
pression and phosphorylation as well as cytokine profile in peripheral
blood of patients with cSLE.
Methods: Whole peripheral blood of 20 healthy donors (HD, mean age
17.2 years), 10 JIA patients (disease control, mean age 11.1 years), and
17 patients with cSLE (mean age 18.0 years) was analysed using the
Phosflow flow cytometry. Cells were analyzed using FACSCantoII Flow
Cytometer (BD Biosciences) and subsequent analysis using FlowJo soft-
ware (Tree Star). We measured concentrations of IL-1α, IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, MCP1, VEGF, TNF-α and IFN-γ in the peripheral blood of
10 healthy donors (mean age 18.9 years), 5 JIA patients (mean age
15.0 years) and 10 patients with cSLE (mean age 18.2 years) using the
multiplex immunoassay on a biochip. Two-tailed Kruskal-Wallis test was
used to evaluate differences between the groups.
Results: Our results demonstrate a significant increase in basal expression
of protein STAT1 (cSLE:JIA p <0.05; cSLE: HD p< 0,0001) and protein STAT5
(cSLE:HD p< 0,001) in Th lymphocytes of cSLE patients compared to con-
trol groups. Basal phosphorylation of STAT1 was also elevated (cSLE:JIA p
<0.05; cSLE: HD p< 0,001), but we found no difference in basal phosphor-
ylation of protein STAT5 between groups.This indicates strong IFN signa-
ture and suggests a mechanism of inflammation self-maintenance utilizing
the JAK-STAT signaling pathway in cSLE patients. No significant differences
were found in the peripheral blood concentrations of IL-1α, IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, MCP1, VEGF, TNF-α and IFN-γ between groups, which sug-
gests a limited role of these cytokines in the pathogenesis of cSLE.
Conclusion: Many IFN regulated genes are dependent o STAT1 for
optimal transcription, and STAT1 protein expression is under control
of IFNs. Our findings support the role of aberrant expression and
phosphorylation of STAT proteins, especially STAT1, but show normal
physiological concentrations of many cytokines, including IFN-γ. This
finding suggests that other cytokines, such as IFN-α and IL-17, may
contribute to the pathogenesis of the disease.
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Introduction: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a
multi-organ autoimmune disease, characterised by autoantibodies di-
rected against nuclear antigens caused in part by increased dysregu-
lated apoptotic neutrophils. Type 1 (α and β) and 2 (γ) interferon (IFN)
expression is increased in both adult-onset and JSLE. An associated
granulocyte and IFN gene signature present in JSLE. IFNs have both
anti- and pro-apoptotic effects, through the activation of anti-apoptotic
STAT3 and pro-apoptotic STAT1 respectively. Previous studies demon-
strated high concentrations of IFN induced apoptosis in primed neutro-
phils. Physiological levels of IFNs induced an increase in pSTAT1 and a
decrease in pSTAT3 in primed neutrophils compared to naïve neutro-
phils. IFN signalling is dependent on IFN receptor chains, which may
contribute to apoptosis. However, expression of IFN receptors that may
contribute to this differential signalling is yet to be established.
Objectives: To investigate the effect of neutrophil activation on the
expression of the type 1 and 2 IFN receptors.
Methods: Neutrophils were isolated from healthy adult control donor
blood, and stimulated with 1 μg/mL each of: TNFα, IFNα, IFNγ, and IFNβ
for 30 mins. Type 1 IFN receptor (IFNAR) and type 2 IFN receptor
(IFNGR) were analysed using flow cytometry. Neutrophils were stainedwith IFNAR1-PE, IFNAR2-APC, IFNGR1-PE and IFNGR2-APC, and analysed
on the flow cytometer. Neutrophil activation markers CD11b and
CD62L were also assessed to confirm TNFα-associated priming.
Results: Activation of neutrophils following TNFα treatment was con-
firmed by: (1) the significant increase in CD11b (geometric mean ± SEM;
2135 ± 289 [IFNAR analysed cells], n = 5, p < 0.05; 2227 ± 310 [IFNGR ana-
lysed cells], n = 5, p < 0.05) compared to unstimulated cells (1259 ± 152
[IFNAR analysed cells]; 1242 ± 107 [IFNGR analysed cells]) and (2) the de-
crease in CD62L (90 ± 15 [IFNAR analysed cells], n = 5, p < 0.05; 68 ± 6
[IFNGR analysed cells] n = 5, p < 0.05) compared to unstimulated cells
(377 ± 53 [IFNAR analysed cells]; 375 ± 51 [IFNGR analysed cells]). IFNα
and IFNγ significantly increased CD11b (IFNα= 1334 ± 139 vs 1259 ± 152,
n = 5, p < 0.05; IFNγ= 1325 ± 120 vs 1242 ± 107, n = 5, p < 0.05). There
was no overall observed change in activation markers upon IFNβ stimula-
tion. IFNAR1 was significantly decreased (53 ± 11 vs 123 ± 36, n = 5, p <
0.05) and IFNGR2 was significantly increased (58 ± 7 vs 47 ± 3, n = 5, p <
0.05) in TNFα activated neutrophils compared to unstimulated neutro-
phils. IFNγ induced a small increase in IFNGR2 (59 ± 10, n = 5, p = 0.345)
compared to unstimulated neutrophils (47 ± 3), although this was not sta-
tistically significant. Overall, IFNs had little effect on receptor expression.
Conclusion: Here we show that in an in vitro model, neutrophils from
healthy adults can be activated using TNFα, determined by the ex-
pression of established activation markers. IFNα and IFNγ have some
activating effect on neutrophils; however IFNβ was shown to have
no overall activating effect. There was a significant increase in the
IFNAR1 expression and a significant decrease in IFNGR2 expression in
activated neutrophils compared to unstimulated neutrophils.
Previous studies have shown an IFN induced increase in apoptosis in
primed neutrophils, which may be due to the increase in pSTAT1
and decrease in pSTAT3 also seen in primed neutrophils. This in-
crease in pSTAT1 and subsequent increase in apoptosis may be due
to the differential expression of the receptors in IFN signalling. These
observations may be important factors in the increase in JSLE neutro-
phil apoptosis, and create a potential therapeutic target.
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Introduction: We present the case of a paediatric male and female sib-
ling pair with severe monogenic lupus due to C1q deficiency, refractory
to prior treatments, who experienced substantial clinical and laboratory
improvement following treatment with fresh frozen plasma (FFP). FFP
has previously been described in the treatment of adult and adolescent
patients with C1q deficiency, with good results. To our knowledge this
is the first description of its use in paediatric patients.
Objectives: To describe fresh frozen plasma as a novel therapy for
the treatment of children with lupus due to C1q-deficiency, and to
describe the clinical and laboratory improvement experienced by a
sibling pair who received this treatment.
Methods: A seven year old girl and her three year old brother were well
known to our paediatric rheumatology service with severe lupus due to
C1q deficiency. The pair were born of consanguineous parents of Pakistani
background. The female patient is known to be homozygous Q208X in
the C1QA gene; both children had unrecordable C1q levels and severely
reduced classical complement pathway functioning (0-1% normal levels).
The female patient presented at 7 months with fever, rash and myo-
sitis. She has had persistent disease activity since, and has failed to
respond adequately to multiple prior therapies including ciclosporin,
methotrexate, azathioprine, hydroxychloroquine, mycophenolate and
rituximab. Her disease was characterised by ongoing severe facial
rashes, scarring alopecia and cytopenias. She was also under
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 75 of 191neurology follow-up for spastic dystonic motor disorder in her lower
limbs which had been extensively investigated with no alternate
cause found. Her disease was complicated by an episode of menin-
gococcal sepsis with acute renal failure aged 13 months.
Her brother was diagnosed with C1q deficiency on sibling screening at
three months of age, and developed malar rashes aged 10 months. His
phenotype is similar to that of his sister but somewhat milder, with
photosensitive rashes, scarring alopecia and cytopenias, as well as in-
creased lower limb tone. He had previously failed to respond adequately
to azathioprine, methotrexate, rituximab and mycophenolate.
Both patients were steroid dependent and showed signs of profound
steroid toxicity including cushingoid habitus, growth restriction, hir-
suitism and hypertension.
In light of ongoing steroid dependence, and limited treatment options, the
pair were commenced on regular infusions of intravenous fresh frozen
plasma. Dosing regimen was: 10 ml/kg given weekly for 4 infusions, and
fortnightly thereafter. Complement function and C1q levels were monitored.
Results: Both siblings experienced a significant improvement in their
skin disease and alopecia, with improved rashes, return of hair
growth and a reduction in their steroid requirements. After pro-
longed periods of steroid dependence, the male sibling came off
steroid therapy 3 months after commencing FFP infusions; his sister
came off steroid therapy 6 months after commencing infusions, by
which point she was seven years old and had been on steroids since
8 months of age. Classical pathway complement function testing nor-
malised in both patients, although measured C1q levels remain
unrecordably low. To date, neither patient has experienced adverse
effects from the FFP infusions.
Conclusion: To our knowledge, this is the first description of the use of
FFP for the treatment of paediatric patients with C1q deficiency, and pro-
poses FFP as a potentially safe and effective treatment for this rare condi-
tion. Further studies are warranted to explore its safety and efficacy
profile, and its role as an adjuvant treatment option in C1q-deficiency
lupus. (Consent for publication was obtained from the children’s mother.)
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Introduction: Complement activation can damage the kidneys by attract-
ing leukocytes, which in turn causes inflammation, contributing to the
pathogenesis of lupus glomerulonephritis (LN). Immunodeficiency of early
classical pathway of Complement components can also induce tissue dam-
age with low complement levels. Anti-DNA antibodies and Complement
C3, C4, CH50, reflecting complement activation, are currently used parame-
ters to assess SLE disease activity, in daily practice. Nevertheless, their utility
remains controversial as C3 and C4 may not accurately reflect complement
activation, due to increased levels during acute phase reaction.
Objectives: Evaluate serum levels of C3, C4, CH50 and anti-DNA anti-
bodies at disease onset and its association with lupus glomerulo-
nephritis (LN) occurrence and outcome, related to the multifactorial
pathogenesis of complement activation in LN.
Methods: We combined a cumulative historical database of childhood-
Systemic Lupus Erythematosus (c-SLE) (Gomes RC et al. Arthritis Care Res
2016 10.1002/acr.22881) to assess clinical and laboratory features and their
relationship with onset age and kidney involvement. It is a retrospective
multicenter cohort started in 2013 enrolling up to 2016, 846 pediatric sub-
jects diagnosed with c-SLE by ACR-1997 criteria, in 10 Pediatric Rheumatol-
ogy centers. Parameters of c-SLE activity were SLEDAI-2 K scores at onsetand the last follow up assessment, major organ involvement and disease
damage scored by SLICC-DI, during the last visit. Laboratory data, including
antibody tests, renal function and Complement tests, were obtained using
standard methods in clinical laboratory according to each center standard
practice. Renal biopsy was performed and classified according to WHO
and ISN/RPS in each of the centers. Subjects were classified in 3 age
groups, <6, 6-12 and >12 years of onset age, and according to the pres-
ence or absence of LN, during the disease course, estimated by clinical
and biopsy findings, during the first and last assessments.Data analyzes
was performed by descriptive and parametric statistics.
Results: Of the 846 subjects enrolled, mean age 11.6 (SD 3.6) years with
5 (SD 3.6) years of disease duration; 427 (50.5%) had LN, of those 228
were diagnosed with renal biopsy in addition to renal function parame-
ters, and 419 (49,5%) did not have LN. Median SLEDAI-2 K scores at the
first and last visits were 15 and 2, respectively. SLICC-DI scores varied
from 0-9, median 0. There was no significant difference (NS) of LN pro-
portion, in the three age groups, <6, 6-12, >12 years onset age. Low C3,
but not C3 levels, associated significantly with LN at any time of disease
course (chi-square test, p = 0.03). Low C4, C4 levels, low CH50 and CH50
levels had no significant association (NS). In the same line, onset
hematuria (p < 0.001), proteinuria (p < 0.001) urine casts (p = 0.02), but
not urine leukocytes (NS), arterial hypertension (p = 0.0005), neuropsychi-
atric events at any time (p = 0.02), high ESR (p = 0.008) but not CRP levels,
had significant association with LN outcome. High anti-DNA antibody test
associated significantly with LN (p < 0.00001), but anti-Sm, anti-RNP, anti-
Ro, anti-La antibodies had no significant association (NS). LN at any time
associated significantly with higher SLICC-DI scores (p = 0.003).
Conclusion: We confirmed in this population of c-SLE with a wide range
of manifestations and organ involvement, the role of C3 and anti-DNA anti-
bodies association with the occurrence and outcome of LN. In the same ex-
tent, the urine parameters and ESR at disease onset may be reliable and
cost-effective tests for identifying early childhood LN flare or remission, and
optimize clinical management and treatment in daily practice.
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Introduction: Systemic lupus erythematosus(SLE) is a multisystem auto-
immune disease primarily affecting young females. SLE patients are sus-
ceptible to infections due to their defective immune system and the
immunosuppressive treatment they receive. However we lack data regard-
ing response to specific vaccines. Rubella infection in pregnant women is
associated with serious neonatal consequences, including miscarriage, fetal
death and congenital rubella syndrome. Thus it is critical that we under-
stand the impact of SLE on young women’s immunity to rubella.
Objectives: In this study we determined the immune status against
rubella in previously vaccinated juvenile SLE (jSLE) patients, prior to
commencement of treatment and at one and three years, and com-
pare this to healthy controls.
Methods: This was a prospective controlled study including 21 newly
diagnosed jSLE patients and 76 healthy controls. The control group
consisted of randomly selected healthy adolescents matched for ethnic
origin, age and gender to the jSLE group, attending the Pediatric Out-
patients Department for routine checks; the same exclusion criteria
were applied. All participants had two doses of the live attenuated
MMR vaccine in early childhood. Exclusion criteria were underlying im-
munodeficiency, recent blood transfusion (<6 months) and previous
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 76 of 191treatment with immunomodulating agents. Demographic, clinical and
laboratory data as well as data regarding immunization status, vaccine
history and mean time between the doses of the vaccine were col-
lected. Seroprotection rates and rubella-IgG titers were measured at en-
rollment and at specific intervals afterwards(0,12,36 months). Total IgG
levels were measured simultaneously. Rubella-IgG antibodies were
assessed by ELISA. The cutoff value for seroprotection was deemed at
200mIU/ml. The Hospital’s Research and Ethics’ Committee approved
the study; written informed consent was obtained. Statistical signifi-
cance was set at p < 0.05 and analyses were conducted using SPSS.
Results: The two groups had similar demographic characteristics, vaccin-
ation history and immunization status. No significant differences were de-
tected in terms of vaccine type, time interval between the two groups as
well as mean time from last vaccination to blood sampling. Seroprotec-
tion rates were adequate for both groups. Nonetheless, the jSLE group
had consistently inferior (but not statistically meaningful) seroprotection
rates at all time-points. Mean rubella-IgG antibodies were significantly
lower in the jSLE compared to the control group(p < 0.01). Similar results
were found at one and three years’ follow up(Table 37). None of the par-
ticipants had hypogammaglobulinaemia at the time of blood sampling.
During the follow up period, the jSLE group had greater decrease in anti-
body levels as indicated from the significant interaction effect of analysis.
There was no association detected between the degree of antibody loss
and type of jSLE treatment received or jSLE disease activity.
Conclusion: Although seroprotection rates were similar between the
two groups, mean rubella-IgG titers were significantly lower in the
jSLE group at all time-points. Further studies are required to address
the question of long-term immunity conveyed by immunizations
given at an early stage in children with rheumatic diseases. However,
evaluation of immunization status against all vaccine preventable dis-
eases in such patients may be beneficiary.
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Parameters SLE group Control group P value
Study sample, n 21 76 0.9*
Age, years, mean (SD) 13.3 (2.3) 13 (2.7) 0.8*
Gender n (%)
female 20 (95%) 72 (95%) 0.83+
male 1 (5%) 4 (5%)
Steroids (21/21) -
- · mean dose 10 mg NA
- · mean duration of treatment 17 months
HCQ (21/21)
- · mean dose 200 mg
- · mean duration of treatment 36 months
Azathioprine (9/21)
- · mean dose 75 mg
- · mean duration of treatment 18 months
SLEDAI score
- · Enrolment 7
- · 1 year 1
- · 3 years 0
Seroprotection rate at diagnosis (%) 95 98 0.4+
Seroprotection rate at 1 year (%) 92 97 0.1+
Seroprotection rate at 3 years (%) 89 96 0.04+
Mean IgG titers at diagnosis, mIU/ml 432 590 < 0.01*
Mean IgG titers at 1 year, mIU/ml 340 554 < 0.01*
Mean IgG titers at 3 years, mIU/ml 298 468 < 0.01*P131
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Introduction: Longer or shorter interval between the first manifest-
ation attributable to SLE and the clinical diagnosis may influence dis-
ease expression in terms of initial clinical and laboratorial presentation
and disease activity in childhood systemic lupus erythematosus (cSLE)
patients.
Objectives: The objective of the present large multicenter study was
to compare demographic data, Systemic Lupus International Collab-
orating Clinics Classification Criteria for Systemic Lupus Erythemato-
sus (SLICC) parameters, neuropsychiatric involvement and SLEDAI-2 K
at diagnosis in three different groups with distinct time intervals be-
tween onset of signs/symptoms and disease diagnosis.
Methods: A retrospective multicenter study was performed in 1,555
cSLE (ACR criteria) patients from 27 Pediatric Rheumatology services of
5 regions of Brazil: North (n = 34), Northeast (n = 259), Central-West (n
= 124), Southeast (n = 1075) and South (n = 63). Patients were divided
in three cSLE groups: A: short time interval to diagnosis (<1 month), B:
intermediate time interval (≥1 and <3 months) and C: long time interval
(≥3 months). An investigator meeting was held to define the protocol
and to harmonize clinical parameters definition in Brasilia, at the time
of Brazilian Congress of Rheumatology in 2016. Demographic data,
SLICC, neuropsychiatric involvement according to ACR classification cri-
teria and disease activity (SLEDAI-2 K) were systematically evaluated.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 77 of 191Results: The number of patients in each group was: A = 60 (4%), B =
522 (33.5%) and C = 973 (62.5%). The median age at diagnosis [11.1
(4.2-17) vs. 12 (1.9-17.7) vs. 12.5 (3-18) years, p = 0.025] was signifi-
cantly lower in the group A compared to B and C. The median num-
ber of diagnostic criteria according to SLICC [7 (4-12) vs. 6 (4-13) vs.
6 (4-12), p < 0.0001] and SLEDAI-2 K score [18 (6-57) vs. 16 (2-63) vs.
13 (1-49), p < 0.0001] were significantly higher in the group A than
the other two groups. cSLE groups were distinct with regard to:
SLEDAI-2 K ≥ 8 (90% vs. 89% vs. 82%, p = 0.002), serositis (37% vs.
33% vs. 25%, p = 0.002), renal disorder (52% vs. 47% vs. 40%, p =
0.009), neuropsychiatric disorder (22% vs. 13% vs. 10%, p = 0.008),
leucopenia/lymphopenia (65% vs. 46% vs. 40%, p < 0.0001) and
thrombocytopenia (32% vs. 18% vs. 19%, p = 0.037); as well as syno-
vitis (61% vs. 66% vs. 71%, p = 0.032) and headache (5% vs. 7% vs.
11%, p = 0.043).
Conclusion: Our large Brazilian multicenter study identified distinct
features of cSLE patients suggesting that a shorter time interval to
diagnosis was associated with a more active disease and multisystem
severe presentation.
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Introduction: Childhood-onset SLE is a lifelong severe disease and re-
sults in significant disease/therapy-related damage. This chronic dis-
ease has a clear impact on HRQoL, requesting adequate resilience
and coping mechanisms. Not much is known regarding coping/resili-
ence capacities in patients with cSLE.
Objectives: To investigate individual resilience capacities and coping
strategies in a large cohort (n = 106) of adults with childhood-onset
SLE and the relation with HRQoL
Methods: Adults with cSLE were included in the CHILL-NL (CHILd-
hood Lupus-NetherLands) study via Dutch medical specialists andpatient organizations. The study consisted of a single study visit con-
taining a structured history and physical examination. Individual re-
silience capacities were assessed using the Brief Resilience Coping
Scale (BRCS). This is a 4-item self-reported questionnaire that aims to
assess the ability to handle stress in an adaptive manner, score range
from 4 to 20: low-resilience ≤ 13, medium-resilience 14-16, high-
resilience: ≥17. Coping strategies were assessed by the Assimilation-
Accommodation Coping Scale (AACS). The AACS was utilized to
measure coping methods, it consists of two subscales: tenacious goal
pursuit (TGP) and flexible goal adjustment (FGA). Higher scores on
one of the subscales indicate more use of that strategy. HRQoL was
assessed with SF-36. Outcomes were compared to Dutch norm data.
Results: 106 cSLE patients (92% female, 73% white) were included,
median age at study visit was 33 years and median disease duration
20 years. 61% had disease damage (SDI ≥ 1). HRQoL of cSLE patients
was impaired (7/8 domains SF36): remarkably mental health was
similar between patients and Dutch norm data. Surprisingly, HRQoL
was not related to disease damage(7/8 domains SF36).
Low-resilient copers (BRCS) had impaired HRQoL in 2/8 domains of
SF36 (general health and vitality), when compared to medium and
high-resilient copers. Preference for a coping strategy (AACS) also in-
fluenced HRQoL: patients who applied tenacious goal pursuit (TGP)
appeared to have impaired HRQoL (5/8 domains SF36) compared to
patients preferring flexible goal adjustment. The extent to which the
coping strategies were scored by patients on a scale from 0 to 60
seemed to relate to their resilience capacities with low-resilient pa-
tients having lower scores on the coping list.
Resilience measured by BRCS: Sinclair, V.G. & Wallston, 2004, Assess-
ment. Individual coping measured by AACS: Brandtstädter & Renner,
1990, Psychology and Aging.
Conclusion: In this large cohort of adults with cSLE, self-reported re-
silience and coping capacities have an impact on HRQoL. This opens
perspective to improve HRQoL with cognitive training methods fo-
cused on improving resilience and coping strategies in individual
patients.
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Introduction: Juvenile-onset systemic lupus erythematosus (JSLE) is
an autoimmune disorder characterized by immune cell dysregulation,
chronic inflammation and increased cardiovascular risk. Disease onset
dominates mid-puberty and the female to male ratio is 4.5:1, sug-
gesting a hormonal importance in disease pathogenesis. JSLE pa-
tients have more aggressive disease, more major organ involvement
and increased standardised mortality ratios compared to patients
with adult-onset SLE yet research into JSLE is uncommon. Our previ-
ous findings show that defects in immune cell lipid metabolism con-
tribute to disease pathogenesis in adult-onset SLE. However, in JSLE
little is known about the immune profile or whether abnormal lipid
metabolism also contributes to pathogenesis.
Objectives: Since altered metabolism plays a role in adult-onset SLE
our objective was to explore this in JSLE through in depth immune
and metabolic phenotyping of a cohort of JSLE patients and age and
gender matched healthy donors (HCs).
Methods: Flow cytometry was carried out using two 15-colour panels
to immune-phenotype peripheral blood mononuclear cells from 39
healthy donors (HCs, 17 male, 22 female, mean age 18) and 35 JSLE
patients (12 male, 23 female, mean age 19). Data was analysed by
cluster and phenotype–phenotype correlation. Flow cytometry was
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 78 of 191also used to measure functional and metabolic marker expression on
immune cell subsets. Data was correlated with clinical assessments
of disease.
Results: Patients with JSLE were characterised by increased naïve
and decreased memory B-cell and T-cell subsets and increased
monocyte frequency (p = 0.0013) compared to HCs. Furthermore,
phenotype-phenotype correlation analysis identified differential asso-
ciations between naïve and memory immune cell subtypes when
comparing the HC and JSLE cohorts.
CD4+ and CD8+ T-cells from JSLE patients had elevated membrane
lipid raft (p = 0.0185, p = 0.0087) and glucose transport receptor
(GLUT-1) (p = 0.0205, p = 0.0017) expression suggesting that they
were more metabolically active. Metabolic defects were also found in
monocytes and plasmacytoid dendritic cells. The expression of these
metabolic markers on different subsets correlated with cell frequency
suggesting a role of cell metabolism in driving the JSLE phenotype.
Furthermore the metabolic immune-phenotype in JSLE correlated
positively with disease activity, erythrocyte sedimentation rate and
dsDNA titre and negatively with complement protein C3 supporting
the hypothesis that altered metabolism is associated with JSLE devel-
opment and severity.
Unsupervised hierarchical cluster analysis of patient clinical data re-
vealed that JSLE patients in this cohort could be stratified into 5
groups each with a unique clinical identity mainly associated with
disease activity markers and the presence of anti-cardiolipin anti-
bodies. Each group had a unique immune-phenotype and metabolic
profile.
Conclusion: Differences in the metabolic profiles of immune cell sub-
sets in JSLE contribute to disease pathogenesis and severity. Cellular
metabolic regulators may therefore have therapeutic benefit for JSLE
patients. Defining these patient groups further may help to deter-
mine the therapeutic benefit of these and other therapeutics and
allow for the treatment patients in a more effective and personalised
manner.
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Introduction: Systemic lupus erythematosus (SLE) is an autoimmune
disease and various infections play significant roles in flares of this
chronic remitting-relapsing disease. Hepatitis A virus is one of these
infectious agents that has high endemicity particularly in developing
countries and countries with poor sanitary conditions. Hence,
immunization via vaccination against this infectious agent would pro-
vide a better management of the disease. However, both immuno-
suppressive drugs and the disease itself are believed to impair the
normal functioning of immune system. Little is known regarding the
safety and immunogenicity of vaccinations in SLE patients. Moreover,
to the best of our knowledge safety and efficacy of hepatitis A vac-
cination were not studied in children with SLE.
Objectives: In the present study, we aimed to compare the antibody
titers and seropositivity in juvenile SLE and healthy subjects after
hepatitis A vaccination. Besides, we examined the effect of immuno-
suppressive drugs and disease activity on antibody responses.
Methods: Sixty-nine juvenile SLE patients were enrolled in the study.
Initially, we evaluated anti-HAV IgM and anti-HAV IgG titers in juven-
ile SLE patients. Of the 69 subjects, 37 patients were seronegative
and eligible for hepatitis A vaccination. However, 7 juvenile SLE pa-
tients refused to participate to the study. Finally, anti-HAV Ig Gnegative 30 patients and 39 healthy subjects were vaccinated with
two doses of hepatitis A vaccine (at 0 months and at sixth months).
After vaccinations, anti-HAV Ig G titers were measured and compared
between two groups.
Results: Anti-HAV Ig G concentrations were measured after vaccin-
ation in 30 patients with juvenile SLE and 39 control subjects. Anti-
HAV Ig G titer of the juvenile SLE patients was significantly lower
than that of the healthy controls (median 4.6 versus 11.9 IU/L, p =
0.02). Although the rate of seropositivity was lower in juvenile SLE
patients (n = 24/30, 80%) compared to healthy controls (n = 33/39,
84.6%); this was not statistically significant (p = 0.6). No adverse reac-
tion was reported after vaccination.
Conclusion: Although anti-HAV Ig G antibody titers after vaccination
have found to be somewhat lower than that of the healthy subjects,
significant portion of juvenile SLE patients were seropositive. Accord-
ing to these results, we conclude that hepatitis A vaccine is ad-
equately immunogenic and quite safe in juvenile SLE patients.
References:
1. Borgia RE, Silverman ED. Childhood-onset systemic lupus erythematosus:
an update. Curr Opin Rheumatol 2015; 27: 483-92.
2. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity
2005; 38: 473–85.
3. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by
infectious agents. J Clin Invest 2001; 108:1097–104.
4. Melhem NM, Talhouk R, Rachidi H, Ramia S. Hepatitis A virus in the
Middle East and North Africa region: a new challenge. Journal of viral
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Introduction: Capillaroscopy findings can be qualitatively described
as: normal, microangiopathy (non-specific abnormalities) or sclero-
derma pattern. Capillary abnormalities, described in varying preva-
lence in patients with systemic lupus erythematosus (SLE), are mainly
described as microangiopathy with nonspecific capillary morphologic
changes
Objectives: To describe the capillary morphologic abnormalities in a
cross-sectional tertiary cohort of patients with childhood-onset SLE
(cSLE) by a detailed quantitative assessment
Methods: Nailfold videocapillaroscopy (NVC) was performed in cSLE-
patients (onset < 18 years) with a x200 magnification lens (Optilia).
All fingers except the thumb were examined with four images per
finger. The following capillaroscopic characteristics were evaluated
per millimeter: density (compared to mean density known for age,
sex and ethnicity), number of abnormal shapes (as defined by the
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 79 of 191EULAR study group on microcirculation in Rheumatic Diseases), giant
capillaries (defined as apical diameter >50 mcm), maximum apical
diameter (dilatations defined as apical diameter 20-50mcm) and
microbleedings (categorized by large hemorrhages and small mul-
tiple point-shaped hemorrhages surrounding the capillary loop)
Results: This cohort of cSLE-patients was predominantly female (n =
19/22, 86.4%), with a median age of 14 years at onset of disease. At
time of capillaroscopy, the median age was 17 years with a median
disease duration of 29.3 months (IQR* 25-75: 12.7-56.5 months). Thir-
teen patients (59.1%) had an African/Afro-Caribbean ethnic back-
ground and seven (31.8%) a Caucasian. Median SLEDAI-score** at
diagnosis was 11, and median SLEDAI-score at moment of capillaro-
scopy was 4.
In total, 4607 capillaries from 22 patients were analyzed. By qualita-
tive analysis, 81.8% (n = 18) showed a pattern of microangiopathy.
Quantitatively, all of these patients showed a specific combination
(observed per finger) of three specific morphological capillary abnor-
malities: apical dilatations, small point-shaped hemorrhages and ab-
normal shapes. Looking at frequency and localization of these
combined capillary abnormalities, three patients (3/22, 13.6%)
showed them in all eight examined fingers, 54.5% (12/22) in four or
more fingers and 72.7% (16/22) in three or more fingers. The fingers
that were most affected were fourth finger left (n = 14), fourth finger
right (n = 13) and fifth finger left (n = 13 patients).
*IQR = InterQuartile Range
**SLEDAI = Systemic Lupus Erythematosus Disease Activity Index
Conclusion: In this pilot (n = 22) of cSLE patients, 81.8% (n = 18)
showed a combination of specific capillary morphological abnormal-
ities: apical dilatations, small point-shaped hemorrhages and abnor-
mal shapes. Up to 72.7% showed this combination in three or more
fingers and 13.6% in all eight examined fingers. More studies in
(c)SLE-patients are needed to assess if these capillary abnormalities
are specific for SLE
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Introduction: Induction therapy combined with corticosteroid and
immunosuppressant from the acute phase improves long-term out-
come in people with systemic lupus erythematosus (SLE). The prog-
nosis of SLE is significantly improved by intravenous
cyclophosphamide (IVCY) and mycophenolate mofetil (MMF). Accord-
ing to major guidelines for lupus nephritis (LN), IVCY and MMF are
recommended as the first line remission induction therapy for adult
proliferative LN (type III or IV), but the use of this strategy in child-
hood LN is not well established.
Objectives: To investigate if early remission induction therapy using
IVCY can improve long-term outcome in childhood proliferative LN
(type III or IV), by comparing patients treated with IVCY at onset ver-
sus later at disease flare.
Methods: Thirty-four children with SLE who were admitted to our in-
stitute from April 1997 to April 2016 were enrolled. Diagnosis of SLE
was based on 1987 ACR criteria and diagnosis of LN was based on
WHO classification or 2003 ISN/RPS classification. Patients were di-
vided into two groups; group A: IVCY was used at the time of onset
(n = 22), and group B: IVCY was used at the first recurrence (sero-
logical and/or clinical flare of SLE/LN) (n = 12). All patients success-
fully achieved remission once. We retrospectively evaluated
parameters before and after IVCY including renal pathology, period
to the first recurrence after IVCY, dose of prednisolone at the last ob-
servation, SLE disease activity index (SLEDAI), anti-double-strand DNA
antibody (anti-dsDNAab), complement, urinary protein, estimatedglomerular filtration rate (eGFR) and immunosuppressant as remis-
sion maintenance therapy.
Results: There was no significant difference in patient’s characteristics
between the two groups. Type IV LN was more common than type III
in both groups. The median number of IVCY was 8.5 (6–12) in group
A and 8.5 (6–9) in group B (p = 0.83). Eleven of 22 patients had recur-
rence in group A (50%) and 8 of 12 patients had recurrence in group
B (67%) after IVCY. The median period to the first recurrence after
IVCY was 74 months in group A and 47.5 months in group B (p =
0.34, log-rank test). At the last observation, daily dose of prednisol-
one did not differ between groups A and B (0.100 vs. 0.155 mg/kg, p
= 0.15). Additionally, there was no significant difference in titer of
anti-dsDNAab, complement, SLEDAI, urinary protein, or eGFR. Regard-
ing remission maintenance therapy after IVCY, 26 patients were
treated with MMF (16 group A, 10 group B), and 8 patients were
treated with other immunosuppressants such as azathioprine and
mizoribine (6 group A, 2 group B). Of note, 12 of 26 patients treated
with MMF (46%) and 7 of 8 patients on non-MMF immunosuppres-
sants (88%) experienced recurrence (p = 0.039, log-rank test). Six of
16 patients on MMF in group A and 6 of 10 on MMF in group B ex-
perienced recurrence (p = 0.47). There were no deaths during the ob-
servation period.
Conclusion: In this study, timing of IVCY did not affect either preven-
tion of recurrence or recurrence-free survival. Despite IVCY as induc-
tion therapy at onset, half the patients later had recurrence.
Surprisingly, choice of MMF as maintenance therapy after IVCY is one
factor to achieve longer remission. A recent meta-analysis showed
that MMF was the most favorable maintenance therapy for adult
SLE/LN1). Our results were consistent with this finding and IVCY
followed by MMF could be a favorable treatment for childhood pro-
liferative LN. However, to avoid gonadal toxicity and malignancy due
to IVCY, remission induction therapy with MMF for childhood prolifer-
ative LN should be evaluated by a prospective randomized-control
trial in the future.
Reference
1)Palmer
SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, et al.
Induction and Maintenance Immunosuppression Treatment of Proliferative
Lupus Nephritis : A Network Meta-analysis of Randomized Trials. Am J Kidney
Dis. 2017 Feb 20. pii: Cited in PubMed ; S0272-6386(17)30036-7. doi: 10.1053/
j.ajkd.2016.12.008. [Epub ahead of print]
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Introduction: Juvenile onset systemic lupus erythematosus (jSLE) is
an interferon alpha (IFNα) driven disease with a higher prevalence in
females after puberty. The median ages of onset for puberty and jSLE
are very similar, implying that puberty acts as a biological switch in
the development of jSLE.
Objectives: 1.To investigate whether transition through puberty is as-
sociated with increased production of IFNα by plasmacytoid dendritic
cells (pDC) in females compared to males. 2.To investigate whether
interferon regulatory factor 5 (IRF5) and interferon stimulated gene
expression (as measured by tetherin expression) change with puberty
or sex.
Methods: Blood from heathy volunteers pre, during and post pu-
berty, was collected and peripheral blood monocytes separated by
ficoll gradient centrifugation. Ex vivo phenotype including cell type
percentage, IRF5 expression and tetherin expression was assessed by
Table 38 (Abstract P138). Demographics clinical and laboratory
characteristics of 225 SLE patients included in analysis
aSLE
139(62%)
cSLE 86
(38%)
P Value
Cutanous 17 (12.2%) 0 (0.0%) 0.004
Arthritis 74 (53.2%) 58 (67.4%) 0.050
Renal 27 (19.4%) 42 (48.8%) P <
0.0005
Hematologic 62 (44.6%) 19 (22.1%) 0.001
Neurologic 12 (8.6%) 15 (17.4%) 0.078
Pulmonary 4 (2.9%) 11 (12.8%) 0.009
SLEDAI at disease onset (Mean ± SD) 8.47 13.27 P < 0.05
SLEDAI over disease course (Mean ±
SD)
11.77 16.34 P < 0.05
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ceptor (TLR) 7 agonist R848 or TLR 9 agonist CPGODN2216, before
assessing for the production of IFNα by pDC by flow cytometry.
Results: 60 young healthy volunteers between ages 6-18 years were
recruited. pDCs from female volunteers produced significantly more
IFNα than males upon TLR7 stimulation, overall (p = 0.01) and after
puberty (p = 0.03) but not before puberty (p = 0.47).There was no dif-
ference in TLR9 stimulated pDCs between sexes across the age
groups. In females, IRF5 expression after puberty was significantly re-
duced in pDCs (p = 0.02), monocytes (p = 0.04) and B cells (p = 0.03)
when compared to males. After puberty, female pDCs (p = 0.04) and
monocytes (p = 0.04) expressed significantly more tetherin (an inter-
feron inducible gene protein product) than males.
Conclusion: Females produce more IFNα than males upon TLR7
stimulation after puberty, but not before. In addition, females express
less IRF5 and may have a higher IFNα signature after puberty. These
unique IFNα-related changes that occur in the immune system be-
tween sexes over puberty may account for the increased incidence
of jSLE in females after sexual maturity and provide insights into the
pathogenesis of jSLE.
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Introduction: SLE is a disease that mainly affects women of child-
bearing age, however, its prevalence is not confined within this
population. A total of 15–20% of cases present in children under
16 years of age. Although adult onset SLE (aSLE) and childhood on-
set SLE (cSLE) share the same clinical features and diagnostic criteria,
differences between the two groups have been identified.
Objectives: The aim of this study is to compare the similarities and
differences in demographics, clinical presentation, serology, out-
comes, treatment, disease severity and damage between aSLE and
cSLE in an Omani cohort. This will be first study of this nature to be
conducted from an Arab population from the Middle East region.
Methods: We evaluated 225 SLE patients, 139 adults and 86 children,
followed at the pediatric and adult rheumatology department from
January 2006 to July 2016 in Sultan Qaboos University Hospital, a ter-
tiary and academic center in Oman. We included all patients with
available clinical data at the disease onset in the hospital information
system. cSLE was defined as children diagnosed at the age of 16 or
below, while those diagnosed above the age of 16 were classified
aSLE. All patients that were included in the study satisfied the 1997
American College of Rheumatology (ACR) Revised Criteria.
Results: The mean age at diagnosis of aSLE 28.1 years (SD ± 8.8 yrs)
and cSLE 9,4 years (SD ± 4.2 yrs.). While the mean disease duration in
aSLE 5.9 years (SD ±4.4) and cSLE 8.9 years (SD ± 5.7). There was
greater female predominance of the disease with increasing age in
cSLE. The F:M ratio in different age groups; less than 5 yrs, 5-12 year
and 13-16 year were 2.5:1, 3.5:1, 6.7:1 respectively. While the female
predominance in aSLE decreased with increasing age. The F:M ratio
in different age groups; 17-25 years, 25-50 year and greater than
50 years were 11.1:1, 6.5:1 and 3:1 respectively. The distribution of
SLE from various regions in the sultanate was proportionate to popu-
lation density in aSLE as would be expected. However, there was
higher prevalence of cSLE in A’Sharqiya, a region in the Sultanate of
Oman with a relatively low population density. The clinical features
in cSLE showed higher frequency of renal, musculoskeletal and pul-
monary involvement; while aSLE showed higher frequency of
hematological and mucocuatnous involvement as shown in Table 38.Serological differences demonstrated significantly higher frequency
of antidsDNA antibody in cSLE, with higher frequency of anti-smith
antibody in aSLE. The mean disease activity sindex (SLEDAI) at dis-
ease onset and over disease course was also higher in cSLE than
aSLE (Table 38). cSLE were more likely to be treated with immuno-
suppressants such as cyclophosphamide and MMF than aSLE (54%,
21.5% vs 69.8%, 51.2%).
Conclusion: Differences between aSLE and cSLE in an Arabic cohort
from Oman were different than the difference noted in other Cauca-
sian cohort. It appears that individual races and ethnicities may ex-
hibit differences in disease susceptibility and disease manifestations
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Introduction: Neonatal lupus erythematosus (NLE) is a rare auto-
immune disease manifested commonly by cutaneous erythema and
congenital heart block. NLE is presumed to result from transplacental
passage of maternal autoantibodies of the Ro/La family.
Objectives: The aim of this study is to investigate clinical manifesta-
tions, treatment and outcomes of NLE.
Methods: Medical records of patients with NLE and their mothers
from Severance children’s hospital in Korea between January 2015
and April 2017 were reviewed. A diagnosis of NLE was made if the
infant had the presence of clinical symptoms plus positive anti-Ro/
SSA or anti-La/SSB or both.
Results: There were 20 cases (male:female ratio of 8:12). Age of onset of
clinical features was from birth to 68 days (median age of 7 days). Cuta-
neous lesions were seen in more than 90% of patients, while hepatobili-
ary, hematologogic, and cardiac abnormalities were present in 45%, 20%
and 10% of cases, respectively. Anti-Ro/SSA and anti-La/SSB were posi-
tive in 100% and 65% of cases. There was no mortality during the study
period. Most neonatal lupus erythematosus mothers (16 cases, 74.2%)
had underlying autoimmune diseases (systemic lupus erythematosus in
11 cases and other autoimmune diseases in 5 cases). However, two of
the mothers without pre-pregnancy autoimmune disease were found to
have autoimmune antibodies in tests after the baby’s diagnosis.
Conclusion: NLE should be screened if infant have congenital heart
block or skin rash with multi-system involvement despite the ab-
sence of history of maternal autoimmune disease. Most NLE patients
without congenital heart block have relatively excellent outcome.
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Introduction: FMF is a hereditary autoinflammatory periodic fever
syndrome that is caused by mutations in the MEFV gene. It is com-
mon in Mediterranean countries and the carrier rate in MEFV gene in
Turkey is reported to be around 20%. It has also been reported that
in many chronic inflammatory diseases, the frequency of MEFV muta-
tions is increased and the course of the disease may be altered.
Objectives: The aim of this study was to assess the frequency of
MEFV gene sequence variants in patients with juvenile SLE and com-
pare the clinical features, disease severity and course of the patients
with or without MEFV sequence variants.
Methods: MEFV gene analysis was studied in 40 jSLE patients that were
being followed in 2 pediatric rheumatology centers in Istanbul and Kay-
seri. None of the patients in the cohort had diagnosis of FMF.
Results: The frequency of MEFV polymorphisms and mutations in juven-
ile SLE patients was found to be 35% (Table 39). The most common of
these was R202Q polymorphism (50%). The significance of the R202Q
and E148Q sequence variants is controversial. After the exclusion of
these variants, re-analysis revealed that the carrier rate was 12.5%.
Age at onset of the disease, duration of the disease, SLICC and SLEDAI
scores did not differ between the carrier and non-carrier groups. Hepatic
involvement was found to be more frequent in MEFV mutation carriers
(p = 0.037). There was no difference regarding fever, hematologic involve-
ment, renal involvement, serositis, neuropsychiatric involvement, mucocu-
taneous findings, and vascular involvement in between the two groups.
Conclusion: In conclusion, we have seen that MEFV carrier rate was
high in SLE patients. But we did not observe any differences in both
clinical findings and disease damage in SLE patients with MEFV vari-
ant carriers except for hepatic involvement.
Disclosure of Interest: None DeclaredTable 39 (Abstract P140). MEFV mutation analysis of SLE patients
Mutation n Min Max Mean ±
SD
Median p
Age of Diagnosis (Year) No 26 3 17 12,6 ± 3 13 0,79
Yes 14 8 17 12,9 ± 2,8 13,5
Duration of disease
(month)
No 26 10 100 34,9 ±
19,8
31 0,69
Yes 14 11 71 37,4 ±
16,8
42
SLICC No 26 0 3 0,4 ± 0,8 0 0,59
Yes 14 0 2 0,5 ± 0,7 0
SLEDAI No 26 0 10 3,1 ± 3,2 2 0,62
Yes 14 0 8 1,8 ± 2,5 1P141
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Pediatric Rheumatology 2017, 15(Suppl 2):P141Introduction: Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease, potentially severe, with broad clinical spectrum,
which can affect multiple organs and systems.
Objectives: To analyze the initial manifestations, laboratory examina-
tions and therapeutic approaches of patients diagnosed with child-
hood onset systemic lupus erythematosus (c-SLE) followed in a
tertiary hospital in the last 14 years.
Methods: Retrospective chart review. Inclusion criteria were: children
under 18 years diagnosed with c-SLE between January 2003 and
January 2017.
Results: During the study period, 38 patients were identified (ratio fe-
male/male: 3/1). The mean age at the onset of disease was 11.5 years
(range 6-17). All had caucasic origin, except 5 coming from South
America, 2 from India and 1 from Africa. Onset of the disease took
place in spring in 22 (58%) patients, while in 10 (26%) patients onset
was in summer, 5 (13%) in autumn and only one (3%) in winter season.
The most frequently clinical manifestations found at the debut were
cutaneous involvement (66%, predominantly in the form of a malar
rash), renal (65%) and joint (60%, 48% arthralgia and 52% polyarthri-
tis). Other manifestations were fever (50%), cytopenias (39%), asthe-
nia (36%), serositis and neurological clinic (both 26%) and oral
aphthosis (23%). Among the neurological manifestations, 4 patients
showed bradypsychia, 3 headache, 2 seizures and 1 manifested a
paralysis of the sixth cranial nerve. Only 1 patient presented macro-
phage activation syndrome after primoinfection by Ebstein Barr Virus.
During the study period, no deaths ocurred.
Ten patients also had some other associated autoimmune disease: 6
hypothyroidisms, 2 IgA deficiency, 1 vitiligo and 1 celiac disease. No
case of diabetes mellitus was identified.
Regarding immunology, in all cases, positive antinuclear antibodies
(ANA) were detected, although with variable titers (1/80 - 1/5120). Of
the 25 patients who presented renal disease at the onset, 19 associated
Anti-dsDNA antibodies positive at the initial time of the determination.
Although antibodies related to antiphospholipid syndrome (APS) (antic-
ardiolipin, anti-2glycoprotein and lupus anticoagulant) were detected
in 12 patients (32%), only two developed associated clinical manifesta-
tions (both deep vein thrombosis in the lower limbs).
Regarding treatment, all patients required corticosteroids. Therapy with
acetylsalicylic acid was indicated in all patients with APS-associated im-
munology. Only 6 patients received treatment with corticosteroids and
hydroxychloroquine exclusively. Nineteen (50%) patients initially re-
ceived azathioprine therapy, being necessary to switch to mycopheno-
late mofetil for lack of response in eleven, receiving the last treatment
20 patients finally (52%). Eighteen patients (47%) received cyclophos-
phamide therapy, 16 of them as a consequence of their renal involve-
ment. In addition, biologic therapy (rituximab and belimumab,
respectively) was used in two multirefractory patients.
Conclusion: As widely already reported, SLE is a disease that affects
predominantly women. Moreover, as it has been previously de-
scribed in the literature the most frequently initial manifestations
found in c-SLE are cutaneous, renal and articular. However, a large
variability of onset symptoms exists, thus c-SLE should be ruled out
in patients with multisystemic involvement.
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Introduction: Childhood Systemic Lupus Erythematosus (cSLE) is a
multisystemic chronic autoimmune disease characterized by a wide
spectrum of clinical manifestations. Renal involvement is one of the
most common manifestations of cSLE, reported in 40-80% of pa-
tients. Growth failure and delayed puberty are features of cSLE,
Table 40 (Abstract P143). See text for description
T1 T2
Mean ± (standard deviation)
Mild Severe Mild Severe
Albumin (mg/dl) 3,4 (± 0,8) 3,7 ± (0,5) 4 ± (0,9) 3,7 ± (0,6)
Total cholesterol (mg/
dl)
203,5 (± 68,5) 187,7 ± (55,5) 197,2
± (51,4)
222,5 ± (52)
HDL-cholesterol (mg/
dl)
57,4 (± 37,4) 39,9 ± (16,2) 69 ± (28,3) 52,5 ± (11,4)
LDL-cholesterol (mg/
dl)
102,6 (± 30,1) 130,2 ± (32,5) 127,5
± (40,3)
124,8
± (33,5)
Triglycerides (mg/dl) 164,7 (±
116,2)
178,5
± (163,4)
129 ± (39,3) 172,1 ± (99)
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cially corticosteroids.
Objectives:
To assess the early influence of SLE Lupus Nephritis disease and
treatment on growth parameters in children.
Methods: Patients diagnosed with cSLE in a tertiary care center in
the past 22 years, with kidney biopsy-proven Lupus Nephritis were
included in our study. Patients were excluded if incomplete data
were available. The WHO classification was considered to evaluate
histological findings. Patients were divided by histological class in
two groups: the mild group (Class II-III) and the severe group (Class
IV-V).
Height (cm) and Weight (kg) were measured with type of stadi-
ometer specified (Harpenden, wall-mounted). BMI (Body Mass Index)
was calculated as weight (kg) divided by height (meter) squared. We
assessed the anthropometric parameters using Atlanta 2000 curves.
Student t test has been calculated for continuous variables to com-
pare the two groups. In all analyses, P < 0.05 was taken to indicate
statistical significance.
Results: From 1994 to 2016, 45 children with lupus nephritis (LN)
were biopsied. 15 of them presented incomplete clinical data and
were excluded. Female-to-male ratio was 3:1., the mean age at onset
was 11.5 ± 3.1 years. The most common class of Lupus Nephritis was
considering WHO classification class IV (40%), followed by class III
(36.7%), II (16.7%) and V (6.7%). We compared all parameters (height,
weight, BMI percentiles) when first renal biopsy was performed and
after 12 months.
Conclusion: This study compared patients with mild and severe
histological assessed LN in the first year of disease. Considering
height percentile, mild LN patients didn’t have a substantial growth
speed deflexion, while severe LN patients had a mild decrease even
in the first year of disease. Comparing weight percentiles, we ob-
served in both groups an increase of weight, more accentuated in se-
vere LN patients.
The BMI percentile of patients with mild LN didn’t register a signifi-
cant mean gain, whereas severe LN patients had a statistical relevant
gain of BMI percentile after 1 year (p value 0.027)
A higher kidney-biopsy grade seems to be related to early change in
growth parameters, even if statistical significativity was reached only
for BMI.
Data collection is still ongoing in order to define the influence of the
treatment performed and to define if early change in growth param-
eters is a related to the long term growth disturbance.
Trial registration identifying number:
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Introduction: Childhood Systemic Erythematosus Lupus (cSLE) is a
severe multisystem autoimmune disease. Renal involvement is a
major cause of morbidity and mortality in cSLE. Serum triglyceride,
total cholesterol, low density lipoprotein (LDL) and apolipoprotein B
(apoB) concentrations were reported significantly higher in patients
with lupus nephritis (LN). It is unclear if abnormality in lipid profile is
related to the severity of renal function, the steroid therapy or both.
Objectives: To evaluate the lipid profile in children with Lupus Nephritis
(LN) at onset and after one year of treatment and to investigate if differ-
ent lipid profile can be related to the severity of renal involvement.
Methods: We performed a retrospective analysis of children with
cSLE and nephritis confirmed at renal biopsy, followed since 1994 to
2016 in a single tertiary care center.Lipid profile (total cholesterol, LDL, HDL and triglycerides), serum al-
bumin level and proteinuria were researched at disease onset (T1)
and after one year of disease duration (T2).
Proteinuria was measured as the quantity of protein in a 24-hour
urine collection test, alternatively, the concentration of protein in the
urine was reported as protein/creatinine ratio.
The WHO classification of LN was used to grade histological findings.
Renal biopsy findings were grouped into two categories: mild (for
class I-III) and severe (class IV-VI).
Dependent T test was performed to evaluate the differences be-
tween the disease onset and the second evaluation. Independent T
test was used to compare the results between mild and severe biop-
tic classes. P < 0.05 was taken to indicate statistical significance.
Results: From 1994 to 2016, 45 children with lupus nephritis (LN)
were biopsied. 15 of them presented incomplete clinical data and
were excluded. In the 30 patients enrolled in the study, the female-
to-male ratio was 3:1, the mean age at onset was 11.5 ± 3.1 years.
The mean disease duration since cSLE onset until renal biopsy was
10 and 19 months for mild and severe involvement respectively.
Patients were distributed among the histological classes as follows:
Class II: 5 patients (16.7%), Class III: 11 patients (36.7%), Class IV: 12
patients (40%) and Class V: 2 patients (6.7%).
Daily proteinuria resulted 672 ± 550 mg/die for mild class and 2475
± 3737,5 g/die for severe class. The urine protein/creatinine ratio re-
sulted 1,08 ± 1,39 and 1,34 ± 1,19 for mild and severe class respect-
ively, the difference was not significant.
Results are displayed in Table 40.
Conclusion: Total cholesterol level at onset resulted higher in pa-
tients with milder renal disease, even if dyslipoproteinemia resulted
more significant in the severe group because of an higher level of
LDL and triglycerides. After one year of disease duration the differ-
ences in lipid profile between the two groups became less relevant.
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Introduction: Systemic lupus erythematosus (SLE) is an autoimmune
disease that is more severe in pediatric population than in adults.
Biological therapy with anti-CD20 (rituximab) is an option in patient
that do not respond to conventional therapy.
Objectives: The aim of this study is to determine the clinical and im-
munological response in 9 patients with childhood-onset systemic
lupus erythematosus (cSLE) that received treatment with rituximab in
a third level hospital.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 83 of 191Methods: This is a retrospective observational study. 9 patients
treated with Rituximab between November 2007 and October 2016
were included and their medical records were reviewed. The re-
sponse to treatment at 6 months and one year after the first infusion
of Rituximab were assessed. Patients with overlap syndromes were
excluded. All patients fulfilled four or more of the 1982 revised
American College of Rheumatology criteria for the diagnosis of SLE
(< 16 years).
Results: Nine pediatric patients with SLE treated with rituximab were
included, all of them were female. The age at diagnosis of SLE was a
mean of 15,22 years. The mean time duration of disease was
87,55 months (5-255 m). 7 patients were caucasians. Rituximab was
indicated in 6 patients with class IV of lupus nephritis (LN) 1/9 with
class III LN, 1/9 with severe cutaneous lupus, and with severe
hematological manifestations in 1 case (haemolytic anemia). In
addition, 6/9 patients had mucocutaneous and articular manifesta-
tions. The disease activity of all patients was assessed using SELENA-
SLEDAI index pre rituximab infusion, the mean was 17,11 (8-33). All
patients had low level of complement C3 and C4 and 8/9 increased
anti-DNA. In 8/9 patients Rituximab was used as a rescue treatment
and in a single case as a first line. 3/6 patients with renal involve-
ment were previously treated with cyclophosphamide (CF) iv and
mycophenolate, 2/6 CF. In case of cutaneous involvement the previ-
ous treatment was methotrexate, azathioprine (AZA) and dapsone
and in case of hemolytic anemia was AZA.The treatment protocol
was 1 gram x 2 (1 cycle) in 7/9 patients, 375 mg/m2x 4 in 1/9 cases
and 600 mg monthly for 5 months in the case of hemolytic anemia.
Five patients received more than 1 cycle. After the administration of
Rituximab, the SELENA-SLEDAI activity index was 4.5 points. At
6 months a complete response was obtained in the case of
hematological and cutaneous manifestations, in 2 cases of lupus
nephritis (proteinuria <0.5 g/day) and partial response was obtained
in 2 cases. Data were not analyzed in 2 patients (death and less than
6 months of the first dose of rituximab). Patients with partial re-
sponse and lack of response achieved complete response at
12 months. 2/9 patients had side effects (Rituximab pneumonitis in 1
case and infections in 2 cases). Mortality was 11.11% (1/9 patients,
per infection and lupus activity, SLEDAI pre rituximab = 33)
Conclusion: In our study, although it consisted of few patients, it was
objected that Rituximab therapy in patients with cSLE is effective, re-
duces lupus activity index, especially in cases of renal, cutaneous and
hematologic involvement, that don’t respond to conventional ther-
apy. It may be consider in the future as an effective alternative treat-
ment at first line treatment.
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Introduction: Lupus erythematosus panniculitis (LEP) is a rare form
of chronic cutaneous lupus erythematosus described from 2% to 5%
of adult SLE. In cSLE, LEP data are limited to few case reportsObjectives: To evaluate prevalence, clinical manifestations, laboratory
abnormalities, treatment and outcome in a multicenter cohort of
childhood-onset systemic lupus erythematosus(cSLE) patients with
and without panniculitis.
Methods: Panniculitis was diagnosed due to painful subcutaneous
nodules and/or plaques in deep dermis/subcutaneous tissues and
lobular/mixed panniculitis with lymphocytic lobular inflammatory in-
filtrate in skin biopsy. Statistical analysis was performed using Bonfer-
roni correction(p < 0.004).
Results: Panniculitis was observed in 6/847(0.7%) cSLE. Painful sub-
cutaneous erythematosus and indurated nodules were observed in
6/6 panniculitis patients and painful subcutaneous plaques in 4/6.
Generalized distribution was evidenced in 3/6 and localized in upper
limbs in 2/6 and face in 1/6. Histopathology features showed lobular
panniculitis without vasculitis in 5/6(one of them had concomitant
obliterative vasculopathy due to antiphospholipid syndrome) and
panniculitis with vasculitis in 1/6. Comparison between cSLE with
panniculitis and 60 cSLE without panniculitis with same disease dur-
ation [2.75(0-11.4) vs. 2.83(0-11.8) years,p = 0.297], showed higher fre-
quencies of constitutional involvement (67% vs. 10%,p = 0.003),
leukopenia (67% vs. 7%,p = 0.002) and median C-reactive protein
(10.5 vs. 0.5 mg/L,p = 0.001). Cutaneous atrophy and hyperpigmenta-
tion occurred in 83% of patients.
Conclusion: Panniculitis is a rare skin manifestation of cSLE occurring
in the first three years of disease with considerable sequelae. The
majority of patients have concomitant mild lupus manifestations.
Disclosure of Interest: None Declared
P146
Prevalence of ena and anti cardiolipin antibodies in different
classes of lupus nephritis.
Giancarla Di Landro, Francesco Baldo, Valentina Litta Modignani, Marisa
Giani, Giovanni Montini, Carlo Virginio Agostoni, Giovanni Filocamo
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Correspondence: Giancarla Di Landro
Pediatric Rheumatology 2017, 15(Suppl 2):P146
Introduction: Childhood Systemic Lupus Erythematosus (cSLE) is a
rare autoimmune disease. Lupus nephritis (LN) is one of the most
serious manifestations of cSLE, associated with poor prognosis and
reported in 40-80% of patients at onset disease. Extractable nuclear
antigen (ENA) antibody can be detected in SLE and some of them
are related to a distinct clinical subset of disease, independently of
their frequency. Autoantibodies against Smith antigen (Sm) are re-
ported in high prevalence in patients with active LN. It is unclear if
the prevalence of ENA autoantibodies is related to the severity of
renal involvement.
Objectives: To evaluate if ENA antibodies positivity in early stage of
SLE disease is associated with the development of more severe dis-
ease, assessed by histological finding.
Methods: We performed a retrospective analysis of children with
cSLE and nephritis confirmed by renal biopsy, followed since 1994 to
2016 in a single tertiary care center.
Clinical features, renal involvement and biopsy findings were col-
lected from patients files as well as the positivity of ENA antibodies
(Anti-RNP, Anti-Sm, anti-Ro/SS-A, anti-La/SS-B, anti-Scl-70, anti-Jo1,
anti-nucleosome, anti-histone), Lupus Anti Coagulant (LAC) test and
Anti- cardiolipin antibodies (ACL).
The WHO classification of LN was used to grade histological findings.
Renal biopsy findings were grouped into two categories: mild (for
class I-III) and severe (class IV-VI).
Chi-Squared Test was used to to determine significant relationship
between categorical variables. P < 0.05 was taken to indicate statis-
tical significance.
Results: From 1994 to 2016, 45 children with LN were biopsied. In 22
of them ENA screening was not reported in clinical records and they
were excluded from the analysis. Between the 23 remaining patients,
12 were included in the mild group, the remaining patients in the se-
vere group; 1 from the severe class had record of ENA positivity, but
not of the specif pattern.
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 84 of 191In the 23 patients enrolled, the female-to-male ratio was 2,6:1, the
mean age at onset was 11.75 ± 3.2 years. The mean disease duration
up to renal biopsy was 15 and 19 months for mild and severe in-
volvement respectively.
ACL and LAC screening record were found for 21 and 20 patients re-
spectively. LAC was present in 19,1% of patients and IgM and IgG
anti-cardiolipin were present in 40% of patients. ENA were positive in
13 out 23 patients (56.5%). Overall the patients enrolled, the most
common positive ENA subtypes were, anti-Ro/SS-A (38%), followed
by anti-Sm and anti-RNP(22,7%). The prevalence of ENA in patients
with mild and severe renal involvement are reported in Table 41.
Conclusion: ENA autoantibodies are present in about half of the pa-
tients with LN. The prevalence of ENA, ACL and LAC does not differ
significantly in patients with different grade of renal involvement.
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AUTOANTIBODIES MILD SEVERE p value
ENA: 7 63,63% 6 50,00% 0,509
anti-RNP 3 27,27% 2 18,18% 0,611
anti-Sm 2 18,18% 3 27,27% 0,611
anti-Ro/SS-A 5 45,45% 4 36,36% 0,665
anti-La/SS-B 1 9,09% 3 27,27% 0,269
Scl-70 1 9,09% 1 9,09% 1
Anti-nucleosome and anti-histone 1 9,09% 0 0 NS
LAC 2 20,00% 2 18,18% 0,91
IgM and IgG aCL > 10 4 40,00% 4 40,00% 1
Table 42 (Abstract P148). Clinical and Laboratory Characteristics; F,
Female; M, Male; SS, Sjögren Syndrome; SLE, Systemic Lupus
Erythematosus; NE, Not Evaluated
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Introduction: Juvenile systemic lupus erythematosus is a chronic multi-
system autoimmune disease of unpredictable course and prognosis. It
manifests with a wide spectrum of clinical and immunological abnor-
malities. To date, no literature has been described about the most fre-
quent clinical manifestations in mexican children with this disease.
Objectives: To define the pattern of disease expression in subjects
with juvenile systemic lupus erythematosus in Mexico and compare
it with what has been reported in other series, in addition to gain a
better understanding of juvenile systemic lupus erythematosus in
mexican children.
Methods: The features of 150 patients with juvenile systemic lupus
erythematosus who had disease onset before the age of 18 years in
the Children’s Hospital of Mexico < <Federico Gómez>>, were retro-
spectively analysed. Demographic, clinical and laboratory manifesta-
tions, therapy were assessed.
Results: A cohort of 150 patients with a mean age at diagnosis of
11.3 ± 3.13 years and a mean period of follow-up of 3.34 ± 2.14 years
were analyzed. One hundred thirty-one (87.3%) patients were female.
The most common manifestations were mucocutaneous (74.7%),
hematological (56%) and musculoskeletal (39.3%) abnormalities.
Upon diagnosis, renal damage was found in 56 patients (37.3%), of
which 28 (18.3%) were diagnosed with lupus nephritis. Antinuclear
and double-stranded anti-DNA antibodies were positive in most pa-
tients, 96.7% and 77.3%, respectively; antiphospholipid antibody posi-
tivity was observed in 40.7%. During follow-up, immunosuppressive
management consisted of azathioprine in 54%, cyclophosphamide in
66.6%, mycophenolate mofetil in 31%, a combination of more thanone of the above in 56.7%, being the most frequent azathioprine and
cyclophosphamide; 22 individuals (14%) were only treated with hydro-
xychloroquine as an immunomodulator.
Conclusion: This study suggests that in our patients the clinical and
laboratory features observed were similar to juvenile systemic lupus
erythematosus patients from other series.
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Introduction: Neonatal Lupus (NL) is a rare condition caused by the
transplacental passage of autoantibodies anti-Ro/SSA, anti-Sa/SSB
and/or anti-U1 RNP antibodies into the fetal circulation which affects
newborns. The mother may be asymptomatic or have a known auto-
immune disorder, like Sjögren syndrome or Systemic Lupus Erythe-
matosus. Clinical manifestations are diverse and have varying
severity, the most common being cutaneous and cardiac.
Objectives: Identify NL cases, describe the clinical manifestations and
its course, evaluate the presence of the most important antibodies
and the history of mother’s disease.
Methods: Retrospective review of case files of all patients diagnosed
with NL in the last eight years, admitted to the Neonatal Unit and/or
followed at the outpatients department of a tertiary teaching hospital.
Results
The authors present a case series which includes eight cases diag-
nosed with NL and a brief review of the literature (Table 42).
Conclusion: Underdiagnosis might explain the reduced number of
patients identified. The positivity of anti-Ro/SSA and anti-Sa/SSB
seems to be associated with higher prevalence of neonatal cardiac
manifestations. Early detection of this condition is paramount since
treatment may reverse lower grade HB. Also, adequate maternal
treatment can reduce the likelihood of NL.
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Introduction: The prevalence of systemic lupus erythematosus (SLE)
is known to be lower in boys than in girls. The female-to-male ratio
of paediatric SLE (pSLE) is 4.5-5:1. Much controversy surrounds the
differences in disease manifestation in both sexes.
Objectives: The aim of this retrospective study is to compare the
gender differences in the age of onset, time to diagnosis, clinical and
laboratory manifestations and medication use in pSLE at
presentation.
Methods: Seventeen patients (11 boys and 6 girls) with newly diag-
nosed pSLE admitted to the Paediatric Rheumatology Department,
Sofia, Bulgaria for a period of 4 years (2013-2017) were included in
the study. The medical records of all patients were retrospectively
reviewed. Patients fulfilled the American College of Rheumatology
(ACR) SLE classification criteria.
Results: The female-to-male ratio in the described cohort of pa-
tients is reversed - 3.6:6.4. The mean age of onset in male pSLE
patients was 12.59 yrs (5.83-17.83 yrs) with mean time to diagno-
sis of 2 ± 1.3 months. The mean age of onset in female patients
was 14.06 yrs (7.5-16.33 yrs) with mean time to diagnosis – 3.5 ±
3.99 months. No statistically significant differences were found
between boys and girls with regard to mean age of onset, mean
time to diagnosis and clinical and laboratory manifestations of
pSLE. The most common clinical sign at presentation in boys was
arthritis (9/11; 81.8%), followed by renal involvement (7/11;
63.6%). Girls presented most frequently with malar rash (5/6;
83.3%), followed by arthritis (3/6; 50%). Renal involvement at
presentation was detected in only one of the girls (1/6; 16.6%).
Serositis was noted as presenting manifestation in one girl (1/6;
16.6%) and was not observed in any of the boys. Vascular throm-
bosis was seen in one boy (1/11; 9.1%). No neurological manifest-
ation was observed in both groups. The most frequently detected
hematological manifestation in the male group was lymphopenia
(7/11; 63.6%) with leucopenia being the most common present-
ing laboratory sign in the female group (5/6; 83.3%). The least
commonly observed laboratory sign in both groups was Coombs-
positive autoimmune hemolytic anemia. Positive anti-dsDNA anti-
bodies were detected in 90.9% of the boys and 100% of the
girls. Antinuclear antibodies were positive in 100% of the boys
and 83.8% of the girls. Low complement levels were seen in
81.8% of the males and 83.8% of the girls. All patients received
corticosteroid therapy with intravenous pulse therapy performed
in one girl and three boys. Cyclophosphamide for the initial 6-
month induction period was used in 50% of the girls and 63.6%
of the boys. Azathioprine was given to one girl and two boys.
Chloroquine was used in 33.3% of the girls and 18.1% of the
boys.
Conclusion: A male predominance of SLE has been observed. The
mean age at disease onset and mean time interval from disease on-
set to diagnosis did not differ in male and female patients. The ob-
served clinical and laboratory manifestations were also comparable
between the two groups. Arthritis and renal involvement were found
to be the commonest clinical manifestation among boys. Renal in-
volvement favored males, however the result was not statistically
significant.
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Introduction: Both juvenile-onset systemic lupus erythematosus
(JSLE) and juvenile idiopathic arthritis (JIA) are autoimmune diseases
which can affect multiple targets in different organs of the body.
Metabolomics studies are a comprehensive way to investigate reac-
tions and interactions of different, potentially important cells contrib-
uting to the immunopathogenesis of these disorders.
Objectives: To compare the metabolite profiles of serum and urine
of patients with JIA and JSLE as well as non-inflammatory paediatric
control patients.
Methods: Serum and urine samples were obtained from children (diag-
nosed <17 years of age) with JIA (n = 5 for serum, n = 4 for urine), with
JSLE (n = 10, n = 8) and from paediatric healthy controls (n = 9, n = 4).
The samples were run at 310 K for serum and at 300 K for urine on a
Bruker 600 MHz AvanceIII with CryoProbe. Resulting 1H NMR spectra
were analysed with Topspin, Chenomx NMR Suite and R.
Results: In serum global changes in spectra analysed via Partial Least
Squares Discriminant Analysis (PLSDA) revealed variation between
JIA, JSLE and control patients. While JSLE and control patients were
separated, the JIA patients fell in-between and a clear clustering was
therefore not possible.
Cross-validation accuracy for this PLSDA was 0.67 with a robustness
(R2) 0.88 and a prediction (Q2) of 0.25 with optimal model using four
linear discriminants. Univariate analysis using ANOVA showed that
Acetoacetate was significantly higher (p < 0.05) in JIA patients com-
pared to healthy controls (1.8-fold) and JSLE patients (1.8-fold). Ala-
nine on the other hand was significantly lower (p < 0.05) with a 0.8-
fold change in JIA patients compared to healthy controls and JSLE
patients. Pyruvate on the other hand was significantly increased (p <
0.05) in JSLE patients compared to JIA patients (1.4-fold) and healthy
controls (1.3-fold).
These differences in the serum indicate that these diseases utilize dif-
ferent pathways to generate energy.
In urine, PLSDA of the spectra resulted in a clear separation of the
three groups with a cross-validation accuracy of 0.75 an R2-value of
0.95 and Q2–value of 0.38 with the optimal model using three linear
discriminants. Metabolites contributing to this separation included
hippurate, taurine, citrate and 4-hydroxybenzoate.
Conclusion: Variation in metabolic profiles was observed in JIA and
JSLE patients compared to paediatric healthy controls. Analysis of
serum and urine indicate urine to be a better biofluid sample to dis-
tinguish between diseases. Investigating changes of metabolites in
serum samples gave us indications of which pathways are differen-
tially regulated between the three conditions. Further analyses are
being undertaken to investigate which pathways are regulated differ-
ently between the two diseases.
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Introduction: Novel urine biomarkers, with a proven specificity for
pediatric Lupus Nephritis (pLN), will facilitate the non-invasive and re-
liable assessment of the disease course and the subsequent choice
of targeted treatment.
Objectives: To explore the relation of urine Neutrophil Gelatinase-
Associated Lipocalin (NGAL) and High-Mobility Group Box 1 (HMGB1)
protein to: (a) the presence of pLN and (b) the pLN activity, in a
homogeneous Caucasian pediatric Systemic Lupus Erythematosus
(pSLE) population from Northern Greece.
Methods: Thirty-three urine samples were collected from 17 pLN pa-
tients and 12 urine samples from 12 pSLE patients without pLN. The
pLN activity was assessed using the renal domain of the Systemic
Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K). The
biomarkers’ levels were determined by ELISA.
Results: The levels of the urine NGAL were higher in the pLN pa-
tients [median (IQR): 33.46 (19.37-84.7) pg/ml] as compared to the
pSLE patients without pLN [14.1 (10.24-21.45) pg/ml] (p = 0.001) and
were correlated with the pLN activity (rho = 0.457, p = 0.008). The
levels of the urine HMGB1 were higher in the pLN patients [5.55
(4.17- 6.54) ng/ml] as compared to the pSLE patients without pLN
[3.81 (2.46-5.1) ng/ml] (p = 0.034) and were correlated with the pLN
activity (rho = 0.685, p < 0.001).
Conclusion: These preliminary findings indicate that the combination
of the urine NGAL and HMGB1 levels may serve as biomarkers of
pLN presence in pSLE patients, and may be considered as another
non-invasive tool for the assessment of pLN activity. Further studies
in Caucasian patients are needed to verify these results.
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Introduction: Children and adolescents diagnosed with Juvenile Idio-
pathic Arthritis (JIA) often exhibit lower physical activity level and
poorer aerobic and anaerobic exercise capacity when compared totheir non-JIA counterparts. Mild intensity exercise regimen has been
proven to be safe in children with JIA and may produce significant
improvements in overall physical function. Inadequate adherence to
the treatment prescribed by paediatric rheumatologists, could also
have a detrimental impact towards different clinical outcomes and
possibly increased disease activity. This includes symptoms such as
pain, fatigue, quality of life, longer term outcomes including joint
damage, as well as increase of healthcare associated costs. Low ad-
herence to medications such as methotrexate and biological-drugs
remains a significant issue in paediatric rheumatology, with evidence
that less than half of the children with JIA are actually compliant to
their drug-therapy. The recent advances in smart technology result-
ing in a variety of wearable user-friendly interactive devices may be-
come a key solution to tackle important challenges in JIA clinical
management.
Objectives: The aim of this review was to explore the current use of
modern interactive technologies in the provision of health care
Methods: A litterature review was performed using MEDLINE,
PUBMED and CINAHL. This review focused in 4 main topics: monitor-
ing symptoms and disease progression using interactive technolo-
gies, adherence to prescribed medications using smart devices,
available app to encourage physical activity and data protection.
Results: The recent advances in smart technology resulting in a var-
iety of wearable user-friendly interactive devices may become a key
solution to tackle important challenges in JIA clinical management.
Fully understanding the impact that JIA and treatment complications
have upon patients and their families has long been a challenge for
clinicians. Modern interactive technologies can be adapted to the in-
dividual requirements and accessed directly in the hands or wrists of
children with JIA. These secured networks could be accessible 'live'
at anytime and anywhere by the child, parents and clinicians.
Multidisciplinary teams in paediatric rheumatology may benefit from
adopting these smart devices to enhance the understanding in dif-
ferent aspects, such as: patient’s biological parameters, symptoms
progression, and adherence to drug-therapy, quality of life, and par-
ticipation in physical activities. Most importantly the use of inter-
active technologies may also promote more timely clinical decisions,
improve self-management and parents active involvement with their
child's disease. Paediatric rheumatology research could also further
advance from the use of these smart devices, as they would enable
real-time access to meaningful data to thoroughly analyse the
disease-patterns of JIA, such as pain and physical activity outcomes.
Data collection that typically occurs once every 1 or 3 months in the
clinical setting could instead be gathered every week, day, minute or
virtually live online. Many limitations in wearing such interactive
technologies still exist and require further developments and
investments.
Conclusion: Further studies in paediatric rheumatology are required
to critically evaluate the effectiveness and acceptability of already
available apps in large number of patients and to develop new de-
vices utilizing valuable input and feedback from patients, carers and
clinicians. Finally, by embracing and adapting these new and now
highly accessible interactive technologies, clinical management and
research progress in paediatric rheumatology could be greatly
advanced.
Trial registration identifying number: NA
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Introduction: Rituximab (RTX) response does not depend on its
serum concentration, so reduced doses (miniRTX) could be an
Table 43 (Abstract P155). ETN treatment retention in pediatric patients
(aged 2-12 years)
Year Tracked Patients, n Retained Patients, n Retention Rate, % P-Value
1 65 44 68
2 41 33 80 0.1501
3 31 28 90 0.0166
4 28 25 89 0.0290
5 25 19 76 0.4411
6 18 15 83 0.1952
Pediatric Rheumatology 2017, 15(Suppl 2):64 Page 87 of 191alternative treatment in pediatric rheumatic diseases (PRD), especially
in low-income countries.
Objectives: To describe the outcome of a longitudinal series of PRD
patients treated with miniRTX.
Methods: A longitudinal, open-label, non-controlled, case series was
conducted. We enrolled all consecutive patients diagnosed with PRD
in whom failure to standard therapy was stablished. Treatment with
miniRTX, defined as either 500 mg in a single dose infusion or
100 mg a week during 4 weeks, were added to patients’ therapy. A
200 mg dose were administered as maintenance treatment at 6 and
12 months after first dose to those patients whom achieved a signifi-
cant clinical response. Clinical outcome were registered in every pa-
tient during a follow up of at least 18 months.
Results: Eight patients were included in this series, seven female, me-
dian age 14 (2 – 17) years old at the time of diagnosis and 18 (11 –
82) months of disease duration. Most of the patients (seven) has ju-
venile systemic lupus erythematosus (JSLE) and one patient pre-
sented with juvenile dermatomyositis (JDM).
Among JSLE patients, previous used treatments were azathioprine (3
patients), mofetil mycophenolate (7 patients), and cyclophosphamide
(5 patients) in different periods. All those patients received cortico-
steroids (both orally and/or IV) and hydroxychloroquine. Patient with
JDM received corticosteroids, methotrexate, azathioprine, cyclospor-
ine A, and hydroxychloroquine prior to miniRTX.
Clinical manifestations presented in JSLE patients at the time of
miniRTX administration were hematological (5 patients), arthritis (4
patients), nephritis (4 patients), vasculitis (2 patients), serositis (1 pa-
tient), secondary antiphospholipid syndrome (APL) and neuropsychi-
atric (1 patient).
Most of the patients received 100 mg/week miniRTX scheme, while
two received a single dose (500 mg).
Two patients presented primary failure to therapy (one JSLE and JDM
patient) so no maintenance doses were administered. One patient
with JSLE and APL presented initial good response but a relapse
were evident 12 months after initial administration. Five patients
completed the 18 months follow up with absence of JSLE signs and
symptoms; however, none of the patients completed an off-
treatment remission criterion.
One patient presented recurrent ear infections and secondary im-
munodeficiency were diagnosed attributable to miniRTX administra-
tion. Patient received complementary IVIG with resolution and no
other complications were presented in this series.
Conclusion: Comparative studies are needed to establish the useful-
ness of miniRTX in PRD; however, the response in most of the pa-
tients of this small series was favorable.
Disclosure of Interest: None Declared
P155
Etanercept (ENBREL®) treatment retention in the sub-population of
pediatric patients from a retrospective cohort study using
Canadian claims-level data
Majed Khraishi1, Brad Millson2, John Woolcott3, Heather Jones4, Lisa
Marshall4
1Faculty of Medicine, Memorial University of Newfoundland, St. Johns,
Canada; 2Health Access and Outcomes, QuintilesIMS, Kanata, Canada;
3Inflammation and Immunology, Global Outcomes and Evidence, Pfizer,
Collegeville, PA, United States; 4Inflammation and Immunology, Global
Medical Affairs, Pfizer, Collegeville, PA, United States
Correspondence: Majed Khraishi
Pediatric Rheumatology 2017, 15(Suppl 2):P155
Introduction: Since its initial approval for the treatment of pa-
tients with moderate to severe refractory rheumatoid arthritis
(RA), etanercept (ETN; Enbrel®), a recombinant fusion protein, has
led the expansion of therapeutic options available for patients
with other inflammatory diseases.1 ETN was the first biologic ap-
proved for use in the treatment of patients with polyarticular-
course juvenile idiopathic arthritis (JIA),2 and is now indicated in
the JIA categories, extended oligoarthritis, enthesitis-related arth-
ritis, and psoriatic arthritis.3 Use of ETN in patients with JIA hasseen significant benefit in reducing disease symptoms4 and radio-
graphic progression.5 There is evidence from registry studies and
real-world data sources that ETN is favored as a first-line biologic
therapy in clinical practice in patients with JIA;6,7 however, the
factors associated with long-term retention of ETN in this patient
population have been little explored.
Objectives: To evaluate retention rates up to 6 years in ETN-treated
pediatric patients in Canada.
Methods: A retrospective cohort study was conducted using lon-
gitudinal prescription drug claims data from QuintilesIMS Private
Drug Plan database (PDP), Ontario Public Drug Plan database
(OPDP), and Quebec Public Drug Plan database (RAMQ). Between
07/2008 and 06/2010, biologic-naïve patients (ie, patients with no
biologic treatment in the preceding 12 months) who initiated
ETN, were identified and followed for 72 months. Disease indica-
tions were inferred through patient drug history. 12-month reten-
tion rates were evaluated in 1-year increments for all patients
retained on therapy at years 1, 2, 3, 4, 5, and 6 post initiation,
and comparisons made to retention rates in the first year with P-
values reported. Two-proportion z-tests were made with reference
to year-1 retention; the Bonferroni method was used to counter-
act the problem of multiple comparisons.
Results: The study identified 4528 ETN-treated patients (61% fe-
male, 85% rheumatic diseases, and 15% psoriasis) across Canada,
who initiated therapy during the selection period. 65 (1.4%)
were identified as pediatric patients (ie, age 2-12 years; 94%
with JIA) at the time of therapy initiation. The majority of pa-
tients were from Ontario (48%) and insured by private drug
plan. 12-month ETN retention rates for the pediatric patients in-
creased following their first year on therapy. 68% of patients
were retained at year 1; 12-month retention rates through years
2-6 are shown in the Table. Retention rates for the correspond-
ing periods in the adult population (>18 years) were: 66%, 79%,
82%, 84%, 83%, and 79%. A total of 23.1% (n = 15) of pediatric
patients remained on ETN treatment for the entire 72 months of
the study.
Conclusion: Pediatric patients who were treated with ETN demon-
strated higher retention rates after the first year, particularly if they
were maintained on ETN for more than 2 years. The sample size of
pediatric patients in this study is relatively small. Further analysis of
the reasons for ETN treatment discontinuation in a larger sample of
pediatric patients may assist in identifying measures to support pa-
tients in maintaining treatment to achieve sustained clinical benefit4
and quality of life.8
References: 1. Scott LJ. Drugs 2014;74:1379-1410; 2. Hinze C, et al. Nat
Rev Rheumatol 2015;11:290-300; 3. Windschall D, et al. Clin Rheumatol
2015;34:61-9; 4. Giannini EH, et al. Arthritis Rheum 2009;60:2794-804; 5.
Nielsen S, et al. Clin Exp Rheumatol 2008;26:688-92; 6. Horneff G, et al.
Arthritis Res Ther 2016;18:272; 7. Verazza S, et al. Pediatr Rheumatol On-
line J 2016;14:68; 8. Klotsche J, et al. Arthritis Care Res (Hoboken)
2014;66:253-62.
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Introduction: IgG4-related disease (IgG4-RD) is a fibroinflammatory
condition that can affect essentially any organ.
Objectives: The disease shows similar histopathological findings
across organs and systems, and consist of a lymphoplasmacytic infil-
trate enriched in IgG4-positive plasma cells. Most patients with IgG4-
RD respond at least partially to glucocorticoids, but is it toxic therapy.
Treatment protocols of IgG4-RD in children are not established.
Methods: We report a case of pediatric patient with orbital IgG4-
related disease and successful treatment JAK inhibitor – ruxolitinib.
Results: Thirteen years old boy has been suffering from hyperemia of
the left eye and edema of the eyelid. The MRI showed a lesion adja-
cent to the orbita. The child underwent biopsy of the tumor, and the
histologic examination revealed lymphoplasmacytic iniltrates with fi-
brosis and vasculitis correlating with IgG4-related disease. Serum
IgG4 level was not elevated. Blood tests and acute phase reactants
were normal. He was started on JAK inhibitor therapy (ruxolitinib)
with good effect. His tumor mass of eyes changed from 25 to10mm
for 2 months. The condition and quality of life of the child became
better. Adverse events were not noted.
Conclusion: In our case of IgG4-RD patient JAK inhibitor – ruxolitinib
therapy was highly effective and is a safe treatment modality but in-
dications for therapy require further investigation.
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Introduction: Serum adalimumab (ADA) levels have been related to
treatment response in juvenile idiopathic arthritis (JIA).
Objectives: The aim of this study is to determine the optimal cutoff
point of adalimumab in our cohort of JIA patients in function of the
variable chosen for remission: inactive JIA.
Methods: Retrospective observational study. Patients with JIA and
pharmacokinetic monitoring of adalimumab, between September
2014 and February 2017, were included. The JIA improvement criteria
were used: visual analogue physician scale (EVA physician), visual
analogue patient scale (EVAp), number of active joints, number of
limited joints, CHAQ (quality of life questionnaire) and ESR. Inactive
JIA was defined according to Wallace criteria as the absence of active
joints, systemic symptoms and uveitis; normal ESR or PCR values;
EVA medical negative and duration of stiffness less than 15 minutes.
The 7 subtypes of JIA were oligorticular, polyarticular, psoriatic and
enthesitis related arthritis.
Results: Thirty-four patients (58.82% female) were included in the
study, with a total of 50 determinations. The mean age was
12.35 years (95% CI: 10.45-14.26). The forms of JIA were: oligoarticular
35.29% (n = 12), polyarticular 29.41% (n = 10), enthesitis related arth-
ritis 23.53% (n = 8) and psoriatic arthritis 11.77% (n = 4). All of pa-
tients were given methotrexate concomitantly. The mean ADA levels
according JIA forms were: oligoarticular 9.21 mcg/mL, polyarticular8.36 mcg/mL, enthesitis related arthritis 7.73 mcg/mL and psoriatic
arthritis 13.44 mcg/mL. In the group with uveítis, ten of them had ac-
tive uveitis, predominantly oligoarticular and polyarticular (90%). The
mean ADA levels were 9.80 and 5.88 mcg/mL (p = 0.019) inactive and
active uveitis respectively. Mean levels were higher in patients with
inactive JIA compared to patients with active JIA (10.76 mcg/mL vs.
7.33 mcg/mL, p = 0.024). AUC (IC95%) according to the ROC curve
was 0.70 (0.53-0.86) with an optimal cutoff of 11 mcg/mL (Sensitivity
(Se) = 52.6%; Specificity (Ep) = 85.5%).
Conclusion: In our cohort of patients, it has been observed that in-
active JIA requires ADA levels higher than those of active JIA. On the
other hand, despite the predominance of oligoarticular and polyarti-
cular forms in active uveitis, psoriatic arthritis requires higher levels
of ADA. Finally, the optimal ADA cut-off point indicates that the
levels of ADA for JIA are higher than those generally established for
adult rheumatology patients.
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Introduction: Chronic Idiopathic Urticaria (CIU) is associated to angio-
edema in 40% of patients, with a prevalence of 0.1-0.3%, a medium
age at the diagnosis of 6-11 years. Furthermore, the 25-85% of cases
remain with a diagnosis of an “idiopathic” disease, for the negativity
of all the diagnostic tests. 30-50% of patients have an autoimmune
origin, although confirmation of the diagnosis in these cases is not
easy. Some patients, in fact, have autoantibodies against the high-
affinity IgE receptor FcεR1 or the IgE. These patients, show an in-
creased incidence of anti-thyroid autoantibodies, and represent 30-
50% of the patients designated as having CIU.
CAPS are Autoinflammatory diseases (AID) classically characterized
by recurrent episodes of fever, rash, significant increase of inflamma-
tory markers (SAA, CRP, ESR, neutrophil leukocytes), arthralgia, myal-
gia, abdominal and chest pain; these patients can have severe
clinical manifestations, which require to be treated with biological
drugs anti-IL-1.
Objectives: However, in some patients genetic analysis of the candi-
date genes (NLRP3, NLRP12…) are negative and the best treatment
is hard to decide.
Methods: We describe the clinical case of a 9-year-olf-female with
recurrent monthly episodes of fever (> 38,5 ° C for about 5 days),
arthralgia, abdominal pain, urticaria-angioedema, without itch, sig-
nificant increase of SAA, CRP, ESR, leucocytosis. ANA, ENA, ASCA,
ANCA, LAC, RAST, IgE, thyroiditis and coeliac disease markers, C3
and C4 anti-C1q inhibitor e C1q inhibitor gene mutations were
negative. The genetic study of AID (FMF, TRAPS, MVK, NLRP3,
NLRP12) was negative.
Results: The attacks only partially responded to high doses of ste-
roids and antihistaminic drugs. She was tested with omalizumab, a
monoclonal humanized murine antibody direct against IgE. The treat-
ment, off-label for age, induced a prompt and persistent resolution
of the clinical manifestations and the normalization of inflammatory
markers. Fever and arthralgia resolved and- after 5 months of treat-
ment- she did not present more attacks.
Conclusion: Omalizumab induced an on-going positive response and
was well tolerated without side effects. The omalizumab effect was
extended on inflammatory markers and symptoms, suggesting the
possible employ of the drug in severely symptomatic patients in
whom urticaria is the dominant sign and genetic analysis does not
support the diagnosis of CAPS.
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Table 44 (Abstract P159). See text for description
Results table
bDMARD No.
patients
No.
treatment
years
Observed
no.
infections
Infections
per 100
patient
years
Observed
no.
adverse
events
Adverse
events
per 100
patient
years
%
changed
for
ongoing
JIA or
uveitis
1st
agent
34 51.1 64 3.68 23 3.68 58.8%
2nd
agent
34 77.8 76 2.87 12 0.45 70%
3rd
agent
10 5.8 10 17.39 2 3.48 25%
4th
agent
4 5.3 8 37.5 0 0 -
Total 1680 158
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Introduction: Biologic DMARDs (bDMARDs) are integral to the man-
agement of paediatric rheumatological disease. There is an increas-
ing cohort of patients who have tried more than one bDMARD and
the indications and side effects are not well studied. In our depart-
ment some have received up to four different bDMARDs. Despite
their widespread use, there is limited evidence about the consequen-
tial use of different bDMARDs in paediatric rheumatology.
Objectives: The aim of this study was to investigate the consequen-
tial use of bDMARDs in the paediatric rheumatology. The outcomes
were to define local practice and the group of patients who clinically
need multiple bDMARDs. We also wanted to look at the adverse ef-
fects of receiving consequential bDMARDs.
Methods: Using hospital pharmacy records, a database of paediatric
rheumatology patients who received two or more bDMARDs was cre-
ated. Patient records were scrutinised for demographics and diagno-
ses. Data collection was completed by documenting bDMARDs, and
recording information pertinent to each course of treatment includ-
ing the duration, side effects, reported infections and reason for
changing to another bDMARD.
Results: From February 2015 to March 2017 there were 34 patients
who received consequential bDMARDs who collectively underwent
48 medication changes. Their diagnoses included juvenile idiopathic
arthritis (JIA) (poly-JIA - 14%; oligo-JIA alone – 8.2%; systemic JIA –
4.1%; oligo JIA and uveitis - 18.8%). Enthesitis-related arthritis, uveitis
and sarcoidosis accounted for the remainder. 25 patients received
two bDMARDs, 10 patients received three bDMARDs and 4 patients
received four bDMARDs. The mean duration of treatment was
49.4 months (range 15 - 132 months).
Etanercept was prescribed 22 times, usually first line (90%). Adalimu-
mab was prescribed 31 times, mostly second line (77%). Infliximab
was prescribed 16 times mostly first line (56%). Tocilizumab was pre-
scribed for 13 patients mostly as third (46%) and fourth line (23%)
therapy and never as first line. Abatacept was prescribed once as
fourth line. Anakinra was used twice. Practice was mostly in keeping
with BSPAR guidance for bDMARD usage.
Many factors contributed to switching. Most common were poor
control of JIA (41.6%), uveitis (18.8%), and infections (5%). Intolerance
to administration for adalimumab and etanercept was common
(22%). Adverse reactions to infliximab accounted for 8%.
Patients requiring three or more bDMARDs had diagnoses of anti-
body negative oligo-JIA (7/10) six of whom also had active uveitis.
The three remaining patients had poly-JIA and two of these were
Rheumatoid Factor positive (RF+).
158 infections were reported, most of which were mild. Eight infec-
tions required hospitalisation. The most common infections were
upper respiratory tract infections (40.5%), urinary tract infections
(12%), ear infections, cellulitis and pneumonia (7% each). Other serious
infections reported were appendicitis, central line sepsis and sialitis.
Minor infections includeded thrush, gastroenteritis, threadworms, tinea,
dental infections, herpes simplex, varicella zoster, paronychia and in-
fected ingrown toenails (Table 44).
Conclusion: This investigation highlights practice at a tertiary centre
in which bDMARD use is frequent. The results show factors contribut-
ing to bDMARD switching and this can aid decision making when
commencing therapy. This needs further studying as 41.6% reported
poor efficacy with their first bDMARD. It appears that patients with
antibody negative oligo-JIA and uveitis, and possibly RF + ve poly-JIA
are at risk of poor response. Infection rates increased during 3rd and
4th bDMARD courses, and although reducing patient numbers are
confounding, this is an interesting area for future research given theimpact on quality of life. Future research should follow patients into
adulthood to demonstrate long term effects of these medications.
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Introduction: Juvenile idiopathic arthritis (JIA) is one of the most fre-
quent rheumathologic conditions in childhood. The most common
extra-articular manifestation of JIA is chronic anterior uveitis (CAU). It
usually has an insidious, asymptomatic onset, with a chronic and re-
current course, being blindness its major complication. Several risk
factors to develop CAU has been reported, including early age at the
onset of arthritis (before 6 years), short disease duration and some
JIA subtypes (oligoarticular-persistent and extended-oligoarticular JIA,
psoriatic arthritis, undifferentiated arthritis). The presence of positive
antinuclear antibodies (ANA) tests is one of the most important risk
factors. In some cases ANA are present at the onset of the disease,
subsequently becoming negative.
Objectives: To determine if the presence of steadily ANA positivity
(>2 determinations) throughout disease course is associated with an
increased risk of developing chronic anterior uveitis
Methods: We performed a retrospective study including JIA patients
with high-risk to develop CAU and at least one positive ANA deter-
mination during the follow-up at the Pediatric Rheumatology Unit of
our center. A cut-off point titer of 1/80 was considered for ANA posi-
tivity. The χ2 test was performed with Fisher's adjustment. The level
of significance was set by the 95% confidence interval (CI) and p
<0.05.
Results: A total of 53 JIA patients were included, 48 (90.5%) of them
are girls, with a mean age at diagnosis of 3 years. 16 patients devel-
oped CAU (31.3% of the girls and 20% of the boys), without a statisti-
cally significant difference in the percentage of patients who
developed CAU between the genders or age. When dividing into
groups, 52% of the girls had 1or 2 positive ANA determinations and
48% had ≥3 positive determinations; 40% of the boys had 1or 2 posi-
tive ANA determinations and 60% had ≥3 positive determinations.
Analysing by groups, patients with 3 or more determinations an OR:
4.93 (95% CI: 1.32-18.31) to develop CAU compared to those with
1or 2 positive determinations.
Conclusion: Our results are similar to others studies previously pub-
lished regarding the absence of association of chronic anterior uveitis
with the female sex, based on the frequency difference in the largest
Table 45 (Abstract P161). Clinical characteristics of patients with JIA-U.
(Abbreviations: MTX, methotrexate)
Patient JIA subtype Gender;
Ethnicity
Age of
uveitis
diagnosis
(years)
Uveitis
diagnosis
from JIA
diagnosis
(years)
Symptom
onset to
diagnosis
(months)
Symptoms Disease
extent
Complication Treatment
1 ERA Male;
Indonesian
9.2 – 3.8 0.6 Pain and
redness
Bilateral;
anterior
– Topical
steroids,
Adalimumab
2 ERA Male;
Indonesian
13.8 1.3 1.1 Redness,
blurring of
vision,
photophobia
Bilateral;
anterior
Macular
oedema
Topical and
systemic
steroids, MTX,
Adalimumab
3 ERA Male;
Indian
13.0 0 1.6 Redness Bilateral;
anterior
– Topical and
systemic
steroids, MTX,
Adalimumab
4 Oligoarticular-
extended
Male;
Indian
5.1 1.5 5.2 Left eye
ptosis
Left;
panuveitis
Macular
oedema,
glaucoma,
cataract
Topical and
systemic
steroids, MTX,
Infliximab;
cataract
surgery; YAG
laser
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positive ANA determinations are considered to be associated with a
high risk of CAU. In addition, the results of our study suggest that
the persistence of ANA is associated with an even higher risk of de-
veloping chronic anterior uveitis. Further studies with a larger cohort
are needed to confirm these findings.
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Introduction: Uveitis is the most frequent extra-articular manifest-
ation in Juvenile Idiopathic Arthritis (JIA) and results in significant
morbidities including vision loss. Paucity of data on JIA-associated
uveitis (JIA-U) in Asia makes it challenging to develop well-informed
clinical practice guidelines for screening of JIA-U in this population.
Objectives: We aim to describe the prevalence, clinical characteristics
and risk factors of JIA-U in patients treated in a Paediatric tertiary
centre in Singapore.
Methods: 103 patients were diagnosed with JIA in our hospital from
Jan 2007 to Feb 2017. We analysed the electronic medical records
(EMRs) of 83 of these patients. Twenty patients were excluded from
our study: 15 did not have available EMRs and 5 made only one visit
to the Paediatric Rheumatology clinic.
Results: Among 83 patients with JIA, 29 (34.9%) were girls and 54
(65.1%) were boys. Most of the patients were Chinese (n = 39, 47.0%),
22 (26.5%) Indonesian, 10 (12.0%) Indian and 2 (2.4%) Malays. Ten
patients were from Bangladesh, Cambodia, Korea, Vietnam, Sri Lanka
and East Timor. The subtypes of JIA were: enthesitis related arthritis
(ERA) (35.7%), oligoarthritis (22.6%), systemic JIA (15.5%), seronega-
tive polyarthritis (15.5%), seropositive polyarthritis (7.1%), psoriatic
arthritis (2.4%) and undifferentiated (1.2%). Twenty five of 72 patients
(34.7%) were positive for ANA.
Four children (4.8%) were diagnosed with uveitis: 3 had ERA and de-
veloped anterior uveitis, while 1 had oligoarticular JIA and had panu-
veitis. All 4 affected patients were negative for ANA and Rheumatoid
factor. All 3 patients with ERA were symptomatic for uveitis and had
bilateral involvement. The patient with oligoarticular JIA presented
with unilateral ptosis only. Mean age at diagnosis of uveitis was
10.3 years (CI 2.34–18.26). Clinical characteristics of the 4 patients
with JIA-U are shown in Table 45.
Conclusion: Our Asian population demonstrates distinct differences
to our Western counterparts:
Our patients have a much lower prevalence at 4.8%. Literature from
Western populations cite prevalence of JIA-U between 11 and 30%.
Even though our Asian patient population is fairly heterogeneous,
our prevalence is consistent with the 4.7% prevalence demonstrated
in a study done in Taiwan, a more homogeneous Asian population.
Our Asian population did not demonstrate the same risk factors for
JIA-U as in previous studies. There was a much higher association of
uveitis with ERA in both our and the Taiwanese study. Frequently re-
ported risk factors of ANA-positivity, young age of disease onset, fe-
male gender were not evident in our population.
Lastly, majority (3 of 4) of our patients were symptomatic for uveitis.
These preliminary findings have implications for screening guidelines
for uveitis in Asian patients with JIA. Larger population studies are re-
quired to characterize the risk factors for JIA-U to guide development
of such guidelines.
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Introduction: Juvenile idiopathic arthritis (JIA) is commonly compli-
cated by chronic uveitis. Therapy of JIA-associated uveitis is guided
by the severity of inflammation and complications. When the stand-
ard anthireumatic drugs and the local eye therapy are insufficient we
need to consider immunosuppressive or biological agents.
Objectives: Observation was aimed at assessing the effectiveness of
adalimumab (ADA) in the treatment of juvenile idiopathic arthritis as-
sociated uveitis in children with disease resistance to standard anti-
rheumatic therapy.
Methods: 7 patients with JIA (5 oligoarticular, 2 polyarticular) and
who experienced eye problems were included in the study, 6 girls
and 1 boy. Mean age was 6.3 years; the age of disease onset was 4.4
± 1.2 years. Prior to ADA administration all children received the top-
ical treatment of uveitis and methotrexate and 4/7 children received
oral corticosteroids. 4 children had bilateral eye involvement and 3
children had unilateral; 5 children had active uveitis; most children
had the moderate activity of arthritis; mean ESR was 23.4 ± 15.3 mm/
h; CRP 72 ± 18.1 mg/dl (ref <3.0 mg/dl).
Results: After 6 months of ADA administration, uveitis remission was
achived in 27.3% eyes, 18.2% eyes showed a reduction in inflamma-
tory activity, flares was observed in 2/7 children; after 12 months of
ADA 42.8% eyes had uveitis remission, 14.3% eyes had sub active
uveitis. Monitoring arthritis for 6 months of ADA administration, 95%
children achieved ACR ped-30, 57.1% ACR ped 50 with substantially
decreased ESR, CRP also; after 12 months of ADA, ACR ped-30 and
ACR ped-50 was achieved in all children, while ACR ped-70 in 4 chil-
dren; mean ESR decreased to 11.4 ± 2.3 mm/h and also CRP from 72
± 18.1 mg/dl to 25.2 ± 2.1 mg/dl.
Conclusion: Our modest experience has confirmed that adalimumab
in the treatment of JIA associated with uveitis has the significant effi-
cacy in the majority of children.
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Introduction: Tubulointerstitial Nephritis and Uveitis syndrome (TINU)
is a rare disorder characterized by inflammation of the tubulointersti-
tium associated with recurrent unilateral or bilateral uveitis. Since
TINU syndrome may not be obvious at initial presentation, it remains
often underdiagnosed.
Objectives: To report a case of recurrent bilateral optic disc edema
in a definite TINU syndrome with limited responsiveness to cortico-
steroid therapy and immunosuppressants. An anti-TNF-α blocking
agent was added in order to control the inflammation.
Methods: Observational report about a 13-year-old Caucasian boy diag-
nosed with TINU syndrome and bilateral papilledema. An extensive gen-
eral and ophthalmological workup confirmed the diagnosis of TINU.Results: A 13-year-old boy diagnosed with TINU syndrome, was
referred to our department with a bilateral papilledema. In a 25-
months follow-up 4 episodes of bilateral anterior uveitis were ob-
served. At the 2nd episode the anterior chamber inflammation
was accompanied by bilateral optic disc edema. The ocular in-
flammation responded initially well to systemic corticosteroids
but after a recurrence-free period of 1-year, bilateral papilledema
recurred. At referral ocular examination showed mild anterior
chamber reaction with bilateral optic disc edema. Visual field
testing was normal and optical coherence tomography showed a
thicker peripapillary retinal nerve fiber layer (PPRNFL). Immuno-
suppressive therapy with mycophenolate mofetil and methotrex-
ate failed to control the inflammation. A treatment with
infliximab, an anti-TNF-α blocking agent, was initiated. Initially re-
mission with a recurrence-free period of 7 months was achieved
but papilledema recurred.
Conclusion: TINU syndrome may rarely manifest with optic disc
edema. To our knowledge, this is the first case of TINU syndrome
with bilateral papilledema treated with infliximab. Despite a
recurrence-free period of 7 months, the anti-TNF-α blocking agent
failed to control the papilledema. Since the limited responsiveness to
anti-TNF-α blocking agents, alternative treatment options need to be
explored.
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